

25  
years/ans

CONFERENCE  
CAHR  
2016



25<sup>th</sup> Annual Canadian  
Conference on  
HIV/AIDS Research

May 12-15, 2016  
Winnipeg, Manitoba

CONGRÈS DE  
L'ACRV  
2016

25<sup>e</sup> Congrès annuel  
canadien de recherche  
sur le VIH/sida

Du 12 au 15 mai 2016  
Winnipeg (Manitoba)

WINNIPEG

Realizing Our Potential:  
Local to Global and Back

Réaliser notre potentiel :  
Du local au mondial et retour



Dan Harper

[www.cahr-acrv.ca](http://www.cahr-acrv.ca)



Nilo Manalo



Dan Harper



CTC/William Au

The Canadian Association for HIV Research  
**welcomes you**  
to its 25<sup>th</sup> Annual Canadian Conference  
on HIV/AIDS Research!

L'Association canadienne de recherche sur le VIH/sida  
**vous souhaite la bienvenue**  
à son 25<sup>e</sup> Congrès annuel canadien  
de recherche sur le VIH/sida !

## Realizing Our Potential: Local to Global and Back

CAHR would like to take this opportunity to welcome you to the 25<sup>th</sup> Annual Canadian Conference on HIV/AIDS Research – CAHR 2016. Once again, CAHR will have a stellar program of world-renowned speakers, allowing you to connect with researchers, frontline public health and community-based workers, policy makers, people living with HIV and AIDS, and others interested in the field of HIV research. We thank you for your active participation as well as the over 100 volunteers who have contributed their time and talents – as committee members, reviewers, sponsors, rapporteurs and on-site volunteers.

## Réaliser notre potentiel : Du local au mondial

L'ACRV aimerait profiter de cette occasion pour vous souhaiter la bienvenue au 25<sup>e</sup> Congrès annuel canadien de recherche sur le VIH/sida (congrès de l'ACRV 2016). Cette année encore, le programme exceptionnel du congrès, dans lequel figurent notamment des conférenciers de renommée mondiale, favorisera l'établissement de liens entre les chercheurs, les travailleurs de la santé publique de première ligne, les intervenants communautaires, les décideurs, les personnes vivant avec le VIH/sida et d'autres personnes s'intéressant au domaine de la recherche sur le VIH. Nous vous remercions de votre participation active et sommes reconnaissants envers la centaine de bénévoles – membres des comités, examinateurs, commanditaires, rapporteurs et bénévoles sur place – pour le temps et les compétences qu'ils ont généreusement consacrés à l'événement.

**Connect with CAHR online!**  
**Suivez l'ACRV en ligne!**



CanadianAssociationforHIVResearch



CAHR\_ACRV



CAHRACRV

## Table of Contents

<b>Programme en français</b> .....	<b>53</b>
CAHR Thanks Our Sponsors and Supporters .....	2
Glossary of Terms and Acronyms .....	3
Welcome to CAHR 2016 .....	4
Message from the CAHR President.....	4
Message from the Conference Co-Chairs .....	5
Appreciation of Volunteers .....	6
CAHR Committees.....	6
CAHR 2016 Awards and Scholarships.....	8
Conference Information .....	11
Exhibition .....	16
Program .....	17
Wednesday, May 11 .....	17
Thursday, May 12.....	18
Friday, May 13.....	27
Saturday, May 14 .....	36
Sunday, May 15 .....	46
Monday, May 16.....	48
Sponsoring Organizations' Profiles .....	49
Oral Presentations .....	109
Friday, May 13 .....	112
Saturday, May 14 .....	126
Posters.....	141
Author Index .....	217
Next Year's Conference.....	245
Downtown Map .....	246
Venue Plan .....	Inside Back Cover
Program at a Glance.....	Back Cover

Canadian Association for HIV Research  
 236 Metcalfe Street, Suite 302  
 Ottawa, ON K2P 1R3  
 Email: [info@cahr-acrv.ca](mailto:info@cahr-acrv.ca)  
 Telephone: 613-747-2465  
[www.cahr-acrv.ca](http://www.cahr-acrv.ca)



Association canadienne de recherche sur le VIH  
 236 rue Metcalfe, Poste 302  
 Ottawa, ON K2P 1R3  
 Courriel : [info@cahr-acrv.ca](mailto:info@cahr-acrv.ca)  
 Téléphone : 613-747-2465  
[www.cahr-acrv.ca](http://www.cahr-acrv.ca)

## CAHR Thanks Our Sponsors and Supporters

### Platinum

Gilead Sciences Canada  
ViiV Healthcare ULC

### Silver

Canadian Institutes of Health Research  
Merck Canada

### Bronze

AbbVie  
CIHR Canadian HIV Trials Network

### Contributors

Canadian Guidelines on HIV PrEP & nPEP  
Canadian Heritage / Patrimoine canadien  
CANFAR  
CANOC  
National Collaborating Centre for Infectious Diseases (NCCID)  
Ontario HIV Treatment Network  
Research Manitoba  
University of Manitoba

### Supporters

Air Canada  
Bedrocan  
CATIE  
CHVI Alliance Coordinating Office  
Hilary Druxman  
Hologic Canada  
Pendopharm  
Public Health Agency of Canada  
The Québec Antiretroviral Therapeutic Drug  
Monitoring Program  
TheraTechnologies  
Tourism Winnipeg  
WestJet

## Glossary of Terms and Acronyms

- AIDS** – Acquired Immune Deficiency Syndrome
- APHA** – Aboriginal People Living with HIV/AIDS
- ART** – Anti-retroviral Therapy
- ARV** – Anti-retroviral Drugs
- ASO** – AIDS Service Organizations
- CAB** – Community Advisory Board
- CBO** – Community-based Organizations
- CDC** – Centers for Disease Control and Prevention
- CIHR** – Canadian Institutes of Health Research
- CHVI** – Canadian HIV Vaccine Initiative
- CSW** – Commercial Sex Worker
- DOT** – Directly Observed Therapy
- GIPA** – Greater Involvement of People Living with HIV/AIDS
- HAART** – Highly Active Anti-retroviral Therapy
- HCV** – Hepatitis C Virus
- HIV** – Human Immune-deficiency Virus
- HPV** – Human Papilloma Virus
- IDU** – Injecting Drug User
- IRIS** – Immune Reconstitution Inflammatory Syndrome
- KTE** – Knowledge Transfer and Exchange
- LGBT** – Lesbian, Gay, Bisexual, Transgendered
- LMIC** – Lower and Middle-income Countries
- MDR-TB** – Multi-drug Resistant Tuberculosis
- MSM** – Men Who Have Sex with Men
- MTCT** – Mother to Child Transmission
- NGO** – Non-governmental Organization
- NPT** – New Prevention Technologies
- OI** – Opportunistic Infections
- PDA** – Personal Digital Assistant
- PEP** – Post-exposure Prophylaxis
- PHAC** – Public Health Agency of Canada
- PLWHA (or PHA)** – Person Living with HIV/AIDS
- PMTCT** – Prevention of Mother-to-Child Transmission
- PrEP** – Pre-exposure Prophylaxis
- QOL** – Quality of Life
- RCT** – Randomized Controlled Trial
- REB** – Research Ethics Board
- SAE** – Serious Adverse Event
- STI** – Sexually Transmitted Infections
- UNAIDS** – Joint United Nations Program on HIV/AIDS
- UNDCP** – United Nations Drug Control Program
- VL** – Viral Load

# Welcome to CAHR 2016

## Message from the CAHR President



**Dr. Michael Grant**



Twenty-five years ago, the 1<sup>st</sup> Annual Canadian Conference on HIV/AIDS Research was held in Montreal. As continues to this day, the event was hosted by the newly created Canadian Association for HIV Research. Today, the tradition continues with the Conference having been held in every time zone, from Victoria to St. John's, over the last three decades.

So much has changed over the last quarter century. Logistically, what started out as a small annual gathering of scientists is now the meeting place for 800-900 Conference goers, made up of researchers from all pillars of research, affected community members, students, policy makers, international delegates, and other interested parties. On the community front, the face of the epidemic has kept changing, severely impinging on the lives of different, mostly marginalized, populations. And on the research front, there have been many advances that have made inroads in tackling the disease – from insights into the biomedical complexities of the virus, to the development of advanced clinical approaches to treat HIV, to new and diverse strategies to reduce risks for individuals and communities.

While so much has changed, the relevance of CAHR and its annual Conference is as strong as it was some 25 years ago. For example, thousands of new infections occur each year in Canada, and the number of people living with HIV in Canada is rising. The Public Health Agency of Canada estimates that 70,000 people in Canada were living with HIV at the end of 2011, and there are over 3,000 new infections each year. Globally, more than 36.9 million people – the equivalent of the population of Canada – were living with HIV in 2014, according to the World Health Organization.

While so much has been achieved, there is clearly so much more to be done. As we look ahead, CAHR will continue to stay relevant, relying on what has become a hallmark of the association: its members' enthusiasm, shared commitment, and great willingness to learn from each other. We hope you enjoy CAHR 2016 and find it a worthwhile learning experience.

## Message from the Conference Co-Chairs



**Dr. Marissa Becker**   **Dr. Keith Fowke**

We are pleased to welcome you to Winnipeg and congratulate CAHR on its 25<sup>th</sup> Annual Canadian Conference on HIV/AIDS Research. For a quarter century Canadian researchers have been making a difference in preventing new HIV infections, improving treatment and outcomes for those living with HIV and working to create a supportive, stigma-free and respectful environment for all persons at risk of being infected with HIV. The annual CAHR conference is where we come together to share our challenges, successes, failures and next steps. While we can be proud of the progress we've made, everyone will agree that there is much more that needs to be accomplished toward our global goal of ending the HIV epidemic.

Toward that goal, the theme of this year's conference is "Realizing Our Potential: Local to Global and Back," and it highlights the leadership that Canadian researchers and their partners have played across Canada, and globally, to address the challenges we face in combatting the HIV epidemic. To make our goal of eliminating HIV a reality we must act locally, wherever local is, and share our lessons learned with the global community as we also learn from them. HIV/AIDS remains a significant challenge and a collective approach is required if we are to hasten our progress toward HIV elimination.

With the largest number of abstracts ever submitted to a CAHR conference, 504, it is clear that there is a great deal of enthusiasm and momentum in the Canadian HIV research scene. This has resulted in a scientific program with tremendous breadth as well as depth. To further foster interdisciplinary collaboration, we've created four concurrent multidisciplinary sessions. Our goal is that by sitting in a single session, you will be able to hear how a particular topic is being approached from all pillars of our research endeavour.

We'd like to thank all those who have made this year's conference possible, especially our Scientific Program Committee and the Conference Management Committee. We hope that you find this year's conference informative and engaging, that you connect with old friends and make new ones and that you even have a little bit of fun.

## Appreciation of Volunteers

CAHR expresses its sincere appreciation to the following volunteers: Scientific Program Committee Members, Abstract Reviewers, Scholarship Selection Committee Members, Session Co-Chairs, Presenters, Rapporteurs, Awards Reviewers, and Conference Volunteers. They have dedicated their time and support in helping to build the conference program for CAHR 2016. Their efforts and commitment have helped to make CAHR 2016 a success!

## CAHR Committees

### CAHR Executive Committee

President:	Dr. Michael Grant
President Elect:	Dr. Curtis Cooper
Past President:	Dr. Robert Hogg
Treasurer:	Dr. Carol Strike
Secretary:	Terry Howard
Executive Director:	Andrew Matejic

### CAHR Board of Directors

Track A: Basic Sciences:	Dr. H�el�ene C�ot�e
Track B: Clinical Sciences:	Dr. Shariq Haider
Track C: Epidemiology and Public Health Sciences:	Dr. Marissa Becker
Track D: Social Sciences:	Dr. Stephanie Nixon
Community Representative:	Stephanie Smith

## Scientific Program Committee

### Conference Co-Chairs

Dr. Marissa Becker  
Dr. Keith Fowke

### Track Co-Chairs

#### *Track A: Basic Sciences*

Dr. Blake Ball  
Dr. Lyle McKinnon

#### *Track B: Clinical Sciences*

Dr. Yoav Keynan  
Dr. Mona Loutfy

#### *Track C: Epidemiology and Public Health Sciences*

Dr. Tony Antoniou  
Dr. Stephen Moses  
Dr. John Wylie

#### *Track D: Social Sciences*

Dr. Saara Greene  
Dr. Javier Mignone



## Community Representative

Mike Payne

## Family Physician

Dr. Laurie Ireland

## Conference Advisory Members

Dr. Michael Grant

Andrew Matejic

## Conference Coordinator

Sea to Sky Meeting Management Inc.

Suite 206, 201 Bewicke Avenue

North Vancouver, BC V7M 3M7 Canada

Tel: 604-984-6455

Fax: 604-984-6434

[www.seatoskymeetings.com](http://www.seatoskymeetings.com)

[conference@cahr-acrv.ca](mailto:conference@cahr-acrv.ca)

President:

Sarah Lewis, CMP, CMM

Project Director:

Ian Holliday, BA Econ

Project Manager:

Donna Roberts, CMP

Conference Coordinator:

Katrina Sutela

## Abstract Reviewers

### Track A: Basic Sciences

Dr. Jonathan Angel

Dr. Blake Ball

Dr. Nicole Bernard

Dr. Mark Brockman

Dr. Zabrina Brumme

Dr. Adam Burgener

Dr. Eric Cohen

Dr. Andrés Finzi

Dr. Michael Grant

Dr. Rupert Kaul

Dr. Lyle McKinnon

Dr. Paul McLaren

Dr. Thomas Murooka

Dr. Mario Ostrowski

Dr. Ralph Pantophlet

Dr. Ken Rosenthal

Dr. Ruey Su

### Track B: Clinical Sciences

Dr. Jean-Guy Baril

Dr. Josée Brouillette

Dr. Jared Bullard

Dr. Adriana Carvalhal

Dr. Curtis Cooper

Dr. Alexandra de Pokomandy

Dr. Joanne Embree

Dr. Michelle Foisy

Dr. Troy Grennan

Dr. Marianne Harris

Dr. Mark Hull

Dr. Marina Klein

Dr. Neora Pick

Dr. Vanessa Poliquin

Dr. Anita Rachlis

Nancy Sheehan

Dr. Darrell Tan

Dr. Sharon Walmsley

Dr. Alex Wong

Dr. Mark Yudin

**Track C: Epidemiology and Public Health Sciences**

Dr. Michel Alary	Dr. Susan Kirkland
Dr. Vanessa Allen	Dr. Lynne Leonard
Dr. Chris Archibald	Dr. Viviane Lima
Dr. Paul Arora	Dr. Peggy Millson
Dr. Shamara Baidooobonso	Dr. Tyler O'Neill
Dr. Greta Bauer	Dr. Janet Raboud
Dr. Ahmed Bayoumi	Dr. Beth Rachlis
Dr. Ann Burchell	Ayden Scheim
Dr. Todd Coleman	Souradet Shaw
Dr. Kathleen Deering	Dr. Jean Shoveller
Dr. Dara Friedman	Dr. Doug Sider
Dr. Jacquie Gahagan	Dr. Ameeta Singh
Dr. Mark Gilbert	Laura Thompson
Dr. Gayatri Jayaraman	Dr. Mark Tyndall
Dr. Claire Kendall	

**Track D: Social Sciences**

Laura Bisailon	Dr. Maria Nengeh Mensa
Dr. Marleny Bonnycastle	Paula Migliardi
Dr. David Brennan	Dr. Kelly O'Brien
Dr. Vera Caine	Doe O'Brien Teengs
Lori Chambers	Dr. Joanne Otis
Dr. Jacquie Gahagan	Dr. Surita Parashar
Dr. Daniel Grace	Dr. Tracey Prentice
Dr. Trevor Hart	Dr. Gayle Restall
Dr. Francisco Ibanez-Carrasco	Dr. Janice Ristock
Randy Jackson	Dr. Sergio Rueda
Dr. Carmen Logie	Jody Shynkaruk
Dr. Robert Lorway	Dr. Alison Symington
Renée Masching	Dr. Cathy Worthington

**CAHR 2016 Awards and Scholarships**

CAHR provides awards, scholarships, and registration support in order to promote research excellence, knowledge exchange, and mentoring within and across various communities of researchers and the broader HIV community.

**Mark A. Wainberg Lecturer****Dr. Stephen Moses**

Professor and Head of the Department Community Health Sciences, University of Manitoba, Winnipeg, Manitoba

***HIV Prevention: Local to Global and Back to the Future***

## Scholarships

### Academic Scholarships (General)

Two Academic Scholarships are awarded to researchers in each scientific track based on the abstracts they submitted. Recipients receive complimentary hotel, registration, and travel.

#### **Track A: Basic Sciences**

Alexander Falkenhagen, University of Toronto  
Stephen McCarthy, University of Toronto

#### **Track B: Clinical Sciences**

Carmine Rossi, McGill University  
Élise Vuille-Lessard, McGill University Health Centre

#### **Track C: Epidemiology and Public Health Sciences (Dr. Robert Remis Scholarships)**

Ashley Lacombe-Duncan, University of Toronto  
Leigh McClarty, University of Manitoba

#### **Track D: Social Sciences**

Elena Argento, BC Centre for Excellence in HIV/AIDS  
Rachel Landy, Memorial University of Newfoundland

### Academic Scholarships in Vaccine Research

In partnership with the Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office, four Academic Scholarships in Vaccine Research are awarded to researchers based on the abstracts they submitted. Recipients receive complimentary hotel, registration, and travel.

Simon de Montigny, CHU Sainte-Justine Research Centre  
Justen Hoffman Russell, University of Toronto  
Robert Omange, University of Manitoba  
Laurence Raymond Marchand, Université de Montréal

### Community Scholarships

To support community attendance and participation at the conference, the CAHR Community Scholarship Program provides community scholarships in the form of financial assistance and support to eight individuals from across Canada and fifteen registration bursaries to community participants from the Greater Winnipeg area. CAHR appreciates the support from the Public Health Agency of Canada in providing these scholarships.

Community Scholarships are awarded to:

Timothy Bartsch, East York, ON  
Brook Biggin, Edmonton, AB  
Alexandra De Kiewit, Montreal, QC  
Wesley G. Keewatin, Regina, SK  
Daniel Jonathan Laroche, Montreal, QC  
Matthew Loosemore, Iqaluit, NU  
Tendai Mpfu, Surrey, BC  
Lorraine O'Leary, Happy Valley-Goose Bay, NL

## Scholarship, Bursary and Registration Support

CAHR recognizes the collaboration of additional partners who are supporting expanded participation at CAHR: CATIE for the Learning Institute and the CIHR Canadian HIV Trials Network (CTN) for assistance with researcher travel. CAHR provides a significantly reduced registration fee for people who are personally affected by HIV/AIDS to support their participation at CAHR 2016.

## Red Ribbon Award

Established in 2001, the Red Ribbon Award is presented annually by CAHR for outstanding service to the cause of research in a way that has increased our understanding of the treatment and prevention of HIV/AIDS, while enhancing the quality of life of those living with this disease.

The Red Ribbon Award will be presented during the Conference Opening on Thursday, May 12<sup>th</sup>.

## New Investigator Awards

Each year since 1992, New Investigator Awards have been provided to recognize promising new researchers from each of CAHR's four tracks. Three of the four awards have been named in honour of three individuals, whose exceptional dedication to the cause of HIV research helped blaze the trails for the many scientific advances that have been achieved in this field during this time: Basic Sciences, Kalpesh Oza (died June 4, 1995); Clinical Sciences, Brian Farlinger (died July 3, 1995); and Epidemiology and Public Health Sciences, Randy Coates (died September 26, 1991). Many of the New Investigator awardees have continued to make significant contributions to HIV/AIDS research.

The New Investigator Awards will be presented at the Awards and Closing Remarks on Sunday, May 15<sup>th</sup>.

## Acknowledgement

The CAHR Conference is taking place on the original lands of Anishinaabeg, Cree, Oji-Cree, Dakota, and Dene peoples, and on the homeland of the Métis Nation. We respect the Treaties that were made on these territories, we acknowledge the harms and mistakes of the past, and we dedicate ourselves to move forward in partnership with Indigenous communities in a spirit of reconciliation and collaboration.

# Conference Information

## Registration

### Registration Hours

The registration desk is located in the South East Concourse – Ground Floor, North Building of the RBC Convention Centre and is open during the following hours:

Thursday, May 12	08:30 – 19:00
Friday, May 13	07:00 – 17:00
Saturday, May 14	08:30 – 17:00
Sunday, May 15	08:30 – 12:30

### Name Badge

In addition to being a means of identification to colleagues, you are required to wear your name badge for admission to conference sessions and events. Room monitors will check name badges on admission to the session or event. Replacement badges are available at the registration desk located in the South East Concourse – Ground Floor, North Building of the RBC Convention Centre at a cost per badge of \$25.

CAHR Executive and Board members, Scientific Program Committee members, volunteers, and staff will be identified by a coloured ribbon on their name badge. Exhibitors will have a different coloured name badge and do not have access to the conference sessions.

### Gala Party – Pre-purchased Tickets

Pre-purchased tickets for the Gala Party are located in your name badge holder. Additional tickets may still be available. If you would like to buy tickets for a registrant (\$75) or a guest (\$125), visit the registration desk located in the South East Concourse – Ground Floor, North Building of the RBC Convention Centre.

### Certificate of Attendance

If you requested a Certificate of Attendance, it will be inserted into your registration package.

## First Aid or Medical Emergency

In case of a medical emergency, security staff are equipped in basic first aid for initial response. There are three automated external defibrillators (AED) in the building (main floor/York entrance; second floor/security desk and third floor/ Hall A east entrance). Alternatively, you may ask any volunteer, or the staff at the registration desk located in the South East Concourse – Ground Floor, North Building of the RBC Convention Centre for help.

If you need immediate, non critical care, the nearest walk-in clinic is the Medical Centre & Lab located in City Place Mall which is adjacent to the RBC Convention Centre and accessible through the Skywalk. The address is Unit 81 – 333 St. Mary Avenue. The telephone number is 204-942-0933. The Medical Centre is open 08:30 to 16:30 from Monday to Friday and closed on weekends.

## Venue Facilities and Services

### Venue Floor Plan

Please see the inside back cover for the RBC Convention Centre floor plan.

### Accessibility

The RBC Convention Centre provides visitors with a fully accessible environment to ensure ease and enjoyment of all activities in and around the Convention Centre.

- Wheelchair accessibility
- Automatic motion activated sliding entrance doors
- Passenger elevators equipped with raised panel and Braille keys
- Designated disabled parking stalls on both levels of parkade
- Escalators in all corners of the building
- TTY Pay Telephone on the Ground Floor of the southeast concourse
- Washrooms with wheelchair accessible stalls and sinks
- Wheelchair access ramp and designate seating area in 2<sup>nd</sup> floor Presentation Theatre
- Climate controlled skywalk system that connects to Delta Winnipeg and other entertainment venues, restaurants and hotels throughout downtown Winnipeg

## Business Centre

Print Express & Copy Centre is located on the Second Floor, North Building of the RBC Convention Centre and can assist with basic copy and print needs.

## Guest Services

The RBC Convention Centre Security Desk is located on the Second Floor, North Building and staff can answer questions about the facility and the City of Winnipeg. Two ATM machines are located on the Second Floor of the North Building, near the top of the stairs near the main entrance.

## Internet Access

Free Wi-Fi is available at the RBC Convention Centre. Turn on Wi-Fi — select the #TELUS network — open a browser — enter your email — accept terms — click submit.

## Conference Administration and Services

### Language of the Conference

The scientific communications of the conference program will be presented according to the language in which the presenters submitted their abstracts. The language of each abstract will be indicated by E for English or F for French. Plenary and special sessions will have PowerPoint presentations in English and French whenever possible.

### Session Room Protocols

Every effort will be made to ensure that all sessions start and end on time. Speakers and participants are asked to work together to respect the conference schedule.

### Cellular Phones and Other Noise-making Devices

Please respect your fellow participants by muting cellular phones and other noise-making devices during the sessions.

### Speaker Ready Room and Presentations

The Speaker Ready Room is intended to support all presenters, chairpersons, and moderators.

Location: Meeting Room 17 – Ground Floor, North Building, RBC Convention Centre

Opening Hours:

Thursday, May 12	13:00 – 17:00
Friday, May 13	07:30 – 15:30
Saturday, May 14	07:30 – 15:30

## Positive Lounge

The Positive Lounge helps participants living with HIV/AIDS to maximize their participation in the conference. The Positive Lounge offers people living with HIV/AIDS a place to rest and retreat from the conference schedule. The lounge provides a calm and supportive environment with spaces for informal discussion and peer support, quiet relaxation, limited complimentary refreshments, and a safe place for taking prescription medication.

Location: VIP Salon – Ground Floor, North Building, RBC Convention Centre

Opening Hours:

Thursday, May 12	14:00 – 20:00
Friday, May 13	07:30 – 18:00
Saturday, May 14	07:30 – 18:00
Sunday, May 15	08:30 – 12:00

## Messages

Hand written messages can be posted on the message board located by the registration desk in the South East Concourse – Ground Floor, North Building, RBC Convention Centre.

## CAHR Job Board

CAHR offers a Job Board for employer organizations. Employers are welcome to post recruitment notices and job postings. The Job Board is located by the registration desk in the South East Concourse – Ground Floor, North Building, RBC Convention Centre.

## CAHR 2016 Mobile App

CAHR has created a CAHR 2016 Mobile App which allows participants to review the program and conference-related information. The app is available for iPhone, iPad and Android users. Visit your app store to download the CAHR 2016 app.

## Evaluation

CAHR's aim is to deliver a conference that is an enjoyable and educational experience. We rely on your full and honest feedback to improve future conferences. We will send an electronic evaluation by email following the conference. Please complete the online evaluation. Note that the evaluations are anonymous and we are not collecting any personal information.

## Security

At the conference, name badges must be worn at all times as they verify that you are a registered conference participant. Keep all personal items with you at all times, as the conference rooms will be locked only when not in use in the evenings.



## Liability

The liability of the conference organizers – for whatever legal reason – shall be limited to intent and gross negligence.

The liability of commissioned service providers shall remain unaffected by this. Participants take part in CAHR 2016 at their own risk. Oral agreements shall not be binding if they have not been confirmed in writing by CAHR or its agents.

## Smoking

Smoking is not permitted during conference sessions or anywhere inside the convention centre.

## Continuing Medical Education Credits

This program has been reviewed by the College of Family Physicians of Canada and is awaiting final accreditation by the College's Manitoba Chapter.

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, and approved by the Association of Medical Microbiology and Infectious Disease (AMMI) Canada.



# Exhibition

## Location and Opening Hours

**Location: Rooms 2FGH – Second Floor, North Building**

### Opening Hours:


Thursday, May 12	19:00 – 20:00
Friday, May 13	08:30 – 15:30
Saturday, May 14	08:30 – 15:30

## Exhibitors

Booth	Booth #
ViiV Healthcare ULC	1 & 14
Gilead Sciences Canada	2 & 3
CIHR Canadian HIV Trials Network	4
Merck Canada	5 & 6
Hologic Canada	7
Canadian Working Group on HIV and Rehabilitation (CWGHR)	8
Canadian Society for International Health (CSIH)	9
National Collaborating Centre for Infectious Diseases (NCCID)	10
Canadian Foundation for AIDS Research (CANFAR)	11
CHVI Alliance Coordinating Office	12
Canadian Institutes of Health Research	13

Table Top	Table Top #
Theratechnologies	TT1
Bedrocan Canada	TT2
Quebec Antiretroviral Therapeutic Drug Monitoring Program	TT3
Focus Africa	TT4
Hilary Druzman Design	TT5
Grands 'n More	TT6
CATIE	TT7

## Exhibit Hall Floor Plan



# Program

## Wednesday, May 11

### Ancillary Event

## Canadian HIV/AIDS Pharmacists Network Annual General Meeting

**Time:** 07:30 – 17:00

**Location:** Charleswood A, Second Floor, Delta Winnipeg

Host: Canadian HIV/AIDS Pharmacists Network (CHAP)

Attendance: Pharmacists attending CAHR 2016 are welcome to attend. Pre-registration is required.

The Annual General Meeting of CHAP consists of a combination of education, practice sharing and business discussion (including ongoing CHAP business and research projects). Pharmacists attending CAHR 2016 are welcome to attend, although the voting at the business portion of the meeting is reserved for working group members only. There are usually approximately 25 people in attendance and all details of the meeting are relayed via the CHAP network list-serve.



# Program

## Thursday, May 12

### Overview

All events take place at the RBC Convention Centre unless otherwise indicated.

Time	Event	Room
07:45 – 16:00	Workshop CAHR New HIV Researcher Workshop	Delta A, Second Floor, Delta Winnipeg
08:00 – 16:00	Ancillary Event CHVI ACO Annual Meeting – HIV Vaccine Research and Development in Canada: How Vaccines Fit within the Prevention Landscape	Meeting Room 3, Ground Level, North Building
08:30 – 12:00	Ancillary Event Mobilizing Across Canada to Build Effective Responses to HIV in African, Caribbean and Black Communities	Kildonan Room, Second Floor, Delta Winnipeg
08:30 – 16:00	Ancillary Event 3 <sup>rd</sup> International Forum on HIV and Rehabilitation Research – HIV and Aging	Delta B, Second Floor, Delta Winnipeg
08:30 – 16:00	Ancillary Event Engage Team Meeting 2016	Meeting Room 9-10, Ground Level, North Building
10:00 – 16:00	Ancillary Event PrEP in the Context of Sex Work: Possibilities and Limitations	Sunshine House, 646 Logan Avenue, Winnipeg
12:00 – 16:00	Ancillary Event CIHR Implementation Science Component 1 Grantees Workshop	Charleswood A, Second Floor, Delta Winnipeg
13:00 – 16:00	Ancillary Event Transforming Canada's Approach to Drugs: A National Conversation	Delta C, Second Floor, Delta Winnipeg
14:00 – 16:00	CATIE-CAHR Learning Institute	Kildonan Room, Second Floor, Delta Winnipeg
16:15 – 17:15	Symposium Canadian Guidelines on HIV PrEP and nPEP	Meeting Rooms 1-2 & 11-13, Ground Level, North Building
17:30 – 19:00	Plenary Conference Opening and Mark A. Wainberg Lecture: HIV Prevention: Local to Global and Back to the Future	Meeting Rooms 1-2 & 11-13, Ground Level, North Building
19:00 – 20:00	Social Event Opening Reception	Rooms 2FGH, Second Floor, North Building

## Program

### Workshop

#### **CAHR New HIV Researcher Workshop**

**Time: 07:45 – 16:00, Evening social to follow**

**Location: Delta A, Second Floor, Delta Winnipeg**

Host: CAHR

Attendance: Pre-registration is required.

The overall goal of the CAHR New HIV Researcher Workshop is to facilitate the career development of aspiring HIV researchers. The meeting fosters the formation of peer networks between new investigators working in related or overlapping areas of research. In addition, a significant portion of the meeting is devoted to mentoring, both through formal presentations by senior scientists followed by discussion, as well as many informal interactions. New investigators are counseled on grant and paper writing, on running a lab/office and other key components of career development. This skills-based workshop is designed to focus on all four CAHR research tracks (Basic Sciences, Clinical Sciences, Epidemiology and Public Health, and Social Sciences).

This annual workshop brings together graduate students, doctoral students, postdoctoral fellows, medical students/interns/residents, trainees and other new HIV researchers. Following the workshop, an evening social is held so aspiring researchers can network with other new investigators in a fun and informal setting and to interact on a more personal level with mentors. As with previous workshops, the 2016 workshop will focus on all pillars of HIV research and include such sessions as CIHR 101, Getting Funding for your Research, Grantscrafting, Mentorship, and Career Development.

CAHR thanks its partners, the CHVI ACO, CIHR, CTN, PHAC and CANFAR for making this workshop possible.

### Ancillary Event

#### **CHVI ACO Annual Meeting – HIV Vaccine Research and Development in Canada: How Vaccines Fit within the Prevention Landscape**

**Time: 08:00 – 16:00**

**Location: Meeting Room 3, Ground Level, North Building**

Host: Canadian HIV Vaccine Initiative Research and Development Alliance Coordinating Office (ACO)

Attendance: This session is open to all CAHR 2016 attendees. Pre-registration is required.

The goal of this event is to provide a forum for HIV vaccine research and development stakeholders to identify and share their achievements, challenges and needs as part of Canada's effort to develop a safe and effective HIV vaccine within a changing prevention landscape.

### **Learning Objectives:**

1. Highlight the achievements of Canadian scientists in HIV vaccine research and development;
2. Identify the challenges faced by Canadians when working on HIV vaccine candidates; and
3. Identify what Canadians need to support ongoing HIV vaccine and prevention research and development efforts.

There will be a facilitated discussion around the role of HIV vaccines in the changing prevention landscape as well as opportunities to discuss the future of HIV vaccine research and development in Canada. There will also be opportunities for dialogue during three panel discussions (HIV Vaccine Research; HIV Vaccine Development and HIV Vaccine Program Science) as well as informal networking opportunities during the breaks and lunch. The list of presenters includes Ralph Pantophlet from Simon Fraser University, Kelly MacDonald from the University of Manitoba, Peter Newman from the University of Toronto, Chil-Yong Kang from Western University, Michael McLean from Platform, Yegor Voronin from the Global HIV Vaccine Enterprise and Robert Reinhard among others.

Thursday

## **Ancillary Event**

### **Mobilizing Across Canada to Build Effective Responses to HIV in African, Caribbean and Black Communities**

**Time: 08:30 – 12:00**

**Location: Kildonan Room, Second Floor, Delta Winnipeg**

Hosts: Canadian HIV/AIDS Black, African, Caribbean Network (CHABAC)

Attendance: This session is open to all CAHR 2016 attendees. Pre-registration is required.

This event will bring together community members, people living with and affected by HIV, researchers and other stakeholders to engage in dialogue around community needs, common areas of work and emerging issues in the HIV response in African, Caribbean and Black communities.

The session will include a panel presentation followed by a discussion. Topics of presentations and discussion will include:

- Community engagement in HIV prevention;
- Expanding HIV prevention approaches: Issues specific to African, Caribbean and Black populations in Canada; and
- CHABAC's role in integrating expanding HIV prevention knowledge into ACB Programming.

## Ancillary Event

### 3<sup>rd</sup> International Forum on HIV and Rehabilitation Research – HIV and Aging

**Time: 08:30 – 16:00**

**Location: Delta B, Second Floor, Delta Winnipeg**

Host: Canada-United Kingdom HIV and Rehabilitation Research Collaborative (CUHRRC) in collaboration with the Canadian Working Group on HIV and Rehabilitation (CWGHR) and CAHR.

Attendance: The Forum is open to all CAHR 2016 attendees. Pre-registration is required.

The aim of the Forum is to facilitate knowledge transfer and exchange on HIV, aging and rehabilitation research, to establish new partnerships in HIV and aging, and to identify new and emerging research priorities in the field.

The Forum will include a series of dynamic and interactive research evidence panel sessions focused on HIV, aging and multi-morbidity, rehabilitation interventions and models of service delivery. The Forum will include people living with HIV, researchers, clinicians, and representatives from community organizations from Canada, the UK, and the US who will speak about a) the role for rehabilitation in the context of HIV, aging and multi-morbidity, b) profile innovative models of rehabilitation service delivery, c) highlight concrete strategies for enhancing access to rehabilitation, and d) identify new and emerging research priorities in the field.

Acknowledgements: The 3<sup>rd</sup> International Forum on HIV and Rehabilitation Research is funded by a Planning and Dissemination Grant from the Canadian Institutes of Health Research (CIHR). CUHRRC acknowledges the generous support from the Canadian Working Group on HIV and Rehabilitation [www.hivandrehab.ca](http://www.hivandrehab.ca).

## Ancillary Event

### Engage Team Meeting 2016

**Time: 08:30 – 16:00**

**Location: Meeting Room 9-10, Ground Level, North Building**

Hosts: Engage Study Team

Attendance: By invitation only.

This ancillary event will be the 2<sup>nd</sup> annual Engage Team meeting. The event will start with a 3-hour half-day focused on research methods and KTE when working with gay, bisexual, and other men who have sex with men. This event will focus on training and research capacity building for the Engage Team trainees, new investigators, and community members. The second three hours of the meeting will be a larger Engage Team meeting for the entire Team.

At this meeting, we will discuss:

1. Progress made to date on data collection;
2. How team members can submit a concept sheet for a collaboration with the larger study;
3. Proposing study ideas from the large study (e.g., a future paper on a given analysis);
4. Developing new grant proposals to follow up with study ideas;
5. HIV prevention interventions to pilot or test based upon current research; and
6. Building further capacity for MSM research in Canada.

## Ancillary Event

### PrEP in the Context of Sex Work: Possibilities and Limitations

**Time: 10:00 – 16:00**

**Location: Sunshine House, 646 Logan Avenue, Winnipeg**

Host: Dalla Lana School of Public Health, University of Toronto and Triple-X Workers' Solidarity Association of B.C.

Attendance: The meeting is a closed meeting, by invitation only. Attendees will be sex workers or Allies from across Canada.

The HIV Social, Behavioural and Epidemiological Studies Unit at the Dalla Lana School of Public Health, University of Toronto in partnership with the Triple-X Workers' Solidarity Association of B.C. is in receipt of funding from the Elton John AIDS Foundation and the Canadian Institutes of Health Research to hold a closed, invite-only meeting to discuss and plan for PrEP in the context of sex work.

In collaboration with Sunshine House, Winnipeg, the meeting will bring together individuals from across Canada, with experience in sex work, to learn about PrEP and to discuss the capacity and research needs of sex workers in Canada with regards to PrEP.

## Ancillary Event

### CIHR Implementation Science Component 1 Grantees Workshop

**Time: 12:00 – 16:00**

**Location: Charleswood A, Second Floor, Delta Winnipeg**

Host: Canadian Institutes of Health Research (CIHR)

Attendance: This will be a closed event and is limited to the successful recipients of a CIHR funding opportunity.

The Canadian Institutes of Health Research (CIHR) HIV/AIDS Research Initiative and its Federal Initiative partners (Correctional Service Canada, Health Canada – First



Nations and Inuit Health Branch and the Public Health Agency of Canada), developed an ***HIV Implementation Science initiative*** in order to address the gap that exists in the application of evidence into health policy and programs. The goal of the initiative is to reduce the incidence of HIV, Hepatitis C (HCV) and other sexually transmitted and blood-borne infections (STBBIs) within and across key populations in Canada. ***Component 1 – Adaptation Grants*** will support the development of multi-sectoral teams, identification of promising or effective interventions and the development of multi-faceted programs through intervention adaptation.

One researcher and one knowledge user from each team will attend this workshop hosted by CIHR and partners.

#### **Learning Objectives :**

1. Providing an opportunity for participants to present their project plans to other grantees; and
2. Interacting with other project teams and facilitating synergies and potential new collaborations.

CIHR will work with the participants to develop the agenda.

## **Ancillary Event**

### **Transforming Canada's Approach to Drugs: A National Conversation**

**Time: 13:00 – 16:00**

**Location: Delta C, Second Floor, Delta Winnipeg**

Hosts: Canadian Drug Policy Coalition/519/Manitoba Harm Reduction Network

Attendance: This session is open to all CAHR 2016 attendees. Pre-registration is required.

This is a critical time in Canada for the development of a comprehensive drug policy based in science, public health and human rights. It is also an important moment in International drug policy.

This CAHR ancillary session will consider the outcomes of the UN General Assembly Special Session (UNGASS) on Drugs that will have just taken place in New York April 19 – 21, 2016. The UNGASS will set in motion a process to review the global response to drugs over the next three years 2016 – 2019. This coincides with the federal government contemplating a new national drug strategy. With a renewed interest in innovation and new approaches to drugs at the federal level there is an opportunity to accelerate the development of a comprehensive health and human rights response to drugs in Canada and to provide leadership in the upcoming global discussions within the UN system post-UNGASS. The session will explore 1. Canada's role in reforming the international drug control system, 2. Building a comprehensive health and human rights approach with a focus on decriminalization and regulation of drugs.

**Learning Objectives:**

1. Learn about the outcomes of the UNGASS meeting that takes place April 19 – 21, 2016; and
2. Explore two components of a public health and human rights approach to drugs – decriminalization and regulation of drugs.

**CATIE-CAHR Learning Institute**

**Times: 14:00 – 16:00 (Continues on Friday and Saturday evenings)**

**Location: Kildonan Room, Second Floor, Delta Winnipeg**

Hosts: CATIE

Attendance: By invitation only.

In partnership with CAHR, CATIE will be holding a Learning Institute. This year's participants, 25 CATIE and CAHR community scholars, will work to bring a community lens to research presented at CAHR. Working with CATIE educators, participants will be assigned to one of the four CAHR research tracks. Learning Institute participants will debrief nightly and collaborate to produce the 'Learning at the Front Lines: Community Rapporteur Session', scheduled as part of the CAHR program on Sunday, May 15<sup>th</sup>. This presentation will subsequently be made available for dissemination in participants' regions for community reportbacks.

Thursday

**Symposium****Canadian Guidelines on HIV PrEP and nPEP**

**Time: 16:15 – 17:15**

**Location: Meeting Rooms 1-2 & 11-13, Ground Level, North Building**

Attendance: This session is open to all CAHR 2016 attendees.

Host: CIHR Canadian HIV Trials Network (CTN)

This session will describe the development and preliminary content of a CIHR-supported, national evidence-based guideline on these antiretroviral-based HIV prevention methods, and provide an opportunity for stakeholder consultation.

**Learning Objectives:**

1. Describe the methodology used to develop the new 2016 Canadian Guidelines on HIV PrEP and nPEP;
2. Review preliminary recommendations on who should receive PrEP and nPEP;
3. Review preliminary recommendations on how and what PrEP and nPEP should be delivered; and
4. Solicit the opinions of the broader Canadian HIV community on the guidelines.

**Presenters:**

**Dr. Darrell Tan**, Clinician-Scientist, St. Michael's Hospital, Toronto, ON

**Dr. Mark Hull**, BC Centre for Excellence on HIV/AIDS, Vancouver, BC

**Deborah Yoong**, Clinical pharmacist, St. Michael's Hospital, Toronto, ON

**Dr. Réjean Thomas**, Clinique L'Actuel, Montreal, QC

**Dr. Cécile Tremblay**, Professeure agrégée, L'Université de Montréal, QC

**Plenary**

## Conference Opening and Mark A. Wainberg Lecture

**Time:** 17:30 – 19:00

**Location:** Meeting Rooms 1-2 & 11-13, Ground Level, North Building

**Welcome**

Welcome by **Dr. Marissa Becker** and **Dr. Keith Fowke**, Conference Co-Chairs

Welcome by **Dr. Ken Kasper**, Director, Manitoba HIV Program

Welcome by **Dr. Michael Grant**, President, CAHR

Welcome by **Dr. Marc Ouellette**, Scientific Director, CIHR Institute of Infection and Immunity

**Mark A. Wainberg Lecture*****HIV Prevention: Local to Global and Back to the Future***

**Dr. Stephen Moses**, Professor and Head of the Department Community Health Sciences, University of Manitoba, Winnipeg, Manitoba



*Dr. Stephen Moses is a physician and scientist who has made major contributions globally to understanding biological and behavioural risk factors for HIV infection, and translating research findings into practice. He has been at the forefront of investigating, and integrating into programs, major innovations*

*for HIV prevention: improved management and control of “conventional” STIs; implementation of focused, peer-mediated educational interventions for high-risk populations; and male circumcision for reducing HIV susceptibility among men. Dr. Moses was co-PI on the landmark RCT of male circumcision for HIV prevention in Kenya, that helped lead to the scale-up of male circumcision services in 14 countries in eastern and southern Africa. He is currently Professor and Head of the Department of Community Health Sciences at the University of Manitoba. He has authored over 230 peer-reviewed publications, as well as several monographs and*

*book chapters, and has made numerous presentations at national and international conferences.*

The evolution of effective HIV prevention responses will be reviewed and examined, with a focus on sub-Saharan Africa and India. The importance of focused HIV prevention programming for high-risk or key populations will be emphasized, and particularly female sex workers, men who have sex with men and people who inject drugs. The introduction of new HIV prevention technologies, such as Treatment as Prevention and Pre-Exposure Prophylaxis, will be discussed in this context. Male circumcision will also be discussed as an HIV prevention method for the general population, in countries where it is not practised traditionally, and where HIV prevalence is high.

### **Learning Objectives:**

1. Understand the importance of focused HIV prevention programs for key populations, in all typologies of HIV epidemics;
2. Describe some of the successes in HIV prevention programming in resource-poor settings over the past three decades;
3. Recognize the importance of making new HIV prevention technologies available and accessible to key populations, along with demand creation; and
4. Gain insights into the role of male circumcision programs and services in responding to the HIV epidemic in eastern and southern Africa, and update their status.

## **Red Ribbon Award Presentation**

Presentation of the 2016 Red Ribbon Award to **Margaret Ormond** (Special Projects Manager, Sunshine House, Winnipeg, MB) by **Dr. Marissa Becker** and **Dr. Keith Fowke**, Conference Co-Chairs.

## **Social Event**

### **Opening Reception**

**Time: 19:00 – 20:00**

**Location: Rooms 2FGH, Second Floor, North Building**

The CAHR 2016 Opening Reception welcomes all participants, sponsors, exhibitors, and volunteers. The Reception offers a hosted bar and hors d'oeuvres amongst the exhibits and poster displays. The Opening Reception is included in the conference registration fee.

# Program

## Friday, May 13

### Overview

All events take place at the RBC Convention Centre unless otherwise indicated.

Time	Event	Room
07:45 – 09:00	Symposium Vaccine Research Plenary HIV Vaccines: Maintaining the Momentum	Meeting Rooms 1-2 & 11-13, Ground Level, North Building
09:00 – 09:45	Plenary Clinical Sciences PrEP at Age 5: Growing up Fast	Meeting Rooms 1-2 & 11-13, Ground Level, North Building
09:45 – 10:30	Plenary Social Sciences Evidentiary Sovereignty across Three Continents: Critical Ethnographies of Community based HIV Research	Meeting Rooms 1-2 & 11-13, Ground Level, North Building
10:30 – 11:00	Exhibit and Poster Viewing Refreshment Break	Rooms 2FGH, Second Floor, North Building
11:00 – 12:30	Concurrent Oral Abstract Sessions	
	Track A: Basic Sciences Prevention	Meeting Room 4, Ground Level, North Building
	Track B: Clinical Sciences Clinical Care	Meeting Room 7-8, Ground Level, North Building
	Track C: Epidemiology and Public Health Sciences HIV Prevention for Key Populations	Meeting Room 3, Ground Level, North Building
	Track D: Social Sciences Indigenous Health	Meeting Room 9-10, Ground Level, North Building
12:30 – 14:00	Lunch Symposium Living Longer and Living Well with HIV: Reaching New Heights in Healthy Aging Co-developed by Canadian Institutes of Health Research (CIHR)	Meeting Rooms 1-2 & 11-13, Ground Level, North Building
14:00 – 15:00	Exhibit and Poster Viewing Refreshment Break with Poster Authors Present Poster Discussions – Basic and Clinical Sciences	Rooms 2FGH, Second Floor, North Building
15:00 – 17:00	Concurrent Oral Abstract Sessions	
	Track A: Basic Sciences Immunology	Meeting Room 4, Ground Level, North Building
	Track B: Clinical Sciences Co-infection	Meeting Room 7-8, Ground Level, North Building
	Track C: Epidemiology and Public Health Sciences Social and Structural Correlates of HIV Risk and Care	Meeting Room 3, Ground Level, North Building
	Track D: Social Sciences Innovative Approaches and Outcomes in Social Science HIV Research	Meeting Room 9-10, Ground Level, North Building
17:00 – 18:30	Symposium Measuring the National HIV Cascade & The UNAIDS 90-90-90 Targets Sponsored by CTN, OHTN & REACH, CANOC, CANFAR	Meeting Rooms 1-2 & 11-13, Ground Level, North Building
18:30 – 20:15	CATIE-CAHR Learning Institute	Meeting Room 7-8, Ground Level, North Building
18:30 – 20:00	Meeting CAHR Annual General Meeting and Reception	Meeting Room 3, Ground Level, North Building

## Program

### Symposium

## Vaccine Research Plenary – HIV Vaccines: Maintaining the Momentum

**Time:** 07:45 – 09:00

**Location:** Meeting Rooms 1-2 & 11-13, Ground Level, North Building

**Attendance:** This session is open to all CAHR 2016 attendees.

The session will be moderated by **Dr. Jonathan Angel** from the Ottawa Hospital Research Institute and **Dr. Michael Grant** from Memorial University.

Featured speakers include **Drs. Marc Ouellette, Jamie Mann** and **Gary Kobinger**.

**Dr. Marc Ouellette** is Scientific Director, CIHR Institute of Infection and Immunity and Canada Research Chair in Antimicrobial resistance, Centre de Recherche en Infectiologie, CHU Québec et Université Laval. The title of his presentation is ***“The current status and future prospects for HIV vaccine research funding in Canada”***

#### Learning Objectives:

1. Describe the past and current CIHR investments in HIV vaccine research;
2. Summarize the outcomes of the recent CIHR vaccine workshop held in March in Ottawa; and
3. Explore possible future CIHR HIV vaccine programs.

**Dr. Jamie Mann** is an Assistant Professor in the Department of Microbiology and Immunology, University of Western Ontario. The title of his presentation is ***“HIV-1 Vaccine Delivery”***

#### Learning Objectives:

1. Recognize how DNA vaccination elicits B and T cell responses;
2. Gain insights into how antigen-specific humoral responses are generated in mucosal tissues; and
3. Explore alternate routes of vaccination and their ensuing immune responses.

**Dr. Gary Kobinger** is the Director of the Centre for Research in Infectious Diseases, Laval University. The title of his presentation is ***“Rapid vaccine development against Ebola and other high consequence pathogens”***

#### Learning Objectives:

1. Identify the different steps required to develop a vaccine from the bench to clinical trials;
2. Recognize the necessity of an international approach to vaccine development; and

- Gain insights into the challenges associated with the acquisition of resources before the need is at the door.

## Plenary

### Clinical Sciences

#### PrEP at Age 5: Growing up Fast

**Time: 09:00 – 09:45**

**Location: Meeting Rooms 1-2 & 11-13, Ground Level, North Building**

**Presenter: Dr. Jared Baeten**



*Dr. Baeten is Vice Chair and Professor in the Department of Global Health at the University of Washington. His research focuses on the prevention of HIV-1 and other sexually transmitted diseases, including clinical trials of novel prevention interventions, epidemiologic studies of risk factors for HIV-1 transmission, and bibehavioral and implementation science*

*research aimed at optimizing prevention delivery. He co-chaired the Partners PrEP Study, a randomized clinical trial that provided definitive evidence that pre-exposure prophylaxis (PrEP) protected against HIV-1 acquisition, and other work includes ASPIRE, a multinational phase III trial of dapivirine vaginal ring for HIV-1 prevention in women, implementation science work to deliver antiretroviral treatment and PrEP for HIV-1 prevention, and studies exploring use of hormonal contraception as a risk factor for HIV-1.*

In 2010-2011, pivotal clinical trials demonstrated for the first time that antiretroviral medications, used as pre-exposure prophylaxis (PrEP), could significantly and safely reduce the risk of HIV acquisition in persons at risk of HIV. The past five years have seen substantial advances in PrEP, including demonstration studies proving that effective delivery of PrEP in a variety of settings is possible, research to understand best practices for PrEP provision, and the development of normative guidance on how to deliver PrEP. PrEP is a new prevention tool and it highlights a multitude of opportunities and challenges: a biomedical intervention (a pill, or other approaches) that requires specific behaviors for successful and safe use (HIV testing, interaction with the health system, perception of risk, adherence), its operation in a diverse social context (sex, stigma, relationships, power, gender) with important public health and public policy implications (costs, trade-offs, legal frameworks). PrEP offers real promise to contribute to turning the tide of the global HIV epidemic, but implementation is just beginning; achieving success will require continued science, education, and advocacy.

**Learning Objectives:**

1. Gain insights into the concept of pre-exposure prophylaxis (PrEP) for HIV prevention;
2. Discuss data from the pivotal studies in men who have sex with men and heterosexual men and women, including clinical trials and implementation evaluations; and
3. Recognize opportunities and challenges in the delivery of PrEP for HIV prevention in multiple settings.

**Plenary****Social Sciences**

## Evidentiary Sovereignty across Three Continents: Critical Ethnographies of Community-based HIV Research

**Time: 09:45 – 10:30**

**Location: Meeting Rooms 1-2 & 11-13, Ground Level, North Building**

**Presenter: Dr. Robert Lorway**



*Robert Lorway is an associate professor in the Centre for Global Public Health, University of Manitoba. Between 2009 and 2014, he held a CIHR New Investigator award in HIV services/population health research. His research is concerned with the social study of global health interventions designed to improve the lives of marginalized populations. His*

*scholarly book, *Namibia's Rainbow Project: Gay Rights in an African Nation*, reveals the long-term effects of a human rights program that inadvertently subjugated the community it aimed to liberate. Robert's theoretical engagements are rooted in applied health projects conducted with members of community-based organizations in Africa and Asia.*

This presentation will explore the effects of evidentiary sovereignty as it interacts with community mobilization in parts of Canada, India, and Kenya. As a complex mode of power enacted in global health interventions, evidentiary sovereignty progressively tightens the perimeters around what is deemed admissible as “legitimate knowledge” in decision making arenas, a process driven by the pursuit of efficiency. Global health funders increasingly demand the production of measurable forms of evidence in an effort to track health outcomes and bind program implementers to relations of accountability. However, as local community organizations, advocacy groups, and community health workers become ever more entangled in evidence production systems, we must ask – what are the consequences for community-level organizing, grassroots social movements, forms of resistance, and political



dissent? This talk will explore this important question through the employment of three geographically and temporally contrasting case studies that pertain to community-based HIV research projects. Although traceable to feminist, queer, and anti-colonial theoretical methodologies that aim to unsettle and transform power relations that inhere in conventional research, community-based research ushers in its own set of problematic unequal power relationships that feed into existing and emerging forms of evidentiary sovereignty. These case studies help to reveal important dimensions of evidentiary sovereignty that hold theoretical, political and applied public health importance.

### **Learning Objectives:**

1. Describe how credentialization alters the very social fabric of HIV community solidarity networks in ways that inadvertently sidelines the insights and experiences of highly marginalized people;
2. Recognize how techno-bureaucratization embroils HIV activists in evidence production activities while increasingly expanding governmental regulation over civil society; and
3. Gain insight into how bio-experimentalism produces clinical trial communities that fulfill the demands of market-oriented logics at the cost of community outreach priorities.

## **Exhibit and Poster Viewing – Refreshment Break**

**Time: 10:30 – 11:00**

**Location: Rooms 2FGH, Second Floor, North Building**

## **Concurrent Oral Abstract Sessions**

**Time: 11:00 – 12:30**

Session descriptions begin on page 112.

### **Track A: Basic Sciences: Prevention**

**Location: Meeting Room 4, Ground Level, North Building**

### **Track B: Clinical Sciences: Clinical Care**

**Location: Meeting Room 7-8, Ground Level, North Building**

### **Track C: Epidemiology and Public Health Sciences: HIV Prevention for Key Populations**

**Location: Meeting Room 3, Ground Level, North Building**

### **Track D: Social Sciences: Indigenous Health**

**Location: Meeting Room 9-10, Ground Level, North  
Building**

## Lunch Symposium

### Living Longer and Living Well with HIV: Reaching New Heights in Healthy Aging

This Symposium was co-developed with the Canadian Institutes of Health Research (CHIR) and was planned to achieve scientific integrity, objectivity and balance

**Time: 12:30 – 14:00**

**Location: Meeting Rooms 1-2 & 11-13, Ground Level, North Building**

Attendance: This session is open to all CAHR 2016 attendees.

This session will include speakers from Canada and the United Kingdom who will discuss the role and evidence for rehabilitation in the context of HIV, aging and comorbidities and reflect on the research evidence emerging in the field. Concrete examples will be provided about rehabilitation in clinical practice for people aging with HIV in Canada, the UK and Sub-Saharan Africa. This session is a collaboration between the Canada-United Kingdom HIV and Rehabilitation Research Collaborative (CUHRRC) and Canadian Working Group on HIV and Rehabilitation (CWGHR).

#### Learning Objectives:

1. Summarize the role, and provide evidence for rehabilitation in the context of HIV and aging;
2. Describe evidence supporting rehabilitation interventions on aging HIV positive individuals;
3. Outline models of rehabilitation service delivery;
4. Gain insights into the strengths of rehabilitation research and practice in Canada, the United Kingdom and Sub-Saharan Africa to support people living with HIV to live well when living longer; and
5. List strategies for enhancing access to rehabilitation for people aging with HIV.

#### Presenters:

**Dr. Patricia Solomon**, Professor, McMaster University, Hamilton, ON

**Dr. Richard Harding**, Reader, Cicely Saunders Institute, King's College London, United Kingdom

**Dr. Stephanie Nixon**, Associate Professor, University of Toronto, Toronto, ON; Director, International Centre for Disability and Rehabilitation (ICDR)

**Darren Brown**, Physiotherapist, Chelsea and Westminster Hospital, London, United Kingdom; Vice Chair, Rehabilitation in HIV Association (RHIVA), United Kingdom

**Chris Lucas**, Community Member, Nine Circles Community Health Centre, Winnipeg, MB

**Kate Murzin**, Health Programs Specialist, Canadian Working Group on HIV and Rehabilitation, Toronto, ON

## Exhibit and Poster Viewing

### – Refreshment Break with Poster Authors Present

**Time: 14:00 – 15:00**

**Location: Rooms 2FGH, Second Floor, North Building**

Poster Discussions:

Basic Sciences: 14:10 – 14:30

Clinical Sciences: 14:30 – 14:50

## Concurrent Oral Abstract Sessions

**Time: 15:00 – 17:00**

Session descriptions begin on page 118.

### Track A: Basic Sciences: Immunology

**Location: Meeting Room 4, Ground Level, North Building**

### Track B: Clinical Sciences: Co-infection

**Location: Meeting Room 7-8, Ground Level, North Building**

### Track C: Epidemiology and Public Health Sciences: Social and Structural Correlates of HIV Risk and Care

**Location: Meeting Room 3, Ground Level, North Building**

### Track D: Social Sciences: Innovative Approaches and Outcomes in Social Science HIV Research

**Location: Meeting Room 9-10, Ground Level, North Building**

## Symposium

### Measuring the National HIV Cascade & the UNAIDS 90-90-90 Targets

This Symposium was co-developed with CTN, OHTN & REACH, CANOC, CANFAR and was planned to achieve scientific integrity, objectivity and balance.

**Time: 17:00 – 18:30**

**Location: Meeting Rooms 1-2 & 11-13, Ground Level, North Building**

Attendance: This session is open to all CAHR 2016 attendees.

UNAIDS has set the ambitious goal that by 2020, 90% of all people living with HIV will know their diagnosis; 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90% of all people receiving antiretroviral therapy will have viral suppression.

From a national perspective, we need to know where Canadian populations stand on achieving these 90-90-90 targets. The Public Health Agency of Canada (PHAC) is developing a national cascade to assess the extent to which people living with HIV are engaged along the continuum of care. Several Canadian regions have laid out 90-90-90 target plans and analyzed their cascade of care. This symposium invites critical engagement around the approaches, opportunities, and implications of the cascade framework and the 90-90-90 targets at national, regional and community levels.

### Learning Objectives:

1. Explore PHAC's national framework for HIV monitoring and its application to achieving the 90-90-90 targets;
2. Identify regions in Canada with contrasting HIV epidemics and discuss Canada's status on achieving the 90-90-90 targets;
3. Recognize the capacities of existing organizations and their contributions to the development of the national HIV cascade measures; and
4. Discuss the opportunities and shortcomings around the approaches of both the national HIV cascade and the 90-90-90 targets.

**Chair:** **Dr. Marina Klein**, Professor of Medicine, McGill University Health Centre, Montréal, QU

### Speakers:

**Claudia Rank**, Senior Epidemiologist, PHAC, Ottawa, ON

**Dr. Réka Gustafson**, Medical Health Officer, Vancouver Coastal Health, Vancouver, BC

**Dr. Ryan Meili**, Family Physician, West Side Community Clinic, Saskatoon, SK

**Dr. Mark Gilbert**, Director of Applied Epidemiology, OHTN, Toronto, ON

**Patti Tait**, Family Violence Support Staff, Saskatoon Indian & Métis Friendship Centre, Saskatoon, SK

### Panelists:

**Dr. Alex Wong**, Infectious Diseases Physician, Regina Qu'Appelle Health Region, Regina, SK

**Dr. Ken Kasper**, Infectious Diseases Physician, University of Manitoba, Winnipeg, MB

**Renée Masching**, Canadian Aboriginal AIDS Network, Halifax, NS

## CATIE-CAHR Learning Institute

**Time:** 18:30 – 20:15 (Continues on Saturday)

**Location:** Meeting Room 7-8, Ground Level, North Building

Continuation of Thursday's event.

## Meeting

# CAHR Annual General Meeting and Reception

**Time: 18:30 – 20:00**

**Location: Meeting Room 3, Ground Level, North Building**

**President: Dr. Michael Grant**

The Association is a community of researchers with expertise in HIV/AIDS. All members and associates may participate in the Annual General Meeting (AGM), however, only members whose memberships are current and in good standing may vote at the meeting. Membership is open to all active researchers in all fields (basic, clinical, epidemiology and public health, and social sciences as well as community-based research) who meet the eligibility requirements. Those with an interest in HIV/AIDS research, including students and trainees may join as Associates.

At the AGM, members meet and hear from the Executive Committee and Board of Directors on the activities of the Association, receive CAHR's financial statement, and transact other business.

Names of the Executive Committee and Board of Directors are listed on page 6.

# Program

## Saturday, May 14

### Overview

All events take place at the RBC Convention Centre unless otherwise indicated.

Time	Event	Room
07:15 – 08:50	Symposium CIHR Canadian HIV Trials Network Postdoctoral Fellows Breakfast Symposium	Meeting Rooms 1-2 & 11-13, Ground Level, North Building
07:30 – 08:45	Ancillary Event Manitoba HIV Collective Impact Research, Evaluation & Action Network – Networking Breakfast	Charleswood A, Second Floor, Delta Winnipeg
09:00 – 09:45	Plenary Basic Sciences Can Inflammation in Chronic HIV Infection Be Reversed?	Meeting Rooms 1-2 & 11-13, Ground Level, North Building
09:45 – 10:30	Plenary Epidemiology and Public Health Sciences Community Mobilization and Structural Interventions in HIV Prevention Programs	Meeting Rooms 1-2 & 11-13, Ground Level, North Building
10:30 – 11:00	Exhibit and Poster Viewing Refreshment Break	Rooms 2FGH, Second Floor, North Building,
11:00 – 12:30	Concurrent Oral Abstract Sessions	
	Multi-disciplinary Session PrEP and Other Novel HIV Prevention Strategies	Meeting Room 3, Ground Level, North Building
	Multi-disciplinary Session HIV in the Global Context	Meeting Room 9-10, Ground Level, North Building
	Multi-disciplinary Session HIV in Indigenous and Local Populations	Meeting Room 4, Ground Level, North Building
	Multi-disciplinary Session Community-based HIV Research	Meeting Room 7-8, Ground Level, North Building
12:30 – 14:00	Lunch Symposium The ART of Managing HIV/HCV Co-infection in the Era of New DAAs Co-developed by Merck Canada	Meeting Rooms 1-2 & 11-13, Ground Level, North Building
14:00 – 15:00	Exhibit and Poster Viewing Refreshment Break with Poster Authors Present Poster Discussions – Epidemiology and Public Health and Social Sciences	Rooms 2FGH, Second Floor, North Building
15:00 – 17:00	Concurrent Oral Abstract Sessions	
	Track A: Basic Sciences Virology	Meeting Room 4, Ground Level, North Building
	Track B: Clinical Sciences HIV and Comorbidities	Meeting Room 7-8, Ground Level, North Building
	Track C: Epidemiology and Public Health Sciences Epidemiology of HIV and Co-infections	Meeting Room 3, Ground Level, North Building
	Track D: Social Sciences Programs and Policy Driven Research	Meeting Room 9-10, Ground Level, North Building
17:00 – 18:30	Concurrent Special Session HIV Prevention and Engagement in Care for Indigenous Peoples	
	Concurrent Special Session Immune Activation and HIV Target Cells: What do we know, what are the next big questions, and can we intervene?	Meeting Rooms 1-2 & 11-13, Ground Level, North Building
18:30 – 20:15	CATIE-CAHR Learning Institute	Meeting Room 7-8, Ground Level, North Building
19:00 – 01:00	Social Event Gala Party	Canadian Museum for Human Rights

## Program

### Symposium

## CIHR Canadian HIV Trials Network Postdoctoral Fellows Breakfast Symposium

**Time:** 07:15 – 08:50

**Location:** Meeting Rooms 1-2 & 11-13, Ground Level, North Building

**Host:** CIHR Canadian HIV Trials Network (CTN)

**Attendance:** This session is open to all CAHR 2016 attendees.

The CIHR Canadian HIV Trials Network Postdoctoral Fellowship Awards Program offers career opportunities to outstanding young clinical scientists. The program facilitates HIV and co-infections research by providing funding to candidates who wish to write a research protocol, and develop and run their own trial. Since 1992, the CTN has awarded over 121 fellowships to 74 individuals. Former CTN postdoctoral fellows during the last decade include some of Canada's current leading HIV clinical investigators. Fellowship awards for the 2016-2017 cycle are available thanks to the generous contributions of the pharmaceutical industry and CANFAR.

#### Presentation 1

##### **Effect on viral fitness of DTG-Resistance mutations in NRTI/NNRTI resistant viruses**

**Hanh Thi Pham**, PhD, CTN Postdoctoral Fellow, McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC

#### Presentation 2

##### **Clinical interventions to enhance gut immune health and to reduce inflammation in people living with HIV**

**Connie J. Kim**, BSc, MSc, PhD, CTN Postdoctoral Fellow, Toronto General Hospital (University Health Network), Toronto, ON

#### Presentation 3

##### **Optimizing Combination HIV Prevention for Younger Gay, Bisexual, Two-Spirit, and Other Men who have Sex with Men**

**Nathan J Lachowsky**, PhD, CANFAR/CTN Postdoctoral Fellow, Faculty of Medicine, University of British Columbia & BC Centre for Excellence in HIV/AIDS, Vancouver, BC

#### Presentation 4

##### **Examining the rural/urban gap in HIV care outcomes in British Columbia**

**Lauren J. MacKenzie**, MD, FRCPC, BMS/CTN Postdoctoral Fellow, BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Clinician Investigator Program, University of Manitoba, Winnipeg, MB, School of Population and Public Health, University of British Columbia, Vancouver, BC

## Ancillary Event

### Manitoba HIV Collective Impact Research, Evaluation & Action Network – Networking Breakfast

**Time: 07:30 – 8:45**

**Location: Charleswood A, Second Floor, Delta Winnipeg**

Hosts: Manitoba HIV Program and the MB CBR-HIV Collaborating Centre

Attendance: This session is open to all CAHR 2016 attendees. Pre-registration is required.

Come join us for a free networking breakfast event at CAHR hosted by the *Manitoba HIV Program and the MB CBR-HIV Collaborating Centre*. This event is a great way for CAHR delegates who are Manitoba researchers, evaluators, community-based organizations, policy-makers, community members, indigenous groups and others to network, exchange ideas and build collaborations & partnerships. Join us as we continue to build the *Manitoba HIV Collective Impact Research, Evaluation & Action Network*.

## Plenary

### Basic Science

#### Can Inflammation in Chronic HIV Infection Be Reversed?

**Time: 09:00 – 09:45**

**Location: Meeting Rooms 1-2 & 11-13, Ground Level, North Building**

**Presenter: Dr. Netanya Sandler Utay**



*Dr. Netanya Sandler Utay is an assistant professor in the Division of Infectious Diseases at the University of Texas Medical Branch at Galveston. She earned her B.S. in Molecular Biophysics and Biochemistry at Yale University and medical degree from Baylor College of Medicine. She trained in internal medicine at the*

*University of Washington and in infectious diseases at the US National Institutes of Health. In 2013, she joined UTMB. In addition to patient care, Dr. Utay runs a laboratory and chairs*



several clinical studies. Her work focuses on the causes and consequences of inflammation in acute and chronic HIV infection.

Serious non-AIDS events, including cardiovascular, liver, and renal disease and non-AIDS malignancies, have emerged as leading causes of morbidity and mortality in HIV-infected persons on combination antiretroviral therapy (ART). Biomarkers of inflammation, coagulation, and fibrosis are strong independent predictors of all-cause morbidity and mortality in HIV-infected persons, highlighting the critical role of chronic inflammation in end-organ disease. Chronic inflammation in treated HIV infection is likely driven by residual HIV replication in reservoirs, decreased immunologic control of co-infections such as cytomegalovirus, gut mucosal injury with translocation of microbial products, tissue fibrosis that destroys the lymphocyte niche, antiretroviral therapy, and conventional risk factors, pathologies that are present or begin during acute HIV infection. Interventions to attenuate inflammation in chronic HIV infection have not been successful to date. Starting suppressive ART during acute HIV infection decreases inflammation but does not abrogate it. Interventions to attenuate inflammation in acute HIV infection warrant further study for safety and efficacy, but the immune dysregulation initiated in acute HIV infection may be irreversible. To date, HIV prevention is the only way to protect against the inflammatory consequences of HIV infection.

#### **Learning Objectives:**

1. Describe the consequences of chronic inflammation in HIV infection;
2. List the drivers of inflammation in chronic HIV infection; and
3. Explore approaches to attenuate inflammation in chronic HIV infection.

## **Plenary**

### **Epidemiology and Public Health Sciences**

#### **Community Mobilization and Structural Interventions in HIV Prevention Programs**

**Time: 09:45 – 10:30**

**Location: Meeting Rooms 1-2 & 11-13, Ground Level, North Building**

**Presenter: Dr. James Blanchard**

Professor and Director, Centre for Global Public Health at the University of Manitoba. Canada Research Chair in Epidemiology and Global Public Health.



*My research focuses on how the characteristics of individuals, communities and large populations contribute to the local and global distribution of communicable and non-communicable diseases. Over the past fifteen years I have provided leadership to the design and implementation of large public health*

*programs related to HIV/AIDS and maternal, neonatal and child health in India, other Asian countries and Africa. I am actively engaged with policy makers and public health leaders to translate scientific knowledge and approaches to improve the effectiveness and efficiency of public health programs, with an emphasis on improving the health of disadvantaged populations.*

Global guidelines for HIV prevention among key populations consistently recommend structural interventions to promote community empowerment, reduce violence and enhance access to services. Still, the incorporation of these interventions into HIV prevention programs remains inconsistent, both in terms of emphasis and design. This presentation will draw from research and programmatic experience in diverse global contexts to highlight why such programs are essential, and to share evidence for how they can improve outcomes. In addition, approaches to designing structural interventions and measuring their effects will be presented.

#### **Learning Objectives:**

1. Outline the definition and components of structural interventions for key populations;
2. Recognize the need for such interventions; and
3. Gain insights into how structural interventions can be designed, delivered and assessed.

## **Exhibit and Poster Viewing – Refreshment Break**

**Time: 10:30 – 11:00**

**Location: Rooms 2FGH, Second Floor, North Building**

## **Concurrent Oral Abstract Sessions**

**Time: 11:00 – 12:30**

Session descriptions begin on page 126.

## **Multi-disciplinary Session: PrEP and Other Novel HIV Prevention Strategies**

**Location: Meeting Room 3, Ground Level, North Building**

## Multi-disciplinary Session: HIV in the Global Context

**Location:** Meeting Room 9-10, Ground Level, North Building

## Multi-disciplinary Session: HIV in Indigenous and Local Populations

**Location:** Meeting Room 4, Ground Level, North Building

## Multi-disciplinary Session: Community-based HIV Research

**Location:** Meeting Room 7-8, Ground Level, North Building

### Lunch Symposium

## The ART of Managing HIV/HCV Co-infection in the Era of New DAAs

This Symposium was co-developed with Merck Canada and was planned to achieve scientific integrity, objectivity and balance.

**Time:** 12:30 – 14:00

**Location:** Meeting Rooms 1-2 & 11-13, Ground Level, North Building

**Attendance:** This session is open to all CAHR 2016 attendees.

*“The ART of Managing HIV/HCV Co-infection in the Era of New DAAs”* is an interactive case-based program that aims to provide clinicians with practical advice on tailoring antiretroviral therapy (ART) and direct acting antivirals (DAA) for long term success in treating HIV/HCV co-infected patients. These discussions will highlight the latest clinical trial data, the importance of recognizing and monitoring drug-drug interactions (DDI) and the optimization of liver health in this special patient population.

### Learning Objectives:

1. Distinguish important DDIs as they apply to HIV/HCV co-infected patients;
2. Identify the impact of liver health in HIV/HCV co-infected patients; and
3. Drive the use of tailored ART and DAAs for long-term success in your patients.

**Dr. Curtis Cooper**, Associate Professor of Medicine, University of Ottawa, Director, The Ottawa Hospital and Regional Hepatitis Program, Ottawa, ON

**Dr. Brian Conway**, President and Medical Director, Vancouver Infectious Diseases Centre, Vancouver, BC

**Dr. Pierre Giguère**, Clinical Pharmacy Specialist, The Ottawa Hospital, Ottawa, ON

**Dr. Giada Sebastiani**, Assistant Professor of Medicine, McGill University Health Centre Junior Scientist, Research Institute of McGill University Health Centre, Montreal, QC

## **Exhibit and Poster Viewing – Refreshment Break with Poster Authors Present**

**Time: 14:00 – 15:00**

**Location: Rooms 2FGH, Second Floor, North Building**

Poster Discussions:

Epidemiology and Public Health Sciences: 14:10 – 14:30

Social Sciences: 14:30 – 14:50

## **Concurrent Oral Abstract Sessions**

**Time: 15:00 – 17:00**

Session descriptions begin on page 133.

### **Track A: Basic Sciences: Virology**

**Location: Meeting Room 4, Ground Level, North Building**

### **Track B: Clinical Sciences: HIV and Comorbidities**

**Location: Meeting Room 7-8, Ground Level, North Building**

### **Track C: Epidemiology and Public Health Sciences: Epidemiology of HIV and Co-infections**

**Location: Meeting Room 3, Ground Level, North Building**

### **Track D: Social Sciences: Programs and Policy Driven Research**

**Location: Meeting Room 9-10, Ground Level, North Building**

## **Concurrent Special Session**

### **HIV Prevention and Engagement in Care for Indigenous Peoples**

**Time: 17:00 – 18:30**

**Location: Meeting Room 4, Ground Level, North Building**

Attendance: This session is open to all CAHR 2016 attendees.

Indigenous Peoples are disproportionately represented among the population of persons vulnerable to and living with HIV in Canada and in many Latin American countries. Innovative approaches that are community-based and culturally sensitive are required to prevent new infections and optimize the health

of the heterogeneous community of Indigenous Peoples living with HIV. This session will provide an overview of effective strategies for preventing HIV in Indigenous Peoples and successfully engaging Indigenous communities in HIV-related care initiatives, highlighting the contextual elements that are critical for success.

### **Learning Objectives:**

1. Explore models for prevention of HIV in Indigenous Peoples, and engaging Indigenous Peoples living with HIV in care;
2. Recognize cultural, social and political barriers to HIV prevention and treatment among Indigenous Peoples; and
3. Describe community-based approaches to conducting and translating research with Indigenous Peoples.

### **Panelists:**

**Leona Star** (Moderator), Research Associate, Manitoba First Nations Regional Coordinator of the Regional Health Survey & Regional Early Childhood, Education and Employment Survey, Nanaandawewigamig, First Nations Health and Social Secretariat of Manitoba

**Jamie Reschny**, PhD Candidate, Health Sciences, University of Northern British Columbia, Prince George, British Columbia

**Dr. Earl Nowgesic**, Assistant Professor and Interim Director of the Waakebiness-Bryce Institute for Indigenous Health, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario

**Dr. Carlos Rojas**, Professor, Facultad Nacional de Salud Pública “Dr. Héctor Abad Gómez”, Universidad de Antioquia, Medellín, Colombia

## **Concurrent Special Session**

### **Immune Activation and HIV Target Cells: What do we know, what are the next big questions, and can we intervene?**

**Time: 17:00 – 18:30**

**Location: Meeting Rooms 1-2 & 11-13, Ground Level, North Building**

Attendance: This session is open to all CAHR 2016 attendees.

A long-standing goal of HIV transmission research has been to better understand how potential target cells at the site of HIV exposure play a role in virus dissemination from the mucosa and ultimately the establishment of HIV infection. During treated HIV, the virus lies latent in a cellular reservoir that is both a target of HIV cure efforts and has only been partially described. While a substantial body of data has emerged from a variety of experimental systems, there are still many questions that remain. More importantly, how this knowledge will translate into safe and effective HIV prevention remains to be seen. The objective of this round table panel is to provide a perspective on

progress in this important area, with a focus on what is on the horizon and how these results might be translated.

### **Learning Objectives:**

1. Discuss why mucosal target cells and immune activation are important in HIV transmission and persistence;
2. Recognize outstanding questions in HIV target cell research; and
3. Consider the current state of translating these findings into something that can be used in the clinic.

### **Panelists:**

**Dr. Thomas Hope**, Northwestern University, Chicago, IL, USA

**Dr. Rupert Kaul**, University of Toronto, Toronto, ON, Canada

**Dr. Petronela Ancuta**, Université de Montréal, Montreal, QC, Canada

**Dr. Nichole Klatt**, University of Washington, Seattle, WA, USA

**Dr. Julie Lajoie**, University of Manitoba, Winnipeg, MB, Canada

**Dr. Lenine Liebenberg**, CAPRISA, Durban, South Africa

**Dr. Adam Burgener**, University of Manitoba, Winnipeg, MB, Canada

## **CATIE-CAHR Learning Institute**

**Time: 18:30 – 20:15**

**Location: Meeting Room 7-8, Ground Level, North Building**

Continuation of Thursday and Friday sessions.



## Social Event

### Gala Party

**Time:** 19:00 – 01:00

**Location:** Canadian Museum for Human Rights, 85 Israel Asper Way

The Gala Party will be held at the Canadian Museum for Human Rights – an iconic building in Winnipeg’s skyline.

The first museum solely dedicated to the evolution, celebration and future of Human Rights, the museum creates inspiring encounters with human rights and engages visitors in an immersive, interactive experience. You will have the opportunity to visit the museum exhibits between 19:00 and 21:00.

The dinner menu will include stations around the room where you can try different dishes that are sure to please your palate.

JD & the Sunshine House Band will kick off the evening’s entertainment. The band is a collaboration between musicians and street-involved folks who participate in Sunshine House programming. Once the party is in full swing a DJ will take the stage and get the crowd dancing into the night.

**Transportation:** Weather permitting, it is a short walk (about 20 minutes) to the Museum. If the weather is not permitting, or if you would prefer to save your feet for the dancing, shuttles will run between the Delta Winnipeg and the Museum between 18:45 to 01:00.

**Note:** Participants and their accompanying guest(s) must provide tickets for admittance. Pre-purchased tickets are located in your name badge holder. Additional tickets may still be available. If you would like to buy tickets for a registrant (\$75) or a guest (\$125), visit the Registration Desk located at the South East Concourse – Ground Floor, North Building of the RBC Convention Centre.

# Program

## Sunday, May 15

### Overview

All events take place at the RBC Convention Centre unless otherwise indicated.

Time	Event	Room
9:45 – 11:15	Special Session The Future of Manitoba's Global Impact in HIV Research	Meeting Rooms 1-2 & 11-13, Ground Level, North Building
11:30 – 12:00	Plenary Learning on the Front Lines: Community Rapporteur Session – CATIE-CAHR Learning Institute Participants	Meeting Rooms 1-2 & 11-13, Ground Level, North Building
12:00 – 12:30	Plenary Awards and Closing Remarks	Meeting Rooms 1-2 & 11-13, Ground Level, North Building

### Program

#### Special Session

### The Future of Manitoba's Global Impact in HIV Research

**Time:** 09:45 – 11:15

**Location:** Meeting Rooms 1-2 & 11-13, Ground Level, North Building

**Attendance:** This session is open to all CAHR 2016 attendees.

The Manitoba HIV research community has been relatively small but it “hits above its weight” in terms of global impact. What does the future hold for how Manitoban and Canadian researchers can make a significant contribution internationally? In this multidisciplinary session, hear five of Manitoba's young researchers, from all 4 tracks, discuss the global impact of their research and where they view the best opportunities for maximal impact in the future lie.

#### Learning Objectives:

1. Outline the research initiatives from five new researchers;
2. Recognize the impact of Manitoba researchers on the global HIV research scene; and
3. Identify future strengths and opportunities in global HIV research.



**Presenters:**

**Dr. Thomas Murooka**, Assistant Professor, University of Manitoba, Winnipeg, MB

**Dr. Javier Mignone**, Associate Professor, University of Manitoba, Winnipeg, MB

**Dr. Yoav Keynan**, Assistant Professor, University of Manitoba, Winnipeg, MB

**Dr. Marissa Becker**, Associate Professor, University of Manitoba, Winnipeg, MB

**Dr. Lyle McKinnon**, Assistant Professor, University of Manitoba, Winnipeg, MB

**Plenary****Learning at the Front Lines: Community Rapporteur Session – CATIE-CAHR Learning Institute Participants**

**Time: 11:30 – 12:00**

**Location: Meeting Rooms 1-2 & 11-13, Ground Level, North Building**

Attendance: This session is open to all CAHR 2016 attendees.

The Rapporteur Session provides the highlights from the scientific program in each of the Conference's scientific tracks. This session draws out linkages and gaps, issues, and challenges that emerge from discussion and debate of the scientific evidence presented during the Conference. The Rapporteur Session is a valuable primer for participants who want to report back on the Conference to their organizations or communities.

**Plenary****Awards and Closing Remarks**

**Time: 12:00 – 12:30**

**Location: Meeting Rooms 1-2 & 11-13, Ground Level, North Building**

The New Investigator Awards will be presented to the outstanding new researcher in each of the four tracks based on their presentations in the concurrent oral sessions. The Closing is the opportunity to recognize the volunteers who worked in building CAHR 2016. The Host City for CAHR 2017 will also be announced.

Closing Remarks by **Dr. Michael Grant**, Past President, CAHR

Closing Remarks by **Dr. Marissa Becker** and **Dr. Keith Fowke**, Conference Co-Chairs.

# Program

## Monday, May 16

### Ancillary Event

## Canadian AIDS Society – Forum, Members' Caucus and Annual Meeting

**Location: Delta Winnipeg**

Host: Canadian Aids Society

Attendance: By invitation only.

This year the Canadian AIDS Society is pleased to host its Forum, Members' Caucus and Annual Meeting as an ancillary CAHR event in Winnipeg between May 16-18, 2016. Both events provide an opportunity to share information, discuss new ideas, contribute to policy development and renew acquaintances.

### **May 16: People Living with HIV Forum: 09:00 – 17:00**

The PLWHIV Forum (Forum) of the Canadian AIDS Society (CAS) is intended to be a means to enable people living with HIV (PLWHIV) to participate in creating the vision for their future. Open exclusively to PLWHIV, the Forum offers an excellent opportunity to network with others from across Canada and to set priorities for the community-based AIDS movement.

Delegates of the Forum will elect their regional PLWHIV Directors to any vacant positions on the CAS Board. In addition, resolutions arising from the Forum are sent to the Board of Directors to help advise and guide the ongoing work of the Canadian AIDS Society. All delegates are encouraged to run for any vacant PLWHIV position on the Canadian AIDS Society's Board of Directors.

### **May 17: Members' Caucus: 09:00 – 17:00**

The Members' Caucus follows on May 16. This meeting is open to any delegates of CAS members and associate organizations.

### **May 18: CAS Annual Meeting: 09:00 – 12:00**

The Canadian AIDS Society's Annual Meeting (AM) is open to all delegates as well as the general public. It is an excellent opportunity to network with delegates of the 80+ member and associate organizations of CAS, and to review the strategic direction of, and set priorities for, the community-based AIDS movement in Canada.

# Sponsoring Organizations' Profiles

## Platinum



### Gilead Sciences Canada

[www.gilead.ca](http://www.gilead.ca)

Gilead Sciences Canada is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, serious respiratory and cardiovascular conditions, cancer and inflammation.

Thanks to great advancements in medicine and education, HIV patients are now living longer. But as they age, this generation of survivors will face additional health issues. That's why creating new therapies remains our priority. We're committed to introducing the next generation of HIV therapies.



### ViiV Healthcare ULC

[www.viivhealthcare.com](http://www.viivhealthcare.com)

ViiV Healthcare Canada works to provide treatment, research and support to people affected by HIV/AIDS. We are committed and engaged to fighting HIV/AIDS by providing quality products, services and programs, as well as building partnerships with all of our stakeholders.

ViiV Healthcare in Canada is part of ViiV Healthcare, a global specialist HIV company established in 2009 by combining the power and expertise in the management of HIV from both GlaxoSmithKline (GSK) and Pfizer. Following a long-term collaboration on the joint development of several novel integrase inhibitors, we were joined by Shionogi, in 2012.

We currently have a portfolio of 12 HIV treatments and, since we are 100% focused on HIV/AIDS, we have a long-term vision

when investing in our new medicines in development. We aim to be the best partner for the long-term health of HIV patients.

ViiV Healthcare's Canadian operations are headquartered in Laval, Quebec. For further information on ViiV Healthcare, please visit [www.viivhealthcare.ca](http://www.viivhealthcare.ca).

## Silver



### Canadian Institutes of Health Research [www.cihr-irsc.gc.ca](http://www.cihr-irsc.gc.ca)

The Canadian Institutes of Health Research (CIHR) is the Government of Canada's health research investment agency. CIHR's mission is to create new scientific knowledge and a strengthened health care system for Canadians. CIHR provides leadership and support to health researchers and trainees across Canada. [www.cihr-irsc.gc.ca](http://www.cihr-irsc.gc.ca)

The CIHR HIV/AIDS Research Initiative is responsible for the management and oversight of the research components of two major Government of Canada initiatives in HIV/AIDS, the Federal Initiative to Address HIV/AIDS in Canada and [www.chvi-icvv.gc.ca/](http://www.chvi-icvv.gc.ca/) Canadian HIV Vaccine Initiative. These initiatives provide \$22.5M annually to support researchers and trainees in HIV/AIDS research.



### Merck Canada [www.merck.ca](http://www.merck.ca)

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information about our operations in Canada, visit [www.merck.ca](http://www.merck.ca) and connect with us on YouTube.

## Bronze

abbvie

**AbbVie**[www.abbvie.com](http://www.abbvie.com)

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs more than 26,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit [www.abbvie.ca](http://www.abbvie.ca). Follow @abbvie on Twitter or view careers on our [www.facebook.com/abbviecareers](https://www.facebook.com/abbviecareers) and [LinkedIn.com/company/abbvie](https://www.linkedin.com/company/abbvie) page.



the CTN  
CIHR Canadian  
HIV Trials Network

le Réseau  
Réseau canadien  
pour les essais VIH des IRSC

**CIHR Canadian HIV Trials Network**[www.hivnet.ubc.ca](http://www.hivnet.ubc.ca)

The CTN is a Canada-wide partnership of researchers, caregivers, governments, health advocates, the innovative pharmaceutical and biotechnology industry, and people living with HIV who are committed to developing treatments, preventions and a cure for HIV and related health conditions, through the conduct of scientifically sound and ethical trials. Established in 1990, the CTN is funded by CIHR, and jointly sponsored by the University of British Columbia and St. Paul's Hospital (Providence Health Care) in Vancouver.

# Notes

A series of horizontal dotted lines for taking notes, spanning the width of the page below the 'Notes' header.

## Table des matières

L'ACRV remercie ses partenaires et ses commanditaires .....	54
Glossaire des termes et acronymes .....	55
Bienvenue au congrès de l'ACRV 2016 .....	56
Message du président de l'ACRV .....	56
Message des coprésidents du congrès.....	57
Merci aux bénévoles .....	58
Comités de l'ACRV .....	58
Prix et bourses de l'ACRV 2016 .....	60
Information sur le congrès .....	63
Exposition .....	68
Programme .....	69
Mercredi 11 mai .....	69
Jeudi 12 mai .....	70
Vendredi 13 mai.....	81
Samedi 14 mai.....	91
Dimanche 15 mai.....	102
Lundi 16 mai.....	104
Organisations appuyant le congrès .....	105
Exposés oraux.....	109
Vendredi 13 mai .....	112
Samedi 14 mai .....	126
Affiches .....	141
Liste des auteurs .....	217
Congrès de l'an prochain.....	245
Plan du centre-ville .....	246
Plan des lieux .....	Troisième de couverture
Aperçu du programme .....	Couverture arrière

Association canadienne de recherche  
sur le VIH  
236 rue Metcalfe, Poste 302  
Ottawa, ON K2P 1R3  
Courriel : [info@cahr-acrv.ca](mailto:info@cahr-acrv.ca)  
Téléphone : 613-747-2465  
[www.cahr-acrv.ca](http://www.cahr-acrv.ca)



## L'ACRV remercie ses partenaires et ses commanditaires

### Platine

Gilead Sciences Canada  
ViiV Soins de santé ULC

### Argent

Instituts de recherche en santé du Canada  
Merck Canada

### Bronze

AbbVie  
Réseau canadien pour les essais VIH des IRSC

### Donateurs

Canadian Guidelines on HIV PrEP & nPEP  
Canadian Heritage / Patrimoine canadien  
CANFAR  
CANOC  
National Collaborating Centre for Infectious Diseases (NCCID)  
Ontario HIV Treatment Network  
Research Manitoba  
University of Manitoba

### Avec le soutien de

Air Canada  
Bedrocan  
CATIE  
CHVI Alliance Coordinating Office  
Hilary Druxman  
Hologic Canada  
Pendopharm  
Public Health Agency of Canada  
The Québec Antiretroviral Therapeutic Drug Monitoring Program  
TheraTechnologies  
Tourism Winnipeg  
WestJet



## Glossaire des termes et acronymes

- APHA** – Aboriginal Persons Living with HIV/AIDS (organisme servant les Autochtones vivant avec le VIH/sida)
- ARV** – Antirétroviral (médicament)
- ASPC** – Agence de la santé publique du Canada
- CCC** – Conseil consultatif communautaire
- CDC** – Centers for Disease Control and Prevention (États-Unis)
- CER** – Comité d'éthique de la recherche
- CV** – Charge virale
- ECR** – Essai contrôlé randomisé
- ÉIG** – Événement indésirable grave
- GIPA** – Participation plus importante des personnes vivant avec le VIH/sida
- GLBT** – Gais, lesbiennes, bisexuels et transgenres
- HAART** – Traitement antirétroviral hautement actif
- HARSAH** – Hommes ayant des relations sexuelles avec d'autres hommes
- ICVV** – Initiative canadienne de vaccin contre le VIH
- IO** – Infection opportuniste
- IRSC** – Instituts de recherche en santé du Canada
- ITS** – Infections transmissibles sexuellement
- NTP** – Nouvelles technologies de prévention
- OC** – Organisme communautaire
- ONG** – Organisation non gouvernementale
- ONUSIDA** – Programme commun des Nations Unies sur le VIH/sida
- OSS** – Organisme de services liés au sida
- PDA** – Assistant numérique personnel
- PNUCID** – Programme des Nations Unies pour le contrôle international des drogues
- PNUD** – Programme des Nations Unies pour le développement
- PPE** – Prophylaxie post-exposition
- PrEP** – Prophylaxie préexposition
- PRFM** – Pays à revenu faible et moyen
- PTME** – Prévention de la transmission du VIH de la mère à l'enfant
- PVVIH/sida** – Personnes vivant avec le VIH/sida
- QV** – Qualité de vie
- SIDA** – Syndrome d'immunodéficience acquise
- SIRI** – Syndrome inflammatoire de reconstitution immunitaire
- TAR** – Traitement antirétroviral
- TB-MR** – Souches multirésistantes de bacille tuberculeux
- TDO** – Traitement directement observé
- TEC** – Transfert et échange de connaissances
- TIS** – Travailleur de l'industrie du sexe
- TME** – Transmission
- UDI** – Utilisateur de drogues injectables
- VHC** – Virus de l'hépatite C
- VIH** – Virus de l'immunodéficience humaine
- VPH** – Papillomavirus

# Bienvenue au congrès de l'ACRV 2016

## Message du président de l'ACRV



**Dr Michael Grant**

Il y a vingt-cinq ans avait lieu à Montréal le premier Congrès annuel canadien de recherche sur le VIH/sida. Tout comme maintenant, l'événement était organisé par l'Association canadienne de recherche sur le VIH, qui venait tout juste de naître. De nos jours, la tradition se poursuit et le Congrès a eu lieu dans tous les fuseaux horaires, de Victoria à St. John's, au long des trois dernières décennies.

Tant de choses ont changé au cours du dernier quart de siècle. Sur le plan logistique, ce qui était au départ une petite réunion annuelle de scientifiques est devenue un congrès rassemblant de 800 à 900 congressistes, composé de chercheurs de tous les piliers de la recherche, de membres des collectivités touchées, d'étudiants, de responsables de l'élaboration des politiques, de délégués étrangers et d'autres parties intéressées. Sur le front communautaire, le visage de l'épidémie n'a cessé de changer, affectant gravement la vie de populations différentes, surtout marginalisées. Par ailleurs, sur le front de la recherche, de nombreux progrès sont intervenus, effectuant des percées vers la victoire contre la maladie, de découvertes sur les complexités biomédicales du virus à l'élaboration d'approches cliniques de pointe pour traiter le VIH et jusqu'aux diverses stratégies nouvelles visant à réduire les risques pour les personnes et les collectivités.

Même si beaucoup de choses ont changé, la pertinence de l'ACRV et de son Congrès annuel demeure d'actualité, tout autant qu'il y a 25 ans. À titre d'exemple, on recense chaque année au Canada des milliers d'infections nouvelles et le nombre de personnes vivant avec le VIH dans notre pays augmente. Selon l'Agence de la santé publique du Canada, 70 000 personnes au pays vivaient avec le VIH à la fin de 2011 et plus de 3 000 nouvelles infections sont recensées chaque année. Globalement, au-delà de 36,9 millions de personnes, soit l'équivalent de la population du Canada, vivaient avec le VIH en 2014, selon la statistique de l'Organisation mondiale de la santé.

Même si nous avons beaucoup accompli, il est évident qu'il reste beaucoup plus à faire. En regardant vers l'avenir, l'ACRV conservera sa pertinence, comptant sur ce qui est devenu la marque de l'association, soit l'enthousiasme, l'engagement commun et l'immense volonté de ses membres d'apprendre les uns des autres. Nous espérons que vous apprécierez tous les instants de l'ACRV 2016 et que vous y trouverez de précieuses expériences d'apprentissage.

## Message des coprésidents du congrès



CONGRÈS DE  
L'ACRV  
2016

*Dr Marissa Becker*    *Dr Keith Fowke*

C'est avec plaisir que nous vous accueillons à Winnipeg et que nous adressons nos félicitations à l'ACRV pour son 25<sup>e</sup> Congrès annuel canadien de recherche sur le VIH/sida. Depuis un quart de siècle, les chercheurs canadiens font la différence dans la prévention des nouvelles infections au VIH, améliorant les traitements et les résultats pour les personnes vivant avec le VIH et œuvrant afin de créer un environnement soutenant, respectueux et sans stigmates pour toutes les personnes à risque de contracter une infection au VIH. Le Congrès annuel de l'ACRV est l'endroit où nous nous rassemblons pour partager nos difficultés, nos succès, nos échecs et réfléchir sur les prochaines étapes. Nous pouvons être fiers des progrès accomplis, mais tous conviendront qu'il reste beaucoup plus à faire pour atteindre notre but global, éradiquer l'épidémie de VIH.

À cette fin, le thème du congrès de cette année est « Réaliser notre potentiel : Du local au mondial et retour », qui fait ressortir le leadership des chercheurs canadiens et de leurs partenaires au Canada et à l'échelle mondiale pour relever les défis auxquels nous faisons face pour lutter contre l'épidémie de VIH. Pour que notre objectif d'éliminer le VIH devienne réalité, nous devons agir au niveau local, quel que soit l'endroit que désigne le mot « local », et partager les leçons que nous avons retenues avec la collectivité mondiale, car nous apprenons également des chercheurs de tous les autres pays. Le VIH/sida demeure un défi de taille et il faut une approche collective si nous voulons accélérer les progrès vers l'élimination du VIH.

Cette année est celle du plus grand nombre d'abrévés jamais présentés à un congrès de l'ACRV, soit 504; il est évident qu'il y a beaucoup d'enthousiasme et d'animation sur la scène canadienne de la recherche sur le VIH. Cela a donné un programme scientifique d'une largeur et d'une profondeur exceptionnelles. Afin de stimuler encore plus la collaboration interdisciplinaire, nous avons mis au point quatre séances multidisciplinaires simultanées. Notre objectif est que, en assistant à une seule séance, vous serez à même de voir de quelle façon tel thème particulier est abordé par tous les paliers de notre entreprise de recherche.

Nous aimerions remercier tous ceux qui ont rendu possible le congrès de cette année, notamment notre comité du programme scientifique et le comité de gestion du congrès. Nous espérons que vous trouverez le congrès de cette année enrichissant et mobilisant, que vous reprendrez contact avec d'anciens amis et vous en ferez de nouveaux et que, même, vous aurez un peu de plaisir.

## Merci aux bénévoles

L'ACRV tient à remercier les membres bénévoles du comité du programme scientifique, les examinateurs des abrégés, le comité de sélection des boursiers, les coprésidents des séances, les conférenciers, les présentateurs, les rapporteurs, les examinateurs des dossiers de candidature aux prix ainsi que les bénévoles du congrès, qui ont offert leur temps et leur soutien pour nous aider à élaborer le programme du congrès de l'ACRV 2016. Leurs efforts et leur engagement ont contribué à la réussite du congrès.

## Comités de l'ACRV

### Conseil de direction de l'ACRV

Président :	Dr Michael Grant
Président désigné :	Dr Curtis Cooper
Ancien président :	Dr Robert Hogg
Trésorière :	Dr Carol Strike
Secrétaire :	Terry Howard
Directeur général :	Andrew Matejic

### Conseil d'administration de l'ACRV

Volet A : Sciences fondamentales	Dr Hélène Côté
Volet B : Sciences cliniques	Dr Shariq Haider
Volet C : Épidémiologie et sciences de la santé publique	Dr Marissa Becker
Volet D : Sciences sociales	Dr Stephanie Nixon
Représentante communautaire	Stephanie Smith

## Comité du programme scientifique

### Coprésidents du congrès

Dr Marissa Becker  
Dr Keith Fowke

### Coprésidents des volets

#### *Volet A : Sciences fondamentales*

Dr Blake Ball  
Dr Lyle McKinnon

#### *Volet B : Sciences cliniques*

Dr Yoav Keynan  
Dr Mona Loutfy

#### *Volet C : Épidémiologie et sciences de la santé publique*

Dr Tony Antoniou  
Dr Stephen Moses  
Dr John Wylie

#### *Volet D : Sciences sociales*

Dr Saara Greene  
Dr Javier Mignone

## Représentant communautaire

Mike Payne

## Médecin de famille

Dr Laurie Ireland

## Membres du comité consultatif du congrès

Dr Michael Grant

Andrew Matejic

## Coordination du congrès

Sea to Sky Meeting Management inc.

201, av. Bewicke, bur. 206

North Vancouver (BC) V7M 3M7 Canada

Tél. : 604-984-6455

Télééc. : 604-984-6434

[www.seatoskymeetings.com](http://www.seatoskymeetings.com)

[conference@cahr-acrv.ca](mailto:conference@cahr-acrv.ca)

Présidente :

Sarah Lowis, CMP, CMM

Directeur de projet :

Ian Holliday

Chargée de projet principale :

Donna Roberts, CMP

Responsable des inscriptions :

Katrina Sutela

## Évaluateurs des abrégés

### Volet A : Sciences fondamentales

Dr Jonathan Angel

Dr Rupert Kaul

Dr Blake Ball

Dr Lyle McKinnon

Dr Nicole Bernard

Dr Paul McLaren

Dr Mark Brockman

Dr Thomas Murooka

Dr Zabrina Brumme

Dr Mario Ostrowski

Dr Adam Burgener

Dr Ralph Pantophlet

Dr Eric Cohen

Dr Ken Rosenthal

Dr Andrés Finzi

Dr Ruey Su

Dr Michael Grant

### Volet B : Sciences cliniques

Dr Jean-Guy Baril

Dr Mark Hull

Dr Josée Brouillette

Dr Marina Klein

Dr Jared Bullard

Dr Neora Pick

Dr Adriana Carvalho

Dr Vanessa Poliquin

Dr Curtis Cooper

Dr Anita Rachlis

Dr Alexandra de Pokomandy

Nancy Sheehan

Dr Joanne Embree

Dr Darrell Tan

Dr Michelle Foisy

Dr Sharon Walmsley

Dr Troy Grennan

Dr Alex Wong

Dr Marianne Harris

Dr Mark Yudin

## Volet C : Épidémiologie et sciences de la santé publique

Dr Michel Alary  
 Dr Vanessa Allen  
 Dr Chris Archibald  
 Dr Paul Arora  
 Dr Shamara Baidooobonso  
 Dr Greta Bauer  
 Dr Ahmed Bayoumi  
 Dr Ann Burchell  
 Dr Todd Coleman  
 Dr Kathleen Deering  
 Dr Dara Friedman  
 Dr Jacquie Gahagan  
 Dr Mark Gilbert  
 Dr Gayatri Jayaraman  
 Dr Claire Kendall

Dr Susan Kirkland  
 Dr Lynne Leonard  
 Dr Viviane Lima  
 Dr Peggy Millson  
 Dr Tyler O'Neill  
 Dr Janet Raboud  
 Dr Beth Rachlis  
 Ayden Scheim  
 Souradet Shaw  
 Dr Jean Shoveller  
 Dr Doug Sider  
 Dr Ameeta Singh  
 Laura Thompson  
 Dr Mark Tyndall

## Volet D : Sciences sociales

Laura Bisailon  
 Dr Marleny Bonnycastle  
 Dr David Brennan  
 Dr Vera Caine  
 Lori Chambers  
 Dr Jacquie Gahagan  
 Dr Daniel Grace  
 Dr Trevor Hart  
 Dr Francisco Ibanez-Carrasco  
 Randy Jackson  
 Dr Carmen Logie  
 Dr Robert Lorway  
 Renée Masching

Dr Maria Nengeh Mensa  
 Paula Migliardi  
 Dr Kelly O'Brien  
 Doe O'Brien Teengs  
 Dr Joanne Otis  
 Dr Surita Parashar  
 Dr Tracey Prentice  
 Dr Gayle Restall  
 Dr Janice Ristock  
 Dr Sergio Rueda  
 Jody Shynkaruk  
 Dr Alison Symington  
 Dr Cathy Worthington

## Prix et bourses de l'ACRV 2015

L'ACRV offre des prix, des bourses d'études et une aide à l'inscription dans le but de promouvoir l'excellence en recherche, l'échange de connaissances et le mentorat auprès des différents groupes de chercheurs et des membres de la collectivité touchés par le VIH.

## Conférence Mark A. Wainberg

### Dr Stephen Moses

Professeur et chef du service des sciences de la santé communautaire à l'Université du Manitoba, Winnipeg, Manitoba

***Prévention du VIH: Du local au mondial et retour vers le futur***

## Bourses

### Bourses universitaires (général)

Deux bourses universitaires sont décernées à des chercheurs dans chaque volet en fonction des abrégés soumis. Ces bourses comprennent l'admission au congrès et les frais d'hébergement et de déplacement.

#### **Volet A : Bourses en sciences fondamentales**

Alexander Falkenhagen, Université de Toronto

Stephen McCarthy, Université de Toronto

#### **Volet B : Bourses en sciences cliniques**

Carmine Rossi, Université McGill

Élise Vuille-Lessard, Centre de santé de l'Université McGill

#### **Volet C : Bourses en épidémiologie et sciences de la santé publique (bourses du Dr Robert Remis)**

Ashley Lacombe-Duncan, Université de Toronto

Leigh McClarty, Université du Manitoba

#### **Volet D : Bourses en sciences sociales**

Elena Argento, BC Centre for Excellence in HIV/AIDS

Rachel Landy, Université Memorial de Terre-Neuve

### Bourses universitaires en recherche sur les vaccins

En partenariat avec le Bureau de coordination de l'Alliance (BCA) de l'Initiative canadienne de vaccin contre le VIH (ICVV), huit bourses de recherche sur les vaccins seront remises à des chercheurs selon les abrégés soumis. Les récipiendaires n'auront pas à défrayer leur hébergement, leur inscription et leur déplacement.

Simon de Montigny, Centre de recherche du CHU Sainte-Justine

Justen Hoffman Russell, Université de Toronto

Robert Omange, Université du Manitoba

Laurence Raymond Marchand, Université de Montréal

### Bourses communautaires

Dans le but de favoriser la présence et la participation de la collectivité au congrès, le programme de bourses communautaires de l'ACRV offre des bourses communautaires sous forme d'aide financière et de soutien à 10 personnes de diverses régions du Canada, ainsi que 10 bourses d'inscription à des participants de la collectivité de la région métropolitaine de Winnipeg. L'ACRV remercie l'Agence de la santé publique du Canada pour ces bourses.

Les récipiendaires des bourses communautaires sont les suivants :

Timothy Bartsch, East York (ON)

Brook Biggin, Edmonton (AB)

Alexandra De Kiewit, Montréal (QC)

Wesley G. Keewatin, Regina (SK)

Daniel Jonathan Laroche, Montréal (QC)

Matthew Loosemore, Iqaluit (NU)  
 Tendai Mpofu, Surrey (BC)  
 Lorraine O'Leary, Happy Valley-Goose Bay (NL)

## Bourses, soutien aux bourses et à l'inscription

L'ACRV est reconnaissante de la collaboration de ses autres partenaires appuyant la participation élargie au congrès de l'ACRV : CATIE pour la participation à l'Institut d'apprentissage; le Réseau canadien pour les essais VIH (IRSC) pour le transport des chercheurs. L'ACRV offre aux personnes personnellement touchées par le VIH/sida une importante réduction sur les frais d'inscription pour les encourager à participer au congrès.

## Prix Ruban rouge

Créé en 2001, le Prix Ruban rouge est remis chaque année par l'Association canadienne de recherche sur le VIH pour souligner la contribution exceptionnelle d'une personne à la cause du VIH/sida et à l'avancement de la recherche sur le traitement, la prévention et l'amélioration de la qualité de vie des personnes vivant avec cette maladie. Le Prix Ruban rouge sera remis au cours de la cérémonie d'ouverture du congrès de l'ACRV 2016, le jeudi 12 mai.

## Prix des nouveaux chercheurs

Chaque année depuis 1992, nous avons décerné les prix des nouveaux chercheurs afin de faire connaître les nouveaux chercheurs prometteurs dans les quatre volets de l'ACRV. Trois de ces quatre prix ont reçu le nom honorifique de personnes dont le dévouement exceptionnel à la cause de la recherche sur le VIH a aidé à dégager la piste pour de nombreuses percées scientifiques atteintes dans ce domaine pendant cette période : Sciences fondamentales, Kalpesh Oza (décédé le 4 juin 1995); Sciences cliniques, Brian Farlinger (décédé le 3 juillet 1995) et Épidémiologie et sciences de la santé publique, Randy Coates (décédé le 26 septembre 1991). Nombre des récipiendaires d'un prix des nouveaux chercheurs ont continué à apporter une contribution importante à la recherche sur le VIH/sida.

Les prix des nouveaux chercheurs seront remis à la fin du congrès, le dimanche 15 mai.

## Accusé de Réception

Le congrès de l'ACRV a lieu sur les terres d'origine des Premières Nations Anishinaabeg, Cri, Oji-cri, Dakota et Déné, et la patrie de la Nation Métis. Nous respectons les traités ratifiés sur ces territoires, reconnaissons les torts et les erreurs du passé et sommes résolus à aller de l'avant en partenariat avec les collectivités autochtones, dans un esprit de réconciliation et de collaboration.



# Information sur le congrès

## Inscription

### Horaire d'inscription

Le bureau des inscriptions est situé dans le hall Sud-Est, rez-de-chaussée, édifice Nord du Centre des congrès RBC et est ouvert aux heures suivantes :

Le jeudi 12 mai	8 h 30 à 19 h
Le vendredi 13 mai	7 h à 17 h
Le samedi 14 mai	8 h 30 à 17 h
Le dimanche 15 mai	8 h 30 à 12 h 30

### Porte-nom

Les porte-noms, qui permettent de vous identifier auprès de vos collègues, sont obligatoires pour entrer aux séances et aux événements organisés dans le cadre du congrès. Si vous perdez votre porte-nom, vous pourrez vous en procurer un autre au bureau des inscriptions situé dans la zone d'inscription du hall Sud-Est, rez-de-chaussée de l'édifice Nord du Centre des congrès RBC, au coût de 25 \$ pièce.

Les membres du conseil, les membres du comité du programme scientifique, les bénévoles et les membres du personnel seront identifiés par un ruban en couleur accroché à leur porte-nom. Les exposants porteront un porte-nom de couleur différente et n'auront pas accès aux séances du congrès.

### Soirée de gala – Billets préachetés

Les billets achetés d'avance pour la soirée de gala sont glissés à l'intérieur de votre porte-nom. Il est possible qu'il reste des billets supplémentaires. Si vous voulez acheter un billet pour vous (60 \$) ou un invité (125 \$), veuillez vous présenter au bureau des inscriptions situé dans la zone d'inscription du hall Sud-Est, rez-de-chaussée de l'édifice Nord du Centre des congrès RBC.

### Certificat de participation

Si vous avez demandé un certificat de participation, celui-ci sera inséré dans votre trousse d'inscription.

## Premiers soins et services médicaux d'urgence

En cas d'urgence médicale, le personnel de sécurité est muni des trousse de premiers soins pour les premières interventions. Nous disposons de trois défibrillateurs externes automatisés (DEA) dans l'immeuble (rez-de-chaussée, entrée York; deuxième étage, poste de sécurité, et troisième étage, entrée Est, salle A). Par ailleurs, vous pouvez demander à tout bénévole ou au personnel du bureau des inscriptions situé dans le hall Sud-Est, rez-de-chaussée de l'édifice Nord du Centre des congrès RBC, afin d'obtenir de l'aide. Si vous avez besoin de soins immédiats non critiques, la clinique sans rendez-vous la plus proche est le Medical Centre & Lab situé dans le centre commercial City Place adjacent au Centre des congrès RBC et accessible par la passerelle. L'adresse est : Unit 81, 333 avenue St. Mary. Le numéro de téléphone est le 204-942-0933. Le centre médical est ouvert de 8 h 30 à 16 h 30 du lundi au vendredi et est fermé les fins de semaine.

## Installations et services offerts

### Plan des étages

Vous trouverez le plan des étages du Centre des congrès RBC à la troisième page de couverture.

### Accessibilité

Le Centre des congrès RBC de Winnipeg offre aux visiteurs un environnement entièrement accessible pour que vous puissiez profiter facilement et sans tracas de toutes les activités dans le Centre des congrès et dans les environs.

- Accessibilité en fauteuil roulant
- Portes d'entrée coulissantes actionnées automatiquement par détecteur de mouvement
- Ascenseur passagers muni d'un panneau surélevé avec touches en Braille
- Places de parking désignées pour les personnes handicapées sur les deux paliers du parc de stationnement
- Escaliers mécaniques à tous les angles de l'immeuble
- Téléphone payant pour malentendants au rez-de-chaussée du hall Sud-Est
- Salles de toilettes avec cuvettes et éviers accessibles en fauteuil roulant
- Rampe d'accès pour fauteuils roulants et zone de sièges désignés au Théâtre Presentation du deuxième étage

- Passerelle à contrôle climatique reliant le Delta Winnipeg et d'autres lieux de divertissement, restaurants et hôtels dans tout le centre-ville de Winnipeg

## Centre d'affaires

Le centre Print Express & Copy est situé au deuxième étage de l'édifice Nord du Centre des congrès RBC et peut vous assister pour tous vos besoins ordinaires de copie et d'impression.

## Services à la clientèle

Le poste de sécurité du Centre des congrès RBC est situé au deuxième étage, édifice Nord, et le personnel peut répondre à vos questions sur l'établissement et la ville de Winnipeg. Deux guichets automatiques sont situés au deuxième étage de l'édifice Nord, près du haut de l'escalier proche de l'entrée principale.

## Accès à Internet

La connexion Wi-Fi gratuite est offerte dans le Centre des congrès RBC. Enclencher le Wi-Fi, sélectionner #TELUS network — ouvrir votre navigateur — inscrire votre adresse de courriel — accepter les conditions et cliquer sur Soumettre.

## Administration et services du congrès

### Langue du congrès

Les communications scientifiques au programme du congrès seront présentées dans la langue du conférencier. Les séances plénières et spéciales seront accompagnées de présentations PowerPoint en anglais et en français autant que possible.

### Protocole des salles de séances

Nous ferons tout en notre pouvoir pour que les séances commencent et se terminent aux heures indiquées. Nous demandons aux conférenciers et aux participants de respecter l'horaire du congrès.

### Téléphones cellulaires et autres appareils bruyants

Veuillez respecter les autres participants en éteignant ou en mettant en mode silencieux votre téléphone cellulaire ou tout autre appareil bruyant pendant les séances.

## Salle de préparation des conférenciers

La salle de préparation des conférenciers vise à aider tous les présentateurs, les présidents et les animateurs.

Lieu : Salle de réunion 17, rez-de-chaussée, édifice Nord, Centre des congrès RBC

Heures d'ouverture :

Le jeudi 12 mai	13 h à 17 h
Le vendredi 13 mai	7 h 30 à 15 h 30
Le samedi 14 mai	7 h 30 à 15 h 30

## Salon des personnes séropositives

Le salon des personnes séropositives a été aménagé pour aider les participants atteints du VIH ou du sida à tirer le plein parti du congrès. Il leur offre une aire de repos entre les séances, ainsi qu'un lieu calme et réconfortant propice à la discussion, au soutien des pairs et à la relaxation. Quelques rafraîchissements seront offerts gratuitement. Les participants pourront également y prendre leurs médicaments sur ordonnance en toute sécurité.

Lieu : Salon VIP – rez-de-chaussée, édifice Nord, Centre des congrès RBC

Heures d'ouverture :

Le jeudi 12 mai	14 h à 20 h
Le vendredi 13 mai	7 h 30 à 18 h
Le samedi 14 mai	7 h 30 à 18 h
Le dimanche 15 mai	8 h 30 à 12 h

## Service de messagerie

Vous pouvez afficher des messages manuscrits sur le babillard situé à côté du bureau des inscriptions dans la zone d'inscription du hall Sud-Est, rez-de-chaussée de l'édifice Nord du Centre des congrès RBC.

## Tableau d'affichage d'offres d'emploi de l'ACRV

L'ACRV tient un tableau d'affichage d'offres d'emploi destiné à différentes organisations à la recherche d'employés. Les employeurs sont invités à y afficher des avis de recrutement et des offres d'emploi. Le tableau d'affichage se trouve près du bureau des inscriptions situé dans la zone d'inscription du hall Sud-Est, rez-de-chaussée de l'édifice Nord du Centre des congrès RBC.

## App mobile ACRV 2016

L'ACRV a créé une application mobile pour le congrès de 2016, laquelle permet aux participants de consulter le programme et l'information relative au congrès. L'application est disponible pour les utilisateurs de iPhones, iPads et systèmes Android. Visitez votre magasin d'applications pour télécharger l'application ACRV 2016.

## Évaluation en ligne

L'ACRV tient à ce que le congrès soit agréable et instructif. Vos commentaires et vos suggestions sont essentiels pour nous aider à améliorer les prochains congrès. Nous vous enverrons un formulaire d'évaluation par courriel après le congrès. Veuillez remplir le formulaire d'évaluation en ligne. Veuillez noter que les évaluations sont confidentielles. Nous n'y recueillons aucun renseignement personnel.

## Sécurité

Les participants au congrès doivent toujours se présenter aux séances avec leur porte-nom pour obtenir l'autorisation d'y assister. Veuillez garder vos effets personnels en tout temps avec vous, car les salles du congrès ne seront verrouillées qu'en soirée, lorsqu'elles ne sont pas utilisées.

## Responsabilité

La responsabilité des organisateurs du congrès, quelle que soit la raison juridique, est limitée à la négligence grossière et à l'inconduite délibérée. La responsabilité des fournisseurs de services mandatés n'est pas touchée par ce qui précède. Les délégués du congrès de l'ACRV 2016 participent à l'événement à leurs propres risques. Les ententes verbales ne lient pas les parties – elles doivent être confirmées par écrit par l'ACRV ou l'un de ses représentants.

## Fumeurs

Il est interdit de fumer au cours des séances du congrès ou n'importe où à l'intérieur du Centre des congrès.

## Crédits de formation médicale

Le programme a été revu par le Collège des médecins de famille du Canada et attend l'accréditation finale de la section manitobaine du Collège.

Cet événement constitue une activité d'apprentissage en groupe agréée (section 1) conformément à la définition précisée par le programme de Maintien du certificat du Collège royal des médecins et chirurgiens du Canada, et approuvée par l'Association pour la microbiologie médicale et l'infectiologie Canada.



# Exposition

## Lieu et heures d'ouverture

**Lieu :** Salles 2FGH, deuxième étage, Édifice Nord

**Heures d'ouverture :**


Le jeudi 12 mai	19 h à 20 h
Le vendredi 13 mai	8 h 30 à 15 h 30
Le samedi 14 mai	8 h 30 à 15 h 30

## Exposants

Stand	N° de stand
ViiV Soins de santé ULC	1 et 14
Gilead Sciences Canada	2 et 3
Réseau canadien pour les essais VIH des IRSC	4
Merck Canada	5 et 6
Hologic Canada	7
Groupe de travail canadien sur le VIH et la réinsertion sociale	8
Société canadienne de santé internationale (SCSI)	9
Centre de collaboration nationale des maladies infectieuses (CCNMI)	10
Fondation canadienne de recherche sur le sida (CANFAR)	11
Bureau de coordination de l'Alliance de l'ICVV	12
Instituts de recherche en santé du Canada (IRSC)	13

Stands de table	N° de stand
Theratechnologies	TT1
Bedrocan Canada	TT2
Programme provincial de dosage des médicaments antirétroviraux	TT3
Focus Africa	TT4
Hilary Druzman Design	TT5
Grands 'n More	TT6
CATIE	TT7

## Plan d'étage de l'exposition



# Programme

## Mercredi 11 mai

### Événement connexe

#### **Assemblée générale annuelle (AGA) de l'Association canadienne des pharmaciens en VIH/SIDA**

**Heure : de 7 h 30 à 17 h**

**Location : Salle Charleswood A, deuxième étage, Delta  
Winnipeg**

Hôte : Association canadienne des pharmaciens en VIH/SIDA  
(CHAP)

Participation : Les pharmaciens présents à l'ACRV 2016 sont  
les bienvenus à cette séance. Préinscription requise.

L'Assemblée générale annuelle de l'Association se compose  
d'une combinaison de débats éducatifs, de partage des  
bonnes pratiques et de discussion sur les affaires courantes  
(notamment les affaires courantes de l'Association et les projets  
de recherche). Les pharmaciens qui assistent à l'ACRV 2016  
sont les bienvenus, mais le vote au volet des affaires courantes  
de la réunion est réservé aux membres du groupe de travail. Il y  
a habituellement 25 personnes environ et toutes les précisions  
sur la réunion sont retransmises par le serveur de liste de  
l'Association.

# Programme

## Jeudi 12 mai

### Aperçu

Sauf mention contraire, les activités se déroulent au centre des congrès RBC.

De 7 h 45 à 16 h	Atelier Atelier destiné aux nouveaux chercheurs dans le domaine du VIH	Salle Delta A, deuxième étage, Delta Winnipeg
De 8 h à 16 h	Événement connexe Assemblée annuelle du BCA de l'ICVV – La recherche-développement de vaccins contre le VIH au Canada : la place des vaccins dans le paysage de la prévention	Salle de réunion 3, rez-de-chaussée, Édifice Nord
De 8 h 30 à 12 h	Événement connexe Mobilisation pancanadienne pour élaborer une réponse efficace contre le VIH dans les collectivités africaines, caraïbéennes et noires	Salle Kildonan, deuxième étage, Delta Winnipeg
De 8 h 30 à 16 h	Événement connexe 3 <sup>e</sup> Forum international de la recherche sur le VIH et la réinsertion sociale – Le VIH et le vieillissement	Salle Delta B, deuxième étage, Delta Winnipeg
De 8 h 30 à 16 h	Événement connexe Réunion 2016 de l'équipe d'Engage	Salles de réunion 9-10, rez-de-chaussée, Édifice Nord
De 10 h à 16 h	Événement connexe La PrEP dans le contexte du travail du sexe : Possibilités et limites	Sunshine House, 646, avenue Logan, Winnipeg
De 12 h à 16 h	Événement connexe Atelier des candidats retenus de la composante 1 – Science de la mise en œuvre des IRSC	Salle Charleswood A, deuxième étage, Delta Winnipeg
De 13 h à 16 h	Événement connexe Transformer l'approche du Canada aux médicaments : dialogue national	Salle Delta C, deuxième étage, Delta Winnipeg
De 14 h à 16 h	Institut d'apprentissage CATIE-ACRV	Salle Kildonan, deuxième étage, Delta Winnipeg
De 16 h 15 à 17 h 15	Colloque Lignes directrices canadiennes sur la PrEP et la PPE dans le contexte du VIH	Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord
De 17 h 30 à 19 h	Séance plénière Ouverture du congrès et conférence Mark Wainberg : Prévention du VIH : Du local au mondial et retour vers le futur	Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord
De 19 h à 20 h	Événement social Réception d'accueil du congrès	Salles 2FGH, deuxième étage, Édifice Nord



## Programme

### Atelier

## Atelier destiné aux nouveaux chercheurs dans le domaine du VIH

**Heure : de 7 h 45 à 16 h, activité sociale en soirée**

**Salle : Delta A, deuxième étage, Delta Winnipeg**

Hôte : ACRV

Participation : Préinscription requise.

L'objectif global de l'atelier des nouveaux chercheurs dans le domaine du VIH est de faciliter le perfectionnement professionnel des aspirants chercheurs dans le domaine du VIH. La rencontre stimule la création de réseaux de pairs entre les nouveaux chercheurs travaillant dans des domaines de recherche connexes ou se chevauchant. De plus, une partie importante de la réunion est consacrée au mentorat, tant par des exposés officiels de scientifiques d'expérience que par des discussions, ainsi que de nombreuses interactions informelles. Les nouveaux chercheurs bénéficient de conseils sur les subventions et la rédaction de communications, l'exploitation d'un laboratoire ou d'un bureau et d'autres éléments clés de leur cheminement professionnel. Cet atelier est axé sur les compétences et conçu pour englober les quatre volets de recherche de l'ACRV (Sciences fondamentales, Sciences cliniques, Épidémiologie et sciences de la santé publique et Sciences sociales).

Cet atelier annuel rassemble les étudiants diplômés, les étudiants au doctorat, les boursiers postdoctoraux ainsi que les étudiants/internes/résidents en médecine, les stagiaires et autres nouveaux chercheurs du domaine du VIH. À la suite de l'atelier, il y a une soirée sociale afin que les aspirants chercheurs puissent établir des contacts avec d'autres nouveaux chercheurs dans un cadre agréable et détendu et interagir de façon plus personnelle avec les mentors. Comme les ateliers précédents, celui de 2016 sera fondé sur les quatre piliers de la recherche sur le VIH et comprendra des séances comme IRSC 101, Obtenir des fonds pour votre recherche, Possibilités de financement, Mentorat et Perfectionnement professionnel.

L'ACRV remercie ses partenaires, le BCA ICVV, les IRSC, CTN, l'ASPC et CANFAR, grâce auxquels cet atelier est possible.

## Événement connexe

### **Assemblée annuelle du BCA de l'ICVV – La recherche-développement de vaccins contre le VIH au Canada : la place des vaccins dans le paysage de la prévention**

**Heure : de 8 h à 16 h**

**Salle : Salle de réunion 3, rez-de-chaussée, Édifice Nord**

Hôte : Bureau de coordination de l'Alliance (BCA) de l'Initiative canadienne de vaccin contre le VIH

Participation : La séance est ouverte à tous les participants au congrès de l'ACRV 2016. Préinscription requise.

L'objectif de l'événement est d'instaurer une tribune à l'intention des intervenants en recherche développement sur un vaccin contre le VIH pour dégager et faire connaître leurs réalisations, leurs défis et leurs besoins dans le cadre des efforts du Canada pour mettre au point un vaccin anti-VIH sûr et efficace dans un paysage de prévention en évolution.

**Les objectifs principaux de la réunion sont les suivants :**

1. Développement d'un vaccin contre le VIH;
2. Préciser les défis que doivent surmonter les Canadiens lorsqu'ils travaillent avec des candidats-vaccin contre le VIH; et
3. Préciser ce dont les Canadiens ont besoin pour appuyer les efforts courants de recherche-développement sur un vaccin anti-VIH et la prévention.

Au programme, une discussion avec animateur sur le rôle des vaccins anti-VIH dans l'évolution du paysage de la prévention, ainsi que les perspectives pour débattre de l'avenir de la recherche-développement d'un vaccin anti-VIH au Canada. Il y aurait également des occasions de dialoguer au cours des trois tribunes-discussions (recherche d'un vaccin anti-VIH; mise au point d'un vaccin anti-VIH et science des programmes pour un vaccin anti-VIH), ainsi que des perspectives de réseautage informel au cours des pauses et du déjeuner. Parmi les présentateurs, mentionnons Ralph Pantophlet de l'Université Simon Fraser, Kelly MacDonald de l'Université du Manitoba, Peter Newman de l'Université de Toronto, Chil-Yong Kang de l'Université Western, Michael McLean de Plantform, Yegor Voronin de Global HIV Vaccine Enterprise, ainsi que Robert Reinhard et plusieurs autres.

## Événement connexe

### **Mobilisation pancanadienne pour élaborer une réponse efficace contre le VIH dans les collectivités africaines, caraïbéennes et noires**

**Heure : de 8 h 30 à 12 h**

**Salle : Kildonan, deuxième étage, Delta Winnipeg**

Host: Réseau national sur le VIH/sida et les communautés noires, africaines et caraïbéennes (CHABAC)

Attendance: Ouvert à tous les délégués au congrès.

Préinscription requise.

L'événement rassemblera des membres de la collectivité, des personnes vivant avec le VIH ou touchées par le VIH, des chercheurs et d'autres intervenants pour entamer un dialogue sur les besoins de la collectivité, les domaines communs de travail et les enjeux naissants dans la réponse contre le VIH dans les collectivités africaines, caraïbéennes et noires.

Au programme de la séance, une table ronde suivie par une discussion. Parmi les thèmes des exposés et discussions, mentionnons :

- L'engagement communautaire dans la prévention du VIH;
- L'expansion des approches de prévention du VIH : Enjeux propres aux populations africaines, caraïbéennes et noires au Canada; et
- Rôle du CHABAC pour intégrer la connaissance de la prévention du VIH dans la programmation concernant les Africains, Antillais et Noirs.

## Événement connexe

### **3<sup>e</sup> Forum international de la recherche sur le VIH et la réinsertion sociale – Le VIH et le vieillissement**

**Heure : de 8 h 30 à 16 h**

**Salle : Delta B, deuxième étage, Delta Winnipeg**

Hôtes : Canada-United Kingdom HIV and Rehabilitation Research Collaborative (CUHRRRC), en collaboration avec le Groupe de travail sur le VIH et la réinsertion sociale (GTCVRS) et l'ACRV.

Participation : Le forum est ouvert à tous les délégués au congrès. Préinscription requise.

L'objectif du forum est de faciliter le transfert et l'échange des connaissances sur la recherche concernant le VIH, le vieillissement et la réinsertion sociale, de créer de nouveaux partenariats sur le vieillissement et le VIH et de dégager les priorités de recherche nouvelles ou qui se dessinent dans le domaine.

Le forum sera composé d'une série de séances dynamiques et interactives en tribune discussion sur les éléments probants de la recherche et axées sur le VIH, le vieillissement et la morbidité multiple, les interventions en réinsertion sociale et les modèles de prestation des services. Le forum réunira des personnes vivant avec le VIH, des chercheurs, des cliniciens et des représentants des organismes communautaires du Canada, du Royaume-Uni et des États-Unis, qui a) s'exprimeront sur le rôle de la réinsertion sociale dans le contexte du VIH, du vieillissement et de la morbidité multiple, b) établiront le profil des modèles innovateurs de prestation des services de réinsertion sociale, c) feront ressortir les stratégies concrètes d'amélioration de l'accès aux services de réinsertion et d) dégageront les priorités de recherche nouvelles et naissantes dans le domaine. Pour en savoir plus, veuillez communiquer avec Ayesha Nayar (coordonnatrice du CUHRRC) à [cuhrrc@utoronto.ca](mailto:cuhrrc@utoronto.ca).

Remerciements : Le 3<sup>e</sup> Forum international de la recherche sur le VIH et la réinsertion sociale bénéficie d'une subvention du programme de planification et d'activités de dissémination des Instituts de recherche en santé du Canada (IRSC). Le CUHRRC tient à souligner le généreux soutien du Groupe de travail canadien sur le VIH et la réinsertion sociale [www.hivandrehab.ca](http://www.hivandrehab.ca).

## Événement connexe

### Réunion 2016 de l'équipe d'Engage

**Heure : de 8 h 30 à 16 h**

**Salle : Salles de réunion 9-10, rez-de-chaussée, Édifice Nord**

Hôte : Équipe de l'étude Engage

Participation : Sur invitation seulement.

Cet événement connexe constitue la deuxième réunion annuelle de l'équipe d'Engage. L'événement commencera par une période d'une demi-journée de trois heures axée sur les méthodes de recherche et le TEC dans leur travail avec les gais, bisexuels et autres hommes ayant des relations sexuelles avec des hommes. L'événement sera axé sur le renforcement des capacités de formation et de recherche des stagiaires de l'équipe d'Engage, des nouveaux chercheurs et des membres de la collectivité. La deuxième tranche de trois heures de la réunion sera une réunion globale pour l'ensemble de l'équipe d'Engage.

Voici ce dont il sera question :

1. Progrès accomplis à ce jour en collecte des données;
2. Modalités par lesquelles les membres de l'équipe peuvent présenter une fiche concept pour une collaboration avec l'étude globale;
3. Proposition d'idées d'études issues de l'étude globale (par exemple une communication future sur une analyse particulière);

4. Préparation de nouvelles propositions de subvention comme suivi aux idées d'études;
5. Interventions de prévention du VIH à lancer en essai pilote ou à titre d'épreuve fondée sur la recherche actuelle; et
6. Renforcement supplémentaire des capacités dans la recherche sur les HARSAH au Canada.

## Événement connexe

### La PrEP dans le contexte du travail du sexe : Possibilités et limites

**Heure : de 10 h à 16 h**

**Location: Sunshine House, 646, avenue Logan, Winnipeg**

Hôte : Dalla Lana School of Public Health, Université de Toronto, et Triple-X Workers' Solidarity Association of B.C.

Participation : La réunion est à huis clos, sur invitation seulement. Les participants seront des travailleurs du sexe ou alliés de l'ensemble du Canada.

L'unité d'étude sociale, comportementale et épidémiologique de la Dalla Lana School of Public Health de l'Université de Toronto, en partenariat avec Triple-X Workers' Solidarity Association of B.C., est bénéficiaire d'une bourse de l'Elton John AIDS Foundation et des Instituts canadiens de recherche en santé afin de tenir une rencontre fermée sur invitation pour amorcer une discussion et élaborer un plan concernant la PrEP dans le contexte du travail du sexe.

En collaboration avec Sunshine House de Winnipeg, la réunion rassemblera des personnes de l'ensemble du pays possédant de l'expérience en matière de travail du sexe, pour en savoir davantage sur la PrEP et discuter de la capacité et des besoins de recherche des travailleurs du sexe au Canada en ce qui a trait à la PrEP.

## Événement connexe

### Atelier des candidats retenus de la composante 1 – Science de la mise en œuvre des IRSC

**Heure : de 12 h à 16 h**

**Salle : Salle Charleswood A, deuxième étage, Delta Winnipeg**

Hôte : Instituts de recherche en santé du Canada (IRSC)

Participation : Il s'agit d'un événement fermé réservé aux candidats retenus dans une occasion de financement des IRSC.

L'initiative de recherche sur le VIH/sida des Instituts de recherche en santé du Canada (IRSC) et ses partenaires de l'initiative fédérale (Service correctionnel Canada, Santé Canada (Direction générale de la santé des Premières Nations

et des Inuits) et l'Agence de la santé publique du Canada) ont mis au point une **initiative sur la science de la mise en œuvre des programmes concernant le VIH**, pour combler les lacunes qui existent au niveau de l'application des données probantes dans la politique et les programmes de santé. L'objet de l'initiative est de réduire l'incidence des diverses maladies à transmission sexuelle ou sanguine (ITSS) dans les populations clés du Canada et entre celles-ci. **Composante 1 – les subventions d'adaptation** visent à appuyer l'élaboration d'équipes multisectorielles, le dégagement des interventions prometteuses ou efficaces et la mise au point d'un programme multifacette par l'adaptation des interventions.

Un chercheur et un utilisateur des connaissances de chaque équipe assisteront à l'atelier organisé par les IRSC et les partenaires.

#### **Objectifs d'apprentissage :**

1. Offrir aux participants l'occasion de présenter leurs plans de projet aux autres candidats retenus; et
2. Interagir avec d'autres équipes de projet et faciliter les synergies et les éventuelles collaborations nouvelles.

Les IRSC travailleront de concert avec les participants pour élaborer le programme.

### **Événement connexe**

## **Transformer l'approche du Canada aux médicaments : dialogue national**

**Heure : de 13 h à 16 h**

**Salle : Delta C, deuxième étage, Delta Winnipeg**

Hôte : Coalition canadienne des politiques sur les drogues/519/Manitoba Harm Reduction Network

Participation : Ouvert à tous les délégués au congrès.  
Préinscription requise.

Nous sommes à un tournant au Canada en ce qui a trait à la mise au point d'une politique globale sur les drogues fondée sur la science, la santé publique et les droits de la personne. C'est également un moment important concernant la politique internationale sur les drogues.

Cet événement connexe de l'ACRV portera sur les résultats de la Session extraordinaire de l'Assemblée générale des Nations Unies (UNGASS) sur les drogues qui se sera déroulée du 19 au 21 avril 2016 à New York. Cette session extraordinaire marquera le lancement d'un processus d'examen des réponses globales aux drogues au cours des trois prochaines années, soit de 2016 à 2019. En même temps, le gouvernement fédéral envisage une nouvelle stratégie nationale sur les drogues. Compte tenu du renouveau d'intérêt pour l'innovation et de nouvelles approches en matière de drogues à l'échelon fédéral, l'occasion se présente d'accélérer l'élaboration d'une réponse exhaustive du Canada aux drogues sur les plans de la santé

et des droits de la personne et d'imprimer un leadership dans les prochains pourparlers mondiaux à l'intérieur du système de l'ONU après l'UNGASS. Les participants étudieront ce qui suit :

- 1) le rôle du Canada dans la réforme du système international de lutte contre les drogues et 2) l'élaboration d'une approche exhaustive en matière de santé et de droits de la personne, axée sur la décriminalisation et la réglementation des drogues.

#### **Objectifs d'apprentissage :**

1. Prendre connaissance des résultats de la Session extraordinaire UNGASS des 19 au 21 avril 2016; et
2. Étudier deux volets de l'approche en matière de drogues sous l'éclairage de la santé et des droits de la personne : décriminalisation et réglementation des drogues.

### **Événement connexe**

#### **Institut d'apprentissage CATIE-ACRV**

**Dates/heures :** Jeudi, 14 h à 16 h; vendredi, 18 h 30 à 20 h 15; samedi 18 h 30 à 20 h 15

**Salle:** Kildonan, deuxième étage, Delta Winnipeg

Hôte : CATIE

Participation : Sur invitation seulement.

En partenariat avec l'ACRV, CATIE tiendra un institut d'apprentissage. Les participants de cette année, 25 boursiers communautaires de CATIE et de l'ACRV, travailleront afin d'imprimer une optique communautaire à la recherche présentée à l'ACRV. Jumelés à des éducateurs de CATIE, les participants sont répartis dans l'un quatre volets de recherche de l'ACRV. Les participants à l'Institut d'apprentissage se rencontreront chaque soir pour un débriefing et coopéreront à la production de la séance des rapporteurs communautaires sur l'apprentissage de première ligne, qui figure au programme du congrès de l'ACRV le dimanche 15 mai. La présentation sera par la suite mise à disposition pour être diffusée dans les régions par les participants pour faire rapport à leurs communautés.

### **Colloque**

#### **Lignes directrices canadiennes sur la PrEP et la PPE dans le contexte du VIH**

**Heure :** de 16 h 15 à 17 h 15

**Lieu:** Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord

Hôte : Réseau canadien pour les essais VIH des IRSC (RCE)

Participation : La séance est ouverte à tous les participants à l'ACRV 2016.

Dans le cadre de cette séance, on décrira l'élaboration et le contenu préliminaire de lignes directrices nationales fondées

sur les données probantes et subventionnées par les IRSC concernant ces méthodes de prévention du VIH fondées sur les antirétroviraux, en donnant l'occasion de consulter les intervenants.

#### **Objectifs d'apprentissage :**

1. Décrire la méthodologie qui sous-tend les lignes directrices canadiennes 2016 sur la PrEP et la PPE concernant le VIH;
2. Examiner les recommandations préliminaires à savoir qui devrait bénéficier de la PrEP/PPE;
3. Examiner les recommandations préliminaires sur la façon dont la PrEP/PPE devrait être administrée et laquelle administrer; et
4. Solliciter les opinions de la collectivité canadienne générale du VIH concernant les lignes directrices.

#### **Présentateurs :**

**Dr Darrell Tan**, chercheur clinicien, Hôpital St. Michael, Toronto (ON)

**Dr Mark Hull**, Centre d'excellence de la C.-B. sur le VIH/sida, Vancouver (BC)

**Deborah Yoong**, pharmacienne clinicienne, Hôpital St. Michael, Toronto (ON)

**Dr Réjean Thomas**, Clinique L'Actuel, Montréal (QC)

**Dr Cécile Tremblay**, professeure agrégée, Université de Montréal (QC)

## **Séance plénière**

### **Ouverture du congrès et conférence Mark A. Wainberg**

**Heure : de 17 h 30 à 19 h**

**Salles : Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord**

#### **Accueil**

Mot de bienvenue par le **Dr Marissa Becker** et le **Dr Keith Fowke**, coprésidents du congrès

Mot de bienvenue par le **Dr Ken Kasper**, directeur, programme VIH du Manitoba

Mot de bienvenue par le **Dr Michael Grant**, président de l'ACRV

Mot de bienvenue par le **Dr Marc Ouellette**, directeur scientifique, Institut des maladies infectieuses et immunitaires des IRSC



## Conférence Mark A. Wainberg

### *Prévention du VIH : Du local au mondial et retour vers le futur*

**Dr Stephen Moses**, Professeur et chef du service des sciences de la santé communautaire à l'Université du Manitoba, Winnipeg, Manitoba



*Le Dr Stephen Moses, médecin et chercheur, a apporté à l'échelle internationale des contributions majeures qui nous ont mieux fait comprendre les facteurs de risque biologiques et comportementaux d'infection au VIH, transposant les conclusions de la recherche dans la pratique. Il a été aux premières lignes de la recherche, intégrant dans les programmes des innovations d'envergure en matière de prévention du VIH : gestion et contrôle meilleurs des IST « classiques »; mise en place d'interventions éducatives ciblées par les pairs pour les populations à risque et circoncision masculine pour réduire la vulnérabilité des hommes au VIH. Le Dr Moses a été co-enquêteur principal des ECR de référence sur la circoncision masculine pour la prévention du VIH au Kenya, ce qui a aidé à étendre les services de circoncision masculine dans 14 pays de l'Est et du Sud de l'Afrique. Il est actuellement professeur et chef du département des sciences de la santé communautaire à l'Université du Manitoba. Il est l'auteur de plus de 230 publications examinées par les pairs et de plusieurs monographies et chapitres de livres et a fait de nombreux exposés lors de congrès nationaux et internationaux.*

Il fera un retour sur l'évolution des réactions efficaces de prévention du VIH, notamment en Afrique subsaharienne et en Inde. Il soulignera l'importance d'une programmation anti-VIH ciblée pour les populations clés ou à risque et particulièrement les travailleuses du sexe, les hommes qui ont des relations sexuelles avec d'autres hommes et les personnes utilisant des drogues injectables. L'avènement de nouvelles technologies de prévention du VIH, par exemple le traitement comme prévention et la prophylaxie préexposition, sera abordé dans ce contexte. La circoncision masculine figure également parmi les thèmes comme méthode de prévention du VIH pour la population en général, dans les pays où elle n'est pas une pratique traditionnelle et où la prévalence du VIH est élevée.

#### **Objectifs d'apprentissage :**

1. Saisir l'importance des programmes de prévention du VIH ciblés sur les populations clés, dans toutes les typologies d'épidémies de VIH;
2. Décrire certaines réussites en matière de programmes de prévention du VIH dans les milieux pauvres en ressources au cours des trois dernières décennies;
3. Reconnaître l'importance de rendre accessibles les nouvelles technologies de prévention du VIH et de les mettre à la disposition des populations clés et de créer la demande; et

4. Mieux saisir le rôle des programmes et services de circoncision des hommes pour répondre à l'épidémie de VIH dans l'Est et le Sud de l'Afrique et faire le point sur la situation.

## Présentation du prix Ruban rouge

Présentation du prix Ruban rouge 2016 à **Margaret Ormond** (Gestionnaire de projets spéciaux, Sunshine House, Winnipeg, MB) par le **Dr Marissa Becker** and **Dr Keith Fowke**, coprésidents du congrès.

## Événement social

### Réception d'accueil du congrès

**Heure : de 19 h à 20 h**

**Salles : 2FGH, deuxième étage, Édifice Nord**

La réception d'accueil du congrès de l'ACRV 2016 est ouverte à tous les participants, commanditaires, exposants et bénévoles. Des consommations et des hors-d'œuvre seront servis dans l'aire d'exposition et de présentation des affiches. La réception d'accueil est comprise dans les frais d'inscription au congrès.



# Programme

## Vendredi 13 mai

### Aperçu

Sauf mention contraire, les activités se déroulent au centre des congrès RBC.

Heure	Événement	Salle
De 7 h 45 à 9 h	Colloque Initiative canadienne de vaccin contre le VIH – Plénière sur la recherche vaccinale – Vaccins anti VIH : Maintenir l'élan	Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord
De 9 h à 9 h 45	Séance plénière Volet Sciences cliniques La PrEP a cinq ans : Croissance rapide!	Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord
De 9 h 45 à 10 h 30	Séance plénière Volet Sciences sociales La souveraineté de la preuve entre trois continents : Ethnographies critiques de la recherche communautaire sur le VIH	Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord
De 10 h 30 à 11 h	Exposition et présentation d'affiches Pause-rafraîchissements	Salles 2FGH, deuxième étage, Édifice Nord
De 11 h à 12 h 30	Séances simultanées de présentation orale des abrégés	
	Volet A : Sciences fondamentales Prévention	Salle de réunion 4, rez-de-chaussée, Édifice Nord
	Volet B : Sciences cliniques Soins cliniques	Salles de réunion 7-8, rez-de-chaussée, Édifice Nord
	Volet C : Épidémiologie et sciences de la santé publique Prévention du VIH dans les populations clés	Salle de réunion 3, rez-de-chaussée, Édifice Nord
De 12 h 30 à 14 h	Volet D : Sciences sociales Santé des Autochtones	Salles de réunion 9-10, rez-de-chaussée, Édifice Nord
De 12 h 30 à 14 h	Déjeuner-colloque Vivre plus longtemps et vivre bien avec le VIH : de nouveaux sommets pour vieillir en santé Préparé conjointement par les Instituts de recherche en santé du Canada (IRSC)	Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord
De 14 h à 15 h	Exposition et présentation d'affiches Pause-rafraîchissements en présence des auteurs Discussion sur les affiches – Sciences fondamentales et sciences cliniques	Salles 2FGH, deuxième étage, Édifice Nord
De 15 h à 17 h	Séances simultanées de présentation orale des abrégés	
	Volet A : Sciences fondamentales Immunologie	Salle de réunion 4, rez-de-chaussée, Édifice Nord
	Volet B : Sciences cliniques Coinfection	Salles de réunion 7-8, rez-de-chaussée, Édifice Nord
	Volet C : Épidémiologie et sciences de la santé publique Corrélats sociaux et structurels du risque et des soins touchant le VIH	Salle de réunion 3, rez-de-chaussée, Édifice Nord
De 17 h à 18 h 30	Volet D : Sciences sociales Recherches sur le VIH en sciences sociales : Approches et résultats innovateurs	Salles de réunion 9-10, rez-de-chaussée, Édifice Nord
De 17 h à 18 h 30	Colloque Mesure de la cascade nationale du traitement du VIH et les cibles 90-90-90 de l'ONUSIDA Préparé conjointement par : RCE, ROTV et PRATICS, CANOC, CANFAR	Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord
De 18 h 30 à 20 h 15	Institut d'apprentissage CATIE-ACRV	Salles de réunion 7-8, rez-de-chaussée, Édifice Nord
De 18 h 30 à 20 h	Assemblée Assemblée générale annuelle de l'ACRV et réception	Salle de réunion 3, rez-de-chaussée, Édifice Nord

## Programme

### Séance spéciale

## Initiative canadienne de vaccin contre le VIH – Plénière sur la recherche vaccinale – Vaccins anti VIH : Maintenir l'élan

**Heure :** de 7 h 45 à 9 h

**Salle :** Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord

Participation : La séance est ouverte à tous les participants à l'ACRV 2016.

La séance sera animée par le **Dr Jonathan Angel** de l'Institut de recherche de l'Hôpital d'Ottawa et le **Dr Michael Grant** de l'Université Memorial.

Parmi les conférenciers invités, mentionnons les **docteurs Marc Ouellette, Jamie Mann et Gary Kobinger**.

**Le Dr Marc Ouellette** est directeur scientifique de l'Institut des maladies infectieuses et immunitaires des IRSC et titulaire de la Chaire de recherche du Canada sur la résistance aux antimicrobiens, Centre de Recherche en Infectiologie, CHU de Québec et Université Laval. Le titre de son exposé est « **La situation actuelle et les perspectives futures de financement de la recherche de vaccins anti-VIH au Canada** ».

#### Objectifs d'apprentissage :

1. Décrire les investissements actuels et passés des IRSC dans la recherche de vaccins anti-VIH;
2. Résumer les résultats du récent atelier des IRSC sur les vaccins des IRSC tenu en mars à Ottawa; et
3. Explorer d'éventuels programmes futurs de vaccin anti-VIH.

**Le Dr Jamie Mann** est chargé d'enseignement au département de microbiologie et d'immunologie de l'Université Western Ontario. Le titre de son exposé est « **Réalisation d'un vaccin anti-VIH** ».

#### Objectifs d'apprentissage :

1. Voir de quelle façon la vaccination par ADN stimule les réponses des cellules B et T;
2. Voir comment les réponses humorales spécifiques à l'antigène sont générées dans les tissus muqueux; et
3. Explorer les voies alternatives de vaccination et les réactions immunitaires subséquentes.

**Le Dr Gary Kobinger** est directeur du centre de recherche sur les maladies infectieuses, Université Laval. Le titre de son exposé est « **Élaboration rapide d'un vaccin contre Ébola et autres pathogènes aux conséquences graves** ».

**Objectifs d'apprentissage :**

1. Préciser les diverses étapes nécessaires dans l'élaboration d'un vaccin, du laboratoire aux essais cliniques;
2. Voir la nécessité d'une démarche internationale à l'élaboration des vaccins; et
3. Mettre en lumière les défis liés à l'acquisition des ressources avant que le besoin soit à la porte.

**Plénière****Sciences cliniques****La PrEP a cinq ans : Croissance rapide!****Heure : de 9 h à 9 h 45****Salle : Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord****Présentateur : Dr Jared Baeten**

*Le Dr Baeten est vice-président et professeur au département de santé globale de l'Université de l'État de Washington. Ses recherches portent sur la prévention du VIH-1 et autres maladies à transmission sexuelle et englobent les essais cliniques d'interventions préventives originales, les études épidémiologiques des facteurs de risque de transmission du*

*VIH-1 et les recherches scientifiques sur le comportement et la mise en œuvre pour optimiser les modalités de prévention. Il a été coprésident de la Partners PrEP Study, essai clinique randomisé qui a permis de réunir des données probantes indiscutables attestant que la prophylaxie préexposition (PrEP ou PPE) protégeait contre l'acquisition du VIH-1; parmi ses autres travaux, mentionnons ASPIRE, essai de phase III multi-nations sur l'anneau vaginal de dapivirine pour la prévention du VIH-1 chez les femmes, des travaux en science de la mise en œuvre pour offrir les traitements antirétroviraux et la PrEP pour la prévention du VIH-1, ainsi que des études sur l'utilisation de la contraception hormonale comme facteur de risque du VIH-1.*

En 2010-2011, des essais cliniques majeurs ont établi pour la première fois que les antirétroviraux utilisés en prophylaxie préexposition (PrEP) pouvaient réduire considérablement et de façon sécuritaire le risque d'acquisition du VIH chez les personnes à risque de le contracter. Les cinq dernières années ont été marqués par des progrès appréciables dans la PrEP, notamment les études de démonstration prouvant que la mise en place effective de la PrEP dans divers cadres est possible, des recherches pour comprendre les pratiques exemplaires de prestation de la PrEP et l'élaboration de guides d'orientation normative sur la façon d'offrir la PrEP. La PrEP est un nouvel outil de prévention et fait ressortir une multitude

de perspectives et de défis : une intervention biomédicale (un comprimé ou d'autres approches) exigeant des comportements spécifiques pour une utilisation sûre et réussie (dépistage du VIH, interaction avec le système de santé, perception du risque, respect du traitement), son fonctionnement dans des contextes sociaux divers (sexe, stigmates, relations, pouvoir, genre) avec des répercussions d'envergure en matière de santé publique et de politique publique (coûts, compromis, cadres juridiques). La PrEP offre vraiment la promesse de contribuer à renverser la vague de l'épidémie mondiale de VIH, mais sa mise en œuvre commence à peine; le succès exigera encore d'autres efforts sur les plans scientifique, de l'éducation et de la défense.

### Objectifs d'apprentissage :

1. Mieux saisir le concept de prophylaxie préexposition (PrEP ou PPE) pour la prévention du VIH;
2. Débattre des données d'études marquantes sur les hommes qui ont des relations sexuelles avec des hommes et des hommes et des femmes hétérosexuels, y compris les essais cliniques et les évaluations de mise en œuvre; et
3. Voir les perspectives et les défis dans la prestation de la PrEP pour la prévention du VIH dans de multiples cadres.

## Plénière

### Sciences sociales

#### La souveraineté de la preuve entre trois continents : Ethnographies critiques de la recherche communautaire sur le VIH

Heure: de 9 h 45 à 10 h 30

Salle : Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord

Présentateur : **Dr Robert Lorway**



*Robert Lorway est professeur agrégé au centre de la santé publique mondiale de l'Université du Manitoba. Entre 2009 et 2014, il a obtenu la bourse de nouveau chercheur des IRSC en recherche sur la santé des populations/services VIH. Sa recherche porte sur les études sociales des interventions en santé mondiale conçues pour améliorer la vie des populations marginalisées. Son ouvrage scientifique intitulé *Namibia's Rainbow Project: Gay Rights in an African Nation*, fait ressortir les effets à long terme d'un programme relatif aux droits de la personne qui a par inadvertance assujéti la collectivité qu'il visait à libérer. Les engagements théoriques de Robert prennent leurs racines dans les projets de recherche appliquée menés avec les membres d'organismes communautaires en Afrique et en Asie.*

Son exposé portera sur les effets de la souveraineté de la preuve dans son interaction avec la mobilisation communautaire dans certaines régions du Canada, de l'Inde et du Kenya. En tant que mode complexe du pouvoir appliqué dans les interventions en matière de santé mondiale, la souveraineté de la preuve rétrécit progressivement les périmètres sur ce qui est réputé admissible comme « connaissance légitime » dans les milieux décisionnels, processus animé par la poursuite de l'efficacité. Les subventionnaires en matière de santé mondiale demandent de plus qu'on produise des formes mesurables de données probantes dans un effort pour suivre les résultats de santé et lier les responsables de la mise en œuvre des programmes dans des relations de responsabilité redditionnelle. Toutefois, à mesure que les organisations communautaires locales, les groupes de défense et les travailleurs en santé communautaire deviennent de plus en plus liés dans des systèmes de production de preuves, il faut se demander : quelles sont les conséquences, pour l'organisation au niveau communautaire, les mouvements sociaux de la base, les formes de résistance et les dissidents politiques? J'étudie cette question importante en ayant recours à trois études de cas contrastantes sur le plan temporel et géographique qui touchent des projets communautaires de recherche sur le VIH. Même si les traces peuvent remonter aux féministes, aux allersexuels et aux méthodologies théoriques anticoloniales dont le but est de perturber et de transformer les relations de pouvoir intrinsèques à la recherche classique, la recherche communautaire introduit par elle-même un ensemble de relations de pouvoir inégales et problématiques qui se répercutent dans les formes existantes et naissantes de souveraineté de la preuve. Ces études de cas aident à faire ressortir les dimensions importantes de la souveraineté de la preuve qui ont une importance en santé publique sur les plans de la théorie, de la politique et de l'application.

### **Objectifs d'apprentissage :**

1. Décrire la façon dont la manie des attestations altère le tissu social même des réseaux communautaires de solidarité sur le VIH de manière à pousser de côté par inadvertance les points de vue et les expériences des personnes très marginalisées.
2. Voir comment la techno-bureaucratization emprisonne les activistes du domaine du VIH dans des activités de production de preuves tout en élargissant de plus en plus la réglementation gouvernementale sur la société civile.
3. Constater comment le bio-expérimentalisme produit des collectivités d'essais cliniques qui répondent aux exigences de la logique axée sur le marché aux dépens des priorités de rayonnement communautaire.

## **Exposition et présentation d'affiches – Pause-rafraîchissements**

**Heure : de 10 h 30 à 11 h**

**Salles : 2FGH, deuxième étage, Édifice Nord**

## **Séances simultanées de présentation des abrégés**

**Heure : de 11 h à 12 h 30**

Les descriptions des séances commencent à la page 112.

## **Volet A : Sciences fondamentales : Prévention**

**Salle : Salle de réunion 4, rez-de-chaussée, Édifice Nord**

## **Volet B : Sciences cliniques : Soins cliniques**

**Salle : Salles de réunion 7-8, rez-de-chaussée, Édifice Nord**

## **Volet C : Épidémiologie et sciences de la santé publique : Prévention du VIH dans les populations clés**

**Salle : Salle de réunion 3, rez-de-chaussée, Édifice Nord**

## **Volet D : Sciences sociales : Santé des Autochtones**

**Salle : Salles de réunion 9-10, rez-de-chaussée, Édifice Nord**

## **Déjeuner-colloque**

## **Vivre plus longtemps et vivre bien avec le VIH : de nouveaux sommets pour vieillir en santé**

Le présent colloque a été préparé conjointement avec les Instituts de recherche en santé du Canada (IRSC) et conçu dans un souci d'intégrité, d'objectivité et d'équilibre scientifique.

**Heure : de 12 h 30 à 14 h**

**Salle : Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord**

**Participation :** La séance est ouverte à tous les participants à l'ACRV 2016.

La séance réunira des conférenciers du Canada et du Royaume-Uni qui débattront du rôle, données probantes incluses, de la réinsertion sociale dans le contexte du VIH, du vieillissement et des comorbidités, tout en formulant des réflexions sur les preuves issues des recherches et qui se dessinent dans le domaine. Les conférenciers donneront des



exemples concrets de réinsertion sociale dans la pratique clinique à l'endroit de personnes vieillissant avec le VIH au Canada, au R.-U. et en Afrique subsaharienne. La séance est une collaboration du Canada-United Kingdom HIV and Rehabilitation Research Collaborative (CUHRRC) et du Groupe de travail canadien sur le VIH et la réinsertion sociale (GTCVRS).

#### **Objectifs d'apprentissage :**

1. Résumer le rôle de la réinsertion sociale dans le contexte du VIH et du vieillissement, et exposer les données probantes à l'appui;
2. Décrire les données probantes justifiant les interventions de réinsertion sociale chez les personnes vieillissantes séropositives au VIH;
3. Décrire les modèles de prestation des services de réinsertion sociale;
4. Mieux connaître les points forts de la recherche et de la pratique en réinsertion sociale au Canada, au Royaume-Uni et en Afrique subsaharienne pour soutenir les personnes vivant avec le VIH et les aider à vivre bien et longtemps; et
5. Énoncer les stratégies visant à augmenter l'accès à la réinsertion sociale pour les personnes vieillissant avec le VIH.

#### **Présentateurs :**

**Dr Patricia Solomon**, professeure, Université McMaster, Hamilton (ON)

**Dr Richard Harding**, lecteur, institut Cicely Saunders, King's College, Londres (Royaume-Uni)

**Dr Stephanie Nixon**, chargée d'enseignement, Université de Toronto, Toronto (ON); directrice, International Centre for Disability and Rehabilitation (ICDR)

**Darren Brown**, physiothérapeute, Hôpital Chelsea and Westminster, Londres, Royaume Uni; vice-président, Rehabilitation in HIV Association (RHIVA), Royaume-Uni

**Chris Lucas**, membre de la collectivité, centre de santé communautaire Nine Circles, Winnipeg (MB)

**Kate Murzin**, spécialiste des programmes de santé, Groupe de travail canadien sur le VIH et la réinsertion sociale, Toronto (ON)

## **Exposition et présentation d'affiches – Pause-rafraîchissements en présence des auteurs**

**Heure : de 14 h à 15 h**

**Salles : 2FGH, deuxième étage, Édifice Nord**

Discussion sur les affiches :

Sciences fondamentales : 14 h 10 – 14 h 30

Sciences cliniques : 14 h 30 – 14 h 50

## Séances simultanées de présentation des abrégés

**Heure : de 15 h à 17 h**

Les descriptions des séances commencent à la page 118.

### **Volet A : Sciences fondamentales : Immunologie**

**Salle : Salle de réunion 4, rez-de-chaussée, Édifice Nord**

### **Volet B : Sciences cliniques : Coinfection**

**Salle : Salles de réunion 7-8, rez-de-chaussée, Édifice Nord**

### **Volet C : Épidémiologie et sciences de la santé : Corrélats sociaux et structurels du risque et des soins touchant le VIH**

**Salle : Salle de réunion 3, rez-de-chaussée, Édifice Nord**

### **Volet D : Sciences sociales : Recherches sur le VIH en sciences sociales : Approches et résultats innovateurs**

**Salle : Salles de réunion 9-10, rez-de-chaussée, Édifice Nord**

## Colloque

### **Mesure de la cascade nationale du traitement du VIH et les cibles 90-90-90 de l'ONUSIDA**

Le présent colloque a été préparé conjointement avec les RCE, ROTV et PRATICS, CANOC, CANFAR et conçu dans un souci d'intégrité, d'objectivité et d'équilibre scientifique.

**Heure : de 17 h à 18 h 30**

**Salle : Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord**

**Participation :** La séance est ouverte à tous les participants à l'ACRV 2016.

L'ONUSIDA a fixé pour 2020 un objectif d'envergure, à savoir que 90 % de toutes les personnes vivant avec le VIH connaîtront leur diagnostic; 90 % de toutes les personnes chez lesquelles on a diagnostiqué une infection au VIH recevront une thérapie antirétrovirale durable et que 90 % de toutes les personnes recevant une thérapie antirétrovirale connaîtront une suppression virale. Du point de vue national, nous devons savoir où se situent les populations canadiennes pour atteindre ces cibles 90-90-90. L'Agence de la santé publique du Canada (ASPC) prépare une cascade nationale afin de savoir dans quelle mesure les personnes vivant avec le VIH sont engagées dans le continuum des soins. Plusieurs régions canadiennes

ont établi des plans cibles 90-90-90 et analysent leur cascade de soins. Le présent colloque invite à une mobilisation critique concernant les approches, les perspectives et les répercussions du cadre en cascade et des cibles 90-90-90 à l'échelon régional et communautaire.

**Objectifs d'apprentissage :**

1. Examiner le cadre national de surveillance du VIH de l'ASPC et son application pour atteindre les cibles 90-90-90;
2. Préciser les régions du Canada aux épidémies de VIH contrastantes et évaluer la situation du pays concernant l'atteinte des cibles 90-90-90;
3. Souligner les capacités des organismes et leur apport à l'élaboration de mesures nationales de la cascade du VIH; et
4. Débattre des perspectives et des lacunes concernant les approches touchant à la fois la cascade nationale du VIH et les cibles 90-90-90.

**Présentateurs :**

**Président : Dr Marina Klein**, professeure de médecine, centre de santé de l'Université McGill, Montréal (QC)

**Conférenciers :**

**Claudia Rank**, épidémiologiste principale, ASPC, Ottawa (ON)

**Dr Réka Gustafson**, médecin hygiéniste, Vancouver Coastal Health, Vancouver (BC)

**Dr Ryan Meili**, médecin de famille, Clinique communautaire West Side, Saskatoon (SK)

**Dr Mark Gilbert**, directeur, épidémiologie appliquée, ROTV, Toronto (ON)

**Patti Tait**, employée de soutien, violence familiale, Centre d'amitié Indiens et Métis de Saskatoon (SK)

**Panélistes :**

**Dr Alex Wong**, médecin infectiologue, Regina Qu'Appelle Health Region, Regina (SK)

**Dr Ken Kasper**, médecin infectiologue, Université du Manitoba, Winnipeg (MB)

**Renée Masching**, Réseau canadien autochtone du sida, Halifax (NS)

**Institut d'apprentissage CATIE-ACRV**

**Heure : de 18 h 30 à 20 h 15 (suite le samedi)**

**Salle : Salles de réunion 7-8, rez-de-chaussée, Édifice Nord**

Suite de l'événement du jeudi.

## Assemblée générale annuelle et réception de l'ACRV

**Heure : de 18 h 30 à 20 h**

**Lieu : Salle de réunion 3, rez-de-chaussée, Édifice Nord**

**Président : Dr Michael Grant**

L'ACRV regroupe des chercheurs spécialisés en VIH/sida. Tous les membres de l'association peuvent participer à l'assemblée générale annuelle (AGA); toutefois, seuls les membres en règle peuvent exercer leur droit de vote à l'assemblée. Peut devenir membre quiconque fait de la recherche dans l'un ou l'autre des domaines visés (sciences fondamentales, sciences cliniques, épidémiologie et santé publique, sciences sociales et recherches communautaires), s'il satisfait aux critères d'admissibilité. Les personnes qui s'intéressent à la recherche sur le VIH/sida, notamment les étudiants et les stagiaires, peuvent adhérer à titre de membres associés.

À l'occasion de l'AGA, les membres se réunissent pour la présentation, par le conseil de l'ACRV, des activités et des états financiers de l'association. On y traite également de questions diverses. La liste des membres du comité directeur et du conseil de l'ACRV se trouve à la page 58.



# Programme

## Samedi 14 mai

### Aperçu

Sauf mention contraire, les activités se déroulent au centre des congrès RBC.

Heure	Événement	Salle
De 7 h 15 à 8 h 50	Colloque Petit-déjeuner colloque des boursiers postdoctoraux du Réseau canadien pour les essais VIH des IRSC	Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord
De 7 h 30 à 8 h 45	Événement connexe Réseau de recherche, d'évaluation et d'action du Manitoba sur les répercussions collectives du VIH – petit-déjeuner de réseautage	Salle Charleswood A, deuxième étage, Delta Winnipeg
De 9 h à 9 h 45	Séance plénière Volet Sciences fondamentales Peut-on inverser l'inflammation dans l'infection chronique au VIH?	Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord
De 9 h 45 à 10 h 30	Séance plénière Volet Épidémiologie et santé publique Mobilisation de la collectivité et interventions structurelles dans les programmes de prévention du VIH	Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord
De 10 h 30 à 11 h	Exposition et présentation d'affiches Pause-rafraîchissements	Salles 2FGH, deuxième étage, Édifice Nord
De 11 h à 12 h 30	Séances simultanées de présentation orale des abrégés	
	Séance simultanée de présentation des abrégés (multidisciplinaire) PrEP/PPE et autres nouvelles stratégies de prévention du VIH	Salle de réunion 3, rez-de-chaussée, Édifice Nord
	Séance simultanée de présentation des abrégés (multidisciplinaire) Le VIH dans le contexte mondial	Salles de réunion 9-10, rez-de-chaussée, Édifice Nord
	Séance simultanée de présentation des abrégés (multidisciplinaire) Le VIH dans les populations autochtones et locales	Salle de réunion 4, rez-de-chaussée, Édifice Nord
	Séance simultanée de présentation des abrégés (multidisciplinaire) La recherche communautaire sur le VIH	Salles de réunion 7-8, rez-de-chaussée, Édifice Nord
De 12 h 30 à 14 h	Déjeuner-colloque L'ART de gérer les co-infections VIH/VHC à l'époque des nouveaux antiviraux directs Préparé conjointement par Merck Canada	Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord
De 14 h à 15 h	Exposition et présentation d'affiches Pause-rafraîchissements en présence des auteurs Discussion sur les affiches – Épidémiologie et sciences de la santé publique et sciences sociales	Salles 2FGH, deuxième étage, Édifice Nord
De 15 h à 17 h	Séances simultanées de présentation orale des abrégés	
	Volet A : Sciences fondamentales Virologie	Salle de réunion 4, rez-de-chaussée, Édifice Nord
	Volet B : Sciences cliniques VIH et comorbidités	Salles de réunion 7-8, rez-de-chaussée, Édifice Nord
	Volet C : Épidémiologie et sciences de la santé publique Épidémiologie du VIH et des coinfections	Salle de réunion 3, rez-de-chaussée, Édifice Nord
	Volet D : Sciences sociales Recherche axée sur les programmes et politiques	Salles de réunion 9-10, rez-de-chaussée, Édifice Nord
De 17 h à 18 h 30	Séance spéciale simultanée : Prévention du VIH et engagement de soins pour les peuples autochtones	Salle de réunion 4, rez-de-chaussée, Édifice Nord
	Séance spéciale simultanée : L'activation immunitaire et les cellules cibles du VIH : État du savoir actuel, les grandes questions qui se posent et... pouvons-nous intervenir?	Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord
De 18 h 30 à 20 h 15	Institut d'apprentissage CATIE-ACRV	Salles de réunion 7-8, rez-de-chaussée, Édifice Nord
De 19 h à 1 h	Événement social Soirée de gala	Musée Canadien Pour Les Droits de la Personne

## Programme

### Colloque

## Petit déjeuner-colloque des boursiers postdoctoraux du Réseau canadien pour les essais VIH des IRSC

**Heure : de 7 h 15 à 8 h 50**

**Salle : Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord**

Hôte : Réseau canadien pour les essais VIH des IRSC (RCE)

Participation : La séance est ouverte à tous les délégués à l'ACRV 2016.

Le programme des boursiers postdoctoraux du Réseau canadien pour les essais VIH des IRSC offre des perspectives de carrière aux jeunes chercheurs cliniciens exceptionnels. Le programme facilite la recherche sur le VIH et les coinfections en offrant une aide financière aux candidats qui souhaitent rédiger un protocole de recherche et préparer et diriger leur propre essai. Depuis 1992, le RCE a accordé plus de 121 bourses de recherche à 74 personnes. On retrouve dans les anciens boursiers postdoctoraux de la dernière décennie certains des principaux chercheurs cliniques actuels du Canada sur le VIH. Les bourses d'études pour le cycle 2016-2017 sont offertes grâce aux contributions généreuses de l'industrie pharmaceutique et de CANFAR.

### Présentation 1

**Effet, sur la valeur adaptative virale, des mutations résistantes à la DTG dans les virus résistant à l'INTI/INNTI**

**Hanh Thi Pham**, PhD, boursier postdoctoral du RCE, centre SIDA de l'Université McGill, Institut de recherche médicale Lady Davis, Hôpital général juif, Montréal (QC)

### Présentation 2

**Interventions cliniques pour stimuler la santé immunitaire intestinale et réduire l'inflammation chez les personnes vivant avec le VIH**

**Connie J. Kim**, B.sc., M.sc., PhD, boursière postdoctorale du RCE, Hôpital General de Toronto (University Health Network), Toronto (ON)

### Présentation 3

**Optimisation de la prévention combinée contre le VIH chez les gais, bisexuels, bi-spirituels et autres hommes ayant des relations sexuelles avec des hommes**

**Nathan J Lachowsky**, PhD, boursier postdoctoral CANFAR/RCE, faculté de médecine, Université de la Colombie-Britannique et Centre d'excellence de la C.-B. sur le VIH/sida, Vancouver (BC)

## Présentation 4

### Examen de l'écart rural/urbain dans les résultats des soins contre le VIH en Colombie-Britannique

**Dr Lauren J. MacKenzie**, FRCPC, boursière postdoctorale RCE/BMS, Centre d'excellence de la C.-B. sur le VIH/sida, Vancouver (BC), programme de recherche clinique, Université du Manitoba, Winnipeg (MB), School of Population and Public Health, Université de la Colombie-Britannique, Vancouver (BC)

## Événement connexe

### Réseau de recherche, d'évaluation et d'action du Manitoba sur les répercussions collectives du VIH – petit-déjeuner de réseautage

**Heure : de 7 h 30 à 8 h 45**

**Salles : Salle Charleswood A, deuxième étage, Delta Winnipeg**

Hôte : Manitoba HIV Program et Centre de collaboration de recherche communautaire sur le VIH/sida du Manitoba

Participation : La séance est ouverte à tous les délégués à l'ACRV 2016. Préinscription requise.

Soyez des nôtres pour un petit-déjeuner de réseautage gratuit de l'ACRV organisé par le Manitoba HIV Program et le Centre de collaboration de recherche communautaire sur le VIH/sida du Manitoba. C'est un excellent moyen pour les chercheurs, évaluateurs, organismes communautaires et décideurs, membres des collectivités, groupes autochtones et autres intervenants du Manitoba délégués à l'ACRV 2016 d'établir des réseaux, d'échanger des idées et de fonder des collaborations et partenariats. Soyez des nôtres tandis que nous continuons à bâtir le réseau de recherche, d'évaluation et d'action sur les répercussions collectives du VIH au Manitoba.

## Séance plénière

### Sciences fondamentales

#### Peut-on inverser l'inflammation dans l'infection chronique au VIH?

**Heure : de 9 h 00 à 9 h 45**

**Salles : Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord**

Présentatrice : **Dr Netanya Sandler Utay**



*Le Dr Netanya Sandler Utay est chargée d'enseignement à la division des maladies infectieuses de la direction des sciences médicales de l'Université du Texas, à Galveston. Elle a obtenu son baccalauréat en sciences, Biophysique et biochimie moléculaire, à l'Université Yale et son diplôme de médecine du*

*collège de médecine Baylor. Elle a suivi une formation en médecine interne à l'Université de Washington et en maladies infectieuses aux National Institutes of Health des É.-U. En 2013, elle s'est jointe à l'UTMB. En plus des soins aux patients, le Dr Utay dirige un laboratoire et occupe la chaire de plusieurs études cliniques. Son travail porte sur les causes et les conséquences de l'inflammation dans l'infection chronique et aigüe au VIH.*

Des événements graves non liés au sida, notamment des maladies cardiovasculaires, hépatiques et rénales et des tumeurs malignes non liées au sida ont émergé comme causes principales de morbidité et de mortalité chez les personnes infectées par le VIH en combinaison avec un traitement antirétroviral (TAR). Les biomarqueurs de l'inflammation, de la coagulation et de la fibrose sont, toutes causes confondues, des prédicteurs indépendants clairs de la morbidité et de la mortalité chez les personnes infectées par le VIH, ce qui fait ressortir le rôle essentiel de l'inflammation chronique dans la maladie de l'organe terminal. L'inflammation chronique dans les infections au VIH traitées est probablement provoquée par la réplication résiduelle du VIH dans les réservoirs, un contrôle immunologique déprimé des coinfections, par exemple le cytomégalovirus, des lésions de la muqueuse intestinale avec translocation des produits microbiens, une fibrose tissulaire détruisant le créneau des lymphocytes, la thérapie antirétrovirale et les facteurs de risque classiques, pathologies qui sont présentes ou commencent au cours de l'infection aigüe au VIH. Les interventions visant à atténuer l'inflammation dans l'infection chronique au VIH n'ont pas connu de succès jusqu'à maintenant. Commencer la TAR suppressive au cours d'une infection aigüe au VIH réduit l'inflammation, mais ne l'élimine pas. Les interventions pour atténuer l'inflammation dans les infections aigües au VIH justifient plus amples études sur le plan de la sûreté et de l'efficacité, mais le dérèglement immunitaire amorcé dans l'infection aigüe au VIH pourrait être irréversible. Jusqu'à maintenant, la prévention du VIH est le seul moyen de protection contre les conséquences inflammatoires de l'infection au VIH.

#### **Objectifs d'apprentissage :**

1. Décrire les conséquences de l'inflammation chronique dans l'infection au VIH;
2. Énumérer les facteurs d'inflammation dans l'infection chronique au VIH; et
3. Explorer les approches mises à l'essai pour atténuer l'inflammation dans l'infection chronique au VIH.



## Séance plénière

### Volet Épidémiologie et santé publique

#### Mobilisation de la collectivité et interventions structurelles dans les programmes de prévention du VIH

Heure : de 9 h 45 à 10 h 30

Salle : Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord

Présentateur : **Dr James Blanchard**

Le Dr James Blanchard possède une maîtrise en santé publique et un PhD. Il est professeur et directeur du centre pour la santé publique globale à l'Université du Manitoba et titulaire de la Chaire de recherche du Canada en épidémiologie et santé publique globale.



*Mes recherches visent à savoir en quoi les caractéristiques des personnes, des collectivités et des grandes populations contribuent à la propagation locale et mondiale des maladies transmissibles et non transmissibles. Au cours des 15 dernières années, j'ai piloté la conception et la mise en œuvre de vastes programmes*

*de santé publique liés au VIH/sida et à la santé maternelle, néonatale et infantile en Inde, dans d'autres pays asiatiques et en Afrique. Je suis directement impliqué auprès des responsables de l'élaboration des politiques et des meneurs de la santé publique afin de traduire les connaissances et approches scientifiques dans la pratique et de relever l'efficacité et l'efficience des programmes de santé publique pour, notamment, améliorer la santé des populations défavorisées.*

Les lignes directrices mondiales de prévention du VIH dans les populations clés recommandent constamment des interventions structurelles afin de promouvoir la responsabilisation de la collectivité, réduire la violence et améliorer l'accès aux services. Par contre, l'intégration de ces interventions dans le programme de prévention du VIH demeure aléatoire, tant sur le plan de l'importance que de la conception. Mon exposé tirera parti de la recherche et de l'expérience de l'exécution de programmes dans divers contextes mondiaux pour faire ressortir les raisons pour lesquelles ces programmes sont essentiels et élaborer sur les éléments de preuve indiquant dans quelle mesure il est possible d'obtenir ainsi de meilleurs résultats. De plus, je traiterai des approches à la conception des interventions structurelles et de la mesure de leurs effets.

#### Objectifs d'apprentissage :

1. Faire ressortir la définition et les composantes des interventions structurelles dans les populations clés;
2. Souligner la nécessité de ces interventions; et

3. Obtenir un meilleur éclairage sur la façon dont les interventions structurelles peuvent être conçues, exécutées et évaluées.

## **Exposition et présentation d'affiches – Pause-rafraîchissements**

**Heure : de 10 h 30 à 11 h**

**Salles : 2FGH, deuxième étage, Édifice Nord**

## **Séances simultanées de présentation orale des abrégés**

**Heure : de 11 h à 12 h 30**

Les descriptions des séances commencent à la page 126.

### **Séance simultanée de présentation des abrégés (multidisciplinaire): PrEP/PPE et autres nouvelles stratégies de prévention du VIH**

**Salle : Salle de réunion 3, rez-de-chaussée, Édifice Nord**

### **Séance simultanée de présentation des abrégés (multidisciplinaire): Le VIH dans le contexte mondial**

**Salle : Salles de réunion 9-10, rez-de-chaussée, Édifice Nord**

### **Séance simultanée de présentation des abrégés (multidisciplinaire): Le VIH dans les populations autochtones et locales**

**Salle : Salle de réunion 4, rez-de-chaussée, Édifice Nord**

### **Séance simultanée de présentation des abrégés (multidisciplinaire): La recherche communautaire sur le VIH**

**Salle : Salles de réunion 7-8, rez-de-chaussée, Édifice Nord**

## **Déjeuner-colloque**

### **L'ART de gérer les co-infections VIH/VHC à l'époque des nouveaux antiviraux directs**

Le présent colloque a été préparé conjointement avec Merck Canada et conçu dans un souci d'intégrité, d'objectivité et d'équilibre scientifique.

**Heure : de 12 h 30 à 14 h**

**Salles : Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord**

Participation : La séance est ouverte à tous les délégués à l'ACRV 2016.

« *The ART of Managing HIV/HCV Co-infection in the Era of New DAAs* » (L'ART de gérer les co-infections VIH/VHC à l'époque des nouveaux antiviraux directs) est un programme interactif de cas visant à fournir aux cliniciens des conseils pratiques pour l'adaptation de la thérapie antirétrovirale (TAR) et des antiviraux directs pour le traitement réussi à long terme des patients ayant une coinfection au VIH/VHC. Ces débats feront ressortir les données les plus récentes des essais cliniques, soulignant l'importance de reconnaître et de surveiller les interactions inter-médicamenteuses ainsi que l'importance de la santé hépatique dans cette population spéciale de patients.

#### **Objectifs d'apprentissage :**

1. Établir la distinction entre les interactions médicamenteuses importantes en ce qu'elles s'appliquent aux patients coinfectés au VIH/VHC;
2. Préciser les répercussions de la santé hépatique chez les patients coinfectés au VIH-VHC; et
3. Orienter l'utilisation de la TAR adaptée et des antiviraux directs pour le succès à long terme du traitement chez vos patients.

**Dr Curtis Cooper**, professeur agrégé de médecine, Université d'Ottawa, directeur, Programme de lutte contre l'hépatite virale de l'Hôpital d'Ottawa, Ottawa (ON)

**Dr Brian Conway**, président et directeur médical, Centre des maladies infectieuses de Vancouver, Vancouver (BC)

**Dr Pierre Giguère**, spécialiste en pharmacie clinique, Hôpital d'Ottawa, Ottawa (ON)

**Dr Giada Sebastiani**, chargée d'enseignement en médecine, scientifique débutante au Centre de santé de l'Université McGill, Institut de recherche du Centre de santé de l'Université McGill, Montréal (QC)

## **Exposition et présentation d'affiches – Pause-rafraîchissements en présence des auteurs**

**Heure : de 14 h à 15 h**

**Salles : 2FGH, deuxième étage, Édifice Nord**

Discussion sur les affiches :

Épidémiologie et sciences de la santé  
publique : 14 h 10 – 14 h 30  
Sciences sociales : 14 h 30 – 14 h 50

## Séances simultanées de présentation orale des abrégés

**Heure : de 15 h à 17 h**

Les descriptions des séances commencent à la page 133.

### **Volet A : Sciences fondamentales : Virologie**

**Salle : Salle de réunion 4, rez-de-chaussée, Édifice Nord**

### **Volet B : Sciences cliniques : VIH et comorbidités**

**Salle : Salles de réunion 7-8, rez-de-chaussée, Édifice Nord**

### **Volet C : Épidémiologie et sciences de la santé publique : Épidémiologie du VIH et des coinfections**

**Salle : Salle de réunion 3, rez-de-chaussée, Édifice Nord**

### **Volet D : Sciences sociales : Recherche axée sur les programmes et politiques**

**Salle : Salles de réunion 9-10, rez-de-chaussée, Édifice Nord**

## Séance spéciale simultanée :

### **Prévention du VIH et engagement de soins pour les peuples autochtones**

**Heure : de 17 h à 18 h 30**

**Salles : Salle de réunion 4, rez-de-chaussée, Édifice Nord**

Participation : La séance est ouverte à tous les délégués à l'ACRV 2016.

Les Autochtones sont représentés de façon disproportionnée dans la population des personnes vulnérables au VIH et vivant avec le VIH au Canada et dans nombre de pays d'Amérique latine. Il faut des approches communautaires innovatrices et adaptées à la culture pour éviter les nouvelles infections et optimiser la santé de la collectivité hétérogène des Autochtones vivant avec le VIH. La séance offre un aperçu des stratégies efficaces de prévention du VIH chez les Autochtones et des succès de mobilisation des collectivités autochtones dans les initiatives liées aux soins relatifs au VIH, en faisant ressortir les éléments contextuels essentiels pour réussir.

#### **Objectifs d'apprentissage :**

1. Explorer les modèles de prévention du VIH chez les Autochtones et d'adhésion des Autochtones vivant avec le VIH à un programme de soins;

2. Souligner les obstacles culturels et sociopolitiques à la prévention et au traitement du VIH chez les Autochtones; et
3. Décrire les approches communautaires à l'exécution et à l'application pratique de la recherche chez les Autochtones.

#### **Panélistes :**

**Leona Star**, modératrice, agrégée de recherche, coordonnatrice régionale pour les Premières Nations du Manitoba de l'enquête régionale sur la santé des Premières Nations, de l'Enquête chez les Premières Nations, Nanaandawewigamig, secrétariat à la santé et aux affaires sociales des Premières Nations du Manitoba

**Jamie Reschny**, candidate au PhD, sciences de la santé, Université Northern British Columbia, Prince George (BC)

**Dr Earl Nowgesic**, chargé d'enseignement et directeur intérimaire du Waakebiness-Bryce Institute for Indigenous Health, école de santé publique Dalla Lana, Université de Toronto, Toronto (ON)

**Dr Carlos Rojas**, professeur, faculté nationale de santé publique, Dr Héctor Abad Gómez, Université de Antioquia, Medellín, Colombie

#### **Séance spéciale simultanée :**

### **L'activation immunitaire et les cellules cibles du VIH : État du savoir actuel, les grandes questions qui se posent et... pouvons-nous intervenir?**

**Heure : de 17 h à 18 h 30**

**Salles : Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord**

Participation : La séance est ouverte à tous les délégués à l'ACRV 2016.

L'un des objectifs de longue date de la recherche sur la transmission du VIH est de mieux comprendre de quelle façon les cellules cibles potentielles au site d'exposition au VIH jouent un rôle dans la diffusion du virus à partir des muqueuses et finalement dans l'établissement de l'infection au VIH. Au cours du traitement, le virus demeure latent dans un réservoir cellulaire qui est à la fois une cible des efforts pour trouver un remède contre le VIH et n'a été décrit que partiellement. Même si une cohorte encore plus appréciable de données est née d'une gamme diverse de systèmes expérimentaux, nombre de questions demeurent. Facteur plus important, il reste à voir de quelle façon cette connaissance sera traduite en programmes sûrs et efficaces de prévention du VIH. L'objectif de cette discussion en table ronde est d'offrir un aperçu des progrès dans ce domaine important en se souciant d'abord de ce qui se dessine et de la façon dont ces résultats peuvent être mis en pratique.

### **Objectifs d'apprentissage :**

1. Préciser pour quelle raison les cellules cibles des muqueuses et l'activation immunitaire sont importantes dans la transmission et la persistance du VIH;
2. Faire ressortir les points en souffrance dans la recherche sur les cellules cibles du VIH; et
3. Évaluer la situation actuelle concernant la mise en pratique de ces constatations dans quelque chose d'utilisable en clinique.

### **Panélistes :**

**Dr Thomas Hope**, Université Northwestern, Chicago, Illinois, É.-U.

**Dr Rupert Kaul**, Université de Toronto, Toronto (ON), Canada

**Dr Petronela Ancuta**, Université de Montréal, Montréal (QC), Canada

**Dr Nichole Klatt**, Université de l'État de Washington, Seattle, WA, É.-U.

**Dr Julie Lajoie**, Université du Manitoba, Winnipeg (MB), Canada

**Dr Lenine Liebenberg**, CAPRISA, Durban, Afrique du Sud

**Dr Adam Burgener**, Université du Manitoba, Winnipeg (MB), Canada

## **Institut d'apprentissage CATIE-ACRV**

**Heure : de 18 h 30 à 20 h 15**

**Salle : Salles de réunion 7-8, rez-de-chaussée, Édifice Nord**  
**Suite de l'événement du jeudi et du vendredi**



## Événement social

### Soirée de gala

**Heure : de 19 h à 1 h**

**Lieu : Musée canadien pour les droits de la personne, 85, Israel Asper Way, Winnipeg**

La soirée de gala aura lieu au Musée canadien pour les droits de la personne –, édifice des plus remarquables dans la silhouette de Winnipeg.

C'est le premier musée consacré uniquement à l'évolution, à la valorisation et à l'avenir des droits de la personne. Le Musée crée un contact inspirant avec les droits de la personne et invite les visiteurs dans une expérience immersive et interactive. Vous aurez l'occasion de visiter les expositions du Musée entre 19 h et 21 h.

Le menu du dîner se compose de stations réparties autour de la salle, où vous pourrez essayer différents mets qui, assurément, sauront réjouir votre palais.

L'orchestre JD & the Sunshine House Band donnera le signal des divertissements de la soirée. Cet orchestre est une collaboration entre musiciens et des personnes présentes dans la rue qui participent à la programmation de Sunshine House. Lorsque la soirée sera bien réchauffée, un disc-jockey prendra la scène et vous fera danser jusqu'à la nuit.

**Transport :** Si le temps le permet, l'endroit est à peu de distance de marche (environ 20 minutes) du Musée. Par contre, s'il fait mauvais ou que vous préférez garder vos pieds en bon état pour la danse, des navettes feront le trajet entre le Delta Winnipeg et le Musée, de 18 h 45 à 1 h du matin.

**Remarque :** Les participants et le ou les personnes qui les accompagnent doivent remettre leurs tickets d'entrée. Les tickets achetés au préalable sont glissés dans votre porte-nom. Il est possible qu'il reste des billets supplémentaires. Si vous souhaitez acheter des billets pour une personne inscrite (75 \$) ou un invité (125 \$), rendez-vous au bureau des inscriptions du foyer, au rez-de-chaussée du Centre des congrès.

# Programme

## Dimanche 15 mai

### Aperçu

Sauf mention contraire, les activités se déroulent au centre des congrès RBC.

Heure	Événement	Salle
De 9 h 45 à 11 h 15	Séance spéciale L'avenir du poids mondial du Manitoba dans la recherche sur le VIH	Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord
De 11 h 30 à 12 h	Séance plénière Séance des rapporteurs communautaires – Participants à l'Institut d'apprentissage CATIE-ACRV	Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord
De 12 h à 12 h 30	Séance plénière Remise des prix et mot de la fin	Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord

## Programme

### Séance spéciale

## L'avenir du poids mondial du Manitoba dans la recherche sur le VIH

**Heure : de 9 h 45 à 11 h 15**

**Salle : Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord**

Participation : La séance est ouverte à tous les participants de l'ACRV 2016.

La collectivité des chercheurs sur le VIH du Manitoba est relativement petite, mais « elle a du poids » en termes de répercussions mondiales. Que réserve l'avenir aux chercheurs manitobains et canadiens en termes de contribution importante à l'échelle internationale? Dans cette séance multidisciplinaire, vous entendrez six jeunes chercheurs manitobains des quatre volets de la recherche traiter des répercussions globales de leurs travaux et qui vous livreront leurs réflexions sur les domaines où les perspectives futures de répercussions maximales sont les meilleures.

#### Objectifs d'apprentissage :

1. Décrire les initiatives de recherche de cinq nouveaux chercheurs;
2. Souligner le poids des chercheurs manitobains sur la scène mondiale de la recherche sur le VIH; et
3. Dégager, pour l'avenir, les points forts les perspectives en recherche mondiale sur le VIH.



**Présentateurs :**

**Dr Thomas Murooka**, chargé d'enseignement, Université du Manitoba, Winnipeg (MB)

**Dr Javier Mignone**, professeur agrégé, Université du Manitoba, Winnipeg (MB)

**Dr Yoav Keynan**, chargé d'enseignement, Université du Manitoba, Winnipeg (MB)

**Dr Marissa Becker**, professeure agrégée, Université du Manitoba, Winnipeg (MB)

**Dr Lyle McKinnon**, chargé d'enseignement, Université du Manitoba, Winnipeg (MB)

**Séance spéciale****Séance des rapporteurs communautaires  
– Participants à l'Institut d'apprentissage  
CATIE-ACRV**

**Heure : de 11 h 30 à 12 h**

**Salles : Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord**

Participation : La séance est ouverte à tous les participants à l'ACRV 2016.

La séance des rapporteurs offre les faits saillants du programme scientifique dans chacun des volets scientifiques du congrès. Dans cette séance, on met en évidence les liens et les lacunes, les enjeux et les défis qui ressortent de la discussion et du débat sur les données scientifiques présentées au cours du congrès. La séance des rapporteurs est une occasion précieuse et originale pour les participants qui veulent, au retour, faire rapport sur le congrès à leur organisme ou à leur collectivité.

**Séance plénière****Remise des prix et mot de la fin**

**Heure : de 12 h à 12 h 30**

**Salles : Salles de réunion 1-2 et 11-13, rez-de-chaussée, Édifice Nord**

Les prix des nouveaux chercheurs seront présentés à des nouveaux chercheurs exceptionnels dans chacun des quatre volets d'après leurs exposés dans les séances orales simultanées. La cérémonie de clôture est l'occasion de souligner le travail des bénévoles qui ont travaillé pour réaliser l'ACRV 2016. Sera également annoncée la ville hôte de l'ACRV 2017.

Mot de clôture par le **Dr Michael Grant**, président sortant de l'ACRV

Mot de clôture par le **Dr Marissa Becker** et le **Dr Keith Fowke**, coprésidents du Congrès

# Programme

## Lundi 16 mai

### Événement connexe

## Société canadienne du sida – Forum, caucus des membres et assemblée annuelle

**Lieu : Delta Winnipeg**

Hôte : Société canadienne du sida

Participation : Sur invitation seulement.

Entre le 16 au 18 mai 2016, la Société canadienne du sida est heureuse de présenter sa Tribune des PVVIH, son Caucus des membres et son Assemblée annuelle comme événement connexe du 25<sup>e</sup> Congrès annuel canadien de recherche sur le VIH/sida qui se tiendra à Winnipeg. Chacun de ces trois événements offre d'excellentes occasions d'échanger de l'information, de discuter de nouvelles idées, de contribuer à l'élaboration des politiques et de renouer des liens.

### 16 mai 2016 | 9 h à 17 h : Tribune des PVVIH

La tribune des Personnes Vivant avec le VIH (PVVIH) offre l'occasion à celles-ci de participer à l'élaboration d'une vision de leur avenir. Accueillant exclusivement les PVVIH, cette Tribune est une excellente occasion de réseauter avec d'autres PVVIH de partout au Canada et d'établir des priorités pour le mouvement communautaire de lutte contre le sida.

Les participants à la Tribune élisent leurs représentants régionaux aux postes vacants du conseil d'administration de la SCS. De plus, les résolutions issues de la Tribune sont transmises au conseil aidant à éclairer et guider le travail de la SCS. Tous les participants sont encouragés à présenter leur candidature pour tout siège vacant destiné aux PVVIH au conseil d'administration de la SCS.

### 17 mai 2016 | 9 h à 17 h : le Caucus des membres

Le jour suivant, le Caucus des membres fait suite. Cette réunion est ouverte à tous les délégués des membres de la SCS et de ses organisations associées.

### 18 mai 2016 | 9 h à 12 h : L'Assemblée annuelle de la SCS

L'Assemblée annuelle de la Société canadienne du sida est ouverte à tous les délégués ainsi qu'au grand public. C'est une excellente occasion de réseauter avec des collègues d'organismes membres et associés de la SCS, d'examiner l'orientation stratégique de la SCS et d'établir les priorités pour le mouvement communautaire de lutte contre le sida.

# Organisations appuyant le congrès

## Platine



### Gilead Sciences Canada

[www.gilead.ca](http://www.gilead.ca)

Gilead Sciences Canada est une société biopharmaceutique axée sur la recherche dont l'objectif est de découvrir, mettre au point et commercialiser des médicaments novateurs dans des domaines dont les besoins médicaux sont insatisfaits. Nous nous employons à transformer et à simplifier les soins de santé pour les personnes atteintes de maladies menaçant le pronostic vital partout à travers le monde. Le portefeuille de produits et de médicaments au stade expérimental de Gilead englobe les traitements pour l'infection au VIH/SIDA, les troubles hépatiques, les affections respiratoires et cardiovasculaires graves, le cancer et l'inflammation. Grâce à de grandes avancées en médecine et en éducation, les patients atteints du VIH vivent maintenant plus longtemps. Mais en vieillissant, cette génération de survivants fera face à de nouvelles problématiques de santé. C'est pour cette raison que la mise au point de nouveaux traitements demeure notre priorité. Nous sommes engagés à présenter la prochaine génération de traitements contre l'infection au VIH.



### ViiV Soins de santé ULC

[www.viivhealthcare.ca](http://www.viivhealthcare.ca)

ViiV Soins de santé Canada est une société vouée à la recherche sur le VIH/sida et son traitement ainsi qu'au soutien des personnes touchées par le VIH/sida. ViiV Soins de santé Canada est résolument engagée dans la lutte contre le VIH/sida. Elle y contribue en offrant des produits, des services et des programmes de qualité, en créant des partenariats et en établissant des relations durables avec tous les intervenants.

ViiV Soins de santé Canada fait partie de ViiV Healthcare, une société mondiale spécialisée dans le traitement du VIH

## Platine

et établie en 2009, qui combine la puissance et l'expertise de GlaxoSmithKline (GSK) et de Pfizer dans la prise en charge du VIH. Au terme d'une collaboration à long terme ayant mené à la mise au point de plusieurs nouveaux inhibiteurs de l'intégrase, Shionogi s'est jointe à nous en 2012.

Notre gamme de produits comprend actuellement 12 traitements anti-VIH. Puisque notre entreprise est vouée exclusivement au VIH/sida, nos investissements dans l'élaboration de médicaments s'inscrivent dans une vision à long terme. Nous visons à être le meilleur partenaire qui soit dans le cadre d'une démarche favorisant la santé à long terme des patients vivant avec le VIH.

Au Canada, le siège social de ViiV Soins de santé est situé à Laval, au Québec. Pour tout renseignement supplémentaire au sujet de ViiV Soins de santé veuillez visiter le site [www.viivhealthcare.ca](http://www.viivhealthcare.ca)

## Argent



**IRSC CIHR**  
 Instituts de recherche en santé du Canada Canadian Institutes of Health Research

## Les Instituts de recherche en santé du Canada (IRSC)

[www.cihr-irsc.gc.ca](http://www.cihr-irsc.gc.ca)

Les Instituts de recherche en santé du Canada (IRSC) sont l'organisme du gouvernement du Canada chargé d'investir dans la recherche en santé. Leur objectif est de créer de nouvelles connaissances scientifiques et de renforcer le système de soins de santé pour les Canadiens. Les IRSC offrent leadership et soutien à des chercheurs et à des stagiaires en santé dans tout le Canada. [www.cihr-irsc.gc.ca](http://www.cihr-irsc.gc.ca) L'Initiative de recherche sur le VIH/sida des IRSC est chargée de la gestion et de la surveillance des éléments de recherche de deux importantes initiatives du gouvernement du Canada en matière de VIH/sida, l'Initiative fédérale de lutte contre le VIH/sida au Canada et l'Initiative canadienne de vaccin contre le VIH. Chaque année, ces initiatives permettent d'attribuer 21,5 M\$ à des chercheurs et à des stagiaires dans le domaine du VIH/sida.

## Argent



### Merck Canada

[www.merck.ca](http://www.merck.ca)

La société Merck d'aujourd'hui est un chef de file mondial dans le domaine des soins de santé et vise à aider le monde à vivre mieux. Merck est connue sous le nom de MSD à l'extérieur des États-Unis et du Canada. Grâce à nos médicaments, vaccins, traitements biologiques et produits de santé animale, nous collaborons avec nos clients et œuvrons à procurer des solutions de santé novatrices dans plus de 140 pays. Nous démontrons également notre détermination à améliorer l'accès aux soins de santé grâce à des politiques, programmes et partenariats d'envergure. Pour de plus amples renseignements à propos de nos activités au Canada, visitez le site [www.merck.ca](http://www.merck.ca) ou suivez-nous sur YouTube.

## Bronze

The AbbVie logo is the word "abbvie" in a lowercase, black, sans-serif font.

### AbbVie

[www.abbvie.com](http://www.abbvie.com)

AbbVie est une société d'envergure mondiale centrée sur la recherche biopharmaceutique, créée en 2013 à la suite de la scission de la société Abbott. La société a pour mission de mettre à profit son expertise, son personnel dévoué et son approche unique de l'innovation au développement et à la commercialisation de traitements évolués qui répondent à certaines des maladies les plus complexes et les plus graves au monde. AbbVie emploie plus de 26 000 personnes et commercialise ses produits dans plus de 170 pays. Pour obtenir de plus amples renseignements sur la société, son effectif, sa gamme de produits et ses engagements, veuillez visiter le [www.abbvie.ca](http://www.abbvie.ca). Vous pouvez aussi suivre la société sur Twitter @abbvie ou consulter les offres d'emploi sur [facebook.com/AbbVieCareers](https://facebook.com/AbbVieCareers) et [LinkedIn.com/company/abbvie](https://LinkedIn.com/company/abbvie)

**Bronze**

the CTN  
CIHR Canadian  
HIV Trials Network

le Réseau  
Réseau canadien  
pour les essais VIH des IRSC

## Réseau canadien pour les essais VIH des IRSC

[www.hivnet.ubc.ca](http://www.hivnet.ubc.ca)

Le Réseau est un partenariat pancanadien qui regroupe chercheurs, professionnels de la santé, gouvernements, défenseurs du droit à la santé, industrie pharmaceutique et biotechnologique novatrice et individus vivant avec le VIH, dans le but de mettre au point des traitements ainsi que de prévenir et éventuellement éradiquer le VIH et les autres maladies connexes par la réalisation d'essais scientifiquement rigoureux et éthiques. Le Réseau, établi en 1990, est subventionné par les Instituts de recherche en santé du Canada (IRSC) et parrainé conjointement par l'Université de la Colombie-Britannique et l'hôpital St. Paul (Providence Health Care) de Vancouver.

# Oral Presentations

## Exposés oraux

Oral Presentations  
Exposés oraux

Overview  
Aperçu

**Friday, May 13 / Vendredi 13 mai**

**11:00 – 12:30**

**Track A: Basic Sciences: Prevention**

**Volet A : Sciences fondamentales : Prévention**

**Meeting Room 4, Ground Level, North Building**

**Salles de réunion 4, rez-de-chaussée, Édifice Nord**

**Track B: Clinical Sciences: Clinical Care**

**Volet B : Sciences cliniques : Soins cliniques**

**Meeting Room 7-8, Ground Level, North Building**

**Salles de réunion 7-8, rez-de-chaussée, Édifice Nord**

**Track C: Epidemiology and Public Health Sciences: HIV Prevention for Key Populations**

**Volet C : Épidémiologie et sciences de la santé publique :  
Prévention du VIH dans les populations clés**

**Meeting Room 3, Ground Level, North Building**

**Salle de réunion 3, rez-de-chaussée, Édifice Nord**

**Track D: Social Sciences: Indigenous Health**

**Volet D : Sciences sociales : Santé des Autochtones**

**Meeting Room 9-10, Ground Level, North Building**

**Salles de réunion 9-10, rez-de-chaussée, Édifice Nord**

**15:00 – 17:00**

**Track A: Basic Sciences: Immunology**

**Volet A : Immunologie**

**Meeting Room 4, Ground Level, North Building**

**Salle de réunion 4, rez-de-chaussée, Édifice Nord**

**Track B: Clinical Sciences: Co-infection**

**Volet B : Sciences cliniques : Coinfection**

**Meeting Room 7-8, Ground Level, North Building**

**Salles de réunion 7-8, rez-de-chaussée, Édifice Nord**

**Track C: Epidemiology and Public Health Sciences: Social and Structural Correlates of HIV Risk and Care**

**Volet C : Épidémiologie et sciences de la santé publique :  
Corrélatés sociaux et structurels du risque et des soins touchant le  
VIH**

**Meeting Room 3, Ground Level, North Building**

**Salle de réunion 3, rez-de-chaussée, Édifice Nord**

**Friday May 13 / Vendredi 13 mai****15:00 – 17:00****Track D: Social Sciences: Innovative Approaches and Outcomes in Social Science HIV Research****Volet D : Sciences sociales : Recherches sur le VIH en sciences sociales : Approches et résultats innovateurs****Meeting Room 9-10, Ground Level, North Building****Salles de réunion 9-10, rez-de-chaussée, Édifice Nord**



**Saturday, May 14 / Samedi 14 mai****11:00 – 12:30****Multi-Disciplinary: PrEP and Other Novel HIV Prevention Strategies****Multidisciplinaire : PrEP/PPE et autres nouvelles stratégies de prévention du VIH****Meeting Room 3, Ground Level, North Building****Salle de réunion 3, rez-de-chaussée, Édifice Nord****Multi-Disciplinary: HIV in Indigenous and Local Populations****Multidisciplinaire : Le VIH dans les populations autochtones et locales****Meeting Room 4, Ground Level, North Building****Salle de réunion 4, rez-de-chaussée, Édifice Nord****Multi-Disciplinary: HIV in the Global Context****Multidisciplinaire : Le VIH dans le contexte mondial****Meeting Room 9-10, Ground Level, North Building****Salles de réunion 9-10, rez-de-chaussée, Édifice Nord****Multi-Disciplinary: Community-based HIV Research****Multidisciplinaire : La recherche communautaire sur le VIH****Meeting Room 7-8, Ground Level, North Building****Salles de réunion 7-8, rez-de-chaussée, Édifice Nord****15:00 – 17:00****Track A: Basic Sciences: Virology****Volet A : Sciences fondamentales : Virologie****Meeting Room 4, Ground Level, North Building****Salle de réunion 4, rez-de-chaussée, Édifice Nord****Track B: Clinical Sciences: HIV and Comorbidities****Volet B : Sciences cliniques : VIH et comorbidités****Meeting Room 7-8, Ground Level, North Building****Salles de réunion 7-8, rez-de-chaussée, Édifice Nord****Track C: Epidemiology and Public Health Sciences: Epidemiology of HIV and Co-infections****Volet C : Épidémiologie et sciences de la santé publique : Épidémiologie du VIH et des coinfections****Meeting Room 3, Ground Level, North Building****Salle de réunion 3, rez-de-chaussée, Édifice Nord****Track D: Social Sciences: Programs and Policy Driven Research****Volet D : Sciences sociales : Recherche axée sur les programmes et politiques****Meeting Room 9-10, Ground Level, North Building****Salles de réunion 9-10, rez-de-chaussée, Édifice Nord****Oral Presentations**  
**Exposés oraux****Overview**  
**Aperçu**

**Friday, May 13 / Vendredi 13 mai**
**11:00 – 12:30**
**Track A: Basic Sciences: Prevention**
**Volet A : Sciences fondamentales :  
Prévention**

Room: 4, Ground Level / Salle : 4, rez-de-chaussée  
 Co-Chairs / Coprésidents : Dr. Andrés Finzi, Dr. Paul J. McLaren

▶ **11:00** **BS1.1**

**Defining the role of the vaginal microbiome in mucosal vulnerability to HIV infection: Sialidase production by Gardnerella vaginalis subgroups (E)**

**John J. Schellenberg**<sup>1</sup>, Teenus Paramel Jayaprakash<sup>1</sup>, Niradha Withana Gamage<sup>1</sup>, Mo H. Patterson<sup>1</sup>, Mario Vanechoutte<sup>2</sup>, Janet E. Hill<sup>1</sup>

1. University of Saskatchewan, Saskatoon, SK, 2. University of Ghent, Ghent, Belgium

▶ **11:15** **BS1.2**

**Comparison of three NRTI backbones Kivexa, Combivir, and Truvada, in a mouse pregnancy model (E)**

**Kayode Balogun**, Nicole Banko, Eszter Papp, Jeffrey Lu, Hakimeh Mohammadi, Lena Serghides

Toronto General Research Institute, University Health Network, Toronto, ON

▶ **11:30** **BS1.3**

**The Effect of E157Q in HIV-1 Integrase on R263K-Mediated Dolutegravir Resistance (E)**

**Kaitlin Anstett**<sup>1, 2</sup>, Vincent Cutillas<sup>1, 2</sup>, Robert Fusco<sup>3</sup>, Thibault Mesplede<sup>1</sup>, Mark A. Wainberg<sup>1, 2</sup>

1. McGill AIDS Centre, Montreal, QC, 2. Department of Microbiology and Immunology, McGill University, Montreal, QC, 3. Currently at Enanta Pharmaceuticals, Watertown, MA, USA

▶ **11:45** **BS1.4**

**Pre-clinical evaluation of the therapeutic application of a vaccine targeting the 12 protease cleavage sites (E)**

**Ma Luo**<sup>1, 2</sup>, David Tang<sup>1</sup>, Jorge Pinto<sup>3</sup>, Mikaela Nykoluk<sup>1</sup>, Philip Lacap<sup>1</sup>, Jeffrey Tuff<sup>1</sup>, Elnaz Shadabi<sup>2</sup>, Chris Czarnecki<sup>1</sup>, James Whitney<sup>4</sup>, Maria Alonso<sup>3</sup>, Terry B. Ball<sup>1</sup>, Gary Kobinger<sup>5</sup>, Paul Sandstrom<sup>1</sup>, Francis A. Plummer<sup>5</sup>

1. National HIV and Retrovirology Laboratory, JC Wilt Infectious Diseases Research Centre, National Microbiology Laboratory, Winnipeg, MB, 2. Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, 3. University of Santiago de Compostela, Santiago de Compostela, Spain, 4. BIDMC, Harvard Medical School, Boston, MA, USA, 5. National Microbiology Laboratory, Winnipeg, MB

▶ 12:00

BS1.5

**Tracing HIV's Footsteps; Dissemination of HIV-1 following Intra-vaginal Infection in a Humanized Mouse Model (E)**

**Jocelyn M. Wessels**<sup>1</sup>, Philip V. Nguyen<sup>1</sup>, Kristen Mueller<sup>1</sup>, Varun Anipindi<sup>1</sup>, Fatemah Vahedi<sup>1</sup>, Uladzimir Karniychuk<sup>1</sup>, Marianne Chew<sup>1</sup>, Alexandre Deshiere<sup>2</sup>, Tony Mazzulli<sup>3</sup>, Michel J. Tremblay<sup>2</sup>, Ali A. Ashkar<sup>1</sup>, Charu Kaushic<sup>1</sup>

1. McMaster University, Hamilton, ON, 2. Université Laval, Québec City, QC, 3. Mount Sinai Hospital, Toronto, ON

▶ 12:15

BS1.6

**Next generation sequencing reveals the temporal complexity of mixed hepatitis C infections among people who inject drugs in Vancouver, BC, Canada (E)**

**Jeffrey B. Joy**<sup>1</sup>, Weiyang Dong<sup>1</sup>, Don R. Kirkby<sup>1</sup>, Jason Grebely<sup>2</sup>, Richard H. Liang<sup>1</sup>, Vera Tai<sup>1</sup>, Anita Howe<sup>1</sup>, P. Richard Harrigan<sup>1</sup>, Art F. Poon<sup>1</sup>

1. BC CFE HIV/AIDS, Vancouver, BC, 2. University of New South Wales, Sydney, NSW, Australia

## Track B: Clinical Sciences: Clinical Care

### Volet B : Sciences cliniques : Soins cliniques

Room: 7-8, Ground Level / Salle : 7-8, rez-de-chaussée

Co-Chairs / Coprésidents : Dr. Melanie Murray, Dr. Jared Bullard

▶ 11:00

CS1.1

**Weekly text-messaging (Weltel) to engage vulnerable HIV+ populations: It works, what does it cost? (E)**

Karen Friesen<sup>2</sup>, Annie Q. Qiu<sup>2</sup>, Evelyn J. Maan<sup>2</sup>, Ozge Goktepe<sup>1</sup>, Neora Pick<sup>3, 2, 1</sup>, Ariane Aliment<sup>3, 2</sup>, Mary Kestler<sup>3, 2</sup>, Deborah Money<sup>3, 2, 1</sup>, Richard Lester<sup>3</sup>, **Melanie C. Murray**<sup>3, 2, 1</sup>

1. Women's Health Research Institute (WHRI), Vancouver, BC, 2. Oak Tree Clinic, BC Women's Hospital, Vancouver, BC, 3. University of British Columbia, Vancouver, BC

▶ 11:15

CS1.2

**Incidence of emergent drug resistance mutations during clinical use of integrase inhibitor-containing antiretroviral regimens in British Columbia (E)**

**Katherine J. Lepik**<sup>1, 2</sup>, P Richard Harrigan<sup>1</sup>, Benita Yip<sup>1</sup>, Conan K. Woods<sup>1</sup>, Marjorie A. Robbins<sup>1</sup>, Ana Ulloa<sup>1</sup>, Rachel A. McGovern<sup>1</sup>, Viviane Dias Lima<sup>1</sup>, Wendy W. Zhang<sup>1</sup>, K Junine Toy<sup>2</sup>, Linda A. Akagi<sup>1, 2</sup>, Silvia Guillemi<sup>1</sup>, Julio S. Montaner<sup>1</sup>, Rolando Barrios<sup>1</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. Pharmacy Department, St Paul's Hospital, Vancouver, BC

▶ 11:30

CS1.3

**Estradiol and Progesterone Levels Across Pregnancy in HIV-positive Women Randomized to Either Lopinavir/ritonavir or Efavirenz Based cART (E)**

Chloe R. McDonald<sup>2</sup>, Andrea L. Conroy<sup>2</sup>, Eszter Papp<sup>1</sup>, Michael Hawkes<sup>3</sup>, Joel Gamble<sup>1</sup>, Moses Kanya<sup>6</sup>, Diane V. Havlir<sup>4</sup>, Grant Dorsey<sup>5</sup>, Kevin C. Kain<sup>1</sup>, **Lena Serghides**<sup>1</sup>

1. Toronto General Research Institute, Toronto, ON, 2. University of Toronto, Toronto, ON, 3. University of Alberta, Edmonton, AB, 4. HIV/AIDS Division, San Francisco General Hospital, San Francisco, CA, USA, 5. University of California San Francisco, San Francisco, CA, USA, 6. Makerere University, Kampala, Uganda

▶ 11:45

CS1.4

**Pregnancy Loss among Women Living with HIV and the Role of Antiretrovirals; a Canadian Perspective (E)**

**Kaitlin Siou**<sup>1</sup>, Kate Salters<sup>2</sup>, Lu Wang<sup>2</sup>, Shahab Jabbari<sup>2</sup>, Mona Loutfy<sup>3, 4, 5</sup>, Angela Kaida<sup>6</sup>, Allison Carlson<sup>3</sup>, Sally Lin<sup>2, 6</sup>, Allie Carter<sup>6</sup>, Karene Proulx-Boucher<sup>7</sup>, Kath Webster<sup>8</sup>, Marisol Desbiens<sup>9</sup>, Paul Sereda<sup>2</sup>, Guillaume Colley<sup>2</sup>, Alexandra de Pokomandy<sup>7</sup>, Robert Hogg<sup>6</sup>, Lena Serghides<sup>1, 5</sup>, CHIWOS Research Team

1. Toronto General Research Institute, Toronto, ON, 2. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 3. Women's College Research Institute, Toronto, ON, 4. Women's College Hospital, Toronto, ON, 5. University of Toronto, Toronto, ON, 6. Simon Fraser University, Burnaby, BC, 7. McGill University Health Centre, Montreal, QC, 8. CHIWOS Research Team, Vancouver, BC, 9. CHIWOS Research Team, Toronto, ON

▶ 12:00

CS1.5

**Non-perinatal HIV acquisition among Canadian born pre-school children in Montreal, Quebec (E)**

Chris Karatzios<sup>2</sup>, Dorothy Moore<sup>2</sup>, Normand Lapointe<sup>1</sup>, Christian Renaud<sup>1</sup>, Valerie Lamarre<sup>1</sup>, **Fatima Kakkar**<sup>1</sup>

1. CHU Sainte-Justine, University of Montreal, Montreal, QC, 2. Montreal Children's Hospital, McGill University Health Center, Montreal, QC

▶ 12:15

CS1.6

**Infant Zidovudine prophylaxis for PMTCT: Is 4 weeks Enough? Data from the Canadian Perinatal HIV/AIDS Surveillance (E)**

**Ariane Alimenti**<sup>1</sup>, Laura J. Sauve<sup>1, 3</sup>, Lindy Samson<sup>5</sup>, Deborah Money<sup>1, 2</sup>, Terry Lee<sup>4</sup>, Ari Bitnun<sup>7</sup>, Jason Brophy<sup>5</sup>, Fatima Kakkar<sup>6</sup>, Neora Pick<sup>1</sup>, and the Canadian Perinatal HIV/AIDS Surveillance Network<sup>4</sup>

1. BC Women's Hospital and Health Centre, University of British Columbia, Vancouver, BC, 2. Women's Health Research Institute, Vancouver, BC, 3. BC Children's Hospital, University of British Columbia, Vancouver, BC, 4. CIHR Canadian HIV/AIDS Trials Network, Vancouver, BC, 5. Children's Hospital of Eastern Ontario (CHEO), Division of Infectious Diseases, Ottawa, ON, 6. CHU Sainte-Justine, Montreal, QC, 7. Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, ON

## Track C: Epidemiology and Public Health Sciences: HIV Prevention for Key Populations

### Volet C : Épidémiologie et sciences de la santé publique : Prévention du VIH dans les populations clés

Room: 3, Ground Level / Salle : 3, rez-de-chaussée

Co-Chairs / Coprésidents : Dr. Sharmistha Mishra, Miss Leigh McClarty

#### ▶ 11:00 EPH1.1

##### **High incidence of subsequent HIV seroconversion among Montreal PEP users (E)**

Nimâ Machouf<sup>1,3</sup>, Benoit Trottier<sup>1,2</sup>, Sylvie Vézina<sup>1</sup>, Chrissi Galanakis<sup>1</sup>, Danièle Longpré<sup>1</sup>, Michel Boissonnault<sup>1</sup>, Emmanuelle Huchet<sup>1</sup>, Louise Charest<sup>1</sup>, Daniel Murphy<sup>1</sup>, **Réjean Thomas**<sup>1,2</sup>

1. Clinique médicale l'Actuel, Montréal, QC, 2. Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, 3. Université de Montréal, Montréal, QC

#### ▶ 11:15 EPH1.2

##### **High incidence of subsequent HIV seroconversion amongst MSM accessing recurrent non-occupational post-exposure prophylaxis (NPEP) in Vancouver, BC (E)**

**Mark Hull**<sup>1</sup>, Nathan Lachowsky<sup>1</sup>, David Moore<sup>1</sup>, Marianne Harris<sup>1</sup>, Silvia Guillemi<sup>1</sup>, Wendy Zhang<sup>1</sup>, Shahab Jabbari<sup>1</sup>, Troy Grennan<sup>2</sup>, Jason Wong<sup>2</sup>, Gina Ogilvie<sup>2</sup>, Irene Day<sup>1</sup>, Julio Montaner<sup>1</sup>

1. BC Centre For Excellence In HIV/AIDS, Vancouver, BC, 2. BC Centre for Disease Control, Vancouver, BC

#### ▶ 11:30 EPH1.3

##### **Understanding HIV Transmission among Persons from African, Caribbean and Black Communities in Canada: Comparison of those Infected Prior to and After Arrival (E)**

**Liviana Calzavara**<sup>1</sup>, Wangari Tharao<sup>2</sup>, Juan Liu<sup>1</sup>, Amrita Daftary<sup>1</sup>, Ann Burchell<sup>3,1</sup>, Mona Loutfy<sup>4,5</sup>, Rupert Kaul<sup>5</sup>, Tola Mbulaheni<sup>6</sup>, Soraya Blot<sup>6</sup>, LaRon Nelson<sup>7</sup>, Winston Husbands<sup>8</sup>, Shannon Ryan<sup>9</sup>, Lynne Leonard<sup>10</sup>

1. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, 2. Women's Health in Women's Hands, Toronto, ON, 3. Department of Family and Community Medicine and Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, ON, 4. Women's College Hospital, Toronto, ON, 5. Department of Medicine, University of Toronto, Toronto, ON, 6. African and Caribbean Council on HIV/AIDS in Ontario, Toronto, ON, 7. School of Nursing, University of Rochester, Rochester, NY, USA, 8. AIDS Committee of Toronto, Toronto, ON, 9. Black Coalition for AIDS Prevention, Toronto, ON, 10. Department of Epidemiology & Community Medicine, University of Ottawa, Ottawa, ON

▶ 11:45

EPH1.4

**Childhood Maltreatment, Protective Factors in Adolescence, and Sexual Risk Behaviour Among Homeless Youth: A Latent Class Analysis of Homeless Youth In Toronto (E)**

Jessica E. Sutherland, **Syed W. Noor**, David M. Day, Trevor A. Hart

Ryerson University, Toronto, ON

▶ 12:00

EPH1.5

**HIV/STI sexual risk among transgender men who are gay, bisexual, or have sex with men: Trans PULSE Project (E)**

**Ayden I. Scheim**<sup>1</sup>, Greta R. Bauer<sup>1</sup>, Robb Travers<sup>2</sup>

1. Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, 2. Department of Health Sciences, Wilfrid Laurier University, Waterloo, ON

▶ 12:15

EPH1.6

**Sustained Reduction in Sexual Risk of HIV Transmission Following Diagnosis with Acute or Recent HIV Infection Among Gay Men in Vancouver, British Columbia (E)**

**Mark Gilbert**<sup>1</sup>, Darlene Taylor<sup>2, 3</sup>, Michael Kwag<sup>4</sup>, Daniel Grace<sup>5</sup>, Elgin Lim<sup>6</sup>, Warren Michelow<sup>7</sup>, Robert Balshaw<sup>3</sup>, David Patrick<sup>3, 7</sup>, Gina Ogilvie<sup>2, 3</sup>, Benedikt Fischer<sup>8</sup>, Daniel Coombs<sup>9</sup>, Richard Rothenberg<sup>10</sup>, Malcolm Steinberg<sup>11</sup>, Michael Rekart<sup>7</sup>

1. Ontario HIV Treatment Network, Toronto, ON, 2. Children's and Women's Health Centre of British Columbia, Vancouver, BC, 3. British Columbia Centre for Disease Control, Vancouver, BC, 4. CATIE, Toronto, ON, 5. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, 6. Positive Living Society of British Columbia, Vancouver, BC, 7. School of Population and Public Health, University of British Columbia, Vancouver, BC, 8. Centre for Addiction and Mental Health, Toronto, ON, 9. Department of Mathematics, University of British Columbia, Vancouver, BC, 10. School of Public Health, Georgia State University, Atlanta, GA, USA, 11. Faculty of Health Sciences, Simon Fraser University, Vancouver, BC

## Track D: Social Sciences: Indigenous Health

### Volet D : Sciences sociales : Santé des Autochtones

Room: 9-10, Ground Level / Salle : 9-10, rez-de-chaussée

Co-Chairs / Coprésidents : Dr. Sharon Bruce, Laverne Gervais

▶ 11:00

SS1.1

**“Condom in Grandma’s Bag:” Experiences of Elders participating in an arts-based HIV/AIDS education workshop for Aboriginal youth (E)**

**Rachel Landy**

Memorial University of Newfoundland, St. John's, NL

▶ 11:15

SS1.2

**Refining the Research Response: An Aboriginal HIV Research Strategy (E)**Tracey Prentice, **Renee Masching**

Canadian Aboriginal AIDS Network, Ottawa, ON

▶ 11:30

SS1.3

**The Cedar Project: Conducting Health Research in a Good Way (E)**Kukpi7 Wunuxtsin M. Christian<sup>2</sup>, **Kate Jongbloed**<sup>1</sup>, Margo E. Pearce<sup>3</sup>, Martin T. Schechter<sup>1</sup>, Patricia M. Spittal<sup>1</sup>, For The Cedar Project Partnership<sup>1</sup>

1. University of British Columbia, Vancouver, BC, 2. Splantsin te Secwepemc, Enderby, BC, 3. McGill University, Montreal, QC

▶ 11:45

SS1.4

**Housing and Health for Indigenous People Living with HIV in Canada: Preliminary Findings from the Stable Homes, Strong Families Community-Based Research Study (E)**Marni Amirault<sup>2</sup>, Jaqueline Anaquod<sup>3</sup>, Patrick Brownlee<sup>2</sup>, **Saara Greene**<sup>1</sup>, Charles Hill<sup>4</sup>, Allyson Ion<sup>1</sup>, Randy Jackson<sup>1</sup>, **Sheila Nyman**<sup>2</sup>, Catherine Worthington<sup>3</sup>

1. McMaster University, Hamilton, ON, 2. Canadian Aboriginal AIDS Network, Halifax, NS, 3. University of Victoria, Victoria, BC, 4. Indigenous Training International, Ohsweken, ON

▶ 12:00

SS1.5

**Digging Deep: Examining the Root Causes of HIV and AIDS Among Aboriginal Women (E)****Carrie A. Bourassa**<sup>1</sup>, **Margaret Poitras**<sup>2</sup>

1. First Nations University of Canada, Regina, SK, 2. All Nations Hope Network, Regina, SK

▶ 12:15

SS1.6

**“What can lower HIV risk in the North is accepting you are LGBT”: Exploring social drivers of HIV with Indigenous and Northern LGBT youth in the Northwest Territories (E)****Carmen H. Logie**<sup>1</sup>, Candice Lys<sup>2, 1</sup>, Nancy MacNeill<sup>2</sup>, Charlotte Loppie<sup>3</sup>, Renée Masching<sup>4</sup>, Dionne Gesink<sup>1</sup>

1. University of Toronto, Toronto, ON, 2. Fostering Open Expression Among Youth (FOXY), Yellowknife, NT, 3. University of Victoria, Victoria, BC, 4. Canadian Aboriginal AIDS Network, Dartmouth, NS

15:00 – 17:00

## Track A: Basic Sciences: Immunology

### Volet A : Sciences fondamentales : Immunologie

Room: 4, Ground Level / Salle : 4, rez-de-chaussée  
 Co-Chairs / Coprésidents : Dr. Michael Grant, Dr. Thomas Murooka

#### ▶ 15:00 BS2.1

#### **TLR10 is Significantly Increased in HIV-1 Infected Breast Milk Cells and Affects the Level of HIV Infection and Integration (E)**

Xiao-Dan Yao<sup>1</sup>, Bethany M. Henrick<sup>2</sup>, Alash'le Abimiku<sup>3</sup>,  
**Kenneth L. Rosenthal**<sup>1</sup>

1. Department of Pathology & Molecular Medicine, McMaster University, Hamilton, ON, 2. Foods for Health Institute, UC Davis, Davis, CA, USA, 3. Institute of Human Virology, Jos, Nigeria

#### ▶ 15:15 BS2.2

#### **DMPA Use Associates with Innate Immune Activation and Reduced Epithelium Repair Pathways in the Female Genital Tract (E)**

**Kenzie Birse**<sup>1, 2</sup>, Brandon Guthrie<sup>3</sup>, Laura Romas<sup>1, 2</sup>, Rose Bosire<sup>5</sup>, James Kiarie<sup>5</sup>, Stuart McCorrister<sup>4</sup>, Garrett Westmacott<sup>4</sup>, Blake Ball<sup>1, 2, 5</sup>, Kristina Broliden<sup>6</sup>, Adam Burgener<sup>1, 2, 6</sup>

1. National HIV and Retrovirology Labs, JC Wilt Infectious Disease Research Centre, Public Health Agency of Canada, Winnipeg, MB, 2. University of Manitoba, Winnipeg, MB, 3. University of Washington, Seattle, WA, USA, 4. Mass Spectrometry Core Facility, National Microbiology Lab, Public Health Agency of Canada, Winnipeg, MB, 5. University of Nairobi, Nairobi, Kenya, 6. Karolinska Institutet, Stockholm, Sweden

#### ▶ 15:30 BS2.3

#### **Inducing immune quiescence with hydroxychloroquine as a new method to prevent HIV infection (E)**

**Keith R. Fowke**<sup>1, 2</sup>, Lucy Mwangi<sup>2</sup>, Genevieve Boily-Larouche<sup>1</sup>, Maureen Akolo<sup>3</sup>, John Mungai<sup>3</sup>, Julianna Cheruiyot<sup>3</sup>, Julius Oyugi<sup>1, 2</sup>, Joshau Kimani<sup>1, 2, 3</sup>, Julie Lajoie<sup>1, 2</sup>

1. University of Manitoba, Winnipeg, MB, 2. University of Nairobi, Nairobi, Kenya, 3. Kenyan AIDS Control Program, Nairobi, Kenya

#### ▶ 15:45 BS2.4

#### **Depletion of Memory and Tfh cells in Mesenteric Lymph Nodes of SIV-infected Rhesus Macaques (E)**

**Felicien Moukambi**<sup>1</sup>, Henintsoa Rabezanahary<sup>1</sup>, Vasco Rodrigues<sup>2</sup>, Yasmina Fortier<sup>2</sup>, Gina Racine<sup>1</sup>, Lynda Robitaille<sup>1</sup>, Guadalupe Andreani<sup>1</sup>, Bernard Krust<sup>2</sup>,



Calayselvy Soundaramourty<sup>2</sup>, Ricardo Silvestre<sup>2</sup>, Mireille Laforge<sup>2</sup>, Jérôme Estaquier<sup>1, 2</sup>

1. Centre de Recherche en Infectiologie du CHU de Québec, Université Laval, Québec, QC, Quebec City, QC, 2. CNRS FR3636, Université Paris Descartes, Paris, France

▶ 16:00

BS2.5

**Profile of B Cell Subsets and Vaccine Responses in HIV-Exposed Uninfected (HEU) Children (E)**

**Laurence Raymond Marchand**<sup>1, 2</sup>, Catherine Gravel<sup>1, 2</sup>, Armelle Le Campion<sup>1, 2</sup>, Marc Boucher<sup>3, 4</sup>, Normand Lapointe<sup>3, 5</sup>, Valérie Lamarre<sup>3, 5</sup>, Fatima Kakkar<sup>3, 5</sup>, Hélène C. Côté<sup>6, 7</sup>, Hugo Soudeyns<sup>1, 2, 5</sup>

1. Centre de recherche du CHU Sainte-Justine, Montreal, QC, 2. Department of Microbiology, Infectiology & Immunology, Université de Montréal, Montreal, QC, 3. Centre maternel et infantile sur le SIDA, CHU Sainte-Justine, Montreal, QC, 4. Department of Obstetrics & Gynecology, Université de Montréal, Montreal, QC, 5. Department of Pediatrics, Université de Montréal, Montreal, QC, 6. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, 7. Women's Health Research Institute, Vancouver, BC

▶ 16:15

BS2.6

**Reconstitution of gut IL-22/IL-22R axis with early initiation of antiretroviral therapy, but evidence of epithelial damage and inflammation (E)**

**Connie J. Kim**<sup>1, 2</sup>, Xin Shu<sup>2</sup>, Sanja Huibner<sup>2</sup>, Rodney Rousseau<sup>2</sup>, Erika Benko<sup>3</sup>, Kamnoosh Shahabi<sup>2</sup>, Gabor Kandel<sup>4</sup>, Colin Kovacs<sup>3</sup>, Mario Ostrowski<sup>2, 4</sup>, Rupert Kaul<sup>2, 1</sup>

1. Toronto General Hospital, Toronto, ON, 2. University of Toronto, Toronto, ON, 3. Maple Leaf Medical Clinic, Toronto, ON, 4. St. Michael's Hospital, Toronto, ON

▶ 16:30

BS2.7

**Evolution-Guided Structural And Functional Analyses Of The HERC Restriction Factor Family Identifies Specificity Determinants Of Anti-HIV-1 Activity (E)**

Matthew W. Woods, Sean K. Tom, Ermela Papparisto, Hinnisan P. Kohio, Macon D. Coleman, Nina R. Hunt, Eric J. Di Gravio, Taryn J. Rohringer, Jonathan Y. Zhang, **Stephen D. Barr**  
Western University, London, ON

▶ 16:45

BS2.8

**The ABL Kinase Inhibitor Dasatinib Inhibits HIV-1 infection in Humanized NSG Mice (E)**

**Stephen D. McCarthy**<sup>1</sup>, Danila Leontyev<sup>1, 2</sup>, Pauline Nicoletti<sup>3</sup>, Raymond Wong<sup>1</sup>, Darinka Sakac<sup>2</sup>, Hannah N. Kozlowski<sup>1</sup>, Donald R. Branch<sup>1, 2, 4</sup>

1. University of Toronto, Toronto, ON, 2. Canadian Blood Services, Toronto, ON, 3. École Supérieure de Biologie-Biochimie-Biotechnologies de Lyon, Lyon, France, 4. Toronto General Research Institute, Toronto, ON

## Track B: Clinical Sciences: Co-infection

### Volet B : Sciences cliniques : Coinfection

Room: 7-8, Ground Level / Salle : 7-8, rez-de-chaussée

Co-Chairs / Coprésidents : Dr. Alex Wong, Dr. Ken Kasper

#### ▶ 15:00 CS2.1

##### **Asymptomatic Neurosyphilis is Common in HIV/Syphilis Co-infection: A Feasibility and Pilot Cohort Study (E)**

**Darrell H. Tan**<sup>1,3</sup>, Sharmistha Mishra<sup>1,3</sup>, Ameeta Singh<sup>2</sup>, Kevin A. Gough<sup>1,3</sup>, Gordon Arbess<sup>4</sup>, Ahmed Bayoumi<sup>5</sup>

1. St. Michael's Hospital Division of Infectious Diseases, Toronto, ON, 2. Alberta Health Services, Edmonton, AB, 3. University of Toronto Department of Medicine, Toronto, ON, 4. St. Michael's Hospital Department of Family and Community Medicine, Toronto, ON, 5. St. Michael's Hospital Department of Medicine, Toronto, ON, 6. National Microbiology Laboratory, Winnipeg, MB

#### ▶ 15:15 CS2.2

##### **Rates and Risk Factors for Hepatitis C Re-Infection or Late Relapse after Sustained Virologic Response to Treatment among HIV Co-Infected Canadians (E)**

**Carmine Rossi**<sup>1</sup>, Mark Hull<sup>2</sup>, Joseph Cox<sup>1</sup>, Curtis Cooper<sup>3</sup>, Valérie Martel-Laferrrière<sup>4</sup>, Marina B. Klein<sup>1</sup>

1. McGill University, Montreal, QC, 2. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 3. The Ottawa Hospital, Ottawa, ON, 4. Centre de recherche de centre hospitalier de l'Université de Montréal, Montreal, QC

#### ▶ 15:30 CS2.3

##### **A Comparison of the Performance of an HPV E6/E7 mRNA Assay With a DNA-based Assay on Anal Samples in HIV-Positive Men Who Have Sex With Men (MSM) (E)**

**Troy Grennan**<sup>1,2</sup>, Mona Loutfy<sup>3,4</sup>, Marek Smieja<sup>5,6</sup>, Dan Jang<sup>6</sup>, Manuel Arias<sup>6</sup>, Alice Cavanagh<sup>7</sup>, Jodi Gilchrist<sup>6</sup>, Irving Salit<sup>3,7</sup>, Jill Tinmouth<sup>3,8</sup>, Max Chernesky<sup>5,6</sup>

1. BC Centre for Disease Control, Vancouver, BC, 2. University of British Columbia, Vancouver, BC, 3. University of Toronto, Toronto, ON, 4. Women's College Hospital, Toronto, ON, 5. McMaster University, Hamilton, ON, 6. St. Joseph's Healthcare, Hamilton, ON, 7. University Health Network, Toronto, ON, 8. Sunnybrook Health Sciences Centre, Toronto, ON

#### ▶ 15:45 CS2.4

##### **Timing of Hepatitis B and C Diagnosis Relative to Hepatocellular Carcinoma Diagnosis in the BC Hepatitis Testers Cohort (BC-HTC) (E)**

**Naveed Janjua**<sup>1,2</sup>, Amanda Yu<sup>1</sup>, Hasina Samji<sup>1,2</sup>, Margot Kuo<sup>1</sup>, Maryam Alavi<sup>4</sup>, Ryan Woods<sup>3</sup>, Maria Alvarez<sup>1</sup>, Gregory Dore<sup>4</sup>, Mark Tyndall<sup>1,2</sup>, Mel Krajden<sup>1,2</sup>

1. British Columbia Centre for Disease Control, Vancouver, BC, 2. University of British Columbia, Vancouver, BC, 3. British Columbia Cancer Agency, Vancouver, BC, 4. The Kirby Institute, Vancouver, BC

▶ 16:00

CS2.5

**Ledipasvir/Sofosbuvir with Ribavirin for 12 Weeks Is Effective and Safe in Treatment-Naïve Genotype-3 HCV-Infected Patients in Canada (E)**

Jordan Feld<sup>1</sup>, Alnoor Ramji<sup>2</sup>, Stephen Shafran<sup>3</sup>, Bernard Willems<sup>4</sup>, Paul Marotta<sup>5</sup>, Emmanuelle Huchet<sup>6</sup>, Marie-Louise Vachon<sup>7</sup>, Nicholas Wong<sup>8</sup>, Evguenia Svarovskaia<sup>8</sup>, KC Huang<sup>8</sup>, Robert Hyland<sup>8</sup>, Chohee Yun<sup>8</sup>, Diana Brainard<sup>8</sup>, Edward Tam<sup>9</sup>, Robert Bailey<sup>10</sup>, Curtis Cooper<sup>11</sup>, Eric Yoshida<sup>12</sup>, Susan Greenbloom<sup>13</sup>, Magdy Elkashab<sup>14</sup>, **Sergio Borgia**<sup>15</sup>, Mark Swain<sup>16</sup>

1. University Health Network, Toronto, ON, 2. GI Research Institute, GI Research Institute, BC, 3. University of Alberta, Edmonton, AB, 4. CHUM. St-Luc Hospital, Montreal, QC, 5. London Health Sciences Centre, London, ON, 6. Clinique médicale l'Actuel, Montreal, QC, 7. CHU de Quebec, Quebec, QC, 8. Gilead Sciences, Inc., Foster City, CA, USA, 9. LAIR Centre, Vancouver, BC, 10. GI Research, Edmonton, AB, 11. The Ottawa General Hospital, Ottawa, ON, 12. Vancouver General Hospital, Vancouver, BC, 13. Toronto Digestive Diseases Associates, Inc., Vaughn, ON, 14. Toronto Liver Center, Toronto, ON, 15. William Osler Health System, Toronto, ON, 16. University of Calgary, Calgary, AB

▶ 16:15

CS2.6

**Tobacco Smoking is Not Associated with Accelerated Liver Disease in HIV-Hepatitis C Co-Infection: A Longitudinal Cohort Analysis (E)**

**Cecilia T. Costiniuk**<sup>1</sup>, Laurence Brunet<sup>2</sup>, Kathleen C. Rollet-Kurhajec<sup>1</sup>, Curtis L. Cooper<sup>3, 5</sup>, Sharon Walmsley<sup>4, 5</sup>, John Gill<sup>6, 5</sup>, Valerie Martel-Laferrriere<sup>7</sup>, Mark Tyndall<sup>8</sup>, Marina B. Klein<sup>1, 5</sup>

1. Chronic Viral Illnesses Service, Division of Infectious Diseases, McGill University Health Centre, Montreal, QC, 2. Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, 3. Division of Infectious Diseases, The Ottawa Hospital, Ottawa, ON, 4. Division of Infectious Diseases, University Health Network, University of Toronto, Toronto, ON, 5. Canadian HIV Trials Network, Vancouver, BC, 6. Southern Alberta HIV Clinic, Calgary, AB, 7. Centre Hospitalier de l'Université de Montréal, Notre-Dame, Montreal, QC, 8. British Columbia Centre for Disease Control and Division of Infectious Diseases, University of British Columbia, Vancouver, BC

▶ 16:30

CS2.7

**Real setting experience of Hepatitis C treatment with Interferon-Free DAA in HCV mono and HIV-HCV-coinfected patients (E)**

Emmanuelle Huchet<sup>1</sup>, Benoit Trottier<sup>1, 2</sup>, Chrissi Galanakis<sup>1</sup>, Marc Poliquin<sup>1</sup>, Sylvie Vézina<sup>1</sup>, Danièle Longpré<sup>1</sup>, Stéphane Lavoie<sup>1</sup>, Caroline Bédard<sup>1</sup>, Nimâ Machouf<sup>1, 3</sup>, **Réjean Thomas**<sup>1, 2</sup>

1. Clinique médicale l'Actuel, Montréal, QC, 2. Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, 3. Université de Montréal, Montréal, QC

▶ 16:45

CS2.8

**Association of Fibroblast Growth Factor 23 and Serum Ferritin with Liver Fibrosis diagnosed by Transient Elastography in HIV/HCV Co-Infected Patients (E)**

 Giada Sebastiani<sup>1</sup>, John Wagner<sup>2</sup>, Marina B. Klein<sup>1</sup>, Kostas Pantopoulos<sup>2</sup>

1. McGill University Health Centre, Montreal, QC, 2. Lady Davis Institute/McGill University, Montreal, QC

**Track C: Epidemiology and Public Health Sciences: Social and Structural Correlates of HIV Risk and Care**
**Volet C : Épidémiologie et sciences de la santé publique : Corrélats sociaux et structurels du risque et des soins touchant le VIH**

Room: 3, Ground Level / Salle : 3, rez-de-chaussée

Co-Chairs / Coprésidents : Souradet Shaw, Dr. John Kim

▶ 15:00

EPH2.1

**The effect of engagement in an HIV/AIDS integrated health program on plasma HIV-1 RNA suppression among HIV-positive people who use illicit drugs (E)**

 Lianping Ti<sup>1,2</sup>, Huiru Dong<sup>1</sup>, Rosalind Baltzer Turje<sup>3</sup>, Surita Parashar<sup>1</sup>, Jeong Eun Min<sup>1</sup>, Thomas Kerr<sup>1,2</sup>, Evan Wood<sup>1,2</sup>, Julio Montaner<sup>1,2</sup>, M-J Milloy<sup>1,2</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. University of British Columbia, Vancouver, BC, 3. Dr. Peter AIDS Foundation, Vancouver, BC

▶ 15:15

EPH2.2

**A population-based study evaluating the impact of physician specialty and physician HIV experience on the delivery of care for people living with HIV in Ontario (E)**

 Claire E. Kendall<sup>1,2</sup>, Monica Taljaard<sup>3,6</sup>, Jaime Younger<sup>4</sup>, William Hogg<sup>1,2</sup>, Richard H. Glazier<sup>4,5</sup>, Douglas G. Manuel<sup>3,4,1</sup>

1. Bruyere Research Institute, Ottawa, ON, 2. Department of Family Medicine, University of Ottawa, Ottawa, ON, 3. Ottawa Hospital Research Institute, Ottawa, ON, 4. Institute for Clinical Evaluative Sciences, Toronto, ON, 5. Department of Family and Community Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, 6. Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON

▶ 15:30

EPH2.3

**The Impact of Drug Coverage on Viral Suppression: Findings from the Ontario HIV Treatment Network Cohort Study (OCS) (E)**

 Beth Rachlis<sup>1</sup>, Sandra Gardner<sup>1,7</sup>, Lucia Light<sup>1</sup>, Tony Antoniou<sup>2,7</sup>, Claire Kendall<sup>3,4</sup>, Frank McGee<sup>5</sup>, Jean Bacon<sup>1</sup>, Anita Rachlis<sup>6,7</sup>, Ann N. Burchell<sup>2,7</sup>, Sean B. Rourke<sup>1,7</sup>, Ontario HIV Treatment Network Cohort Study

1. Ontario HIV Treatment Network, Toronto, ON, 2. St. Michael's Hospital, Toronto, ON, 3. Bruyere Research Institute, Ottawa, ON, 4. University of Ottawa, Ottawa, ON, 5. AIDS Bureau, Ministry of Health and Long Term Care, Toronto, ON, 6. Sunnybrook Health Sciences Centre, Toronto, ON, 7. University of Toronto, Toronto, ON

▶ 15:45

EPH2.4

**Multilevel correlates of delayed access to HIV-related care among women living with HIV in the Greater Toronto Area, Canada (E)**

**Ashley Lacombe-Duncan**<sup>1</sup>, Mina Kazemi<sup>2</sup>, Nadine Kronfli<sup>9</sup>, Carmen H. Logie<sup>1</sup>, Yasmeen Persad<sup>2</sup>, Kerrigan Beaver<sup>2</sup>, Marisol Desbiens<sup>2</sup>, Allison Carter<sup>3</sup>, Allison Carlson<sup>2</sup>, Muna Aden<sup>2</sup>, Anita C. Benoit<sup>2</sup>, Mandy Mack<sup>2</sup>, Art Zoccole<sup>4</sup>, Wangari Tharao<sup>5</sup>, V L. Kennedy<sup>2</sup>, Ann Burchell<sup>6</sup>, Angela Kaida<sup>7</sup>, Alexandra de Pokomandy<sup>8</sup>, Robert Hogg<sup>3</sup>, CHIWOS Research Team<sup>2</sup>

1. Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, ON, 2. Women's College Research Institute, Women's College Hospital, Toronto, ON, 3. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 4. 2 Spirit, Canada, ON, 5. Women's Health in Women's Hands, Canada, ON, 6. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, 7. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, 8. McGill University, Montreal, QC, 9. Department of Infectious Diseases, McMaster University, Hamilton, ON

▶ 16:00

EPH2.5

**The Cedar Project: Longitudinal health outcomes associated with childhood neglect among young Indigenous people who use drugs in BC (E)**

Margo E. Pearce<sup>1</sup>, **Kate A. Jongbloed**<sup>1</sup>, Wayne M. Christian<sup>3</sup>, Earl W. Henderson<sup>4</sup>, Martin T. Schechter<sup>1</sup>, Patricia M. Spittal<sup>1</sup>, For the Cedar Project Partnership

1. The Cedar Project, Vancouver, BC, 2. UBC - CHEOS, Vancouver, BC, 3. Splatstin/Secwepemc Nation, Enderby, BC, 4. Metis/Cree, University of Northern British Columbia, Prince George, BC

▶ 16:15

EPH2.6

**Condomless sex among virally suppressed women living with HIV with serodiscordant sexual partners (E)**

**Sophie E. Patterson**<sup>1,2</sup>, Allison Carter<sup>1,2</sup>, Erin Ding<sup>2</sup>, Shahab Jabbari<sup>2</sup>, Mary Kestler<sup>3,4</sup>, Gina Ogilvie<sup>3,4</sup>, Valerie Nicholson<sup>1</sup>, Kath Webster<sup>1</sup>, Marisol Desbiens<sup>5</sup>, Daniele Dubuc<sup>6</sup>, Karène Proulx-Boucher<sup>6</sup>, Robert Hogg<sup>1,2</sup>, Alexandra de Pokomandy<sup>6</sup>, Mona Loutfy<sup>5,7</sup>, Angela Kaida<sup>1</sup>

1. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, 2. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, 3. British Columbia Women's Hospital and Healthcare Centre, Vancouver, BC, 4. Department of Medicine, University of British Columbia, Vancouver, BC, 5. Women's College Research Institute, Women's College Hospital, Toronto, ON, 6. McGill University Health Centre, Montreal, QC, 7. Department of Medicine, University of Toronto, Toronto, ON

▶ 16:30

EPH2.7

### **Coercive sex as a mode of HIV acquisition among a cohort of women with HIV in Canada: an under-recognized public health concern (E)**

**Mona Loutfy**<sup>1</sup>, Carmen Logie<sup>2</sup>, Anita Benoit<sup>1</sup>, Alexandra de Pokomandy<sup>3</sup>, Pat O'Campo<sup>6</sup>, Nadia O'Brien<sup>3</sup>, Saara Greene<sup>4</sup>, Wangari Tharao<sup>5</sup>, Jay MacGillivray<sup>6</sup>, Lu Wang<sup>7</sup>, Shahab Jabbari<sup>7</sup>, Nikita Arora<sup>4</sup>, V Logan Kennedy<sup>1</sup>, Allison Carter<sup>7</sup>, Karène Proulx-Boucher<sup>3</sup>, Allison Carlson<sup>1</sup>, Sally Lin<sup>7</sup>, Marisol Desbiens<sup>1</sup>, Kath Webster<sup>4</sup>, Danièle Dubuc<sup>3</sup>, Paul Sereda<sup>7</sup>, Guillaume Colley<sup>7</sup>, Robert Hogg<sup>7</sup>, Angela Kaida<sup>7</sup>

1. Women's College Research Institute, Women's College Hospital, Toronto, ON, 2. University of Toronto, Toronto, ON, 3. McGill University, Montreal, QC, 4. McMaster University, Hamilton, ON, 5. Women's Health in Women's Hands, Toronto, ON, 6. St. Michael's Hospital, Toronto, ON, 7. BC Centre for Excellence in HIV/AIDS, Vancouver, BC

▶ 16:45

EPH2.8

### **The impact of food insecurity on sexual HIV risk negotiation with clients among youth sex workers in Metro Vancouver, Canada (E)**

**Daniella F. Barreto**<sup>1, 2</sup>, Kate Shannon<sup>1, 3</sup>, Chrissy Taylor<sup>1</sup>, Sabina Dobrer<sup>1</sup>, Jessica St. Jean<sup>2</sup>, Shira M. Goldenberg<sup>1, 4</sup>, Putu Duff<sup>1, 3</sup>, Kathleen N. Deering<sup>1, 3</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. YouthCO HIV & Hep C Society, Vancouver, BC, 3. Faculty of Medicine, University of British Columbia, Vancouver, BC, 4. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC

## **Track D: Social Sciences: Innovative Approaches and Outcomes in Social Science HIV Research**

### **Volet D : Sciences sociales : Recherches sur le VIH en sciences sociales : Approches et résultats innovateurs**

Room: 9-10, Ground Level / Salle : 9-10, rez-de-chaussée  
 Co-Chairs / Coprésidents : Paula Migliardi, Dr. Gayle Restall

▶ 15:00

SS2.1

### **Are public testimonials effective in fighting stigma? Lessons learned from a community-based evaluation project in Québec (E)**

**Alexandra de Kiewit**<sup>2</sup>, **Aurélie Hot**<sup>1</sup>, Maria N. Mensah<sup>3</sup>, Thomas Haig<sup>3</sup>, Kenneth Monteith<sup>1</sup>, Marie Houzeau<sup>4</sup>

1. COCQ-SIDA, Montréal, QC, 2. Chez Stella, Montréal, QC, 3. UQAM, Montréal, QC, 4. GRIS Montréal, Montréal, QC

▶ **15:15** **SS2.2**  
**Transforming Interlocking Stigmas To Understanding, Compassion, and Hope: Critical Insights from CHAMP (E)**  
**Josephine P. Wong**<sup>2, 5</sup>, Kenneth Fung<sup>3, 5</sup>, Henry Luyombya<sup>4</sup>, Christian Hui<sup>4</sup>, Alexandro Bisignano<sup>4</sup>, Dale Maitland<sup>4</sup>, Alan Li<sup>1, 4</sup>  
 1. Regent Park Community Health Centre, Toronto, ON, 2. Ryerson University, Toronto, ON, 3. University Health Network, Toronto, ON, 4. Committee for Accessible AIDS Treatment, Toronto, ON, 5. University of Toronto, Toronto, ON

▶ **15:30** **SS2.3**  
**HAART in Art: Historical Reflections on Artwork, Corporeality, and HIV Treatment Adherence (E)**  
**Eli Manning**  
 Simon Fraser University, Vancouver, BC

▶ **15:45** **SS2.4**  
**Multi-Pronged Approach to Promote Integrative Knowledge Translation of Effective HIV Stigma Reduction Interventions (E)**  
**Alan T. Li**<sup>1, 2</sup>, **Josephine P. Wong**<sup>5</sup>, Henry Luyombya<sup>2</sup>, Fanta Ongoiba<sup>4</sup>, Rene Lopez<sup>9</sup>, Richard Utama<sup>3</sup>, Shannon Ryan<sup>8</sup>, Omer Abdulghani<sup>10</sup>, Kenneth Fung<sup>6, 7</sup>  
 1. Regent Park Community Health Centre, Toronto, ON, 2. Committee for Accessible AIDS Treatment, Toronto, ON, 3. Asian Community AIDS Services, Toronto, ON, 4. Africans in Partnerships Against AIDS, Toronto, ON, 5. Ryerson University, Toronto, ON, 6. University Health Network, Toronto, ON, 7. University of Toronto, Toronto, ON, 8. Black Coalition for AIDS Prevention, Toronto, ON, 9. Centre for Spanish Speaking Peoples, Toronto, ON, 10. Alliance for South Asians AIDS Prevention, Toronto, ON

▶ **16:00** **SS2.5**  
**Presenting research as visual narrative: Representing Black men, masculinity and HIV in “The Test” (E)**  
**Wesley Oakes**<sup>1</sup>, Winston Husbands<sup>2</sup>, Fanta Ongoiba<sup>1</sup>, Valérie Pierre-Pierre<sup>3</sup>, Henry Luyombya<sup>2</sup>, Yohannes Ayalew<sup>1</sup>, Patrick Soje<sup>1</sup>, Tola Mbulaheni<sup>3</sup>, Caroline Godbout<sup>4</sup>  
 1. Africans in Partnership Against AIDS, Toronto, ON, 2. AIDS Committee of Toronto, Toronto, ON, 3. African and Caribbean Council on HIV/AIDS in Ontario, Toronto, ON, 4. The CIHR Social Research Centre in HIV Prevention, University of Toronto, Toronto, ON

▶ **16:15** **SS2.6**  
**HIV Criminalization: Racialization, Immigration and the Media (E)**  
**Eric Mykhalovskiy**<sup>1</sup>, **Colin Hastings**<sup>1</sup>, **Chris Sanders**<sup>2</sup>, Laura Bisailon<sup>3</sup>  
 1. York University, Toronto, ON, 2. Lakehead University, Thunder Bay, ON, 3. University of Toronto, Scarborough, ON

▶ 16:30 SS2.7

**Number of Psychosocial Strengths Predicts Reduced HIV Sexual Risk Behaviours Above and Beyond Syndemic Problems Among Gay and Bisexual Men (E)**

**Trevor A. Hart**<sup>1, 3</sup>, Syed Noor<sup>1</sup>, Barry D. Adam<sup>2, 4</sup>, David Brennan<sup>3</sup>, Sandra Gardner<sup>3, 4</sup>, Winston Husbands<sup>5</sup>, Ted Myers<sup>3</sup>, Jessica Cattaneo<sup>5</sup>

1. Ryerson University, Toronto, ON, 2. University of Windsor, Windsor, ON, 3. University of Toronto, Toronto, ON, 4. Ontario HIV Treatment Network, Toronto, ON, 5. AIDS Committee of Toronto, Toronto, ON

▶ 16:45 SS2.8

**“More Than Fiction: Phase 2” – ASAAP Anthology Project for People Living with HIV/AIDS (E)**

**Shazia Islam**<sup>1</sup>, Sudin Sherchan<sup>1</sup>, Jaspreet Soor<sup>1</sup>, Haran Vijayanathan<sup>1</sup>, Lori A. Chambers<sup>2</sup>, Vijaya Chikermane<sup>1</sup>, Chhiring D. Sherpa<sup>1</sup>

1. Alliance for South Asian AIDS Prevention, Toronto, ON, 2. McMaster University, Hamilton, ON

**Saturday, May 14 / Samedi 14 mai**

**11:00 – 12:30**

**Multi-Disciplinary: PrEP and Other Novel HIV Prevention Strategies**

**Multidisciplinaire : PrEP/PPE et autres nouvelles stratégies de prévention du VIH**

Room: 3, Ground Level / Salle : 3, rez-de-chaussée

Co-Chairs / Coprésidents : Dr. Laurie Ireland, Dr. John Wylie

▶ 11:00 MD1.1

**High adherence but modest risk compensation among MSM in a PrEP demonstration project (E)**

**Darrell H. Tan**<sup>1, 2, 9</sup>, Alexandre Schnubb<sup>1</sup>, James Lawless<sup>1</sup>, Troy Grennan<sup>3</sup>, James Wilton<sup>4</sup>, Shawn Fowler<sup>5</sup>, Trevor A. Hart<sup>6, 7</sup>, John Maxwell<sup>8</sup>, Janet Raboud<sup>9, 7</sup>

1. St. Michael’s Hospital Division of Infectious Diseases, Toronto, ON, 2. University of Toronto Department of Medicine, Toronto, ON, 3. BC Centre for Disease Control, Vancouver, BC, 4. Ontario HIV Treatment Network, Toronto, ON, 5. Hassle Free Clinic, Toronto, ON, 6. Ryerson University Department of Psychology, Toronto, ON, 7. University of Toronto Dalla Lana School of Public Health, Toronto, ON, 8. AIDS Committee of



Toronto, Toronto, ON, 9. Toronto General Research Institute, Toronto, ON

▶ **11:15** **MD1.2**  
**Importance of Recruitment Process and Epidemic Initiation in Mathematical Models for Evaluating HIV Prevention Interventions (E)**

**Simon de Montigny**<sup>1</sup>, Benoît R. Mâsse<sup>1</sup>, Dobromir T. Dimitrov<sup>2</sup>  
 1. CHU Sainte-Justine Research Center, Montreal, QC, 2. Fred Hutchinson Cancer Research Center, Seattle, WA, USA

▶ **11:30** **MD1.3**  
**PrEP in Montreal: Good Adherence, No Seroconversion and No Evidence of Risk Compensation (E)**

**Réjean Thomas**<sup>1, 2</sup>, Chrissi Galanakis<sup>1</sup>, Sylvie Vézina<sup>1</sup>, Danièle Longpré<sup>1</sup>, Jean P. Kerba<sup>1</sup>, Gabrielle Landry<sup>1</sup>, Louise Charest<sup>1</sup>, Stéphane Lavoie<sup>1</sup>, Emmanuelle Huchet<sup>1</sup>, Benoit Trottier<sup>1, 2</sup>, Nimâ Machouf<sup>1, 3</sup>

1. Clinique médicale l'Actuel, Montréal, QC, 2. Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, 3. Université de Montréal, Montréal, QC

▶ **11:45** **MD1.4**  
**KONTAK: a service offered to guys who f\*\*\* other guys. You demand.....we supply ! (E)**

**Daniel J. Laroche**<sup>1</sup>, Nicolas Hamel<sup>2</sup>  
 1. AIDS Community Care Montreal, Montreal, QC, 2. Public Health Department of Montreal, Montreal, QC

▶ **12:00** **MD1.5**  
**Rectal 1% Tenofovir Gel use Modulates Epidermal Protein Expression (E)**

**Laura Romas**<sup>1, 2</sup>, Kenzie Birse<sup>1, 2</sup>, Kenneth H. Mayer<sup>3</sup>, Max Abou<sup>1</sup>, Garrett Westmacott<sup>4</sup>, Rebecca Guiguere<sup>5</sup>, Irma Febo<sup>6</sup>, Ross D. Cranston<sup>7</sup>, Alex Carballo-Diéguez<sup>5</sup>, Ian McGowan<sup>7</sup>, Adam Burgener<sup>1, 2, 8</sup>

1. National Laboratory for HIV Immunology, Public Health Agency of Canada, Winnipeg, MB, 2. University of Manitoba, Winnipeg, MB, 3. Fenway Health and Harvard Medical School, Boston, MA, USA, 4. Mass Spectrometry and Proteomics Core Facility, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, 5. HIV Center for Clinical and Behavioral Studies, Columbia University, New York, NY, USA, 6. University of Puerto Rico, San Juan, PR, USA, 7. Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA, 8. Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden

▶ **12:15** **MD1.6**  
**Daily oral use of acetylsalicylic acid (ASA) reduces HIV target cells at the female genital tract (E)**

**Julie Lajoie**<sup>1</sup>, Lucy Mwangi<sup>2</sup>, Geneviève Boily-Larouche<sup>1</sup>, Maureen Akolo<sup>3</sup>, John Mungai<sup>3</sup>, Juliana Cheruiyot<sup>3</sup>, Makubo Kimani<sup>3</sup>, Joshua Kimani<sup>2</sup>, Julius Oyugi<sup>2</sup>, Keith R. Fowke<sup>1, 2</sup>

1. University of Manitoba, Winnipeg, MB, 2. University of Nairobi, Nairobi, Kenya, 3. Kenyan AIDS Control Program, Nairobi, Kenya

## Multi-Disciplinary: HIV in Indigenous and Local Populations

### Multidisciplinaire : Le VIH dans les populations autochtones et locales

Room: 4, Ground Level / Salle : 4, rez-de-chaussée

Co-Chairs / Coprésidents : Renee Masching, Dr. Javier Mignone

#### ▶ 11:00 MD2.1

#### **Antiretroviral drug resistance among people experiencing treatment interruption in rural regions of British Columbia (E)**

**Denise Jaworsky**<sup>1</sup>, Geoff Shumilak<sup>1</sup>, Lauren J. MacKenzie<sup>4</sup>,<sup>1,2</sup>, Shahab Jabbari<sup>3</sup>, William Chau<sup>3</sup>, Wendy Zhang<sup>3</sup>, Viviane D. Lima<sup>3</sup>, Robert S. Hogg<sup>5,3</sup>, Julio S. Montaner<sup>3,1</sup>, Richard P. Harrigan<sup>3</sup>, Mark Hull<sup>3,1</sup>

1. University of British Columbia, Vancouver, BC, 2. Clinician Investigator Program, University of Manitoba, Winnipeg, MB, 3. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 4. CIHR Canadian HIV Trials Network, Vancouver, BC, 5. Simon Fraser University, Burnaby, BC

#### ▶ 11:15 MD2.2

#### **A Community Needs Assessment with Indigenous Peoples Living with HIV/AIDS in Saskatoon, Saskatchewan (E)**

**Andrew R. Hatala**<sup>1</sup>, **Ryan Meili**<sup>2</sup>, Michael Schwandt<sup>2</sup>, Kelley Bird-Naytowhow<sup>3</sup>, Tamara Pearl<sup>2</sup>, Adaobi Enyioma<sup>2</sup>, Jen Peterson<sup>4</sup>, Eddie Rooke<sup>5</sup>, Sugandhi Delcanto<sup>6</sup>

1. University of Manitoba, Winnipeg, MB, 2. University of Saskatchewan, Saskatoon, SK, 3. First Nations University of Canada, Saskatoon, SK, 4. Saskatoon Indian and Metis Friendship Centre, Saskatoon, SK, 5. SWITCH community Clinic, Saskatoon, SK, 6. Saskatchewan HIV/AIDS Research Endeavour (SHARE), Saskatoon, SK

#### ▶ 11:30 MD2.3

#### **The Cedar Project: Longitudinal health outcomes associated with childhood physical and sexual abuse among young Indigenous people who use drugs in BC (E)**

Margo E. Pearce<sup>1</sup>, **Kate A. Jongbloed**<sup>1</sup>, Wayne M. Christian<sup>2</sup>, Earl W. Henderson<sup>3</sup>, Martin T. Schechter<sup>1</sup>, Patricia M. Spittal<sup>1</sup>, For the Cedar Project Partnership

1. The Cedar Project, Vancouver, BC, 2. Splatshin/Secwepemc Nation, Enderby, BC, 3. Metis/Cree, University of Northern British Columbia, Prince George, BC

#### ▶ 11:45 MD2.4

#### **Developing Women-Centered HIV/AIDS Services in Manitoba: A Community-Based Participatory Research Study (E)**

**Laverne Gervais**<sup>2</sup>, **Sharon G. Bruce**<sup>1</sup>, Michael Payne<sup>3</sup>, Shohan Illsley<sup>4</sup>, Gayle Restall<sup>1</sup>, Theresa Sullivan<sup>1</sup>, Eve Cheuk<sup>1</sup>, Tammy Reimer<sup>3</sup>, Marissa Becker<sup>1</sup>

1. University of Manitoba, Winnipeg, MB, 2. Ka Ni Kanichihk, Winnipeg, MB, 3. Nine Circles, Winnipeg, MB, 4. 595 Prevention Team, Winnipeg, MB

▶ 12:00

MD2.5

### High Mortality Rates in HIV-Positive Individuals from Southern Saskatchewan – A Comparative Analysis Between Two Canadian Prairie Clinics (E)

Janessa Mann<sup>1</sup>, Briana Hagen<sup>2</sup>, Susanne Nasewich<sup>2</sup>, Julie Reed<sup>2</sup>, Cara Benz Tramer<sup>2</sup>, Maurice Hennink<sup>2</sup>, Tania Diener<sup>2</sup>, John Gill<sup>3</sup>, **Alexander Wong**<sup>2</sup>

1. University of Saskatchewan, Regina, SK, 2. Regina Qu'Appelle Health Region, Regina, SK, 3. Alberta Health Services, Calgary, AB

▶ 12:15

MD2.6

### HIV Transmission Networks in the Province of Saskatchewan (E)

Denise Werker<sup>1</sup>, **Rupert Capina**<sup>2</sup>, Paul Levett<sup>3</sup>, Greg Horsman<sup>3</sup>, Christina Daniuk<sup>2</sup>, Tracy Taylor<sup>2</sup>, Claudia Rank<sup>4</sup>, Mark Vanderkloot<sup>4</sup>, Susanna Ogunnaike-Cooke<sup>4</sup>, Chris Archibald<sup>4</sup>, James Brooks<sup>2</sup>, P. Richard Harrigan<sup>5</sup>, Paul Sandstrom<sup>2</sup>, Notifiable Disease Surveillance and Population Health Branch Teams<sup>1</sup>

1. Population Health Branch, Saskatchewan Ministry of Health, Regina, SK, 2. National Microbiology Laboratory at JC Wilt Infectious Diseases Research Center, Winnipeg, MB, 3. Saskatchewan Disease Control Laboratory, Regina, SK, 4. Surveillance and Epidemiology Division, Public Health Agency of Canada, Ottawa, ON, 5. BC Centre for Excellence in HIV/AIDS, Vancouver, BC

## Multi-Disciplinary: HIV in the Global Context

## Multidisciplinaire : Le VIH dans le contexte mondial

Room: 9-10, Ground Level / Salle : 9-10, rez-de-chaussée  
Co-Chairs / Coprésidents : Dr. Julius Oyugi, Dr. Sharmistha Mishra

▶ 11:00

MD3.1

### Social Construction of HIV/AIDS in an Indigenous population in Colombia (E)

Diana M. Castro<sup>1, 2</sup>, Juan F. Gamella<sup>2</sup>, **Carlos A. Rojas**<sup>1</sup>

1. Universidad de Antioquia, Medellín, Colombia, 2. Universidad de Granada, Granada, Spain

▶ 11:15

MD3.2

### Predictors and evolution of antiretroviral therapy adherence among HIV-infected adolescents in Brazil: results from a one-year longitudinal study (E)

Philippe Delmas<sup>1</sup>, José Côté<sup>2</sup>, Daisy M. Machado<sup>3</sup>, Eliana Galano<sup>4</sup>, **Patricia Auger**<sup>2</sup>, Hélène Sylvain<sup>5</sup>

1. University of Applied Sciences, School of Nursing, La Source, Lausanne, Switzerland, 2. Research Centre of the Centre Hospitalier de l'Université de Montréal, Montreal, QC, 3. Escola Paulista de Medicina/Universidade Federal De São Paulo, São

Paulo, SP, Brazil, 4. Centro de Referencia e Treinamento DST/Aids – Programa Estadual de São Paulo, São Paulo, SP, Brazil, 5. Université du Québec à Rimouski, Rimouski, QC

▶ 11:30

MD3.3

**Intervention fidelity, process evaluation and effectiveness of complex HIV prevention intervention for female sex workers in Bangladesh (E)**

**Nazmul Alam**<sup>1</sup>, Anadil Alam<sup>2</sup>, Quamrun Nahar<sup>2</sup>

1. University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, 2. International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh

▶ 11:45

MD3.4

**Low frequency AZT Drug Resistance in Ugandan Patients Failing ART with Susceptible HIV Sanger Genotyping (E)**

**Richard M. Gibson**<sup>1</sup>, Gabrielle Nickels<sup>2</sup>, Fred Kyeyune<sup>2,3</sup>, Colin Venner<sup>1</sup>, Immaculate Nankya<sup>3</sup>, Eva Nabulime<sup>3</sup>, Emmanuel Ndashimye<sup>3</sup>, Robert Salata<sup>2</sup>, Peter Mugenyi<sup>3</sup>, Miguel Quinones-Mateu<sup>2</sup>, Eric Arts<sup>1</sup>

1. University of Western Ontario, London, ON, 2. Case Western Reserve University, Cleveland, OH, USA, 3. Joint Clinical Research Centre, Kampala, Uganda

▶ 12:00

MD3.5

**Integrin a4b7 expression on CD4+ T cells as a predictor of HIV acquisition and disease progression (E)**

**Aida Sivo**<sup>2</sup>, Kerry Leask<sup>2</sup>, Anisha Balgobin<sup>2</sup>, Nigel Garrett<sup>2</sup>, Fatima Nawaz<sup>3</sup>, Claudia Cicala<sup>3</sup>, James Arthos<sup>3</sup>, Aftab A. Ansari<sup>4</sup>, Quarraisha Abdool Karim<sup>2</sup>, Salim Abdool Karim<sup>2</sup>, Lyle R. McKinnon<sup>1,2</sup>

1. Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, 2. Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, Durban, South Africa, 3. National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA, 4. Department of Pathology, Emory University School of Medicine, Atlanta, GA, USA

▶ 12:15

MD3.6

**Evidence for HIV-1 subtype-specific constraints on viral escape from host cellular immunity (E)**

Guinevere Lee<sup>2</sup>, Natalie N. Kinloch<sup>1</sup>, Jonathan M. Carlson<sup>3</sup>, Chanson J. Brumme<sup>2</sup>, Helen Byakwaga<sup>4,5</sup>, Conrad Muzoora<sup>5</sup>, Kyle Cobarrubias<sup>1</sup>, Mark A. Brockman<sup>1,2</sup>, Peter W. Hunt<sup>4</sup>, Jeff N. Martin<sup>4</sup>, Mary N. Carrington<sup>6</sup>, David R. Bangsberg<sup>7</sup>, P R. Harrigan<sup>2</sup>, **Zabrina L. Brumme**<sup>1,2</sup>

1. Simon Fraser University, Burnaby, BC, 2. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 3. Microsoft Research, Seattle, WA, USA, 4. University of California San Francisco, San Francisco, CA, USA, 5. Mbarara University, Mbarara, Uganda, 6. Frederick National Laboratory for Cancer Research, Frederick, MD, USA, 7. Harvard University, Boston, MA, USA

## Multi-Disciplinary: Community-based HIV Research

### Multidisciplinaire : La recherche communautaire sur le VIH

Room: 7-8, Ground Level / Salle : 7-8, rez-de-chaussée

Co-Chairs / Coprésidents : Margaret Ormond, Michael Payne

► 11:00

MD4.1

#### Use of the Vidaview Life Story Board as a novel qualitative interview tool for community-based research among people who use drugs (E)

**John V. Flynn**<sup>3, 1</sup>, Lisa M. Boucher<sup>1</sup>, Zack Marshall<sup>2</sup>, Katharine Larose-Hebert<sup>3</sup>, Alana Martin<sup>1, 4</sup>, Jenn Bigelow<sup>4</sup>, Christine Lalonde<sup>4</sup>, Dave Pineau<sup>4</sup>, Tiffany Rose<sup>4</sup>, Rob Chase<sup>5</sup>, Mark Tyndall<sup>6</sup>, Claire E. Kendall<sup>1</sup>

1. Bruyere Research Institute, Ottawa, ON, 2. Division of Community Health & Humanities, Faculty of Medicine, Memorial University, St-Johns, ON, 3. School of Social Work, Faculty of Social Sciences, University of Ottawa, Ottawa, ON, 4. Participatory Research Ottawa: Understanding Drugs. Community Advisory Committee, Ottawa, ON, 5. Department of Community Sciences, Faculty of Medicine, University of Manitoba, Winnipeg, MB, 6. British Columbia Centre for Disease Control, Vancouver, BC, 7. Department of Family Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON

► 11:15

MD4.2

#### The Spectrum of ARVs – What are Women Taking and How Well are they Doing? Findings from the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS) (E)

**Nadine Kronfli**<sup>1</sup>, Alexandra de Pokomandy<sup>2, 3</sup>, Lu Wang<sup>4</sup>, Erin Ding<sup>4</sup>, Shahab Jabbari<sup>4</sup>, Anita Benoit<sup>5</sup>, Ann Burchell<sup>6</sup>, Wangari Tharao<sup>7</sup>, Carmen Logie<sup>8</sup>, Neora Pick<sup>9</sup>, Mary Kestler<sup>9</sup>, Marisol Desbiens<sup>5</sup>, Kerrigan Beaver<sup>5</sup>, Tracey Conway<sup>5</sup>, Kath Webster<sup>10</sup>, Valerie Nicholson<sup>10</sup>, Allison Carlson<sup>5</sup>, Allison Carter<sup>10</sup>, Karène Proulx-Boucher<sup>3</sup>, Nadia O’Brien<sup>2, 10</sup>, Guillaume Colley<sup>4</sup>, Robert S. Hogg<sup>4, 10</sup>, Angela Kaida<sup>10</sup>, Mona Loutfy<sup>5, 11</sup>

1. Department of Infectious Diseases, McMaster University, Hamilton, ON, 2. Department of Family Medicine, McGill University, Montreal, QC, 3. Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, 4. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 5. Women’s College Research Institute, Women’s College Hospital, Toronto, ON, 6. Ontario HIV Treatment Network (OHTN), Toronto, ON, 7. Women’s Health in Women’s Hands Community Health Centre, Toronto, ON, 8. Faculty of Social Work, University of Toronto, Toronto, ON, 9. Oak Tree Clinic, Vancouver, BC, 10. Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, 11. Faculty of Medicine, University of Toronto, Toronto, ON

▶ 11:30

MD4.3

**“Who is there to support our women?”: Positive Aboriginal Women (PAW) speak out about health care experiences and needs during pregnancy and birth (E)**
**Saara Greene<sup>1</sup>, Allyson Ion<sup>1</sup>, Valerie Nicholson<sup>2</sup>, Kerrigan Beaver<sup>1</sup>**

1. McMaster University, Hamilton, ON, 2. Simon Fraser University, Faculty of Health Sciences, Burnaby, BC

▶ 11:45

MD4.4

**Mapping Home: Using Maps of Living Spaces to Augment Interview Data on HIV and Housing (E)**
**Darren Lauscher<sup>4</sup>, Heather J. Picotte<sup>1</sup>, Erin Anderlini<sup>5</sup>, Megan Deyman<sup>2, 1</sup>, Devyn Flesher<sup>1</sup>, Andrea Langlois<sup>1</sup>, Mona Lee<sup>1</sup>, Vicki Nygaard<sup>1</sup>, Charles Osborne<sup>6</sup>, Sherri Pooyak<sup>3</sup>, Jamie Reschny<sup>7</sup>, Catherine Worthington<sup>2</sup>**

1. Pacific AIDS Network, Vancouver, BC, 2. University of Victoria, Victoria, BC, 3. Canadian Aboriginal AIDS Network, Victoria, BC, 4. McLaren Housing Society of BC, Vancouver, BC, 5. Prince George Native Friendship Centre, Prince George, BC, 6. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 7. University of Northern British Columbia, Prince George, BC

▶ 12:00

MD4.5

**Exploring harm reduction practices among people who use injection drugs through use of qualitative interviews with the Vidaview Life Story Board (E)**
**Lisa M. Boucher<sup>1</sup>, Katharine Larose-Hebert<sup>2</sup>, John V. Flynn<sup>1, 2</sup>, Zack Marshall<sup>3</sup>, Alana Martin<sup>1, 4</sup>, Jenn Bigelow<sup>4</sup>, Christine Lalonde<sup>4</sup>, David Pineau<sup>4</sup>, Tiffany Rose<sup>4</sup>, Rob Chase<sup>5</sup>, Rob Boyd<sup>6</sup>, Mark Tyndall<sup>7</sup>, Claire E. Kendall<sup>1, 8</sup>**

1. Bruyère Research Institute, Ottawa, ON, 2. School of Social Work, Faculty of Social Sciences, University of Ottawa, Ottawa, ON, 3. Division of Community Health &amp; Humanities, Faculty of Medicine, Memorial University, St. John's, NL, 4. Participatory Research Ottawa: Understanding Drugs. Community Advisory Committee, Ottawa, ON, 5. Department of Community Health Sciences, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, 6. Sandy Hill Community Health Centre, Ottawa, ON, 7. BC Centre for Disease Control, Vancouver, BC, 8. Department of Family Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON

▶ 12:15

MD4.6

**“My focus is getting out into society.” Exploring activity and social participation needs and goals of people living with HIV (E)**
**Gayle Restall<sup>1</sup>, Tara Carnochan<sup>2</sup>, Pumulo Roddy<sup>3</sup>, Emily Etcheverry<sup>1</sup>, Kerstin Roger<sup>1</sup>, Theresa Sullivan<sup>1</sup>**

1. University of Manitoba, Winnipeg, MB, 2. Currently - Private Consultant; at the time of the study, Nine Circles Community Health Centre, Campbell River, BC, 3. Sexuality Education Resource Centre (SERC), Winnipeg, MB

15:00 – 17:00

**Track A: Basic Sciences: Virology****Volet A : Sciences fondamentales :  
Virologie**

Room: 4, Ground Level / Salle : 4, rez-de-chaussée

Co-Chairs / Coprésidents : Dr. Zabrina Brumme, Dr. Ruey-Chyi Su

▶ 15:00

BS3.1

**In Vivo Control of HIV Infection via Gene Therapy with a Secreted Entry Inhibitor (E)****Alexander Falkenhagen**<sup>1</sup>, Jastaranpreet Singh<sup>2</sup>, Sabah Asad<sup>3</sup>, Masoud Ameli<sup>4</sup>, Stanley Read<sup>1, 3</sup>, Juan C. Zúñiga-Pflücker<sup>2</sup>, Sadhna Joshi<sup>1, 4</sup>

1. Department of Laboratory Medicine &amp; Pathobiology, University of Toronto, Toronto, ON, 2. Department of Immunology, University of Toronto, Toronto, ON, 3. Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, 4. Department of Molecular Genetics, University of Toronto, Toronto, ON

▶ 15:15

BS3.2

**Leveraging Human Genetic Diversity to Define the Role of Siglec-1 in HIV Infection In Natura (E)****Paul J. McLaren**<sup>1, 2</sup>, Javier Martinez-Picado<sup>3</sup>, Nuria Izquierdo-Useros<sup>3</sup>, Amalio Telenti<sup>4</sup>

1. National HIV and Retrovirology Laboratory, JC Wilt Infectious Disease Research Center, Winnipeg, MB, 2. Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, 3. AIDS Research Institute IrsiCaixa, Universitat Autònoma de Barcelona, Barcelona, Spain, 4. Genomic Medicine, The J Craig Venter Institute, San Diego, CA, USA

▶ 15:30

BS3.3

**Role of Antibody-Dependent Cell-mediated Cytotoxicity in HIV-1 Uninfected Bystander CD4+ T Cell Killing (E)**Jonathan Richard<sup>1</sup>, Maxime Veillette<sup>1</sup>, Shilei Ding<sup>1</sup>, Daria Zoubchenok<sup>1</sup>, Nirmin Alshahafi<sup>2</sup>, Mathieu Coutu<sup>3</sup>, Nathalie Brassard<sup>3</sup>, Jongwoo Park<sup>4</sup>, Joel R. Courter<sup>4</sup>, Bruno N. Melillo<sup>4</sup>, Amos B. Smith III<sup>4</sup>, George M. Shaw<sup>4</sup>, Beatrice H. Hahn<sup>4</sup>, Joseph Sodroski<sup>5</sup>, Daniel E. Kaufmann<sup>1</sup>, **Andrés Finzi**<sup>1, 2</sup>

1. CRCHUM / Université de Montréal, Montreal, QC, 2. McGill, Montreal, QC, 3. CRCHUM, Montreal, QC, 4. University of Pennsylvania, Philadelphia, PA, USA, 5. DFCI / Harvard, Boston, MA, USA

Oral Presentations  
Exposés orauxSaturday  
Samedi

Track / Volet A

▶ **15:45** **BS3.4**  
**Combination of RNA molecules targeting the HIV-1 RNA for use in gene and drug therapy (E)**

Robert J. Scarborough, Olivier Del Corpo, Kelsey L. Adams, Aïcha Daher, **Anne Gatignol**

Lady Davis Institute for Medical Research/McGill University, Montréal, QC

▶ **16:00** **BS3.5**  
**HIV-1 Env but not Nef protein overcomes the inhibition by the ectopically expressed SERINC5 (E)**

**Saina Beitari**

McGill University, Montreal, QC

▶ **16:15** **BS3.6**  
**Plasma MicroRNA profiling predicts HIV-Associated Neurocognitive Disorder (E)**

**Eugene L. Asahchop**<sup>1</sup>, Segun M. Akinwumi<sup>5</sup>, William G. Branton<sup>1</sup>, Esther Fujiwara<sup>2</sup>, John M. Gill<sup>3, 6</sup>, Christopher Power<sup>1, 2, 4</sup>

1. Department of Medicine, University of Alberta, Edmonton, AB, 2. Department of Psychiatry, University of Alberta, Edmonton, AB, 3. Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, AB, 4. Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, AB, 5. Department of Mathematics and Statistics, University of Alberta, Edmonton, AB, 6. Southern Alberta Clinic, Calgary, Calgary, AB

▶ **16:30** **BS3.7**  
**Latently HIV-1 infected cells have defects in the type I IFN response that can be exploited for killing by oncolytic viruses (E)**

**Nischal Ranganath**<sup>1</sup>, Teslin S. Sandstrom<sup>1</sup>, Sandra C. Côté<sup>1, 2</sup>, Jonathan B. Angel<sup>1, 2</sup>

1. University of Ottawa, Ottawa, ON, 2. Ottawa Hospital Research Institute, Ottawa, ON

▶ **16:45** **BS3.8**  
**A significant role for Nef's N-terminal alpha-helix domain in its ability to sequester Lck and inhibit T cell signalling (E)**

**Tristan Markle**<sup>1</sup>, Steven Jin<sup>1</sup>, Tallie Kuang<sup>1</sup>, Philip Mwimanzi<sup>1</sup>, Gursev Anmole<sup>1</sup>, Mark Brockman<sup>2</sup>

1. Simon Fraser University, Vancouver, BC, 2. BC Centre for Excellence in HIV/AIDS, Vancouver, BC



## Track B: Clinical Sciences: HIV and Comorbidities

### Volet B : Sciences cliniques : VIH et comorbidités

Room: 7-8, Ground Level / Salle : 7-8, rez-de-chaussée

Co-Chairs / Coprésidents : Dr. Troy Grennan, Dr. Yoav Keynan

▶ 15:00

CS3.1

#### Mitigating the impact of selection bias on estimates of HAND prevalence (E)

**Nourane Ennabil**<sup>1</sup>, Marie-Josée Brouillette<sup>1</sup>, Lesley K. Fellows<sup>2</sup>, Nancy Mayo<sup>1</sup>, Positive Brain Health Now investigators  
1. McGill University Health Centre, Montreal, QC, 2. Montreal Neurological Hospital and Institute, Montreal, QC

▶ 15:15

CS3.2

#### Brain Dysfunction in HIV: Clustering of Cognitive and Motivational/Affective Symptoms (E)

**Marie-Josée Brouillette**<sup>1</sup>, Lesley K. Fellows<sup>2</sup>, Susan Scott<sup>1</sup>, Nancy E. Mayo<sup>1</sup>  
1. McGill University Health Centre, Montreal, QC, 2. Montreal Neurological Hospital and Institute, Montreal, QC

▶ 15:30

CS3.3

#### Prevalence and Cofactors of Nonalcoholic Fatty Liver Disease diagnosed by Transient Elastography with Controlled Attenuation Parameter in HIV Mono-infection (E)

**Elise Vuille-Lessard**, Bertrand Lebouche, Lynda Lennox, Costas Pexos, Alexandra De Pokomandy, Andreas Giannakis, Jason Szabo, Marina B. Klein, Giada Sebastiani  
McGill University Health Centre, Montreal, QC

▶ 15:45

CS3.4

#### Association between HIV-related factors and white matter hyperintensities (WMH) on brain MRI among HIV+ adults treated with HAART (E)

**Sean H. Ling**<sup>1</sup>, Shervin Mortazavi<sup>5</sup>, Wendy Zhang<sup>4</sup>, Guillaume Colley<sup>4</sup>, Aiko Yamamoto<sup>1</sup>, Mark Hull<sup>4, 3</sup>, Julio S. Montaner<sup>4</sup>, Ging-Yuek R. Hsiung<sup>6</sup>, Marianne Harris<sup>1, 2, 3</sup>, Silvia A. Guillemi<sup>1, 2, 3</sup>

1. AIDS Research Program, St. Paul's Hospital, Vancouver, BC, 2. Department of Family Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, 3. Division of HIV/AIDS, Department of Medicine, University of British Columbia, Vancouver, BC, 4. BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, 5. Department of Microbiology and Immunology, Faculty of Science, University of British Columbia, Vancouver, BC, 6. Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, BC

▶ 16:00

CS3.5

**The State of Health: The Impact of Select Co-morbidities on Life Expectancy (E)**

**Robert S. Hogg**<sup>1, 2, 3</sup>, Julio Montaner<sup>1, 2</sup>, Oghenowede Eyawo<sup>1, 3</sup>, Alex Collins<sup>1</sup>, Wendy Zhang<sup>1</sup>, William Chau<sup>1</sup>, Mark W. Hull<sup>1, 2</sup>, Viviane D. Lima<sup>1, 2</sup>, Jeannie Shoveller<sup>1, 4</sup>, Rolando Barrios<sup>1, 2</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, BC, 3. Faculty Health Sciences, Simon Fraser University, Burnaby, BC, 4. School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC

▶ 16:15

CS3.6

**Mitochondrial DNA Content in HIV-unexposed uninfected (HUU) and HIV-Exposed Uninfected (HEU) Children with Autism Spectrum Disorder (E)**

**Matthew Budd**<sup>1, 2</sup>, Kristina Calli<sup>3</sup>, Lindy Samson<sup>4, 5</sup>, Jennifer Bowes<sup>5</sup>, Ari Bitnun<sup>6</sup>, Fatima Kakkar<sup>7</sup>, Ariane Alimenti<sup>8</sup>, Evelyn J. Maan<sup>8, 9</sup>, M.E. S. Lewis<sup>3</sup>, Hélène C. Côté<sup>1, 2, 9</sup>, Jason Brophy<sup>4, 5</sup>, The CIHR Team on Cellular Aging and HIV Comorbidities in Women and Children (CARMA)

1. Dept of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, 2. Centre for Blood Research, Vancouver, BC, 3. Dept of Medical Genetics, University of British Columbia, Vancouver, BC, 4. Dept of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, ON, 5. Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, 6. The Hospital for Sick Children, University of Toronto, Toronto, ON, 7. CHU Sainte-Justine, Université de Montréal, Montréal, QC, 8. Oak Tree Clinic, BC Women's Hospital and Health Centre, Vancouver, BC, 9. Women's Health Research Institute, Vancouver, BC

▶ 16:30

CS3.7

**Impact of syndemics of substance use and depression on annual HIV care engagement and treatment outcomes: Results from the OHTN Cohort Study (OCS) (E)**

**Sean B. Rourke**<sup>1, 2, 3</sup>, Sandra Gardner<sup>1, 4</sup>, Tsegaye M. Bekele<sup>1</sup>, Beth Rachlis<sup>1</sup>, Ann Burchell<sup>2, 4</sup>, Mark Gilbert<sup>1</sup>, Frank McGee<sup>5</sup>, Jean Bacon<sup>1</sup>, Claire Kendall<sup>6</sup>, Conall O'Cleirigh<sup>7</sup>

1. The Ontario HIV Treatment Network, Toronto, ON, 2. St. Michael's Hospital, Toronto, ON, 3. Department of Psychiatry, University of Toronto, Toronto, ON, 4. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, 5. AIDS Bureau, Ontario Ministry of Health and Long-term Care, Toronto, ON, 6. University of Ottawa, Ottawa, ON, 7. Massachusetts General Hospital, Boston, MA, USA

▶ 16:45

CS3.8

**What Happens in Childhood Matters for Life: Childhood Adversities and Poor Health Outcomes among Participants of the Ontario Cohort Study (OCS) (E)**

Evan Collins<sup>1</sup>, **Tsegaye Bekele**<sup>2</sup>, Sandra Gardner<sup>2</sup>, Robert Maunder<sup>1</sup>, Jon Hunter<sup>1</sup>, Sergio Rueda<sup>1</sup>, Jason Globberman<sup>2</sup>, Anita Benoit<sup>3</sup>, Stephanie Choi<sup>2</sup>, Sean Rourke<sup>1, 2</sup>

1. Department of Psychiatry, University of Toronto, Toronto, ON, 2. Ontario HIV Treatment Network, Toronto, ON, 3. Dalla Lana School of Public Health, Toronto, ON

## Track C: Epidemiology and Public Health Sciences: Epidemiology of HIV and Co-infections

### Volet C : Épidémiologie et sciences de la santé publique : Épidémiologie du VIH et des coinfections

Room: 3, Ground Level / Salle : 3, rez-de-chaussée

Co-Chairs / Coprésidents : Dr. Claire Kendall, Dr. Tyler O'Neill

► 15:00

EPH3.1

#### Incidence of end-stage liver disease and liver-related mortality in HCV mono-infected vs. HIV/HCV co-infected patients in British Columbia (E)

Mark Hull<sup>1</sup>, Lianping Ti<sup>1</sup>, Oghenowede Eyawo<sup>1</sup>, Wendy Zhang<sup>1</sup>, Shahab Jabbari<sup>1</sup>, Robert S. Hogg<sup>2</sup>, Julio Montaner<sup>1</sup>

1. BC Centre For Excellence In HIV/AIDS, Vancouver, BC, 2. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC

► 15:15

EPH3.2

#### The British Columbia Hepatitis Testers Cohort (E)

Naveed Z. Janjua<sup>1, 2</sup>, Margot Kuo<sup>1</sup>, Chong Mei<sup>3</sup>, Amanda Yu<sup>1</sup>, Maria Alvarez<sup>1</sup>, Darrel Cook<sup>1</sup>, Rosemary Armour<sup>4</sup>, Aiken Ciaran<sup>5</sup>, Seyed Ali Mussavi Rizi<sup>6</sup>, Ryan Woods<sup>7</sup>, Jason Wong<sup>1, 2</sup>, Mark Tyndall<sup>1, 2</sup>, Mel Kraiden<sup>1, 3</sup>

1. Clinical Prevention Services, BC Centre for Disease Control, Vancouver, BC, 2. School of Population and Public Health, University of British Columbia, Vancouver, BC, 3. Communicable Disease Prevention and Control Services, BC Centre for Disease Control, Vancouver, BC, 4. British Columbia Ministry of Health, Victoria, BC, 5. BC Public Health Analytics, Vancouver, BC, 6. Performance Measurement and Reporting, PHSA, Vancouver, BC, 7. BC Cancer Registry, Vancouver, BC

► 15:30

EPH3.3

#### Update on HIV Strains and Transmitted Drug Resistance in Canada (E)

Claudia Rank<sup>1</sup>, Mark Vanderkloot<sup>1</sup>, Susanna Ogunnaike-Cooke<sup>1</sup>, Rupert Capina<sup>2</sup>, Christina Daniuk<sup>2</sup>, Tracy Taylor<sup>2</sup>, Paul Sandstrom<sup>2</sup>, Chris Archibald<sup>1</sup>

1. Surveillance and Epidemiology Division, Public Health Agency of Canada, Ottawa, ON, 2. National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, Public Health Agency of Canada, Winnipeg, MB

▶ **15:45** **EPH3.4**

**Rise in early stage diagnosis among key populations with expanded HIV testing in Vancouver, BC (E)**

Ellen Demlow<sup>1</sup>, Reka Gustafson<sup>1</sup>, Tianxin Chu<sup>1</sup>, Lauren MacDonald<sup>2</sup>, Afshan Nathoo<sup>1</sup>, Kate Heath<sup>3</sup>, Benita Yip<sup>3</sup>, William Chau<sup>3</sup>, Guillaume Colley<sup>3</sup>, Mark Gilbert<sup>4</sup>, Rolando Barrios<sup>1</sup>, Julio Montaner<sup>3</sup>, Jat Sandhu<sup>1</sup>, Patty Daly<sup>1</sup>

1. Vancouver Coastal Health Authority, Vancouver, BC, 2. British Columbia Centre for Disease Control, Vancouver, BC, 3. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, 4. Ontario HIV Treatment Network, Toronto, ON

▶ **16:00** **EPH3.5**

**Estimated national HIV incidence rates among key sub-populations in Canada, 2014 (E)**

Qiuying Yang, Susanna Ogunnaike-Cooke, **Jessica Halverson**, Ping Yan, Fan Zhang, Kristina Tomas, Dena Schanzer, Chris P. Archibald

Public Health Agency of Canada, Ottawa, ON

▶ **16:15** **EPH3.6**

**Canadian Perinatal HIV Surveillance Program (CPHSP): Demographics, Perinatal HIV Transmission, and Treatment in Pregnancy in Canada (E)**

**Joel Singer**<sup>1</sup>, Ari Bitnun<sup>7</sup>, Ariane Alimenti<sup>2</sup>, Terry Lee<sup>6</sup>, Lindy Samson<sup>3, 8</sup>, Jason Brophy<sup>3, 8</sup>, Deborah Money<sup>2</sup>, Wendy Vaudry<sup>4</sup>, Fatima Kakkar<sup>5</sup>, Normand Lapointe<sup>5</sup>, Laura Sauve<sup>2</sup>

1. University of British Columbia, Vancouver, BC, 2. BC Women's Hospital and Health Centre, Vancouver, BC, 3. Children's Hospital of Eastern Ontario, Ottawa, ON, 4. University of Alberta, Edmonton, AB, 5. Ste Justine Hospital, Montreal, QC, 6. Canadian HIV Trials Network, Vancouver, BC, 7. Department of Pediatrics, University of Toronto, Toronto, ON, 8. Department of Pediatrics, University of Ottawa, Ottawa, ON

▶ **16:30** **EPH3.7**

**HIV and other Sexually Transmitted Infections among African, Caribbean, and Black Men in Toronto, Canada (E)**

**LaRon E. Nelson**<sup>1, 3</sup>, Wangari Tharao<sup>2</sup>, Winston Husbands<sup>4</sup>, Ting Sa<sup>6</sup>, Nanhua Zhang<sup>6</sup>, Valerie Pierre-Pierre<sup>5</sup>, Sameer Kushwaha<sup>3</sup>, Rupert Kaul<sup>3</sup>

1. University of Rochester, Rochester, NY, USA, 2. Women's Health in Women's Hands, Toronto, ON, 3. University of Toronto, Toronto, ON, 4. AIDS Committee of Toronto, Toronto, ON, 5. African Caribbean Council on HIV/AIDS in Ontario (ACCHO), Toronto, ON, 6. Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

▶ **16:45** **EPH3.8**

**Characterizing Manitoba's HIV epidemic: A profile of the Manitoba HIV Program clinical cohort (E)**

**Leigh M. McClarty**<sup>1</sup>, Laurie Ireland<sup>2, 5</sup>, Nicole Herpai<sup>9</sup>, Eve Cheuk<sup>1</sup>, Souradet Y. Shaw<sup>1</sup>, Christine Bibeau<sup>7</sup>, Carla Ens<sup>8, 9</sup>, Claire Kendall<sup>6, 10</sup>, Clare Liddy<sup>6, 10</sup>, Yoav Keynan<sup>3, 4, 5</sup>, Ken Kasper<sup>3, 4, 5</sup>, Marissa L. Becker<sup>1, 3, 5</sup>

1. Centre for Global Public Health, Department of Community Health Sciences, University of Manitoba, Winnipeg, MB, 2. Nine Circles Community Health Centre, Winnipeg, MB, 3. Department of Internal Medicine, University of Manitoba, Winnipeg, MB, 4. Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, 5. Manitoba HIV Program, Winnipeg, MB, 6. Bruyère Research Institute, University of Ottawa, Ottawa, ON, 7. Community Scholar, LHIV Team, Winnipeg, MB, 8. Manitoba Health, Health Living and Seniors, Winnipeg, MB, 9. Department of Community Health Sciences, Winnipeg, MB, 10. Department of Family Medicine, University of Ottawa, Ottawa, ON

## Track D: Social Sciences: Programs and Policy Driven Research

### Volet D : Sciences sociales : Recherche axée sur les programmes et politiques

Room: 9-10, Ground Level / Salle : 9-10, rez-de-chaussée  
Co-Chairs / Coprésidents : Dr. Trevor Hart, Renee Masching

▶ 15:00

SS3.1

#### Living Life on ART: Results of the Sepo II Study in Lusaka, Zambia (E)

**Stephanie Nixon**<sup>1</sup>, Virginia A. Bond<sup>3</sup>, Patty Solomon<sup>4</sup>, Cathy Cameron<sup>2</sup>, Chanda Mwamba<sup>3</sup>, Jill Hanass-Hancock<sup>5</sup>, Anitha Menon<sup>6</sup>, Phillimon Simwaba<sup>7</sup>, Robert Sinyinza<sup>7</sup>, Margaret Siwale<sup>8</sup>, Tammy Yates<sup>9</sup>, Stephen Tattle<sup>9</sup>

1. University of Toronto, Toronto, ON, 2. International Centre for Disability and Rehabilitation (ICDR), Toronto, ON, 3. Zambart, Lusaka, Zambia, 4. McMaster University, Hamilton, ON, 5. University of KwaZulu-Natal, Durban, South Africa, 6. University of Zambia, Lusaka, Zambia, 7. Disability HIV&AIDS Trust (DHAT), Lusaka, Zambia, 8. Lusaka Trust Hospital, Lusaka, Zambia, 9. Canadian Working Group on HIV and Rehabilitation (CWGHR), Toronto, ON

▶ 15:15

SS3.2

#### Women Aging with HIV/AIDS and Housing: Experiences of Refugee Women (E)

**Amrita Ahluwalia**<sup>1, 2</sup>, Jeffrey Aguinaldo<sup>3</sup>, Joanne Lindsay<sup>1</sup>, Rajesh Pisharody<sup>4</sup>, Marisol Desbiens<sup>1</sup>, Rose Kangabe<sup>1</sup>, Lori Chambers<sup>5</sup>, Art Zoccole<sup>6</sup>, Kay Roeslein<sup>7</sup>, Mariama Leblanc<sup>2</sup>

1. Fife House Foundation, Toronto, ON, 2. Ryerson University, Toronto, ON, 3. Wilfrid Laurier University, Waterloo, ON, 4. Toronto People with AIDS Foundation, Toronto, ON, 5. McMaster University, Hamilton, ON, 6. 2-Spirited People of the 1st Nations, Toronto, ON, 7. Loft Community Services/McEwan Housing Support Service, Toronto, ON

▶ **15:30** **SS3.3**

**The Loss of Boystown and Transition to Online Sex Work: Strategies and Barriers to Increase Safety among Men Sex Workers and Clients of Men (E)**

**Elena Argento**<sup>1</sup>, Matthew Taylor<sup>2</sup>, Jody Jollimore<sup>2</sup>, Chrissy Taylor<sup>1</sup>, James Jennex<sup>2</sup>, Andrea Krusi<sup>1</sup>, Kate Shannon<sup>1,3</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. HUSTLE, Health Initiative for Men, Vancouver, BC, 3. Department of Medicine, University of British Columbia, Vancouver, BC

▶ **15:45** **SS3.4**

**Understanding The Health Status and Healthcare Needs of Gay And Other MSM In The Ottawa Area (E)**

**Nicholas Valela**<sup>1,2,3</sup>, Patrick O'Byrne<sup>2,3</sup>, Elliott Faller<sup>1</sup>, Andre Betim<sup>1</sup>, Paul MacPherson<sup>1,2</sup>

1. Ottawa Hospital Research Institute, Ottawa, ON, 2. University of Ottawa, Ottawa, ON, 3. Ottawa Public Health, Ottawa, ON

▶ **16:00** **SS3.5**

**Ethical Considerations of Providing Online Sexual Health Outreach for Gay, Bisexual, Two-Spirit and Other MSM (GB2M) among Outreach Workers (E)**

Sophia Fantus<sup>1</sup>, **David J. Brennan**<sup>1</sup>, Rusty Souleymanov<sup>1</sup>, Nathan J. Lachowsky<sup>1,2</sup>

1. Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, ON, 2. Faculty of Medicine, University of British Columbia, Vancouver, BC

▶ **16:15** **SS3.6**

**Demographic, Sexual, Testing, and Online Behavioural Differences of Bisexual Men Who Have Sex With Men (MSM) in Ontario (E)**

**Rusty Souleymanov**<sup>1</sup>, David Brennan<sup>1</sup>, Nathan J. Lachowsky<sup>1</sup>, Sophia Fantus<sup>1</sup>, Andre Ceranto<sup>1,2</sup>

1. Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, ON, 2. Fife House, Toronto, ON

▶ **16:30** **SS3.7**

**Assessing the Comprehensiveness of HIV Prevention, Treatment and Care Services for People Who Inject Drugs in Northern BC (E)**

**Jamie A. Reschny**

PhD Candidate, UNBC, Prince George, BC

▶ **16:45** **SS3.8**

**From One Ally to Another: Practical Guidelines to Better Include People who Use Drugs at Decision-making Tables (E)**

**Lynne Belle-Isle**<sup>1,2</sup>, Bernadette Pauly<sup>1</sup>, Cecilia Benoit<sup>1</sup>

1. Centre for Addictions Research of BC, University of Victoria, Victoria, BC, 2. Canadian AIDS Society, Ottawa, ON

# Posters

## Affiches

The posters are set up in the Exhibit and Poster Hall located in rooms 2FGH – Second Floor, North Building, RBC Convention Centre

Les affiches sont installées dans la salle des exposants et de présentation des affiches située dans la Salles 2FGH, deuxième étage, Édifice Nord, Centre des congrès RBC.

<b>Friday, May 13 / Vendredi 13 mai</b>	
<b>Time / Heure</b>	<b>Event / Événement</b>
<b>10:30 – 11:00</b>	<b>Exhibit and Poster Viewing – Refreshment Break</b> Exposition et présentation d'affiches – Pause-rafraîchissements
<b>14:00 – 15:00</b>	<b>Exhibit and Poster Viewing – Refreshment Break with Poster Authors Present</b> Exposition et présentation d'affiches – Pause-rafraîchissements en présence des auteurs <b>Poster Discussions – Basic and Clinical Sciences</b> Discussion sur les affiches – Sciences fondamentales et sciences cliniques
<b>Saturday, May 14 / Samedi 14 mai</b>	
<b>10:30 – 11:00</b>	<b>Exhibit and Poster Viewing – Refreshment Break</b> Exposition et présentation d'affiches – Pause-rafraîchissements
<b>14:00 – 15:00</b>	<b>Exhibit and Poster Viewing – Refreshment Break with Poster Authors Present</b> Exposition et présentation d'affiches – Pause-rafraîchissements en présence des auteurs <b>Poster Discussions – Epidemiology and Public Health and Social Sciences</b> Discussion sur les affiches – Épidémiologie et sciences de la santé publique et sciences sociales





▶ **BSP1.02****Validation of Multiplexed Quantum Dot-Barcode Diagnostic Technology to Detect HIV and Hepatitis B Virus Nucleic Acid (E)**

**Mia J. Biondi**<sup>1</sup>, Jisung Kim<sup>2</sup>, Kevin Ming<sup>2</sup>, Abdullah Syed<sup>2</sup>, Albert Lam<sup>2</sup>, Kun Chen<sup>2</sup>, Mario Ostrowski<sup>3</sup>, Anu Rebbapragada<sup>4</sup>, Warren C. Chan<sup>2</sup>, Jordan J. Feld<sup>1</sup>

1. Toronto General Research Institute, University Health Network, Toronto, ON, 2. Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, 3. Department of Immunology, University of Toronto, Toronto, ON, 4. Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON

▶ **BSP1.03****Inflammation Accompanies Immune Senescence in Human Immunodeficiency Virus Infection (E)**

**John Heath**, Neva Fudge, Maureen Gallant, Michael Grant  
Division of Biomedical Sciences, Memorial University of Newfoundland, St. John's, NL

▶ **BSP1.04****Hepatitis C virus core protein reduces CD8+ T-cell proliferation and perforin production (E)**

**Sarwat T. Khan**<sup>1,2</sup>, Curtis L. Cooper<sup>2</sup>, Angela M. Crawley<sup>1,2</sup>

1. Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, 2. The Ottawa Hospital Research Institute, Ottawa, ON

▶ **BSP1.05****Immunological Investigation into HIV/Mycobacterium tuberculosis co-Infection and Disease (E)**

**Jillian L. Waruk**<sup>1,6</sup>, Zipporah Machuki<sup>1,6</sup>, Christine Mesa<sup>5,2</sup>, Omu Anzala<sup>3,4</sup>, Meenu Sharma<sup>5,2</sup>, T Blake Ball<sup>1,6,4</sup>, Julius Oyugi<sup>4,1</sup>, Sandra Kiazzyk<sup>1,5,6</sup>

1. University of Manitoba, Winnipeg, MB, 2. Public Health Agency of Canada, Winnipeg, MB, 3. Kenyan AIDS Vaccine Initiative, Nairobi, Kenya, 4. University of Nairobi, Nairobi, Kenya, 5. National Reference Centre for Mycobacteriology, Winnipeg, MB, 6. National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, Winnipeg, MB

**HIV Immunology****Immunologie du VIH**▶ **BSP2.01****IL-32 is a Reliable Biomarker for HIV Disease Progression (E)**

Mohamed El Far<sup>1</sup>, Terry Lee<sup>2</sup>, Jean-Pierre Routy<sup>3</sup>, Marianne Harris<sup>4</sup>, Jean-guy Baril<sup>5</sup>, Benoit Trottier<sup>6</sup>, Petronela Ancuta<sup>7</sup>, Nicole Bernard<sup>8</sup>, **Cécile Tremblay**<sup>1</sup>

1. Centre Hospitalier de l'Université de Montréal, Montréal, QC, 2. CIHR Canadian HIV Trials Network, St. Paul's Hospital, Vancouver, BC, 3. Chronic Viral Illness Service, McGill University Health Centre, Montréal, QC, 4. AIDS Research Program, St. Paul's Hospital, Vancouver, BC, 5. Clinique Médicale Quartier Latin, Montréal, QC, 6. Clinique l'Actuel, Montréal, QC, 7.

Département de Microbiologie, Infectiologie et Immunologie,  
Faculté de Médecine, Université de Montréal, Montréal, QC, 8.  
Research Institute, McGill University Health Centre, Montréal,  
QC

▶ **BSP2.02**

**Assessment of the LAG-3 Inhibitory Mechanism on T cell Activation (E)**

**Colin G. Graydon**, Andrew T. Stalker, Jen A. Juno, Genevieve Boily-Larouche, Julie Lajoie, Keith R. Fowke  
University of Manitoba, Winnipeg, MB

▶ **BSP2.03**

**Reducing endogenous IRF-7 expression limits trans-activation of HIV-1 genes in primary human CD4+ T cells (E)**

**Angela Harris**<sup>1, 2</sup>, Ruey-Chyi Su<sup>1, 2</sup>, Blake Ball<sup>1, 2</sup>  
1. University of Manitoba, Winnipeg, MB, 2. National HIV and Retrovirology Laboratories, JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, MB

▶ **BSP2.04**

**Effect of Sex Work on the Vaginal Microbiome in a Cohort of Women from Nairobi, Kenya (E)**

Jocelyn M. Wessels<sup>1</sup>, Julie Lajoie<sup>2</sup>, Keith R. Fowke<sup>2, 3</sup>, Joshua Kimani<sup>2, 3</sup>, Mike Surette<sup>1</sup>, **Charu Kaushic**<sup>1</sup>  
1. McMaster University, Hamilton, ON, 2. University of Manitoba, Winnipeg, MB, 3. University of Nairobi, Nairobi, Kenya

▶ **BSP2.05**

**Inducing immune quiescence to reduce the number of HIV target cells in the female genital tract does not suppress the local innate immune response (E)**

**Monika M. Kowatsch**<sup>1</sup>, Lucy Mwangi<sup>2</sup>, Joshua Kimani<sup>1, 2</sup>, Julius Oyugi<sup>1, 2</sup>, Julie Lajoie<sup>1, 2</sup>, Keith R. Fowke<sup>1, 2</sup>  
1. University of Manitoba, Winnipeg, MB, 2. University of Nairobi, Nairobi, Kenya

▶ **BSP2.06**

**The effect of depot medroxyprogesterone acetate (DMPA) on the mucosal immune system in the female genital tract: implications for HIV risk (E)**

**Julie Lajoie**<sup>1, 2</sup>, Kenneth Omollo<sup>2</sup>, Maria Rohl<sup>3</sup>, Geneviève Boily-Larouche<sup>1</sup>, Juliana Cheruiyot<sup>4</sup>, Joshua Kimani<sup>2, 4, 1</sup>, Julius Oyugi<sup>1, 2</sup>, Kristina Broliden<sup>3</sup>, Keith R. Fowke<sup>1, 2</sup>  
1. University of Manitoba, Winnipeg, MB, 2. University of Nairobi, Nairobi, Kenya, 3. Karolinska Institute, Stockholm, Sweden, 4. Kenyan AIDS Control Program, Nairobi, Kenya

▶ **BSP2.07**

**Dynamics of antibody-mediated neutralization and ADCC response in HIV-positive individuals under suppressive antiretroviral therapy (E)**

**Jiaming Liang**<sup>1, 2</sup>, Bluma Brenner<sup>1</sup>, Jean-Pierre Routy<sup>3</sup>, **Thibault Mesplede**<sup>1</sup>, Mark A. Wainberg<sup>1, 2</sup>  
1. McGill AIDS Centre, Lady Davis Institute, McGill University, Montreal, QC, 2. Division of Experimental Medicine, McGill University, Montreal, QC, 3. For Montreal PHI Cohort Study Group, Montreal, QC

▶ **BSP2.08****Dichotomous Relationship of TLR7 and TLR8 Responses in HIV Exposed Seronegative Sex-Workers and Its Linkage to HIV Susceptibility in vitro (E)**

**Robert W. Omange**<sup>1</sup>, Ruey C. Su<sup>1, 5</sup>, Nyla Dil<sup>2</sup>, Winnie A. Apidi<sup>1</sup>, Cisily K. Meeme<sup>3</sup>, Nazanin Tatari<sup>1</sup>, Ayub K. Maina<sup>4</sup>, Meyers A. Adrienne<sup>1, 3, 5</sup>, Makobu Kimani<sup>3</sup>, Joshua Kimani<sup>3</sup>, Christine Mesa<sup>1</sup>, Sue Ramdahin<sup>1</sup>, Abdellilah S. Gounni<sup>1</sup>, Francis A. Plummer<sup>1, 3</sup>, Terry B. Ball<sup>1, 3, 5</sup>

1. University of Manitoba, Winnipeg, MB, 2. University of Central Florida, Orlando, FL, USA, 3. University of Nairobi, Nairobi, Kenya, 4. Jomo Kenyatta University of Agriculture and Technology, Juja, Kenya, 5. National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, Winnipeg, MB

▶ **BSP2.09****Interruption of sex work has subtle effects on systemic immune activation in sex workers from Nairobi, Kenya (E)**

**Kenneth Omollo**<sup>1</sup>, Geneviève Boily-Larouche<sup>2</sup>, Julie Lajoie<sup>2, 1</sup>, Makobu Kimani<sup>3</sup>, Juliana Cheuiyot<sup>3</sup>, Joshua Kimani<sup>2, 3, 1</sup>, Julius Oyugi<sup>1, 2</sup>, Keith R. Fowke<sup>1, 2</sup>

1. University of Nairobi, Nairobi, Kenya, 2. University of Manitoba, Winnipeg, MB, 3. Kenyan AIDS Control Program, Nairobi, Kenya

▶ **BSP2.10****Depot Medroxyprogesterone Acetate Increases T cell Activation Markers in the Female Genital Tract (E)**

**Kenneth Omollo**<sup>1</sup>, Julie Lajoie<sup>1, 2</sup>, Geneviève Boily-Larouche<sup>2</sup>, Juliana Cheuiyot<sup>3</sup>, Joshua Kimani<sup>1, 3, 2</sup>, Julius Oyugi<sup>1, 2</sup>, Kristina Broliden<sup>4</sup>, Keith R. Fowke<sup>1, 2</sup>

1. University of Nairobi, Nairobi, Kenya, 2. University of Manitoba, Winnipeg, MB, 3. Kenyan AIDS control Program, Nairobi, Kenya, 4. Karolinska Institute, Stockholm, Sweden

▶ **BSP2.11****Retinoic acid-mediated imprinting for gut homing renders Th17 cells highly permissive to HIV-1 infection by modulating the mTORC1 pathway (E)**

**Delphine Planas**<sup>1, 2</sup>, Yuwei Zhang<sup>1, 2</sup>, Patricia Monteiro<sup>1</sup>, Jean-Philippe Goulet<sup>3</sup>, Annie Gosselin<sup>1</sup>, Aurelie Cleret-Buhot<sup>1</sup>, Sandrina Da Fonseca<sup>1</sup>, Jean-Pierre Routy<sup>4</sup>, Petronela Ancuta<sup>1, 2</sup>

1. CHUM-Research Center, Montreal, QC, 2. University of Montreal, Montreal, QC, 3. Caprion, Montreal, QC, 4. McGill University Health Center, Montreal, QC

▶ **BSP2.12****The Effects of Oxytocin on the Immune Cytokine Profile of Vaginal, Ectocervical, and Endocervical Epithelial Cells (E)**

**Andrew M. Plesniarski**<sup>1, 2</sup>, Terry B. Ball<sup>1, 2</sup>, Ruey-Chyi Su<sup>1, 2</sup>

1. Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, 2. National HIV and Retrovirology Laboratories, JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, MB

▶ **BSP2.13****The Testis as an Immune Privileged site and its contribution to HIV Persistence: Assessing Myeloid-Derived Suppressor Cell distribution (E)**

**Rosalie Ponte**<sup>1,2</sup>, Vikram Mehraj<sup>1,2</sup>, Danica Albert<sup>1,2</sup>, Franck Dupuy<sup>1,2</sup>, Pierre Brassard<sup>3</sup>, Maud Bélanger<sup>3</sup>, Mohammad-Ali Jenabian<sup>4</sup>, Jean-Pierre Routy<sup>1,2</sup>

1. Research Institute of the McGill University Health Centre, Montreal, QC, 2. Chronic Viral Illness Service and Division of Hematology, McGill University Health Centre, Glen site, Montreal, QC, 3. Metropolitan Centre of Plastic Surgery, Montreal, QC, 4. Université du Québec à Montréal (UQAM), Montreal, QC

▶ **BSP2.14****Systemic Inflammation before and after antiretroviral therapy initiation as a predictor of immune response among HIV-infected individuals in Manitoba (E)**

**Quinlan D. Richert**<sup>1</sup>, Adriana Trajtman<sup>1</sup>, Julia Toews<sup>1</sup>, Marissa Becker<sup>1</sup>, Ken Kasper<sup>1</sup>, Zulma Rueda<sup>2</sup>, Yoav Keynan<sup>1</sup>

1. University of Manitoba, Winnipeg, MB, 2. Universidad Pontificia Bolivariana, Medellín, Colombia

▶ **BSP2.15****Immunologic non-response during HIV infection is associated with increased immune activation and markers of intestinal damage (E)**

**Rodney Rousseau**<sup>1</sup>, Connie J. Kim<sup>2</sup>, Erika Benko<sup>3</sup>, Sanja Huibner<sup>1</sup>, Kamnoosh Shahabi<sup>1</sup>, Colin Kovacs<sup>3</sup>, Rupert Kaul<sup>1</sup>

1. University of Toronto, Toronto, ON, 2. University Health Network, Toronto, ON, 3. Maple Leaf Medical Clinic, Toronto, ON

▶ **BSP2.16****Plasma Antibodies to HIV-1 Protease Cleavage Sites and HIV Infection (E)**

**Lukas T. Schroeder**<sup>1,2</sup>, Philip Lacap<sup>1</sup>, T B. Ball<sup>1,2</sup>, Joshua Kimani<sup>3,2</sup>, Francis A. Plummer<sup>2</sup>, Ma Luo<sup>1,2</sup>

1. National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, 2. Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, 3. Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya

▶ **BSP2.17****Activating Natural Killer (NK) Receptor (aNKR) Ligand Profile of HLA-Null and HIV-1 Infected CD4+ T Cells (E)**

**Alexandra Tremblay-McLean**<sup>1,2</sup>, Julie Bruneau<sup>3,4</sup>, Bertrand Lebouché<sup>2,5,6</sup>, Nicole F. Bernard<sup>1,2,6</sup>

1. Division of Experimental Medicine, McGill University, Montreal, QC, 2. Research Institute, McGill University Health Centre, Montreal, QC, 3. Department of Family Medicine, Université de Montréal, Montreal, QC, 4. Centre de Recherche de Centre Hospitalier de l'Université de Montréal, Montreal, QC, 5. Department of Family Medicine, McGill University, Montreal, QC, 6. Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC

## HIV Molecular Epidemiology, Including Host Genetics and HIV Evolution

### Épidémiologie moléculaire du VIH, y compris la génétique des hôtes et l'évolution du virus

#### ► BSP3.01

##### Expression Profiling Of Key Genes Involved In Glucose Metabolism in HIV Highly Exposed Yet Seronegative Commercial Sex Workers, Nairobi, Kenya (E)

Winnie A. Apidi<sup>1</sup>, Ruey C. Su<sup>1, 3</sup>, Joshua Kimani<sup>1, 2</sup>, Charles Wachihi<sup>2</sup>, Blake Ball<sup>1, 2, 3</sup>

1. Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, 2. Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya, 3. National HIV & Retrovirology Laboratory, J.C. Wilt Infectious Disease Research Centre, Public Health Agency of Canada, Winnipeg, MB

#### ► BSP3.02

##### Identification of endogenous retroviral protein coding sequences in the Major Histocompatibility Complex region of Cynomolgus Macaque (E)

Tomasz M. Bielawny<sup>1</sup>, Chris Czarnecki<sup>1</sup>, Dallas Orysiuk<sup>1</sup>, Frank Plummer<sup>2, 3</sup>, Paul Sandstrom<sup>1, 2</sup>, Ma Luo<sup>1, 2</sup>

1. National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, National Microbiology Laboratory, Winnipeg, MB, 2. Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, 3. National Microbiology Laboratory, Winnipeg, MB

#### ► BSP3.03

##### HIV-1 residues under strong functional constraint are predicted by measures of evolutionary rather than population-level genetic conservation (E)

Mina John<sup>2</sup>, Silvana Gaudieri<sup>2, 1, 3</sup>, Abha Chopra<sup>2</sup>, Shay Leary<sup>2</sup>, Jessica Jorritsma<sup>2</sup>, Simon Malla<sup>2, 3</sup>, Bemuluyigza Baraki<sup>1</sup>, Mark A. Brockman<sup>1, 4</sup>, **Zabrina L. Brumme**<sup>1, 4</sup>

1. Simon Fraser University, Burnaby, BC, 2. Murdoch University, Perth, WA, Australia, 3. Vanderbilt University, Nashville, TN, USA, 4. BC Centre for Excellence in HIV/AIDS, Vancouver, BC

#### ► BSP3.04

##### HIV Transmission Networks among Injection Drug Users in Pakistan (E)

Francois Cholette<sup>1</sup>, Laura Thompson<sup>2</sup>, John Ho<sup>1</sup>, Hillary McCoubrey<sup>1</sup>, Kiana Kadivar<sup>1</sup>, James Blanchard<sup>2</sup>, Faran Emmanuel<sup>2</sup>, James Brooks<sup>3</sup>, John Kim<sup>1</sup>, Paul Sandstrom<sup>1</sup>

1. National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, Public Health Agency of Canada, Winnipeg, MB, 2. Community Health Sciences, Centre for Global Public Health, University of Manitoba, Winnipeg, MB, 3. Communicable Disease Prevention and Control, British Columbia Centre for Disease Control, Vancouver, BC

▶ **BSP3.05****Killer-cell immunoglobulin-like receptor (KIR) 3DL/DS1 and HLA class I interactions associated with HIV-1 resistance or susceptibility (E)**

**Christopher K. Czarnecki**<sup>1</sup>, Michelle Nebroski<sup>1</sup>, David La<sup>1</sup>, Joshua Kimani<sup>2,3</sup>, Charles Wachih<sup>3</sup>, Francis Plummer<sup>1,2,3</sup>, Ma Luo<sup>1,2</sup>

1. Public Health Agency of Canada, Winnipeg, MB, 2. Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, 3. Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya

▶ **BSP3.06****Blind Dating: A Phylogenetic Approach to Dating HIV Reservoir Sequences (E)**

**Bradley R. Jones**<sup>1</sup>, Joshua Horacsek<sup>2</sup>, Jeffrey B. Joy<sup>1</sup>, Zabrina L. Brumme<sup>2</sup>, Art F. Poon<sup>1</sup>

1. BC CFE HIV/AIDS, Vancouver, BC, 2. Simon Fraser University, Burnaby, BC

▶ **BSP3.07****Phylogenetic clustering reveals some concordance with respondent-driven sampling recruitment chains among men who have sex with men (E)**

**Jeffrey B. Joy**<sup>1</sup>, Ashleigh Rich<sup>1</sup>, Nathan J. Lachowsky<sup>1</sup>, Susan Shurgold<sup>1</sup>, Art F. Poon<sup>1</sup>, Julio S. Montaner<sup>1</sup>, Eric A. Roth<sup>2</sup>, David M. Moore<sup>1</sup>, Robert S. Hogg<sup>1</sup>

1. BC CFE HIV/AIDS, Vancouver, BC, 2. University of Victoria, Victoria, BC

▶ **BSP3.09****Potential effects of TILRR (FREM1 isoform 2) in HIV-1 vaginal infection through interacting with TNF $\alpha$  and RANTES (E)**

**Mohammad A. Kashem**<sup>1,2</sup>, Philip Lacap<sup>2</sup>, Were Omange<sup>1</sup>, Francis A. Plummer<sup>1,3</sup>, Ma Luo<sup>1,2</sup>

1. Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, 2. National HIV and Retrovirology Laboratory, JC Wilt Infectious disease Research Centre, National Microbiology Laboratory, Winnipeg, MB, 3. National Microbiology Laboratory, Winnipeg, MB

▶ **BSP3.10****Higher Sequence Diversity in the Vaginal Tract than in Blood at 3 Months Post Infection (E)**

**Katja Klein**<sup>1</sup>, Gabrielle Nickel<sup>2</sup>, Immaculate Nankya<sup>3</sup>, Eric Arts<sup>1</sup>

1. University of Western Ontario, London, ON, 2. Case Western Reserve University, Cleveland, OH, USA, 3. Joint Clinical Research Centre, Kampala, Uganda

▶ **BSP3.11****Mining transcriptome data to train a classification model for the host resistance to HIV acquisition phenotype (E)**

**Lewis R. Liu**<sup>1,2</sup>, Paul J. McLaren<sup>1,2</sup>, Binhua Liang<sup>1,2</sup>, Brian Fristensky<sup>2</sup>, Blake T. Ball<sup>1,2</sup>, Francis A. Plummer<sup>1,2</sup>, Ma Luo<sup>1,2</sup>

1. National HIV and Retrovirology Laboratories, Winnipeg, MB, 2. University of Manitoba, Winnipeg, MB

**▶ BSP3.12****The Effects of Sex Hormones on Intravaginal HIV Infection in a Humanized Mouse Model (E)**

**Philip V. Nguyen**<sup>1</sup>, Jocelyn M. Wessels<sup>1</sup>, Kristen Mueller<sup>1</sup>, Varun Anipindi<sup>1</sup>, Fatemah Vahedi<sup>1</sup>, Uladzimir Karniychuk<sup>1</sup>, Marianne Chew<sup>1</sup>, Alexandre Deshiere<sup>2</sup>, Tony Mazzulli<sup>3, 4</sup>, Michel J. Tremblay<sup>2</sup>, Ali A. Ashkar<sup>1</sup>, Charu Kaushic<sup>1</sup>

1. McMaster University, Hamilton, ON, 2. Laval University, Quebec City, QC, 3. Ontario Public Health Laboratories, Toronto, ON, 4. Mt. Sinai Hospital, Toronto, ON

**▶ BSP3.13****Mutations in HIV-1 Nef associated with distinct disease outcome and their compensatory mutations (E)**

**Elnaz Shadabi**<sup>1</sup>, Binhua Liang<sup>2</sup>, Jonathan Carlson<sup>3</sup>, Raghavan Sampathkumar<sup>1</sup>, John Ho<sup>2</sup>, David La<sup>2</sup>, Francis A. Plummer<sup>2</sup>, Ma Luo<sup>2</sup>

1. University of Manitoba, Winnipeg, MB, Canada, 2. Public Health Agency of Canada, Winnipeg, MB, Canada, 3. Microsoft Research, Redmon, WA, USA

**▶ BSP3.14****Increased Copy Number of Interferon-Stimulated Response Element (ISRE) in HIV-1 Long Terminal Repeat (LTR) is Associated with Hastened HIV Disease Progression (E)**

Ramon J. Sales<sup>1, 2</sup>, Bernard Abrenica<sup>1</sup>, Ian MacArthur<sup>1</sup>, Joel Scott-Herridge<sup>1</sup>, Binhua Liang<sup>3</sup>, Depeng Jiang<sup>4</sup>, Joshua Kimani<sup>6</sup>, Lyle McKinnon<sup>5</sup>, T. B. Ball<sup>1, 5</sup>, Ma Luo<sup>1, 5</sup>, **Ruey-Chyi Su**<sup>1, 5</sup>

1. National HIV & Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, Public Health Agency of Canada, Winnipeg, MB, 2. Department of Biology, University of Winnipeg, Winnipeg, MB, 3. Bioinformatics, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, 4. Department of Community Health Sciences, University of Manitoba, Winnipeg, MB, 5. Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, 6. Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya

**▶ BSP3.15****Using CD4-aptamer-siRNA chimera to mimic the modestly reduced IRF-1 expression observed in HIV-exposed seronegative (HESN) Kenyan female sex workers (E)**

**Ruey-Chyi Su**<sup>1, 2</sup>, **Bernard Abrenica**<sup>1</sup>, Thomas Murooka<sup>3</sup>, T. Blake Ball<sup>1, 2, 3</sup>

1. National HIV & Retrovirology Laboratories, JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, MB, 2. Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, 3. Department of Immunology, University of Manitoba, Winnipeg, MB

▶ **BSP3.16****Comparison of two methodologies for an Illumina MiSeq-based HIV drug resistance assay (E)**

Tracy Taylor<sup>1</sup>, Mikaela M. Nykoluk<sup>1</sup>, Eric Enns<sup>2</sup>, Aileen Patterson<sup>1</sup>, Rupert Capina<sup>1</sup>, Francois Cholette<sup>1</sup>, Emma R. Lee<sup>1</sup>, Paul Sandstrom<sup>1,3</sup>, Hezhao Ji<sup>1,3</sup>

1. National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, Public Health Agency of Canada, Winnipeg, MB, 2. Bioinformatics Core Facility, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, 3. Department of Medical Microbiology, University of Manitoba, Winnipeg, MB

▶ **BSP3.17****Fine Mapping of the 9p22.3 Locus Implicates a Novel Microsatellite with the HIV-Exposed Seronegative Phenotype (E)**

Jeffrey F. Tuff<sup>1</sup>, David La<sup>1</sup>, Natasha Klavonski<sup>2</sup>, Valentina Ly<sup>2</sup>, Angela Yuen<sup>1</sup>, Binhua Liang<sup>2,4</sup>, Shaun Tyler<sup>2</sup>, Francis A. Plummer<sup>2,3</sup>, Ma Luo<sup>1,3</sup>

1. National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, Winnipeg, MB, 2. National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, 3. Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, 4. Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, MB

## HIV Prevention (Preclinical), Including Antiretrovirals, Microbicides, Vaccines, and HIV Resistance

### Prévention (préclinique) du VIH, antirétroviraux, microbicides, vaccins et résistance au VIH compris

▶ **BSP4.01****Differential Efficacy of Antiretroviral Drugs in Different Cellular Reservoirs (E)**

Eugene L. Asahchop<sup>1</sup>, Wing F. Chan<sup>1</sup>, William G. Branton<sup>1</sup>, Gail Rauw<sup>2</sup>, Glen B. Baker<sup>2</sup>, Christopher Power<sup>1,2,3</sup>

1. Department of Medicine, University of Alberta, Edmonton, AB, 2. Department of Psychiatry, University of Alberta, Edmonton, AB, 3. Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, AB

▶ **BSP4.02****Regulation of Mucosal and Systemic Immune Activation and Inflammation During the Menstrual Cycle of Female Sex Workers from Nairobi, Kenya (E)**

Geneviève Boily-Larouche<sup>1</sup>, Julie Lajoie<sup>1,3</sup>, Kenneth O. Omollo<sup>3</sup>, Julianna Cheruiyot<sup>2</sup>, Kara Lipski<sup>1</sup>, Monika Kowatsch<sup>1</sup>, Jane Njoki<sup>2</sup>, Makobu Kimani<sup>2</sup>, Julius Oyugi<sup>3</sup>, Joshua Kimani<sup>2</sup>, Keith R. Fowke<sup>1,3</sup>



1. Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, 2. Kenyan AIDS Control Program, University of Nairobi, Nairobi, Kenya, 3. Department Medical Microbiology, University of Nairobi, Nairobi, Kenya

▶ **BSP4.03**

**Sexual Activity Induced Differential Alterations in T cell Activation in HIV-Susceptible and Naturally Protected Female Sex Workers from Nairobi, Kenya (E)**

**Geneviève Boily-Larouche**<sup>1</sup>, Julie Lajoie<sup>1, 2</sup>, Kenneth O. Omollo<sup>2</sup>, Julianna Cheruiyot<sup>3</sup>, Jane Njoki<sup>3</sup>, Kara Lipski<sup>1</sup>, Monika Kowatsch<sup>1</sup>, Makobu Kimani<sup>3</sup>, Julius Oyugi<sup>2</sup>, Joshua Kimani<sup>3</sup>, Keith R. Fowke<sup>1, 2</sup>

1. Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, 2. Department Medical Microbiology, University of Nairobi, Nairobi, Kenya, 3. Kenyan AIDS Control Program, University of Nairobi, Nairobi, Kenya

▶ **BSP4.04**

**Hydroxychloroquine-loaded Implantable Device Suppresses Nonoxynol-9 Induced Inflammation and T-cell Activation in a Rabbit Vaginal Mucosal Model (E)**

**Yufei Chen**<sup>1</sup>, Yannick L. Traore<sup>1</sup>, Sidi Yang<sup>1</sup>, Andrew T. Stalker<sup>2</sup>, Julie Lajoie<sup>2, 5</sup>, Keith R. Fowke<sup>2, 3, 5</sup>, Daniel W. Rickey<sup>4</sup>, Emmanuel A. Ho<sup>1</sup>

1. Laboratory for Drug Delivery and Biomaterials. College of Pharmacy, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, 2. Department of Medical Microbiology and Infectious Diseases, College of Medicine, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, 3. Department of Community Health Sciences, College of Medicine, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, 4. Department of Radiology, College of Medicine, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, 5. Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya

▶ **BSP4.05**

**Protection from vaginal infection with HIV-1 and HSV-2 using a recombinant *C. crescentus* based microbicide (E)**

**Christina Farr Zuend**, John F. Nomellini, John Smit, Marc S. Horwitz

University of British Columbia, Vancouver, BC

▶ **BSP4.06**

**Multivalent HIV-1 env-based pseudovirus vaccines elicit broad humoral immune response in human CD4 B cell transgenic mouse model (E)**

Bernard S. Bagaya<sup>2</sup>, Meijuan Tian<sup>1</sup>, Jose Vega<sup>3</sup>, Yuejin Li<sup>3</sup>, Eric J. Arts<sup>1</sup>, **Yong Gao**<sup>1</sup>

1. University of Western Ontario, London, ON, 2. Makerere University, Kampala, Uganda, 3. Case Western Reserve University, Cleveland, OH, USA

**▶ BSP4.07****Development of a Mass Spectrometry-Based Absolute Quantitation Method of Griffithsin, a Viral-Entry Inhibitor and Candidate Microbicide Against HIV (E)**

**Lauren M. Girard**<sup>1, 2</sup>, Derek Davlut<sup>3</sup>, Max Abou<sup>1</sup>, Stuart McCorrister<sup>3</sup>, Patrick Chong<sup>3</sup>, Kenzie Birse<sup>1, 2</sup>, Garrett Westmacott<sup>3</sup>, Kenneth E. Palmer<sup>4, 5</sup>, Adam Burgener<sup>1, 2, 6</sup>

1. National HIV and Retrovirology Laboratories, JCVI Infectious Disease Research Centre, PHAC, Winnipeg, MB, 2. University of Manitoba, Winnipeg, MB, 3. National Microbiology Laboratory, PHAC, Winnipeg, MB, 4. Owensboro Cancer Research Program, Owensboro, KY, USA, 5. Department of Pharmacology and Toxicology, James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY, USA, 6. Karolinska Institutet, Stockholm, Sweden

**▶ BSP4.08****Development of Antibody-modified Chitosan Nanoparticles for the Targeted Delivery of siRNA Across the BBB as a Strategy for Inhibiting HIV Replication in Brain (E)**

**Jijin Gu**, Karam Al-Bayati, Emmanuel A. Ho  
University of Manitoba, Winnipeg, MB

**▶ BSP4.09****Investigating stHIV-1 Integrase Drug Resistance Profiles (E)**

Said Hassounah<sup>1, 2</sup>, **Thibault Mesplède**<sup>2</sup>, Maureen Oliveira<sup>2</sup>, Melissa Wares<sup>1, 2</sup>, Paul Sandstrom<sup>3</sup>, Mark Wainberg<sup>1</sup>

1. McGill University, Montreal, QC, 2. McGill AIDS CENTRE, Jewish General Hospital, Montréal, QC, 3. National HIV and Retrovirology Laboratory, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB

**▶ BSP4.10****Development of an assay to differentiate de novo HIV-1 virus from a latency reversing activator vector vaccine (E)**

Jessica L. Hill, Eric J. Arts, **Jamie F. Mann**  
University of Western Ontario, London, ON

**▶ BSP4.11****Expression of a SIVmac239 Gag-Pol Fusion Protein by Cynomolgus Macaque Cytomegalovirus for use in a SIV – Cynomolgus Macaque Vaccine Challenge Model (E)**

**Justen N. Hoffman Russell**<sup>1</sup>, Angie K. Marsh<sup>1</sup>, David O. Willer<sup>2</sup>, Aruna P. Ambagala<sup>2</sup>, Fatima C. Csordas<sup>2</sup>, Jacqueline K. Chan<sup>2, 3</sup>, Richard Pilon<sup>4</sup>, Joseph M. Antony<sup>2, 3</sup>, Paul Sandstrom<sup>4</sup>, Kelly S. MacDonald<sup>1, 2, 5</sup>

1. Department of Immunology, University of Toronto, Toronto, ON, 2. Department of Medicine, University of Toronto, Toronto, ON, 3. Department of Microbiology, Mount Sinai Hospital, Toronto, ON, 4. National HIV & Retrovirology Laboratories, Public Health Agency of Canada, Ottawa, ON, 5. Section of Infectious Diseases, Department of Internal Medicine, University of Manitoba, Winnipeg, MB

▶ **BSP4.12****Development and characterization of a modified R88-Apobec3G-based anti-HIV approach (E)**Zhujun Ao<sup>1</sup>, **Jing Huang**<sup>1, 2</sup>, Chongbo Zhao<sup>1</sup>, Xiaojian Yao<sup>1</sup>

1. Laboratory of Molecular Human Retrovirology, Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, 2. Department of Microbiology, School of Basic Medical Sciences, Central South University, Changsha, China

▶ **BSP4.14****The Presence of Natural SIV Antibodies and Inducible Endogenous SIV-like Antigens in Mauritian Cynomolgus Macaques (E)**

**Hongzhao Li**<sup>1, 2</sup>, Mikaela Nykoluk<sup>1</sup>, David Tang<sup>1</sup>, Jeff Tuff<sup>1</sup>, Christina Daniuk<sup>1</sup>, Lin Li<sup>1</sup>, Lewis Liu<sup>1</sup>, Kenzie Birse<sup>1</sup>, Chris Grant<sup>1</sup>, Garrett Westmacott<sup>1</sup>, Geoff Soule<sup>3</sup>, Thomas Bielawny<sup>1</sup>, Chris Czarnecki<sup>1</sup>, Philip Lacap<sup>1</sup>, Were Omange<sup>1</sup>, Meika Richmond<sup>1</sup>, Paul Lopez<sup>1</sup>, Nancy Schultz-Darken<sup>4</sup>, Maria Alonso<sup>5</sup>, James Whitney<sup>6</sup>, Ruey Su<sup>1</sup>, Adam Burgener<sup>1</sup>, Gary Kobinger<sup>3</sup>, Blake Ball<sup>1</sup>, Frank Plummer<sup>1</sup>, Paul Sandstrom<sup>1</sup>, Ma Luo<sup>1</sup>

1. National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, Winnipeg, MB, 2. Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, 3. National Microbiology Laboratory, Winnipeg, MB, 4. Wisconsin National Primate Research Center, Madison, WI, USA, 5. CIMUS Research Institute, University of Santiago de Compostela, Santiago de Compostela, Spain, 6. Harvard Medical School, Boston, MA, USA

▶ **BSP4.15****Sequential purification of highly specific antibodies against peptides of SIV protease cleavage sites (PCS) from crude monkey plasma (E)**

**Lin Li**<sup>1</sup>, Hongzhao Li<sup>1, 2</sup>, Tomasz M. Bielawny<sup>1</sup>, Christina A. Daniuk<sup>1</sup>, T B. Ball<sup>1, 2</sup>, Francis A. Plummer<sup>1, 2</sup>, Paul Sandstrom<sup>1, 2</sup>, Ma Luo<sup>1, 2</sup>

1. National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, Winnipeg, MB, 2. University of Manitoba, Winnipeg, MB

▶ **BSP4.16****Genital – Systemic chemokine gradients and the risk of HIV acquisition in women (E)**

**Lenine J. Liebenberg**<sup>1, 6</sup>, Lindi Masson<sup>2</sup>, Kelly B. Arnold<sup>3</sup>, Lyle R. McKinnon<sup>1, 4, 6</sup>, Lise Werner<sup>1</sup>, Elizabeth Proctor<sup>5</sup>, Derseree Archary<sup>1, 6</sup>, Leila E. Mansoor<sup>1</sup>, Douglas A. Lauffenberger<sup>5</sup>, Quarraisha Abdool Karim<sup>1, 7</sup>, Salim S. Abdool Karim<sup>1, 7</sup>, Jo-Ann S. Passmore<sup>1, 2, 8</sup>

1. Centre for the AIDS Programme of Research In South Africa, Durban, South Africa, 2. Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town, South Africa, 3. Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA, 4. Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, 5. Department of Biological Engineering, Massachusetts Institute

of Technology, Cambridge, MA, USA, 6. Department of Medical Microbiology, University of KwaZulu-Natal, Durban, South Africa, 7. Department of Epidemiology, Columbia University, New York, NY, USA, 8. National Health Laboratory Service, Johannesburg, South Africa

▶ **BSP4.17**

**Dolutegravir resistance alters HIV replicative capacity (E)**

Diane N. Singhroy, **Thibault Mesplède**, Maureen Oliveira, Susan Colby-Germinario, Bluma Brenner, Bonnie Spira, Mark Wainberg

McGill AIDS Centre-Lady Davis Institute, Montréal, QC

▶ **BSP4.18**

**Dolutegravir resistance decreases HIV-1 DNA integration (E)**

**Thibault Mesplède**, Jing Leng, Jiaming Liang, Kaitlin Anstett, Said Hassounah, Maureen Oliveira, Nathan Osman, Bonnie Spira, Hanh Thi Pham, Yingshan Han, Bluma Brenner, **Mark Wainberg**

McGill AIDS Centre-Lady Davis Institute, Montréal, QC

▶ **BSP4.19**

**Integrase Inhibitor Selection in Tissue Culture Using NRTI Mutant Viruses Favours Dolutegravir as an Effective Therapeutic Partner (E)**

**Maureen Oliveira**, Ilinca Ibanescu, Olga Golubkov, Bonnie Spira, Bluma Brenner, Thibault Mesplède, Mark A. Wainberg  
McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, QC

▶ **BSP4.20**

**Effect On Viral Fitness Of DTG-Resistance Mutations In NRTI/NNRTI Resistant Viruses (E)**

**Hanh T. Pham**<sup>1</sup>, Thibault Mesplède<sup>1</sup>, Mark A. Wainberg<sup>1, 2, 3</sup>

1. McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, 2. Division of Experimental Medicine, Faculty of Medicine, McGill University, Montréal, QC, 3. Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montréal, QC

▶ **BSP4.21**

**Development of a microscopy based high-throughput HIV phenotypic resistance assay (E)**

**Manraj Sidhu**<sup>1</sup>, Peter Cheung<sup>2</sup>, Wendy W. Zhang<sup>1</sup>, Aniqah Shahid<sup>2</sup>, Marjorie Robbins<sup>1, 2</sup>

1. University of British Columbia, Vancouver, BC, 2. BC Centre for Excellence in HIV/AIDS, Vancouver, BC

▶ **BSP4.22**

**Early Expression of Lymphocyte Activation Gene-3 on Human T cells (E)**

**Andrew T. Stalker**<sup>1</sup>, Jennifer Juno<sup>1</sup>, Keith R. Fowke<sup>1, 2</sup>

1. University of Manitoba, Winnipeg, MB, 2. University of Nairobi, Nairobi, Kenya

▶ **BSP4.23****Expression of SIVmac239 Gag and Env Genes and Protease Cleavage Site Sequences Using the Vesicular Stomatitis Virus Vector System (E)**

**David Tang**<sup>1</sup>, Gary Wong<sup>2,3</sup>, Hongzhao Li<sup>1</sup>, Chris Czarnecski<sup>1</sup>, Xin-Yong Yuan<sup>2</sup>, Gary Kobinger<sup>2,3</sup>, Francis Plummer<sup>2,3</sup>, Paul Sandstrom<sup>1</sup>, Ma Luo<sup>1,3</sup>

1. National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, 2. Canadian Science Centre for Human and Animal Health, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, 3. Department of Medical Microbiology, College of Medicine, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB

▶ **BSP4.24****Impact of Hydroxychloroquine-Loaded Polyurethane Intravaginal Rings on Lactobacilli (E)**

**Yannick L. Traore**<sup>1</sup>, Yufei Chen<sup>1</sup>, Anne-Marie Bernier<sup>2</sup>, Emmanuel Ho<sup>1</sup>

1. University of Manitoba, Winnipeg, MB, 2. Université de Saint-Boniface, Winnipeg, MB

▶ **BSP4.25****Combination Nanomicrobicide for the Efficient Gene Knockdown of CCR5 and Nef in CD4+ Immune Cells (E)**

**Sidi Yang**, Jijin Gu, Emmanuel A. Ho  
University of Manitoba, Winnipeg, MB

▶ **BSP4.26****Drug selection facilitates phenotypic examination of integrase inhibitor resistance in a HIV variant mixture (E)**

**Wendy W. Zhang**<sup>1</sup>, Peter Cheung<sup>2</sup>, Manraj Sidhu<sup>1</sup>, Aniq Shahid<sup>2</sup>, Zabrina Brumme<sup>2,3</sup>, Mark Brockman<sup>2,3</sup>, Stephen Shafran<sup>4</sup>, Karen Doucette<sup>4</sup>, Marjorie Robbins<sup>1,2</sup>

1. University of British Columbia, Vancouver, BC, 2. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 3. Simon Fraser University, Burnaby, BC, 4. University of Alberta, Edmonton, AB

**HIV Virology/Pathogenesis, Including Antiviral Mechanisms****Virologie/pathogénèse du VIH, mécanismes antiviraux compris**▶ **BSP5.01****A Highly-Conserved Residue of the HIV-1-gp120 Inner Domain is Important for ADCC Responses Mediated by Anti-Cluster A Antibodies (E)**

Shilei Ding<sup>1,2</sup>, Maxime Veillette<sup>1,2</sup>, Mathieu Coutu<sup>2</sup>, Jérémie Prévost<sup>1,2</sup>, Louise Scharf<sup>3</sup>, Pamela J. Bjorkman<sup>3</sup>, Christina Stürzel<sup>4</sup>, Daniel Sauter<sup>4</sup>, Frank Kirchhoff<sup>4</sup>, Marzena Pazgier<sup>5</sup>, **Andrés Finzi**<sup>1,2</sup>

1. Université de Montréal, Montreal, QC, 2. CRCHUM, Montreal,

QC, 3. Caltech, Pasadena, CA, USA, 4. Ulm University, Ulm, Germany, 5. University of Maryland, Baltimore, MD, USA

► **BSP5.02**

**Nef Protein from HIV-1 elite controllers are inefficient at preventing ADCC (E)**

Nirmin Alshafiq<sup>1, 2</sup>, Shilie Ding<sup>2, 3</sup>, Jonathan Richard<sup>2, 3</sup>, Tristan Markle<sup>4</sup>, Nathalie Brassard<sup>2</sup>, Bruce Walker<sup>6, 7</sup>, George K. Lewis<sup>8</sup>, Daniel E. Kaufmann<sup>2, 7, 3</sup>, Mark A. Brockman<sup>4, 5</sup>, **Andrés Finzi**<sup>1, 2, 3</sup>

1. McGill University, Montreal, QC, 2. Centre de Recherche du CHUM, Montreal, QC, 3. Université de Montréal, Montreal, QC, 4. Simon Fraser University, Vancouver, BC, 5. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, 6. Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA, 7. Howard Hughes Medical Institute, Chevy Chase, MD, USA, 8. Institute of Human Virology/ University of Maryland School of Medicine, Baltimore, MD, USA

► **BSP5.03**

**Activation of HIV-1 Gene Expression in Latently Infected PBMCs by a Small Molecule PKC-412 (E)**

Zhujun Ao, Xiaoli Tan, Jing Huang, Rong Zhu, **Xiaojuan Yao**  
University of Manitoba, Winnipeg, MB

► **BSP5.04**

**Longitudinal Quantitative Proteomics Study of Gut Dysfunction during Acute SIV Infection in Rhesus Macaques (E)**

Tiffany Hensley-McBain<sup>1</sup>, **Alicia R. Berard**<sup>2, 3</sup>, Kenzie Birse<sup>2, 3</sup>, Max Abou<sup>2</sup>, Laura Romas<sup>2, 3</sup>, Garrett Westmacott<sup>2</sup>, Stuart McCorry<sup>2</sup>, Nichole R. Klatt<sup>1</sup>, Adam Burgener<sup>2, 3, 4</sup>

1. Department of Pharmaceutics, Washington National Primate Research Centre, University of Washington, Seattle, WA, USA, 2. National HIV and Retrovirology Labs, JC Wilt Infectious Disease Research Centre, PHAC, Winnipeg, MB, 3. University of Manitoba, Winnipeg, MB, 4. Karolinska Institutet, Stockholm, Sweden

► **BSP5.05**

**Optimisation of the TILDA assay for the quantification of HIV reservoirs (E)**

**Liam Châtel**<sup>1, 2</sup>, François Cholette<sup>1</sup>, Xuefen Yang<sup>1</sup>, Maricar De Leon<sup>1, 3</sup>, Rémi Fromentin<sup>4</sup>, Nicolas Chomont<sup>4</sup>, Paul Sandstrom<sup>1</sup>, Carole Lavigne<sup>1, 2, 3</sup>

1. National HIV & Retrovirology Laboratories, JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, MB, 2. Université de Saint-Boniface, Winnipeg, MB, 3. College of Pharmacy, University of Manitoba, Winnipeg, MB, 4. Université de Montréal, Montréal, QC

► **BSP5.07**

**Evaluation of the MOLT-4 Viral Outgrowth Assay for the Quantification of the HIV Viral Reservoir (E)**

**Maricar De Leon**<sup>1, 2</sup>, Xuefen Yang<sup>1</sup>, Tae-Wook Chun<sup>3</sup>, Paul Sandstrom<sup>1</sup>, Carole Lavigne<sup>1, 2</sup>

1. National HIV & Retrovirology Laboratories, JC Wilt Infectious

Diseases Research Centre, Public Health Agency of Canada, Winnipeg, MB, 2. College of Pharmacy, University of Manitoba, Winnipeg, MB, 3. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA

▶ **BSP5.08**

**Variable Nef expression results in differences in Nef-mediated downregulation of MHC I and CD4 between HIV-1 subtypes (E)**

**Aaron L. Johnson**, Logan R. Van Nynatten, Mansour Haeryfar, Jimmy D. Dikeakos  
Western University, London, ON

▶ **BSP5.09**

**Lentiviral Counteraction of Oncogenic APOBEC3 Proteins (E)**

**Allison M. Land**

Minnesota State University Mankato, Mankato, MN, USA

▶ **BSP5.10**

**Development of a latency reversing activator vaccine (ACT-VEC) platform as a curative approach for SIV (E)**

**Jamie F. Mann**<sup>1</sup>, Ronald Veazey<sup>2</sup>, Joshua Pankrac<sup>1</sup>, Katja Klein<sup>1</sup>, Robin J. Shattock<sup>3</sup>, Eric J. Arts<sup>1</sup>

1. University of Western Ontario, London, ON, 2. Tulane National Primate Research Center, Covington, LA, USA, 3. Imperial College London, London, United Kingdom

▶ **BSP5.11**

**Dynamics of DC:T cell interactions and their implications on HIV-1 dissemination (E)**

Paul Lopez, **Thomas T. Murooka**  
University of Manitoba, Winnipeg, MB

▶ **BSP5.12**

**Insulin suppresses virus replication and neuroinflammation with improved neurological outcomes in models of HIV/AIDS (E)**

Manmeet K. Mamik<sup>1</sup>, **Eugene L. Asahchop**<sup>1</sup>, Yu Zhu<sup>1</sup>, William G. Branton<sup>1</sup>, Brienne A. McKenzie<sup>2</sup>, Christopher Power<sup>1, 2, 3</sup>

1. Department of Medicine, University of Alberta, Edmonton, AB, 2. Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, AB, 3. Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB

▶ **BSP5.13**

**In vitro assessment of the function of naturally occurring Vpu sequences without codon optimization or rev-dependent expression (E)**

**Asa Rahimi**<sup>1</sup>, Kyle Cobarrubias<sup>1</sup>, Gursev Anmole<sup>1</sup>, Tristan Markle<sup>1</sup>, Tania Jimena Escamilla Gómez<sup>2</sup>, Maribel Soto Nava<sup>2</sup>, Santiago Avila<sup>2</sup>, Gustavo Reyes-Teran<sup>2</sup>, Mark A. Brockman<sup>1</sup>, Zabrina L. Brumme<sup>1</sup>

1. Simon Fraser University, Burnaby, BC, 2. Centro de Investigación en Enfermedades Infecciosas, Mexico City, MEX, Mexico

**▶ BSP5.14****Stimulation of HIV transcription by virion-associated envelope glycoprotein (gp120) through manipulating different cellular machineries (E)**

Xiaozhuo Ran<sup>1</sup>, Zhujun Ao<sup>1</sup>, Xu Zhang<sup>1</sup>, Adriana Trajtman<sup>2</sup>, Yoav Keynan<sup>2</sup>, Xiaojian Yao<sup>1</sup>

1. Laboratory of Molecular Human Retrovirology, Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Canada, Winnipeg, MB, 2. Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Canada, Winnipeg, MB

**▶ BSP5.15****Single-Particle Characterization of MLV and HIV by Flow Virometry (E)**

Tyler M. Renner, Vera A. Tang, Marc-André Langlois  
University of Ottawa, Ottawa, ON

**▶ BSP5.16****Characterizing the impaired type I interferon response in HIV-infected myeloid cells (E)**

Teslin S. Sandstrom<sup>1</sup>, Nischal Ranganath<sup>1</sup>, Sandra C. Côté<sup>1,2</sup>, Jonathan B. Angel<sup>1,2</sup>

1. Biochemistry, Microbiology & Immunology, University of Ottawa, Ottawa, ON, 2. Ottawa Hospital Research Institute, Ottawa, ON

**▶ BSP5.17****Slow disease progression of women infected with HIV-1 subtype C versus subtype A and D: Implications for the epidemic (E)**

Colin M. Venner<sup>1</sup>, Immaculate Nankya<sup>2</sup>, Eric Arts<sup>1</sup>

1. University of Western Ontario, London, ON, 2. Joint Clinical Research Centre, Kampala, Uganda

**▶ BSP5.18****The V3 Loop of HIV-1 Env Regulates Virus Susceptibility to IFITM Inhibition (E)**

Yimeng Wang

McGill University, Montréal, QC

**▶ BSP5.19****Investigation of the effect of IL-34 on HIV-1 infection in CD4+ T lymphocytes, matured macrophages and underlying mechanisms (E)**

Xu Zhang, Xiaozhuo Ran, Zhujun Ao, Xiaojian Yao

Laboratory of Molecular Human Retrovirology, Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Canada, Winnipeg, MB



## Lab Testing and Monitoring

### Épreuves de laboratoire et surveillance

#### ▶ **BSP6.01**

#### **HIV Drug Resistance Mutation Genotyping from Low Viral Load Specimens Stored as Dried Blood Spots (E)**

**Francois Cholette**<sup>1</sup>, Emma Lee<sup>1</sup>, Tracy Taylor<sup>1</sup>, Rupert Capina<sup>1</sup>, Hezhao Ji<sup>1</sup>, Christina A. Daniuk<sup>1</sup>, Aileen Patterson<sup>1</sup>, James Brooks<sup>2</sup>, Paul Sandstrom<sup>1</sup>

1. National HIV and Retrovirology Laboratories, JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, MB, 2. Communicable Disease Prevention and Control, British Columbia Centre for Disease Control, Vancouver, BC

#### ▶ **BSP6.02**

#### **Evaluation of the Pima Analyser for CD4 enumeration in HIV patients (E)**

**Tamsir O. Diallo**<sup>1</sup>, Margot Plews<sup>1</sup>, Michele Bergeron<sup>1</sup>, Linda Ares<sup>1</sup>, Syeda Rahman<sup>1</sup>, Xuefen Yang<sup>1</sup>, Paul Sandstrom<sup>1,2</sup>, Blake T. Ball<sup>1,2,3</sup>, Adrienne F. Meyers<sup>1,2,3</sup>

1. National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, Public Health Agency of Canada, Winnipeg, MB, 2. Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, 3. Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya

#### ▶ **BSP6.03**

#### **Comparison of two HTLV confirmatory assays : INNO-LIA™ HTLV I/II Score and in-house HTLV-I RIPA (E)**

**John K. Ho**, Kiana Kadivar, Stephanie S. Lavoie, Dione Ng, Laurie Malloch, John Kim

National HIV and Retrovirology Laboratories, NML-PHAC, Winnipeg, MB

#### ▶ **BSP6.04**

#### **Modernizing the data reviewing strategies for enhanced HIV virology quality assurance in next generation sequencing era (E)**

Tracy Taylor<sup>1</sup>, Rupert Capina<sup>1</sup>, Aileen Patterson<sup>1</sup>, Francois Cholette<sup>1</sup>, Emma R. Lee<sup>1</sup>, Christina A. Daniuk<sup>1</sup>, Paul Sandstrom<sup>1,2</sup>, **Hezhao Ji**<sup>1,2,3</sup>

1. National HIV and Retrovirology Laboratories, JC Wilt Infectious Diseases Research Center, Public Health Agency of Canada, Winnipeg, MB, 2. Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, 3. Department of Biology, University of Winnipeg, Winnipeg, MB

#### ▶ **BSP6.05**

#### **What impact does plasma storage temperature have on HIV-1 viral load quantification? (E)**

**Kiana Kadivar**, Stephanie Lavoie, John Kim, Canadian Public Health Labs

National HIV and Retrovirology Laboratories, JCWilt Infectious Disease Center, NML-PHAC, Winnipeg, MB

▶ **BSP6.06****Specimens from Pregnant Women yielding False-Reactive Results on the Abbott Architect HIV Ag/Ab Combo Assay Leading to mis-Diagnosis and Negative Patient Impact (E)**

**John Kim**<sup>1</sup>, Kamran Kadkhoda<sup>2</sup>, John Gill<sup>3</sup>, Debbie Caswell<sup>4</sup>, Paul Levett<sup>4</sup>, Stephanie Lavoie<sup>1</sup>, Kiana Kadivar<sup>1</sup>

1. National HIV and Retrovirology Laboratories, JCWilt Infectious Disease Center, NML-PHAC, Winnipeg, MB, 2. Cadham Provincial Public Health Laboratory, Winnipeg, MB, 3. Southern Alberta HIV Clinic, Calgary, AB, 4. Saskatchewan Disease Control Laboratory, Regina, SK

▶ **BSP6.07****Development and Validation of a Whole-Genome Sequencing and Analysis Pipeline for the Clinical Testing of HTLV-I Positive Patients (E)**

**David La**, Emma R. Lee, John Kim

National HIV and Retrovirology Laboratories, JCWilt Infectious Disease Center, NML-PHAC, Winnipeg, MB

▶ **BSP6.08****Comparison of Two Digital PCR Platforms and Development of an HIV-2 Quantitative Assay (E)**

**Stephanie Lavoie**, François Cholette, Dione Ng, John Kim  
National HIV and Retrovirology Laboratories, JCWilt Infectious Disease Center, NML-PHAC, Winnipeg, MB

▶ **BSP6.09****IL-33/sST2 axis in HIV Infection and its Correlation with Patient Outcomes and Markers of Gut damage (E)**

**Vikram Mehraj**<sup>1, 2</sup>, Mohammad-Ali Jenabian<sup>3</sup>, Rosalie Ponte<sup>1, 2</sup>, Bertrand Lebouché<sup>1, 2, 4</sup>, Cecilia Costiniuk<sup>1</sup>, Réjean Thomas<sup>5</sup>, Benoit Trottier<sup>5</sup>, Jean-Guy Baril<sup>6</sup>, Roger LeBlanc<sup>7</sup>, Cécile Tremblay<sup>8, 9</sup>, Jean-Pierre Routy<sup>1, 2, 10</sup>

1. Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, 2. Research Institute of the McGill University Health Centre, Montreal, QC, 3. Department of Biological Sciences and BioMed Research Centre, Université du Québec à Montréal (UQAM), Montreal, QC, 4. Department of Family Medicine, McGill University, Montreal, QC, 5. Clinique Médicale l'Actuel, Montréal, QC, 6. Clinique Médicale Quartier Latin, Montréal, QC, 7. Clinique Médicale OPUS, Montréal, QC, 8. Centre de recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC, 9. Département de microbiologie, infectiologie et immunologie, Université de Montréal, Montréal, QC, 10. Division of Hematology, McGill University Health Centre, Montreal, QC

▶ **BSP6.10****Bio-Rad Geenius™ HIV-1/2 versus Bio-Rad HIV-1/2 Multispot and Fujirebio INNO-LIA™ HIV I/II Score as a suitable confirmatory test for the CLSI-M53 HIV Guideline (E)**

**Dione Ng**, Laurie Malloch, Kiana Kadivar, Stephanie Lavoie, Barb Calder-Kent, Yawa Adonsou-Hoyi, John Ho, David La, Brynn Mistafa, John Kim

National HIV and Retrovirology Laboratories, JCWilt Infectious Disease Center, NML-PHAC, Winnipeg, MB

▶ **BSP6.11****Point of Care Technology within the Quality Assessment and Standardization for Immunological measures relevant to HIV/AIDS (QASI) Program (E)**

**Margot Plews**<sup>1</sup>, Tamsir O. Diallo<sup>1</sup>, Linda Ares<sup>1</sup>, Michele Bergeron<sup>1</sup>, T. Blake Ball<sup>1, 2, 3</sup>, Paul Sandstrom<sup>1, 2</sup>, Adrienne F. Meyers<sup>1, 2, 3</sup>

1. National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, Public Health Agency of Canada, Winnipeg, MB, 2. Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, 3. Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya

**Basic Sciences Other****Sciences fondamentales, Autre**▶ **BSP7.01****A Social Networking Analysis of the Canadian HIV Vaccine Initiative Research and Development Alliance (E)**

**Deborah Douglas**<sup>1, 2</sup>, Tanya Merke Epp<sup>1, 2</sup>, Allan Ronald<sup>1, 2, 3</sup>

1. Alliance Coordinating Office, Winnipeg, MB, 2. International Centre for Infectious Disease, Winnipeg, MB, 3. University of Manitoba, Winnipeg, MB

▶ **BSP7.02****Full-Length Ultra-Deep Sequencing Reveals Novel Alleles in SIVmac239 isolated from Non-Controller SIV-infected Cynomolgus Macaques (E)**

**Emma R. Lee**<sup>1</sup>, Eric Enns<sup>5</sup>, Tracy Taylor<sup>1</sup>, Rupert Capina<sup>1</sup>, Francois Cholette<sup>1</sup>, Hezhao Ji<sup>1, 2</sup>, Paul McLaren<sup>1, 2</sup>, James Brooks<sup>3</sup>, Kelly S. MacDonald<sup>1, 4</sup>, Paul Sandstrom<sup>1, 2</sup>

1. National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Center, Public Health Agency of Canada, Winnipeg, MB, 2. Department of Medical Microbiology and Infectious Disease, University of Manitoba, Winnipeg, MB, 3. Communicable Disease Prevention and Control, British Columbia Centre for Disease Control, Vancouver, BC, 4. Department of Medicine, University of Manitoba, Winnipeg, MB, 5. Bioinformatics Core Facility, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB

▶ **BSP7.03****Connecting you to the Canadian HIV Vaccine Initiative Research and Development Alliance (E)**

**Tanya Merke Epp**<sup>1</sup>, Allan Ronald<sup>1, 2</sup>, Deborah Douglas<sup>1</sup>

1. Alliance Coordinating Office, International Centre for Infectious Diseases, Winnipeg, MB, 2. University of Manitoba, Winnipeg, MB

▶ **BSP7.04****The impact of the CIHR-funded International Infectious Diseases and Global Training Program on HIV research trainees from developing nations (E)**

**Julius Oyugi**<sup>1, 2</sup>, Natasha Hollett<sup>2</sup>, Carlos Rojas<sup>3</sup>,

Krishnamurthy Jayanna<sup>4</sup>, Stephen Moses<sup>2</sup>, John Wylie<sup>2</sup>, Javier Mignone<sup>2</sup>, Keith Fowke<sup>2, 1</sup>

1. University of Nairobi, Nairobi, Kenya, 2. University of Manitoba, Winnipeg, MB, 3. Universidad du Antioquia, Medellin, Colombia, 4. Karnataka Health Promotion Trust, Bangalore, KA, India

## Track B: Clinical Sciences

### Volet B : Sciences cliniques

## Adherence

### Respect du traitement

#### ► CSP1.01

**Virtual nursing intervention (VIH-TAVIE) efficacy in empowering HIV patients to manage ART optimally: Quantitative and qualitative results (E)**

José Côté<sup>1, 2</sup>, Gaston Godin<sup>3</sup>, Pilar Ramirez-Garcia<sup>2</sup>, **Geneviève Rouleau**<sup>1</sup>, Anne Bourbonnais<sup>2</sup>, Yann-Gaël Guéhéneuc<sup>4</sup>, Cécile Tremblay<sup>1, 2</sup>, Joanne Otis<sup>5</sup>

1. Centre de recherche du CHUM, Montréal, QC, 2. Université de Montréal, Montréal, QC, 3. Université Laval, Québec, QC, 4. École Polytechnique, Montréal, QC, 5. Université du Québec à Montréal, Montréal, QC

#### ► CSP1.03

**Proving adherence to sexual abstinence after cervical biopsies performed in the context of basic science studies in female sex workers from Nairobi, Kenya (E)**

**Natasha Hollett**<sup>1</sup>, Julie Lajoie<sup>1, 2</sup>, Geneviève Boily-Larouche<sup>1</sup>, Kelsie Doering<sup>1</sup>, Juliana Cheuiyot<sup>3</sup>, Joshua Kimani<sup>1, 3, 2</sup>, Keith R. Fowke<sup>1, 2</sup>

1. University of Manitoba, Winnipeg, MB, 2. University of Nairobi, Nairobi, Kenya, 3. Kenyan AIDS control Program, Nairobi, Kenya

#### ► CSP1.04

**Utility of a Brief Screening Intervention in Improving Depression and Antiretroviral Adherence in Patients with HIV (E)**

Michelle Joseph<sup>1, 2</sup>, Julia Cahill<sup>3</sup>, Melanie McQueen<sup>1</sup>, **Linda Robinson**<sup>1</sup>

1. Windsor Regional Hospital, Windsor, ON, 2. University of Toronto, Toronto, ON, 3. Queen's University, Kingston, ON

#### ► CSP1.05

**Factors affecting adherence to Antiretroviral Therapy Among School Going Adolescents in Uganda (E)**

**Annet Kawuma**<sup>1</sup>, David R. Bangsberg<sup>2</sup>

1. Makerere University College of Agricultural and Environmental Sciences NILA Study, Kampala, Uganda, 2. Massachusetts General Hospital, Boston, MA, USA

## Clinical Trials and Observational Studies of Antiretrovirals and Other HIV Therapies

### Essais cliniques et études d'observation des antirétroviraux et autres thérapies anti-VIH

#### ► CSP2.01

##### Timing and Type of Maternal Combination Antiretroviral Therapy during Pregnancy Affects Placental Telomeres and Mitochondrial DNA Content (E)

**Abhinav Ajaykumar**<sup>1,2</sup>, Annie Qiu<sup>1,3</sup>, Sara Saberi<sup>1,2</sup>, Deborah M. Money<sup>1,3,4</sup>, **Hélène Côté**<sup>1,2,4</sup>

1. University of British Columbia, Vancouver, BC, 2. Centre for Blood Research, Vancouver, BC, 3. BC Women's Hospital and Health Centre, Vancouver, BC, 4. Women's Health Research Institute, Vancouver, BC

#### ► CSP2.02

##### Switching Tenofovir DF to Tenofovir Alafenamide in Virologically Suppressed Adults (E)

**Jason Brunetta**<sup>1</sup>, Jonathan Angel<sup>2</sup>, Joel Gallant<sup>3</sup>, Eric Daar<sup>4</sup>, Peter Ruane<sup>5</sup>, Harout Tossonian<sup>6</sup>, Lauren Dau<sup>7</sup>, Yan Mingjin<sup>7</sup>, Andrew Plummer<sup>7</sup>, Andrew Cheng<sup>7</sup>, Martin Rhee<sup>7</sup>

1. Maple Leaf Medical Clinic, Toronto, ON, 2. Division of Infectious Disease, The Ottawa Hospital, Ottawa, ON, 3. Southwest Care Center, Santa Fe, NM, USA, 4. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, Los Angeles, CA, USA, 5. Peter J Ruane MD Inc, Los Angeles, CA, USA, 6. Gilead Sciences Canada, Inc, Mississauga, ON, 7. Gilead Sciences, Inc, Foster City, CA, USA

#### ► CSP2.03

##### Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) plus Darunavir (DRV) in Treatment-Experienced HIV-1 infected Adults (E)

**Brian Conway**<sup>1</sup>, Ken Kasper<sup>2</sup>, Benoit Trottier<sup>3</sup>, Gregory Huhn<sup>4</sup>, Joel Gallant<sup>5</sup>, Timothy Wilkin<sup>6</sup>, Christian Callebaut<sup>7</sup>, Marshall Fordyce<sup>7</sup>, Moupali Das<sup>7</sup>, Josee Brisebois<sup>8</sup>, Scott McCallister<sup>7</sup>

1. Vancouver Infectious Diseases Centre, Vancouver, BC, 2. WRHA - Health Sciences Centre, Winnipeg, MB, 3. Clinique medicale l'Actuel, Montreal, QC, 4. The Ruth M. Rothstein CORE Center, Chicago, IL, USA, 5. Southwest Care Centre, Santa Fe, NM, USA, 6. Weill Cornell Medical College, New York, NY, USA, 7. Gilead Sciences, Inc, Foster City, CA, USA, 8. Gilead Sciences Canada, Inc, Mississauga, ON

#### ► CSP2.04

##### A Prospective Pilot Study of Treatment Simplification to elvitegravir/cobicistat/emtricitabine/tenofovir DF (E/C/F/TDF) plus darunavir (E)

**Bruce Ganase**, Marianne Harris, Mark Hull, Birgit Watson, Richard Harrigan, Julio Montaner  
BC Center for Excellence in HIV/AIDS, Vancouver, BC

▶ **CSP2.05**

**The Impact of the Composition of Physicians' Practices on Mortality (E)**

**Robert S. Hogg**<sup>1, 2, 3</sup>, Zishan Cui<sup>1</sup>, Lianping Ti<sup>1</sup>, Sophie Patterson<sup>1, 2</sup>, Surita Parashar<sup>1, 2</sup>, Viviane D. Lima<sup>1, 3</sup>, Jason Chia<sup>1</sup>, Benita Yip<sup>1</sup>, Rolando Barrios<sup>1, 3</sup>, Julio Montaner<sup>1, 3</sup>  
1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, 3. Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, BC

▶ **CSP2.06**

**Integrase Inhibitor-Based Antiretroviral Therapy in Vulnerable Populations (E)**

**Ghazaleh Kiani**  
Vancouver Infectious Diseases Centre, Vancouver, BC

▶ **CSP2.07**

**Privacy-Preserving Genomic Testing in the Clinic – a Model Using HIV Treatment (E)**

**Paul J. McLaren**<sup>1, 2</sup>, Jean-Louis Raisaro<sup>3</sup>, Jean-Pierre Hubaux<sup>3</sup>, Amalio Telenti<sup>4</sup>  
1. National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Center, Winnipeg, MB, 2. Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, 3. Computer Communications and Applications Laboratory, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland, 4. Genomic Medicine, J Craig Venter Institute, San Diego, CA, USA

▶ **CSP2.08**

**Persistent CD8 T-cell elevation: Contribution of Microbial Translocation, Inflammation and ART following Primary HIV-1 Infection (E)**

**Jean-Pierre Routy**<sup>1, 2, 3</sup>, Vikram Mehraj<sup>1, 2</sup>, Rosalie Ponte<sup>1, 2</sup>, Bertrand Lebouché<sup>1, 2</sup>, Réjean Thomas<sup>4</sup>, Benoit Trottier<sup>4</sup>, Jean-Guy Baril<sup>8</sup>, Pierre Côté<sup>8</sup>, Roger LeBlanc<sup>5</sup>, Cécile Tremblay<sup>6, 7</sup>, Mohammad-Ali Jenabian<sup>9</sup>  
1. Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, 2. Research Institute of the McGill University Health Centre, Montreal, QC, 3. Division of Hematology, McGill University Health Centre, Montreal, QC, 4. Clinique Médicale l'Actuel, Montréal, QC, 5. Clinique Médicale OPUS, Montréal, QC, 6. Centre de recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC, 7. Département de microbiologie, infectiologie et immunologie, Université de Montréal, Montréal, QC, 8. Clinique Médicale Quartier Latin, Montréal, Montréal, QC, 9. Department of Biological Sciences and BioMed Research Centre, Université du Québec à Montréal (UQAM), Montréal, QC

► **CSP2.09**

**Predictors of Viral Suppression and Rebound among HIV-Positive Men who have Sex with Men in a Large Multi-Site Canadian Cohort (E)**

Zachary P. Tanner<sup>1</sup>, Nathan J. Lachowsky<sup>1, 2</sup>, Erin Ding<sup>1</sup>, Hasina Samji<sup>1</sup>, Mark Hull<sup>1, 2</sup>, Angela Cescon<sup>3</sup>, Sophie Patterson<sup>1, 4</sup>, **Jason Chia**<sup>1</sup>, Alia Leslie<sup>1</sup>, Janet M. Raboud<sup>5</sup>, Mona R. Loutfy<sup>6</sup>, Curtis Cooper<sup>7</sup>, Marina B. Klein<sup>8</sup>, Nima Machouf<sup>10</sup>, Julio S. Montaner<sup>1</sup>, Christos Tsoukas<sup>8</sup>, Robert S. Hogg<sup>1, 4</sup>, Canadian Observational Cohort (CANOC) Collaboration

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. University of British Columbia, Vancouver, BC, 3. Northern Ontario School of Medicine, Sudbury, ON, 4. Simon Fraser University, Burnaby, BC, 5. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, 6. Faculty of Medicine, University of Toronto, Toronto, ON, 7. The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, 8. Faculty of Medicine, McGill University, Montreal, QC, 9. The Montreal Chest Institute, McGill University Health Centre, Montreal, QC, 10. Clinique Medicale l'Actuel, Montreal, QC

**Co-infections (including HCV, HBV, HPV, Syphilis, TB)**

**Coinfections (y compris VHC, VHB, papillomavirus, syphilis, tuberculose)**

► **CSP3.01**

**Determining Hepatitis C Treatment Eligibility in a HIV/HCV Co-infected Northern B.C. Population: a Cross-sectional Chart Review (E)**

**Sara Cassidy**, Jennifer Hawkes

University Hospital of Northern B.C., Prince George, BC

► **CSP3.03**

**Ledipasvir/Sofosbuvir is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono-and HCV/HIV Co-infected Patients (E)**

Annie Luetkemeyer<sup>1</sup>, **Curtis Cooper**<sup>2</sup>, Paul Kwo<sup>3</sup>, K Kowdley<sup>4</sup>, Steeve Houle<sup>5</sup>, Sarjita Naik<sup>6</sup>, Macky Natha<sup>6</sup>, Luisa Stamm<sup>6</sup>, Diana Brainard<sup>6</sup>, Polina German<sup>6</sup>, Mark Sulkowski<sup>7</sup>, Susanna Naggie<sup>8</sup>, Sarah Kleinstein<sup>9</sup>, Patrick Shea<sup>9</sup>

1. University of California, San Francisco, CA, USA, 2. The Ottawa Hospital, Ottawa, ON, 3. Indiana University, Division of Gastroenterology/Hepatology, Indianapolis, IN, USA, 4. Swedish Liver Center, Department of Gastroenterology/Hepatology, Seattle, WA, USA, 5. Gilead Sciences Canada, Inc., Mississauga, ON, 6. Gilead Sciences, Inc., Foster City, CA, USA, 7. Johns Hopkins University School of Medicine, Baltimore, MD, USA, 8. Duke Clinical Research Institute, Infectious Diseases Research, Durham, NC, USA, 9. Institute for Genomic Medicine, Columbia University, New York, NY, USA

▶ **CSP3.04****Risk Factors for Oncogenic, High-Risk Human Papillomavirus Infection of the Anal Canal in Men Who Have Sex With Men (MSM) (E)**

**Troy Grennan**<sup>1,2</sup>, Ann Burchell<sup>3,4</sup>, Jill Timmouth<sup>4,5</sup>, Jason Brunetta<sup>6</sup>, Anu Rebbapragada<sup>4</sup>, Rupert Kaul<sup>4</sup>, Juan Liu<sup>8</sup>, Graham Smith<sup>6</sup>, Robert Remis<sup>4</sup>, Mona Loutfy<sup>4,6,9</sup>

1. BC Centre for Disease Control, Vancouver, BC, 2. University of British Columbia, Vancouver, BC, 3. St. Michael's Hospital, Toronto, ON, 4. University of Toronto, Toronto, ON, 5. Synnybrook Health Sciences Centre, Toronto, ON, 6. Maple Leaf Medical Clinic, Toronto, ON, 7. University Health Network, Toronto, ON, 8. Public Health Ontario, Toronto, ON, 9. Women's College Hospital, Toronto, ON

▶ **CSP3.05****HCV Treatment of HIV-HCV Co-Infected PWID at a Tertiary Clinic (E)**

**Syune Hakobyan**

Vancouver ID Research and Care Centre Society, Vancouver, BC

▶ **CSP3.06****Real world outcomes with hepatitis C direct acting antiviral agents are similar to those achieved in clinical trials in HIV/HCV co-infected patients (E)**

**Mark Hull**<sup>1</sup>, Wendy Zhang<sup>1</sup>, Benita Yip<sup>1</sup>, Leslie Beech<sup>2</sup>, Jennifer Dmytryshyn<sup>2</sup>, Vickie Lau<sup>2</sup>, Junine Toy<sup>2</sup>, Val Montessori<sup>1</sup>, Julio Montaner<sup>1</sup>

1. BC Centre For Excellence In HIV/AIDS, Vancouver, BC, 2. Providence Health Care, Vancouver, BC

▶ **CSP3.07****Sampling for Herpesvirus Reactivations in Hospitalized HIV+ Adults: a Pilot Study (E)**

**Brian H. Kim**<sup>1</sup>, Kevin Venus<sup>1</sup>, Rupert Kaul<sup>1,2</sup>, Kevin Gough<sup>1,3</sup>, Ignatius Fong<sup>1,3</sup>, Darrell H. Tan<sup>1,3</sup>

1. Faculty of Medicine, University of Toronto, Toronto, ON, 2. Department of Immunology, University of Toronto, Toronto, ON, 3. Division of Infectious Diseases, St. Michael's Hospital, Toronto, ON

▶ **CSP3.09****HCV Direct Acting Antivirals (DAA) are Metabolically Safe and Highly Curative Irrespective of HIV Status (E)**

**Michaeline McGuinty**<sup>1</sup>, Daniel J. Corsi<sup>1</sup>, **Curtis Cooper**<sup>1</sup>

1. The Ottawa Hospital Research Institute, Ottawa, ON, 2. The Ottawa Hospital, Ottawa, ON

▶ **CSP3.10****Hepatitis B Vaccination Response Rates in Canadian Pediatric Patients Living with HIV (E)**

Gail Robson<sup>1</sup>, **Sarah Khan**<sup>1,2</sup>, Stanley Read<sup>1,3</sup>, Ari Bitnun<sup>1,3</sup>

1. The Hospital for Sick Children, Toronto, ON, 2. McMaster University, Hamilton, ON, 3. University of Toronto Department of Pediatrics, Toronto, ON



▶ **CSP3.11****Viral Hepatitis Co-Infection and Chronic Kidney Disease Progression among HIV-Infected Canadians Initiating Antiretroviral Therapy (E)**

**Carmine Rossi**<sup>1</sup>, Curtis Cooper<sup>2</sup>, Janet Raboud<sup>5</sup>, Tony Antoniou<sup>4</sup>, Mona Loutfy<sup>3</sup>, Chris Tsoukas<sup>1</sup>, Nima Machouf<sup>6</sup>, Marina B. Klein<sup>1</sup>

1. McGill University, Montreal, QC, 2. Ottawa Hospital Research Institute, Ottawa, ON, 3. Women's College Research Institute, Toronto, ON, 4. St. Michael's Hospital, Toronto, ON, 5. University Health Network, Toronto, ON, 6. Clinique L'actuel, Montreal, QC

▶ **CSP3.12****Correlates of syphilis treatment success in a population with high rates of HIV co-infection in British Columbia (E)**

**Hasina Samji**<sup>1,3</sup>, Mark Hull<sup>2</sup>, Carolyn Montgomery<sup>1</sup>, Sylvia Makaroff<sup>1</sup>, Travis S. Hottes<sup>1</sup>, Troy Grennan<sup>1,3</sup>, Gina Ogilvie<sup>1,3</sup>, Mark Gilbert<sup>1</sup>, Muhammad Morshed<sup>1</sup>, Mark Tyndall<sup>1,3</sup>, Jason Wong<sup>1,3</sup>

1. British Columbia Centre for Disease Control, Vancouver, BC, 2. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, 3. University of British Columbia, Vancouver, BC

▶ **CSP3.13****Drug-Drug Interactions Studies between HCV Antivirals Sofosbuvir and Velpatasvir and HIV Antiretrovirals (ARVs) (E)**

Erik Mogalian<sup>1</sup>, **Stephen Shafran**<sup>2</sup>, Hugh Ngo<sup>3</sup>, Sarjita Naik<sup>1</sup>, Macky Natha<sup>1</sup>, Luisa Stamm<sup>1</sup>, Anu Osinusi<sup>1</sup>, Gong Shen<sup>1</sup>, Karim Sajwani<sup>1</sup>, John McNally<sup>1</sup>, Anita Mathias<sup>1</sup>

1. Gilead Sciences, Inc., Foster City, CA, USA, 2. University of Alberta, Edmonton, AB, 3. Gilead Sciences Canada, Inc., Mississauga, ON

▶ **CSP3.14****Improving Hepatitis C Care at an Indigenous focused urban-core clinic in Vancouver (E)**

Piotr Klakowicz<sup>1,2</sup>, **David Tu**<sup>1,2</sup>, Aida Sadr<sup>1,2</sup>, **Greta Pauls**<sup>1</sup>, David M. Henderson<sup>1</sup>

1. Vancouver Native Health Society Medical Clinic, Vancouver, BC, 2. University of British Columbia, Department of Family Practice, Vancouver, BC

▶ **CSP3.15****Characteristics of Pneumonia Admissions in HIV Positive Individuals: A Single Centre 10 Year Cross-sectional Retrospective Analysis (E)**

**Sarah M. van Gaalen**<sup>1,2</sup>, Zulma Rueda<sup>3,4</sup>, Luisa F. Arroyave<sup>4</sup>, Ken Kasper<sup>1,2</sup>, Yoav Keynan<sup>1,2</sup>

1. University of Manitoba, Winnipeg, MB, 2. Health Sciences Centre, Winnipeg, MB, 3. Universidad Pontificia Bolivariana, Medellin, Colombia, 4. Universidad de Antioquia, Medellin, Colombia

▶ **CSP3.16****The final frontier: Successful Treatment for HCV genotype 1 in those with HIV with access to treatment (E)**

**David K. Wong**, Lise Bondy, Alice Tseng, Pauline Murphy, Sharon Walmsley  
Toronto General Hospital, Toronto, ON

## Complications of Antiretroviral Therapy Complications des thérapies antirétrovirales

▶ **CSP4.01****Potential Synergistic Effect of Tesamorelin, a GHRH Analogue, and Fibrates to Decrease Triglycerides in HIV-Infected Patients with Excess Abdominal Fat (E)**

Julian Falutz<sup>2</sup>, **Jean-Claude Mamputu**<sup>1</sup>, Christian Marsolais<sup>1</sup>, Takara Stanley<sup>3</sup>, Steven Grinspoon<sup>3</sup>

1. Theratechnologies Inc., Montreal, QC, 2. Montreal General Hospital, McGill University Health Centre, Montreal, QC, 3. Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

▶ **CSP4.02****Incidence of renal stones in persons treated with atazanavir versus other antiretrovirals: A population-based study (E)**

**Katherine J. Lepik**<sup>1, 4</sup>, Conrado Franco-Villalobos<sup>1</sup>, Shahab Jabbari<sup>1</sup>, Ryan F. Paterson<sup>2</sup>, Mark W. Hull<sup>1, 2</sup>, Oghenowede Eyawo<sup>1, 3</sup>, Robert S. Hogg<sup>1, 3</sup>, Viviane Dias Lima<sup>1, 2</sup>, Julio S. Montaner<sup>1, 2</sup>, Rolando Barrios<sup>1, 2</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. University of BC, Faculty of Medicine, Vancouver, BC, 3. Simon Fraser University, Faculty of Health Sciences, Burnaby, BC, 4. University of BC, Faculty of Pharmaceutical Sciences, Vancouver, BC

▶ **CSP4.03****Longer Term Safety of Tenofovir Alafenamide in Renal Impairment (E)**

Frank Post<sup>1</sup>, Amanda Clarke<sup>2</sup>, Laurent Cotte<sup>3</sup>, William Short<sup>4</sup>, Moupali Das<sup>5</sup>, **Orson Wedgwood**<sup>6</sup>, Marshall Fordyce<sup>5</sup>

1. King's College Hospital NHS Foundation Trust, London, United Kingdom, 2. Brighton & Sussex University Hospitals NHS Trust, Brighton, United Kingdom, 3. Hôpital de la Croix Rousse, Lyon, France, 4. University of Pennsylvania, Philadelphia, PA, USA, 5. Gilead Sciences, Inc, Foster City, CA, USA, 6. Gilead Sciences Canada, Inc, Mississauga, ON

## HIV and Aging and Comorbidities

### Le VIH, le vieillissement et les comorbidités

#### ▶ CSP5.01

##### **Outcomes among persons with HIV following acute myocardial infarction: a population-based study (E)**

Cindy Lau<sup>2</sup>, Janet Raboud<sup>4</sup>, Ahmed Bayoumi<sup>1</sup>, Ann Burchell<sup>1</sup>, Claire Kendall<sup>5</sup>, Mona Loutfy<sup>3</sup>, Sean Rourke<sup>6</sup>, Richard Glazier<sup>1</sup>, **Tony Antoniou**<sup>1</sup>

1. St. Michael's Hospital, Toronto, ON, 2. Institute for Clinical Evaluative Sciences, Toronto, ON, 3. Women's College Research Institute, Toronto, ON, 4. Toronto General Research Institute, Toronto, ON, 5. C.T. Lamont Primary Health Care Research Centre, Bruyère Research Institute, Ottawa, ON, 6. Ontario HIV Treatment Network, Toronto, ON

#### ▶ CSP5.02

##### **Presence of complex comorbidity and functional disability when ageing with HIV; review of referrals to specialist HIV outpatient physiotherapy in the UK (E)**

**Darren Brown**<sup>1</sup>, Mark Nelson<sup>1,3</sup>, Mark Bower<sup>1,3</sup>, Richard Harding<sup>2</sup>

1. Chelsea and Westminster NHS Foundation Trust, London, United Kingdom, 2. Kings College London, Cicely Saunders Institute, London, United Kingdom, 3. Imperial College London, London, United Kingdom

#### ▶ CSP5.03

##### **People living with HIV have worse health status than elderly people at risk of hospitalisation, when referred to specialist HIV outpatient physiotherapy in the UK (E)**

**Darren Brown**<sup>1</sup>, Mark Nelson<sup>1,3</sup>, Mark Bower<sup>1,3</sup>, Richard Harding<sup>2</sup>

1. Chelsea and Westminster NHS Foundation Trust, London, United Kingdom, 2. Kings College London, Cicely Saunders Institute, London, United Kingdom, 3. Imperial College London, London, United Kingdom

#### ▶ CSP5.04

##### **Improved function, strength, quality of life & goal attainment in people with HIV attending UK specialist physiotherapy-led group rehabilitation intervention (E)**

Richard Harding<sup>1</sup>, **Darren Brown**<sup>2</sup>, Austin Claffey<sup>3</sup>

1. King's College London, London, United Kingdom, 2. Chelsea and Westminster NHS Foundation Trust, London, United Kingdom, 3. London South Bank University, London, United Kingdom

#### ▶ CSP5.05

##### **Rapid Decrease in Leukocyte Telomere Length Following HIV Seroconversion, but not HCV Seroconversion (E)**

Alejandro Gonzalez-Serna<sup>2,3</sup>, Abhinav Ajaykumar<sup>1,4</sup>, Izabella Gadawski<sup>1</sup>, Maria Angeles Muñoz-Fernández<sup>2</sup>, Kanna Hayashi<sup>3,1</sup>, P R. Harrigan<sup>3,1,4</sup>, **Helene Cote**<sup>1,4</sup>

1. University of British Columbia, Vancouver, BC, 2. Hospital

General Universitario Gregorio Marañón, Madrid, Spain, 3. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 4. Centre for Blood Research, Vancouver, BC

▶ **CSP5.06**

**Evidence of monocyte inflammation in HIV+ patients on effective combination antiretroviral therapy (E)**

Elliott M. Faller<sup>1</sup>, Cathy Kelly<sup>2</sup>, Girish Dwivedi<sup>2</sup>, Paul MacPherson<sup>1</sup>

1. Ottawa Hospital-Division of Infectious Diseases, Ottawa, ON, 2. Ottawa Heart Institute, Ottawa, ON

▶ **CSP5.07**

**Impact of Expanded Access to Highly Active Antiretroviral Therapy on Chronic Comorbidities among HIV-Positive individuals in British Columbia (E)**

Brent J. Gali<sup>1, 2</sup>, Shahab Jabbari<sup>2</sup>, Huiting Ma<sup>2</sup>, Oghenowede Eyawo<sup>2, 3</sup>, Viviane Lima<sup>2, 1</sup>, Kimberlyn McGrail<sup>1</sup>, Robert Hogg<sup>2, 3</sup>, David Moore<sup>2, 1</sup>

1. University of British Columbia, British Columbia, BC, 2. BC - Centre for Excellence in HIV/AIDS, Vancouver, BC, 3. Simon Fraser University, Burnaby, BC

▶ **CSP5.08**

**Factors Associated with Incidence of Diabetes Mellitus (DM) in Older HIV Positive Patients (E)**

Silvia A. Guillemi<sup>1, 4</sup>, Marianne Harris<sup>1, 3</sup>, Sarah A. Chacko<sup>2</sup>, Huiting Ma<sup>1</sup>, Jason Chia<sup>1</sup>, Greg Bondy<sup>1, 3</sup>, Julio G. Montaner<sup>1, 3</sup>, Viviane D. Lima<sup>1, 3</sup>

1. BC Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, BC, 2. Norwich Medical School, Norwich, United Kingdom, 3. Department of Medicine, University of British Columbia, Vancouver, BC, 4. Department of Family Practice, University of British Columbia, Vancouver, BC

▶ **CSP5.09**

**Associations Between White Matter Hyperintensities (WMH) and Neuropsychological Performance for Individuals with HIV (E)**

Aiko Yamamoto<sup>1</sup>, Marianne Harris<sup>3</sup>, Shervin Mortazavi<sup>2</sup>, Sean Ling<sup>4</sup>, Ging-Yuek R. Hsiung<sup>2</sup>, Mark Hull<sup>3</sup>, Julio Montaner<sup>3</sup>, Sylvia Guillemi<sup>3</sup>

1. Neuropsychology Service, St. Paul's Hospital, Vancouver, BC, 2. Division of Neurology, University of British Columbia, Vancouver, BC, 3. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 4. AIDS Research Program, St. Paul's Hospital, Vancouver, BC

▶ **CSP5.10**

**Associations between HIV-related factors and neurocognitive impairment based on results of two validated screening tests among HIV+ adults treated with HAART (E)**

Sean H. Ling<sup>1</sup>, Wendy Zhang<sup>4</sup>, Guillaume Colley<sup>4</sup>, Aiko Yamamoto<sup>1</sup>, Mark Hull<sup>3</sup>, Julio S. Montaner<sup>4</sup>, Ging-Yuek R. Hsiung<sup>5</sup>, Marianne Harris<sup>1, 2, 3</sup>, Silvia A. Guillemi<sup>1, 2, 3</sup>

1. AIDS Research Program, St. Paul's Hospital, Vancouver, BC, 2. Department of Family Medicine, Faculty of Medicine,

University of British Columbia, Vancouver, BC, 3. Division of HIV/AIDS, Department of Medicine, University of British Columbia, Vancouver, BC, 4. BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, 5. Department of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, BC

► **CSP5.11**

**Will the next generation of rehabilitation professionals be ready to treat people living with HIV?: Results of a survey of UK Higher Education Institutions (E)**

Esther McDonnell<sup>1, 2</sup>, Will Chegwiddden<sup>3, 2</sup>, **Darren Brown**<sup>1, 2</sup>, Katie Hamilton<sup>5, 2</sup>, Camilla Hawkins<sup>4, 2</sup>, Kirsti Loughran<sup>6</sup>, Rosemary Rich<sup>2</sup>, Elizabeth Stevens<sup>7, 2</sup>, Carrie-Ann Wood<sup>8, 2</sup>

1. Chelsea and Westminster Hospital, London, United Kingdom, 2. Rehabilitation in HIV Association (RHIVA), London, United Kingdom, 3. University College London Hospitals NHS Foundation Trust, National Hospital for Neurology and Neurosurgery, London, United Kingdom, 4. Mildmay UK, London, United Kingdom, 5. NHS Greater Glasgow and Clyde, Glasgow, Glasgow, United Kingdom, 6. Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom, 7. Heart of England NHS Foundation Trust, Birmingham, United Kingdom, 8. Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

► **CSP5.12**

**Greater Gastrointestinal Symptom Distress Negatively Impacts Health-Related Quality of Life: Results from the Ontario HIV Treatment Network Cohort Study (OCS) (E)**

**Tyler J. O'Neill**<sup>1, 2</sup>, Janet Raboud<sup>2, 3</sup>, Jill Tinmouth<sup>4</sup>, Sean B. Rourke<sup>1</sup>, Sergio Rueda<sup>6</sup>, Trevor A. Hart<sup>9</sup>, Curtis Cooper<sup>5</sup>, Anita Rachlis<sup>7</sup>, Ann N. Burchell<sup>8, 9</sup>

1. Ontario HIV Treatment Network, Toronto, ON, 2. Dalla Lana School of Public Health, Toronto, ON, 3. Toronto General Research Institute, University Health Network, Toronto, ON, 4. Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, 5. Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, 6. Social and Epidemiologic Research Dept., Centre for Addiction and Mental Health, Toronto, ON, 7. Sunnybrook Health Sciences Centre, Toronto, ON, 8. Li Ka Shing, St. Michael's Hospital, Toronto, ON, 9. Dept. Psychology, Ryerson University, Toronto, ON

► **CSP5.13**

**A Meta-Analysis of the Incidence of Colorectal Cancer in Persons with HIV (E)**

**Tyler J. O'Neill**<sup>1, 2</sup>, Joseph N. Djioemetio<sup>3</sup>, Anne-Marie Tynan<sup>3</sup>, Ann N. Burchell<sup>4, 5</sup>, Tony Antoniou<sup>3</sup>

1. Dalla Lana School of Public Health, Toronto, ON, 2. Ontario HIV Treatment Network, Toronto, ON, 3. St. Michael's Hospital, Toronto, ON, 4. Dept. Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, 5. Li Ka Shing, St. Michael's Hospital, Toronto, ON

▶ **CSP5.14****Cytokeratin 18 and Transient Elastography with Controlled Attenuation Parameter as Screening Tools for Nonalcoholic Steatohepatitis in HIV Mono-Infection (E)**

**Giada Sebastiani**, Lynda Lennox, Costas Pexos, Cecilia Costiniuk, Roger LeBlanc, Jean-Pierre Routy, Joseph Cox, Bertrand Lebouche, Marina B. Klein  
McGill University Health Centre, Montreal, QC

**HIV in Children and Adolescents****Le VIH chez les enfants et les adolescents**▶ **CSP6.01****Realizing Youth Potential: A New Group Clinic Model to Facilitate Improved Adherence and Outcomes among Youth with HIV (E)**

Jennifer Smitten<sup>1,2</sup>, Laura J. Sauve<sup>1,2</sup>, Shannon Krell<sup>1</sup>, Karen Friesen<sup>1</sup>, Sarah Chown<sup>5</sup>, Neora Pick<sup>1,4</sup>, Melanie C. Murray<sup>1,3,4</sup>, Mary Kestler<sup>1,4</sup>, Alicia Hornsberger<sup>1</sup>, **Ariane Alimenti**<sup>1,2</sup>  
1. Oak Tree Clinic, BC Women's Hospital, Vancouver, BC, 2. Department of Pediatrics, University of British Columbia, Vancouver, BC, 3. Women's Health Research Institute, BC Women's Hospital, Vancouver, BC, 4. Department of Medicine, University of British Columbia, Vancouver, BC, 5. YouthCO HIV & HepC Society, Vancouver, BC

▶ **CSP6.03****IFN-gamma Responses against HIV-1 Gag in Children with Long-Term Viral Suppression (E)**

**Hinatea Dieumegard**<sup>1,3</sup>, Amélie Pagliuzza<sup>2</sup>, Fatima Kakkar<sup>4,5</sup>, Jason Brophy<sup>6,7</sup>, Lindy Samson<sup>6,7</sup>, Stanley Read<sup>8,9</sup>, Michael Hawkes<sup>10</sup>, Nicolas Chomont<sup>2,3</sup>, Ari Bitnun<sup>8,9</sup>, Hugo Soudeyns<sup>1,3,5</sup>

1. Centre de recherche du CHU Sainte-Justine, Montréal, QC, 2. Centre de recherche du CHUM, Montréal, QC, 3. Department of Microbiology, Infectiology & Immunology, Université de Montréal, Montréal, QC, 4. Infectious Diseases Service, CHU Sainte-Justine, Montréal, QC, 5. Department of Pediatrics, Université de Montréal, Montréal, QC, 6. Children's Hospital of Eastern Ontario, Ottawa, ON, 7. Department of Pediatrics, University of Ottawa, Ottawa, ON, 8. Hospital for Sick Children, Toronto, ON, 9. Department of Pediatrics, University of Toronto, Toronto, ON, 10. Department of Pediatrics, University of Alberta, Edmonton, AB

▶ **CSP6.04****Impact of Low Level Viremia on Virological Failure in HIV-1 Infected Children Undergoing Antiretroviral Therapy (E)**

**Shivani Gupta**<sup>1,2</sup>, Binhua Liang<sup>1,2</sup>, Hezhao Ji<sup>2</sup>, Joseph Kabogo<sup>3</sup>, Elijah Songok<sup>1,3</sup>, Gary V. Domselaar<sup>1,2</sup>

1. University of Manitoba, Winnipeg, MB, 2. Public Health Agency of Canada, Winnipeg, MB, 3. Kenya Medical Research Institute, Nairobi, Kenya

▶ **CSP6.05****The Second-Generation of HIV-1 Vertically Exposed Infants: Challenges in their Management and Long-Term Care (E)**

Maire-Julie Trahan<sup>1</sup>, Christian Renaud<sup>1</sup>, Normand Lapointe<sup>1</sup>, Valerie Lamarre<sup>1</sup>, **Fatima Kakkar**<sup>1</sup>

1. CHU Sainte-Justine, University of Montreal, Montreal, QC, 2. Centre Maternel et Infantile sur le SIDA, Montreal, QC

▶ **CSP6.06****“Read to succeed”: Literacy promotion for HIV exposed infants and children (E)**

**Laura J. Sauve**<sup>1, 2, 3</sup>, Alison Nutter<sup>2, 3</sup>, Meghan Gilley<sup>2, 3</sup>, Jessica Breton<sup>4</sup>, Ariane Alimenti<sup>1, 2</sup>

1. BC Women’s Hospital, Vancouver, BC, 2. University of British Columbia, Vancouver, BC, 3. BC Children’s Hospital, Vancouver, BC, 4. Université de Montreal, Montreal, QC

▶ **CSP6.07****HIV Exposed, but Uninfected Infants: Missed Opportunities for Early Developmental Services from a Canadian Tertiary Care Centre (E)**

Kamal Abdulwahab<sup>2, 3</sup>, Zahra Pakzad<sup>1</sup>, Arash Adjudani<sup>2, 3</sup>, Ariane Alimenti<sup>1, 2</sup>, Lanna Olson<sup>2, 3</sup>, **Laura J. Sauve**<sup>1, 2, 3</sup>

1. BC Women’s Hospital, Vancouver, BC, 2. University of British Columbia, Vancouver, BC, 3. BC Children’s Hospital, Vancouver, BC

**HIV in Vulnerable Populations and Global Health Issues****Le VIH dans les populations vulnérables et les enjeux sanitaires mondiaux**▶ **CSP7.01****Characteristics of HIV-Positive Patients Requiring Salvage Therapy in Downtown Vancouver, BC (E)**

**Tyler Raycraft**, Syune Hakobyan, Sahand Vafadary, Shawn Sharma, Brian Conway

Vancouver Infectious Diseases Centre, Vancouver, BC

▶ **CSP7.02****Factors Leading to Regimen Change in HIV-Positive Patients (E)**

**Tyler Raycraft**, Syune Hakobyan, Sahand Vafadary, Shawn Sharma, Brian Conway

Vancouver Infectious Diseases Centre, Vancouver, BC

▶ **CSP7.03****Impact of Short-Term Incarceration on HIV Outcomes (E)**

Yazhini Subramanian<sup>1, 2</sup>, Muhammad N. Khan<sup>2</sup>, Sara Berger<sup>2, 3</sup>, **Michelle M. Foisy**<sup>2, 3</sup>, Ameeta Singh<sup>1, 2</sup>, Dan Woods<sup>2</sup>, Diane Pyne<sup>2</sup>, Rabia Ahmed<sup>1, 2, 3</sup>

1. University of Alberta, Edmonton, AB, 2. Alberta Health Services, Edmonton, AB, 3. HIV Northern Alberta Program, Edmonton, AB

▶ **CSP7.04****Characteristics of HIV Positive Patients Who Were Lost to Follow-Up in the Inner City (E)**Sahand Vafadary, **Syune Hakobyan**

Vancouver Infectious Diseases Centre, Vancouver, BC

**HIV in Women and in Pregnancy****Le VIH chez les femmes et pendant la grossesse**▶ **CSP8.01****Attitudes and Practices of Canadian Healthcare Providers on Breastfeeding by HIV-Infected Women (E)****Sarah Khan**<sup>1</sup>, Meghan McConnell<sup>1</sup>, V. L. Kennedy<sup>2, 3</sup>, Mark Yudin<sup>4, 6</sup>, Marek Smieja<sup>1, 7</sup>, Lehana Thabane<sup>1, 7</sup>, Mona Loutfy<sup>2, 3, 4</sup>, Stanley Read<sup>4, 5</sup>, **Ari Bitnun**<sup>4, 5</sup>

1. McMaster University, Hamilton, ON, 2. Women's College Hospital, Toronto, ON, 3. Women's College Research Institute, Toronto, ON, 4. University of Toronto, Toronto, ON, 5. The Hospital for Sick Children, Toronto, ON, 6. St. Michael's Hospital, Toronto, ON, 7. St Joseph's Healthcare, Hamilton, ON

▶ **CSP8.02****Canadian Health Care Provider Knowledge on Breastfeeding by HIV-Infected Women (E)****Sarah Khan**<sup>1, 7</sup>, Meghan McConnell<sup>1</sup>, V. L. Kennedy<sup>2, 3</sup>, Mark Yudin<sup>4, 5</sup>, Marek Smieja<sup>1, 6</sup>, Lehana Thabane<sup>1, 6</sup>, Mona Loutfy<sup>2, 3, 5</sup>, Stanley Read<sup>5, 7</sup>, **Ari Bitnun**<sup>5, 7</sup>

1. McMaster University, Hamilton, ON, 2. Women's College Hospital, Toronto, ON, 3. Women's College Research Institute, Toronto, ON, 4. St. Michael's Hospital, Toronto, ON, 5. University of Toronto, Toronto, ON, 6. St Joseph's Healthcare, Hamilton, ON, 7. The Hospital for Sick Children, Toronto, ON

▶ **CSP8.03****Key Interventions and Populations to Target to Facilitate ART Use: Findings from the Canadian HIV Women's Sexual and Reproductive Health Cohort Study (CHIWOS) (E)****Nadine Kronfli**<sup>1</sup>, Angela Kaida<sup>2</sup>, Alexandra de Pokomandy<sup>3, 4</sup>, Lu Wang<sup>5</sup>, Shahab Jabbari<sup>5</sup>, Anita Benoit<sup>6</sup>, Ann Burchell<sup>7</sup>, Wangari Tharao<sup>8</sup>, Carmen Logie<sup>9</sup>, Neora Pick<sup>10</sup>, Mary Kestler<sup>10</sup>, Marisol Desbiens<sup>6</sup>, Kerrigan Beaver<sup>6</sup>, Tracey Conway<sup>6</sup>, Kath Webster<sup>2</sup>, Valerie Nicholson<sup>2</sup>, Allison Carlson<sup>6</sup>, Allison Carter<sup>2</sup>, Karène Proulx-Boucher<sup>3</sup>, Nadia O'Brien<sup>2, 4</sup>, Guillaume Colley<sup>5</sup>, Robert S. Hogg<sup>2, 5</sup>, Mona Loutfy<sup>6, 11</sup>

1. Department of Infectious Diseases, McMaster University, Hamilton, ON, 2. Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, 3. Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, 4. Department of Family Medicine, McGill University, Montreal, QC, 5. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 6. Women's College Research Institute, Women's College Hospital, Toronto, ON, 7. Ontario HIV Treatment Network (OHTN), Toronto, ON, 8. Women's Health in Women's Hands Community Health Centre, Toronto, ON, 9. Faculty of Social Work, University of Toronto,



Toronto, ON, 10. Oak Tree Clinic, Vancouver, BC, 11. Faculty of Medicine, University of Toronto, Toronto, ON

#### ► CSP8.04

### **A Message from MoM: Anti-Oppressive Approaches to Clinical HIV Care Throughout Pregnancy, Birth and Motherhood (E)**

Saara Greene<sup>4</sup>, Angela Underhill<sup>1</sup>, V Logan Kennedy<sup>1</sup>, Johanna Lewis<sup>1</sup>, Daina Stanley<sup>4</sup>, **Allyson Ion**<sup>4</sup>, Mark Yudin<sup>3, 2</sup>, Mona Loutfy<sup>1, 2</sup>

1. Women's College Research Institute, Toronto, ON, 2. University of Toronto, Toronto, ON, 3. St. Michael's Hospital, Toronto, ON, 4. McMaster University, Hamilton, ON

## **HIV Prevention**

### **Prévention du VIH**

#### ► CSP9.01

### **Reducing Risk of HIV Transmission among Gay and Other Men Who Have Sex With Men in Smaller Urban Settings Requires Greater Attention to Their Mental Health (E)**

Andre L. Betim<sup>1</sup>, **Nicholas Valela**<sup>1</sup>, Elliott Faller<sup>1</sup>, Patrick O'Byrne<sup>2</sup>, Paul MacPherson<sup>1</sup>

1. Ottawa Hospital Research Institute, Ottawa, ON, 2. University of Ottawa, Ottawa, ON

#### ► CSP9.02

### **Adherence counseling in a community-based setting for daily oral TDF/FTC-based HIV pre-exposure prophylaxis (PrEP) (E)**

John Larsson<sup>2</sup>, John Maxwell<sup>2</sup>, Janet Raboud<sup>3, 10</sup>, James Wilton<sup>8</sup>, Trevor A. Hart<sup>9, 10</sup>, Shawn Fowler<sup>6</sup>, Troy Grennan<sup>7</sup>, Alan Li<sup>4</sup>, **Darrell H. Tan**<sup>1, 3, 5</sup>

1. St. Michael's Hospital, Toronto, ON, 2. AIDS Committee of Toronto, Toronto, ON, 3. Toronto General Research Institute, Toronto, ON, 4. Regent Park Community Health Centre, Toronto, ON, 5. University of Toronto Department of Medicine, Toronto, ON, 6. Hassle Free Clinic, Toronto, ON, 7. BC Centre for Disease Control, Vancouver, BC, 8. Ontario HIV Treatment Network, Toronto, ON, 9. Ryerson University Department of Psychology, Toronto, ON, 10. University of Toronto Dalla Lana School of Public Health, Toronto, ON

#### ► CSP9.03

### **Recruitment of Healthy Kenyan Women into the KAVI-VZV 001 Study: a Trial Designed to Characterize Mucosal Immune Responses Induced by VZV Vaccination (E)**

**Catia T. Perciani**<sup>1</sup>, Bashir Farah<sup>2</sup>, Omu Anzala<sup>2, 3</sup>, Walter Jaoko<sup>2, 3</sup>, Mario Ostrowski<sup>1</sup>, Kelly S. MacDonald<sup>1, 4</sup>, KAVI-ICR Team

1. Department of Immunology, University of Toronto, Toronto, ON, 2. KAVI - Institute of Clinical Research (KAVI-ICR), Nairobi, Kenya, 3. Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya, 4. Section of Infectious Diseases, Department of Internal Medicine, University of Manitoba, Winnipeg, MB

▶ **CSP9.04****HIV-1 Infection With Multi-class Resistance Despite Pre-Exposure Prophylaxis (PrEP) (E)**David Knox<sup>1</sup>, Peter Anderson<sup>2</sup>, Richard Harrigan<sup>3</sup>, Darrell Tan<sup>4</sup>

1. Maple Leaf Medical Clinic, Toronto, ON, 2. University of Colorado Anschutz Medical Campus, Aurora, CO, USA, 3. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 4. Division of Infectious Diseases, St. Michael's Hospital, Toronto, ON

**Mental Health Issues for HIV Positive Persons****Questions de santé mentale pour les personnes séropositives au VIH**▶ **CSP10.01****Health service outcomes among persons with HIV following a mental health admission: a population-based study (E)**Cindy Lau<sup>5</sup>, Paul Kurdyak<sup>1</sup>, Claire Kendall<sup>3</sup>, Ahmed Bayoumi<sup>2</sup>, Ann Burchell<sup>2</sup>, Mona Loutfy<sup>4</sup>, Janet Raboud<sup>6</sup>, Sean Rourke<sup>7</sup>, Tony Antoniou<sup>2</sup>

1. Centre for Addiction and Mental Health, Toronto, ON, 2. St. Michael's Hospital, Toronto, ON, 3. C.T. Lamont Primary Health Care Research Centre, Bruyère Research Institute, Ottawa, ON, 4. Women's College Research Institute, Toronto, ON, 5. Institute for Clinical Evaluative Sciences, Toronto, ON, 6. Toronto General Research Institute, Toronto, ON, 7. Ontario HIV Treatment Network, Toronto, ON

**Pharmacology, Pharmacokinetics and Pharmacoeconomics****Pharmacologie, pharmacocinétique et pharmacoéconomie**▶ **CSP11.01****Nevirapine Pharmacokinetics in HIV-exposed Neonates Receiving Triple Combination Antiretroviral Therapy as Post-Exposure Prophylaxis (E)**Elaine Lau<sup>1</sup>, Lindy Samson<sup>2</sup>, Jason Brophy<sup>2</sup>, Douglas Campbell<sup>3</sup>, Mark Yudin<sup>3</sup>, Kellie Murphy<sup>4</sup>, Winnie Seto<sup>1</sup>, David Colantonio<sup>1</sup>, Stanley Read<sup>1</sup>, Fatima Kakkar<sup>5</sup>, **Ari Bitnun**<sup>1</sup>

1. Hospital for Sick Children, Toronto, ON, 2. Children's Hospital of Eastern Ontario, Ottawa, ON, 3. St. Michael's Hospital, Toronto, ON, 4. Mount Sinai Hospital, Toronto, ON, 5. CHU Sainte-Justine, Montreal, ON

▶ **CSP11.02****Escalating Doses of Levothyroxine due to a Probable Drug Interaction in a Patient Receiving a Ritonavir-Boosted HIV Protease Inhibitor Regimen (E)**Rahul Sahajpal<sup>1</sup>, Rabia A. Ahmed<sup>2</sup>, Christine A. Hughes<sup>1, 3</sup>, **Michelle M. Foisy**<sup>3</sup>

1. Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, AB, 2. Department of Medicine, University of Alberta, Edmonton, AB, 3. Northern Alberta Program, Alberta Health Services, Edmonton, AB

▶ **CSP11.03**

**Lack of Drug Interactions between Tenofovir Alafenamide-based Antiretroviral Single Tablet Regimens and anti-HCV Single Tablet Regimen Ledipasvir/Sofosbuvir (E)**

Joseph Custodio<sup>1</sup>, Eileen Doyle<sup>1</sup>, Phillip Pang<sup>1</sup>, Moupali Das<sup>1</sup>, Huyen Cao<sup>1</sup>, Grace Ma<sup>1</sup>, Anita Mathias<sup>1</sup>, **Rene-Pierre Lorgeoux<sup>2</sup>**, Julia Zack<sup>1</sup>

1. Gilead Sciences, Inc, Foster City, CA, USA, 2. Gilead Sciences Canada, Inc, Mississauga, ON

▶ **CSP11.04**

**Development of an HIV and Hepatitis C Drug Therapy/Drug Interaction Application (E)**

Alice Tseng<sup>1</sup>, **Michelle Foisy<sup>2</sup>**, Pierre Giguere<sup>3</sup>

1. University Health Network, Toronto General Hospital, Toronto, ON, 2. Northern Alberta Program, Alberta Health Services, Edmonton, AB, 3. The Ottawa Hospital, Ottawa, ON

▶ **CSP11.05**

**A probable drug interaction between lurasidone and atazanavir-based antiretroviral therapy: a case report (E)**

**Alan Wai<sup>1</sup>**, Mark Naccarato<sup>2</sup>, Elise Hall<sup>2</sup>, Mario Ostrowski<sup>2</sup>, Adriana Carvalho<sup>2</sup>

1. University of Toronto, Toronto, ON, 2. St. Michael's Hospital, Toronto, ON

## Resistance

## Résistance

▶ **CSP12.01**

**HyDRA -- A novel bioinformatics tool for next generation sequencing-based HIV drug resistance data analysis (E)**

**Eric Enns<sup>1</sup>**, Binhua Liang<sup>1</sup>, Hezhao Ji<sup>2</sup>, James Brooks<sup>2</sup>, Tracy Taylor<sup>2</sup>, Aileen Patterson<sup>2</sup>, Paul Sandstrom<sup>2</sup>, Gary Van Domselaar<sup>1</sup>

1. National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, 2. National HIV and Retrovirology Laboratories at JC Wilt Infectious Diseases Research Center, Public Health Agency of Canada, Winnipeg, MB

▶ **CSP12.02**

**Simplification of Antiretroviral Therapy to Stribild/Darunavir in Treatment-Experienced HIV Positive Patients: a Case Series (E)**

Jessica Karam<sup>1</sup>, Julia Cahill<sup>2</sup>, **Linda Robinson<sup>1</sup>**

1. Windsor Regional Hospital, Windsor, ON, 2. Queen's University, Kingston, ON

▶ **CSP12.03****Genotypic and phenotypic drug resistance of Human Immunodeficiency Virus type 1 strains to Reverse Transcriptase Inhibitors in Suzhou, China (E)**

Feng Qian<sup>2</sup>, **Meijuan Tian**<sup>1</sup>, Yuejin Li<sup>3</sup>, Lingjie Liao<sup>4</sup>, Wei Jiang<sup>5</sup>, Eric J. Arts<sup>1</sup>, Yiming Shao<sup>4</sup>, Chuanwu Zhu<sup>2</sup>, **Yong Gao**<sup>1</sup>

1. University of Western Ontario, London, ON, 2. The Fifth People's Hospital, Suzhou, China, 3. Case Western Reserve University, Cleveland, OH, USA, 4. Chinese Center for Disease Control and Prevention, Beijing, China, 5. Medical University of South Carolina, Charleston, SC, USA

▶ **CSP12.04****Tenofovir and Emtricitabine Resistance in the CANOC Collaboration: Implications for PrEP (E)**

**Jaime Younger**<sup>1</sup>, Janet Raboud<sup>1, 2</sup>, Richard Harrigan<sup>3, 10</sup>, Marina Klein<sup>4</sup>, Curtis Cooper<sup>5</sup>, Ann Burchell<sup>2, 6</sup>, Ahmed Bayoumi<sup>2, 6</sup>, Sharon Walmsley<sup>1, 2</sup>, Nima Machouf<sup>7</sup>, Robert Hogg<sup>3, 8</sup>, Mona Loutfy<sup>2, 9</sup>, Mark Hull<sup>3, 10</sup>, Julio Montaner<sup>3, 10</sup>, Bohdan Nosyk<sup>3, 8</sup>, Sean Rourke<sup>2, 6, 11</sup>, Stephen Sanche<sup>12</sup>, Chris Tsoukas<sup>4</sup>, Alexander Wong<sup>12</sup>, Tony Antoniou<sup>2, 6</sup>

1. Toronto General Research Institute, University Health Network, Toronto, ON, 2. University of Toronto, Toronto, ON, 3. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 4. McGill University, Montreal, QC, 5. Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, 6. St. Michael's Hospital, Toronto, ON, 7. Clinique Médicale l'Actuel, Montreal, QC, 8. Simon Fraser University, Burnaby, BC, 9. Women's College Research Institute, Toronto, ON, 10. University of British Columbia, Vancouver, ON, 11. Ontario HIV Treatment Network, Toronto, ON, 12. University of Saskatchewan, Saskatoon, SK

**Substance Use and HIV****Toxicomanies et VIH**▶ **CSP13.01****A Latent Class Analysis of Substance Use Patterns Among Canadian Women Living with HIV: Implications for Improving Health Equity by Addressing Social Determinants (E)**

Allison Carter<sup>1, 4</sup>, Erin Ding<sup>1</sup>, **Eric A. Roth**<sup>2</sup>, M-J Milloy<sup>1</sup>, Mary Kestler<sup>3</sup>, Shahab Jabbari<sup>1</sup>, Kath Webster<sup>4</sup>, Marisol Desbiens<sup>6</sup>, Danièle Dubuc<sup>5</sup>, Robert S. Hogg<sup>1, 4</sup>, Alexandra de Pokomandy<sup>5</sup>, Mona Loutfy<sup>6</sup>, Angela Kaida<sup>4</sup>

1. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. University of Victoria, Victoria, BC, 3. Division of Medicine, University of British Columbia, Vancouver, BC, 4. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, 5. Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, 6. Women's College Research Institute, Women's College Hospital, Toronto, ON

▶ **CSP13.02****Morbidity and Mortality Among HIV-Infected Substance Users in Manitoba (E)**

**Adam Erickson**<sup>1</sup>, Marissa Becker<sup>1,2</sup>, Souradet Shaw<sup>1</sup>, Ken Kasper<sup>1,2</sup>, Yoav Keynan<sup>1,2</sup>

1. University of Manitoba, Winnipeg, MB, 2. Health Sciences Centre, Winnipeg, MB

▶ **CSP13.03****Characteristics of women living with HIV who use illicit drugs and experience incarceration in a Canadian setting (E)**

Sophie Patterson<sup>1,2</sup>, Neora Pick<sup>3</sup>, Karen Friesen<sup>3</sup>, Huiru Dong<sup>1</sup>, Sabina Dobrer<sup>1</sup>, Angela Kaida<sup>2</sup>, Sally Lin<sup>1</sup>, Silvia Guillemi<sup>1</sup>, Robert Hogg<sup>1,2</sup>, Julio Montaner<sup>1,4</sup>, **M-J Milloy**<sup>1</sup>

1. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, 3. British Columbia Women's Hospital and Healthcare Centre, Vancouver, BC, 4. Department of Medicine, University of British Columbia, Vancouver, BC

▶ **CSP13.04****Stribild: a Promising New Treatment for Suppression of HIV Viral Load in People Who Inject Drugs (E)**

Sahand Vafadary, **Syune Hakobyan**

Vancouver Infectious Diseases Centre, Vancouver, BC

**Clinical Sciences Other****Sciences cliniques, Autre**▶ **CSP14.01****HIV-Specific Patient-Reported Outcome Measures: A Scoping Review of Available Tools in 2015 (E)**

**Kim Engler**<sup>1,2</sup>, David Lessard<sup>1,2,3</sup>, Bertrand Lebouche<sup>1,2,3</sup>

1. McGill University Health Centre, Royal Victoria Hospital, Chronic Viral Illness Service, Montreal, QC, 2. McGill University Health Centre, Research Institute, Montreal, QC, 3. McGill University, Department of Family Medicine, Montreal, QC

▶ **CSP14.02****Patterns of Physical Activity and Associations with Metabolic Health in Men Living with HIV Compared to Age Matched Controls (E)**

**Cuisle Forde**<sup>1</sup>, Aisling Loy<sup>2</sup>, Siobhan ODea<sup>2</sup>, Fiona Mulcahy<sup>2</sup>, John Gormley<sup>1</sup>, Caroline Daly<sup>2,1</sup>

1. Trinity College Dublin, Dublin, Ireland, 2. Saint James's Hospital, Dublin, Ireland

▶ **CSP14.03****The effects of a 16 week aerobic exercise programme on cognitive function in people living with HIV (E)**

Adam McDermott<sup>1,2</sup>, Lilia Vaporojan<sup>2</sup>, **Cuisle Forde**<sup>1</sup>, Mikel Egana<sup>1</sup>, John Gormley<sup>1</sup>, Colm Bergin<sup>2,1</sup>

1. Trinity College Dublin, Dublin, Ireland, 2. Saint James's Hospital, Dublin, Ireland

**▶ CSP14.04****Characteristics of Persons Living with HIV attending Self-Management Programs offered in the Manitoba HIV Program (E)**

**Laurie Ireland**<sup>1, 5</sup>, Tania Wiebe<sup>1</sup>, Shauna Fay<sup>1</sup>, Tammy Reimer<sup>1</sup>, Leigh McClarty<sup>2, 6</sup>, Eve Cheuk<sup>2, 6</sup>, Gayle Restall<sup>7</sup>, Marissa Becker<sup>2, 6, 8</sup>, Claire Kendall<sup>3, 4</sup>, Clare Liddy<sup>3, 4</sup>

1. Nine Circles Community Health Centre, Winnipeg, MB, 2. Department of Community Health Sciences, University of Manitoba, Winnipeg, MB, 3. Bruyere Research Institute, Ottawa, ON, 4. Department of Family Medicine, University of Ottawa, Ottawa, ON, 5. Department of Family Medicine, University of Manitoba, Winnipeg, MB, 6. Centre for Global Public Health, Winnipeg, MB, 7. Department of Medical Rehabilitation, University of Manitoba, Winnipeg, MB, 8. Department of Medical Microbiology, University of Manitoba, Winnipeg, MB

**▶ CSP14.05****Blood-Brain Barrier Dysfunction as a Novel Biomarker and Therapeutic Target for HIV-Associated Neurocognitive Disorders (E)**

**Yonatan Serlin**<sup>1</sup>, Alon Friedman<sup>1, 2</sup>, Yoav Keynan<sup>3, 4, 5</sup>

1. Department of Medical Neuroscience, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada, Halifax, NS, 2. Department of Physiology and & Cell Biology, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel, Beer-Sheva, Israel, 3. Manitoba HIV Program, Winnipeg, MB, Canada, Winnipeg, MB, 4. Department of Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, Winnipeg, MB, 5. Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, Winnipeg, MB, 6. Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada, Winnipeg, MB

**▶ CSP14.06****The impact of the episodic nature of chronic illness: a comparison of Fibromyalgia, Multiple Sclerosis and Human Immunodeficiency Virus (HIV) (E)**

**Saipriya Vajravelu**<sup>1</sup>, Kelly O'Brien<sup>2</sup>, Sandra Moll<sup>1</sup>, Patricia Solomon<sup>1</sup>

1. McMaster University, Hamilton, ON, 2. University of Toronto, Toronto, ON

## Track C: Epidemiology and Public Health Sciences

### Volet C : Épidémiologie et sciences de la santé publique

## Data Science, Data Visualization and Big Data in Public Health Research

### Science des données, visualisation des données et mégadonnées dans la recherche en santé publique

#### ► EPHP1.01

#### #PrEP @ #CROI2015: Exploring the roles of Twitter user types in sharing and discussing new evidence on HIV pre-exposure prophylaxis (PrEP) (E)

Iradele Plante<sup>1</sup>, James Wilton<sup>2</sup>, Hadaf Zubi<sup>2</sup>, Maggie MacAulay<sup>3</sup>, Nathan Lachowsky<sup>4</sup>, Lori Donelle<sup>5</sup>, Paul Flowers<sup>6</sup>, Susan Martin<sup>7</sup>, Lisa McDaid<sup>7</sup>, Daniel Grace<sup>1</sup>, Olivier Ferlatte<sup>8</sup>, Mark Gilbert<sup>2</sup>

1. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, 2. Ontario HIV Treatment Network, Toronto, ON, 3. Simon Fraser University, Burnaby, BC, 4. B.C. Center for Excellence in HIV/AIDS, Vancouver, BC, 5. Western University, London, ON, 6. Glasgow Caledonian University, Glasgow, United Kingdom, 7. University of Glasgow, Glasgow, United Kingdom, 8. Community-Based Research Centre for Gay Men's Health, Vancouver, BC

## Demography of HIV and Estimates of Key Population Sizes

### Démographie du VIH et estimations de la taille des populations clés

#### ► EPHP2.01

#### Assessing Injection Drug Use from Diagnostic Codes in Administrative Healthcare Data: the British Columbia Hepatitis Testers Cohort (E)

Naveed Z. Janjua<sup>1,2</sup>, Margot Kuo<sup>1</sup>, Amanda Yu<sup>1</sup>, Hasina Samji<sup>1,2</sup>, Nazrul Islam<sup>1,2</sup>, Butt Zahid<sup>1</sup>, Jason Wong<sup>1,2</sup>, Mark Tyndall<sup>1,2</sup>, Mel Kraiden<sup>1,3</sup>

1. Clinical Prevention Services, BC Centre for Disease Control, Vancouver, BC, 2. School of Population and Public Health, University of British Columbia, Vancouver, BC, 3. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC

▶ **EPHP2.02****HIV Incidence among MSM Attendees of Sexually Transmitted Infection Clinics across British Columbia, Canada (E)**

**Hasina Samji**<sup>1, 2</sup>, Jia Hu<sup>1</sup>, David Moore<sup>1, 2, 3</sup>, Mark Hull<sup>3</sup>, Michael Otterstatter<sup>1</sup>, Troy Grennan<sup>1, 2</sup>, Naveed Janjua<sup>1, 2</sup>, Bobbi Brownrigg<sup>1</sup>, Dean Mirau<sup>1</sup>, Mark Tyndall<sup>1, 2</sup>, Gina Ogilvie<sup>1, 2</sup>, Jason Wong<sup>1, 2</sup>

1. British Columbia Centre for Disease Control, Vancouver, BC, 2. University of British Columbia, Vancouver, BC, 3. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC

**Economic Evaluation of Policies, Programs or Interventions****Évaluation économique des politiques, des programmes ou des interventions**▶ **EPHP3.01****The Need for Compassionate Supply of Antiretroviral Medications Provided Through the Manitoba HIV Program: A Retrospective Review (E)**

**Shanna Chan**<sup>1, 2, 3</sup>, Laurie Ireland<sup>1, 4</sup>, Marissa Becker<sup>1, 2</sup>, Yoav Keynan<sup>1, 2</sup>, Ken Kasper<sup>1, 2</sup>

1. Manitoba HIV Program, Winnipeg, MB, 2. University of Manitoba, Winnipeg, MB, 3. Winnipeg Regional Health Authority, Winnipeg, MB, 4. Nine Circles Community Health Centre, Winnipeg, MB

▶ **EPHP3.02****In What Circumstances Could Non-daily Pre-exposure Prophylaxis (PrEP) Substantially Reduce Program Costs (HPTN 067)? (E)**

**Kate M. Mitchell**<sup>1</sup>, Dobromir Dimitrov<sup>2</sup>, James P. Hughes<sup>2, 3</sup>, Fan Xia<sup>3</sup>, Deborah Donnell<sup>2</sup>, Linda-Gail Bekker<sup>4</sup>, Timothy H. Holtz<sup>5, 6</sup>, Sharon Mannheimer<sup>7, 8</sup>, Robert M. Grant<sup>9</sup>, Marie-Claude Boily<sup>1</sup>

1. Imperial College London, London, United Kingdom, 2. Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 3. University of Washington, Seattle, WA, USA, 4. University of Cape Town, Cape Town, South Africa, 5. Thailand Ministry of Public Health – U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand, 6. U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA, 7. Columbia University, New York, NY, USA, 8. Harlem Hospital Center, New York, NY, USA, 9. University of California, San Francisco, CA, USA



## Epidemiology and Surveillance of HIV Co-infections

### Épidémiologie et surveillance des coinfections au VIH

#### ► EPHP4.01

#### **HCV Re-Infection in High-Risk HIV Co-Infected People Who Inject Drugs in a Multidisciplinary Clinic (E)**

**Brian Conway**

Vancouver ID Research and Care Centre Society, Vancouver, BC

#### ► EPHP4.02

#### **Characterization of HCV Infected PWID in the Setting of Clinical Care in Canada (CAPICA): A retrospective study (E)**

**Curtis Cooper**<sup>1</sup>, Brian Conway<sup>2</sup>, Julie Bruneau<sup>3</sup>, Lucie Deshaies<sup>5</sup>, Chris Fraser<sup>6</sup>, Gisela MacPhail<sup>7</sup>, Jeff Powis<sup>8</sup>, Chris Steingart<sup>9</sup>, Kris Stewart<sup>10</sup>, Rejean Thomas<sup>11</sup>, Duncan Webster<sup>12</sup>, Joseph Cox<sup>13</sup>, Janie Trepanier<sup>14</sup>, Mark McGovern<sup>14</sup>, Martine Drolet<sup>14</sup>

1. The Ottawa Hospital Research Institute, Ottawa, ON, 2. Vancouver ID Research & Care Centre, Vancouver, BC, 3. CHUM: Hôpital St-Luc, Montréal, QC, 4. Toronto Western Hospital, Toronto, ON, 5. Clinique Medicale Lauberiviere, Lévis, QC, 6. Cool Aid Community Health Centre, Victoria, BC, 7. Calgary Urban Project Society (CUPS), Calgary, AB, 8. Toronto Community Hep C Program, Toronto, ON, 9. Sanguen Health Center, Waterloo, ON, 10. Saskatoon Infectious Disease Care Network, Saskatoon, SK, 11. Clinique Medicale l'Actuel, Montréal, QC, 12. Dalhousie University, Saint John, NB, 13. McGill University Health Center, Montréal, QC, 14. Merck Canada Inc, Kirkland, QC

#### ► EPHP4.03

#### **Trends in causes of mortality in the Canadian Co-infection cohort (CCC) 2005 – 2015 (E)**

**Mark Hull**<sup>1</sup>, Sahir Bhatnagar<sup>2</sup>, Erica Moodie<sup>2</sup>, Joseph Cox<sup>2</sup>, Jeffrey Cohen<sup>3</sup>, Curtis Cooper<sup>4</sup>, Brian Conway<sup>5</sup>, Sharon Walmsley<sup>6</sup>, Anita Rachlis<sup>6</sup>, John Gill<sup>7</sup>, Danielle Rouleau<sup>8</sup>, Alexander Wong<sup>9</sup>, Shariq Haider<sup>10</sup>, Neora Pick<sup>11</sup>, Marina Klein<sup>2</sup>

1. BC Centre For Excellence In HIV/AIDS, Vancouver, BC, 2. University of McGill, Montreal, QC, 3. Windsor Regional Hospital, Windsor, ON, 4. University of Ottawa, Ottawa, ON, 5. Vancouver Infectious Diseases Centre, Vancouver, BC, 6. University of Toronto, Toronto, ON, 7. University of Calgary, Calgary, AB, 8. University of Montreal, Montreal, QC, 9. University of Saskatchewan, Regina, SK, 10. University of McMaster, Hamilton, ON, 11. Oak Tree Clinic, BC Women's Hospital, Vancouver, BC

▶ **EPHP4.04****Characteristics of a Core Group of Gay, Bisexual and Men Who Have Sex with Men (MSM) with  $\geq 4$  Infectious Syphilis Infections in British Columbia (BC) from 2005 to 2014 (E)**

Stephanie Konrad<sup>1</sup>, Donna Mak<sup>2</sup>, Troy Grennan<sup>3, 4</sup>, Bobbi Brownrigg<sup>3</sup>, Gina Ogilvie<sup>3, 4</sup>, Mel Krajden<sup>3, 4</sup>, Morshed Muhammad<sup>4</sup>, Mark Tyndall<sup>3, 4</sup>, **Jason Wong**<sup>3, 4</sup>

1. Public Health Agency of Canada, Vancouver, BC, 2. University of Notre Dame, Australia and Department of Health, Government of Western Australia, Sydney, WA, Australia, 3. British Columbia Centre for Disease Control, Vancouver, BC, 4. University of British Columbia, Vancouver, BC

▶ **EPHP4.05****HIV a Risk factor for Reinfections of Infectious Syphilis among Gay, Bisexual, and Other Men Who Have Sex With Men (MSM) in British Columbia (BC), 2005-2014 (E)**

Stephanie Konrad<sup>1</sup>, Hasina Samji<sup>2, 4</sup>, Donna Mak<sup>3</sup>, Troy Grennan<sup>2, 4</sup>, Bobbi Brownrigg<sup>2</sup>, Gina Ogilvie<sup>2, 4</sup>, Mel Krajden<sup>2, 4</sup>, Morshed Muhammad<sup>4</sup>, Mark Tyndall<sup>2, 4</sup>, **Jason Wong**<sup>2, 4</sup>

1. Public Health Agency of Canada, Vancouver, BC, 2. British Columbia Centre for Disease Control, Vancouver, BC, 3. University of Notre Dame, Australia and Department of Health, Government of Western Australia, Sydney, WA, Australia, 4. University of British Columbia, Vancouver, BC

▶ **EPHP4.06****The Hepatitis C Cascade of Care in a Women-Centered HIV Clinic in Canada (E)**

A. Mah<sup>1</sup>, **Z. Pakzad**<sup>2</sup>, M. Murray<sup>1, 2</sup>, M. Kestler<sup>1, 2</sup>, A. Hornsberger<sup>2</sup>, M. Thumath<sup>3</sup>, E. J. Maan<sup>2</sup>, D. Money<sup>2</sup>, N. Pick<sup>1, 2</sup>

1. Division of Infectious Diseases, University of British Columbia, Vancouver, BC, 2. Oak Tree Clinic, Provincial Health Services Authority, Vancouver, BC, 3. British Columbia Center for Disease Control, Provincial Health Services Authority, Vancouver, BC

▶ **EPHP4.07****Epidemiology of Spine Infection in Patients with History of IV Drug Use and HIV Infection. Possibility of the Secondary Prevention (E)**

**Kotoo Meguro**<sup>1</sup>, Ryan Meil<sup>2</sup>

1. Division of Neurosurgery, University of Saskatchewan, Saskatoon, SK, 2. Department of Community Health and Epidemiology, University of Saskatchewan, Saskatoon, SK

▶ **EPHP4.08****A history of HIV and syphilis co-infection in Winnipeg, Manitoba (E)**

**Souradet Y. Shaw**<sup>1, 2</sup>, Craig P. Ross<sup>2</sup>, Deborah Nowicki<sup>2, 1</sup>, Shelley Marshall<sup>2</sup>, Alicia Lapple<sup>2</sup>, Jennifer Riddell<sup>2</sup>, Christina Davies<sup>2</sup>, Sandy Stephen<sup>2</sup>, Kim Bailey<sup>2</sup>, Pierre J. Plourde<sup>2, 1</sup>, Joss N. Reimer<sup>2, 1</sup>

1. University of Manitoba, Winnipeg, MB, 2. Winnipeg Regional Health Authority, Winnipeg, MB

▶ **EPHP4.09****Is the Face of Hepatitis C Changing in Montreal? (E)**

Benoit Trottier<sup>1, 2</sup>, **Réjean Thomas**<sup>1, 2</sup>, Chrissi Galanakis<sup>1</sup>, Danièle Longpré<sup>1</sup>, Sylvie Vézina<sup>1</sup>, Marc Poliquin<sup>1</sup>, Emmanuelle Huchet<sup>1</sup>, Stéphane Lavoie<sup>1</sup>, Caroline Bédard<sup>1</sup>, Nimâ Machouf<sup>1</sup>  
 1. Clinique médicale l'Actuel, Montréal, QC, 2. Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, 3. Université de Montréal, Montréal, QC

## **Epidemiology and Surveillance of HIV/AIDS** **Épidémiologie et surveillance of du VIH/** **sida**

▶ **EPHP5.01**
**I-Track: Enhanced surveillance of HIV and hepatitis C risk behaviours among people who inject drugs in Canada, 2002 to 2012 (E)**

Jill Tarasuk, Xiaoquan Yao, Stephen Cule, Qiong Li, **Parminder Dhami**, Susanna Ogunnaike-Cooke, **Chris P. Archibald**  
 Public Health Agency of Canada, Ottawa, ON

▶ **EPHP5.02**
**Factors Associated with Incidence of Type 2 Diabetes among HIV-Positive and HIV-Negative British Columbians (E)**

**Sarah Kesselring**<sup>1</sup>, Shahab Jabbari<sup>1</sup>, Conrado Franco-Villalobos<sup>1</sup>, Oghenowede Eyawo<sup>1, 2</sup>, Tareq Ahmed<sup>1</sup>, Mark Hull<sup>1</sup>, Robert Hogg<sup>1, 2</sup>  
 1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. Simon Fraser University, Burnaby, BC

▶ **EPHP5.03**
**Factors Associated with Mood Disorder Diagnosis Among HIV-Positive and HIV-Negative Individuals in British Columbia (E)**

Kalysha Closson<sup>1, 2</sup>, **Chuck Osborne**<sup>1</sup>, Sarah Kesselring<sup>1</sup>, Shahab Jabbari<sup>1</sup>, Conrado Franco-Villalobos<sup>1</sup>, Danielle Smith<sup>1, 2</sup>, Tareq Ahmed<sup>1</sup>, Oghenowede Eyawo<sup>1, 2</sup>, Thomas Patterson<sup>3</sup>, Mark Hull<sup>1, 4</sup>, Robert Hogg<sup>1, 2</sup>  
 1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. Simon Fraser University, Burnaby, BC, 3. University of California, San Diego, San Diego, CA, USA, 4. UBC School of Medicine, Vancouver, BC

▶ **EPHP5.04**
**HIV Incidence Rate and Predictors Among Gay and other Men Who Have Sex With Men (MSM) in Vancouver: Additional Benefit of an Administrative Health Data Linkage (E)**

**Nathan J. Lachowsky**<sup>1, 2</sup>, Zishan Cui<sup>1</sup>, Paul Sereda<sup>1</sup>, Kristine Stephenson<sup>3</sup>, Ashleigh Rich<sup>1</sup>, Jesse Brown<sup>4</sup>, Jody Jollimore<sup>5</sup>, David Hall<sup>3</sup>, Jason Wong<sup>6</sup>, Mark Hull<sup>1, 2</sup>, Julio S. Montaner<sup>1, 2</sup>, Eric A. Roth<sup>7, 8</sup>, Robert S. Hogg<sup>9, 1</sup>, David M. Moore<sup>1, 2</sup>  
 1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2.

University of British Columbia, Vancouver, BC, 3. Vancouver Coastal Health Authority, Vancouver, BC, 4. YouthCO HIV & Hep C Society, Vancouver, BC, 5. Health Initiative for Men, Vancouver, BC, 6. BC Centre for Disease Control, Vancouver, BC, 7. University of Victoria, Victoria, BC, 8. Centre for Addictions Research BC, Victoria, BC, 9. Simon Fraser University, Burnaby, BC

► **EPHP5.05**

**Clinical and socio-demographic characteristics and early ART initiation during Primary HIV Infection (E)**

**Vikram Mehraj**<sup>1, 2</sup>, Wei Cao<sup>3</sup>, Rosalie Ponte<sup>1, 2</sup>, Mario Legault<sup>4</sup>, Bertrand Lebouché<sup>1, 2, 5</sup>, Réjean Thomas<sup>6</sup>, Jean-Guy Baril<sup>7</sup>, Roger LeBlanc<sup>8</sup>, Cécile Tremblay<sup>4, 9</sup>, Jean-Pierre Routy<sup>1, 2, 10</sup>

1. Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, 2. Research Institute of the McGill University Health Centre, Montreal, QC, 3. Department of Infectious Diseases, Peking Union Medical College Hospital, Beijing, China, 4. Centre de recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC, 5. Department of Family Medicine, McGill University, Montreal, QC, 6. Clinique Médicale l'Actuel, Montréal, QC, 7. Clinique Médicale Quartier Latin, Montréal, QC, 8. Clinique Médicale OPUS, Montréal, QC, 9. Département de microbiologie, infectiologie et immunologie, Université de Montréal, Montréal, QC, 10. Division of Hematology, McGill University Health Centre, Montreal, QC

► **EPHP5.06**

**Prevalence and correlates of reporting antiretroviral therapy is difficult to take among HIV-positive illicit drug users in Vancouver, Canada (E)**

Bianca Yeung<sup>1</sup>, Evan Wood<sup>1, 2</sup>, Huiru Dong<sup>1</sup>, Thomas Kerr<sup>1, 2</sup>, Julio Montaner<sup>1, 2</sup>, **M-J Milloy**<sup>1, 2</sup>

1. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. University of British Columbia, Vancouver, BC

► **EPHP5.07**

**Incidence and Survival of Non-Small-Cell Lung Cancer Among HIV Positive and HIV Negative Individuals in British Columbia, Canada (E)**

**Danielle M. Smith**<sup>1, 2</sup>, Conrado Franco-Villalobos<sup>2</sup>, Guillaume Colley<sup>2</sup>, Tareq Ahmed<sup>2</sup>, Oghenowede Eyawo<sup>1, 2</sup>, Mark Hull<sup>2</sup>, Robert Hogg<sup>1, 2</sup>

1. Simon Fraser University, Burnaby, BC, 2. BC Centre for Excellence in HIV/AIDS, Vancouver, BC

## Evaluations of Public Health Programs and Interventions

### Évaluation des programmes et des interventions en santé publique

#### ► EPHP6.01

##### **What Sets it Apart: Client Experiences at the Dr. Peter Centre (E)**

**Rosalind Baltzer Turje**<sup>2</sup>, Saranee M. Fernando<sup>1</sup>, Surita Parashar<sup>1</sup>, Catherine Worthington<sup>3</sup>, M-J Milloy<sup>1</sup>, Patrick McDougall<sup>2</sup>, Natalia Oliveira<sup>1</sup>, Robert Hogg<sup>1</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. Dr. Peter AIDS Foundation, Vancouver, BC, 3. University of Victoria, Victoria, BC

#### ► EPHP6.02

##### **HIV Researchers Mentoring the Next Generation of Clinician Scientists (E)**

Jan Klimas<sup>1, 2</sup>, Ryan McNeil<sup>1</sup>, Keith Ahamad<sup>1</sup>, Annabel Mead<sup>1</sup>, Launette Rieb<sup>1</sup>, **Katelyn G. Merritt**<sup>1</sup>, Walter Cullen<sup>2</sup>, Evan Wood<sup>1</sup>, William Small<sup>1</sup>

1. University of British Columbia, Vancouver, BC, 2. University College Dublin, Dublin, Ireland

#### ► EPHP6.03

##### **Nutritional status, Symptoms of depression and anxiety among patients living with HIV on Highly Active Anti Retroviral Therapy in Malaysia (E)**

**Maryam Shafiei Sabet**<sup>1</sup>, Roslee Rajikan<sup>1</sup>, Christopher Lee Kwok Choong<sup>2</sup>, Jason Yeo<sup>3</sup>

1. Dietetics Program, School of Health Care Sciences, Faculty of Health Sciences, University Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia, 2. Medical and Infection Diseases Department, Hospital Sungai Buloh, Ministry of Health Malaysia, Kuala Lumpur, Malaysia, 3. Department of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, University Putra Malaysia, Selangor, Malaysia

#### ► EPHP6.04

##### **Demand for Anonymous HIV Testing (AHT) in British Columbia (BC) for Clients Vulnerable to HIV Infection (E)**

**Theodora B. Consolacion**<sup>1</sup>, Bobbi Brownrigg<sup>1</sup>, Dean Mirau<sup>1</sup>, Annelies Becu<sup>1</sup>, Glenn Doupe<sup>2</sup>, Wendy Stark<sup>3</sup>, Michelle Murti<sup>4</sup>, Troy Grennan<sup>1</sup>, Mel Krajden<sup>5, 6, 7</sup>, Mark Gilbert<sup>8</sup>, Jason Wong<sup>1</sup>, David Moore<sup>1, 9</sup>

1. Clinical Prevention Services, BC Centre for Disease Control, Vancouver, BC, 2. Vancouver Coastal Health Authority, Vancouver, BC, 3. Vancouver Island Health Authority, Victoria, BC, 4. Fraser Health Authority, Surrey, BC, 5. Hepatitis Services, BC Centre for Disease Control, Vancouver, BC, 6. Dept. of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, 7. BCCDC Public Health Laboratories, Vancouver, BC, 8. Ontario HIV Treatment Network, Toronto, ON, 9. BC Centre for Excellence in HIV/AIDS, Vancouver, BC

## HIV Prevention for Key Populations

### La prévention du VIH dans les populations clés

#### ► EPHP7.01

**The Cedar Project: Understanding the increased vulnerability to contracting Herpes Simplex Virus 2 among a cohort of young Aboriginal people who use drugs in British Columbia (E)**

**Negar Chavoshi**<sup>1</sup>, Wunuxtsin M. Christian<sup>2</sup>, Shannon Waters<sup>1</sup>, Martin T. Schechter<sup>1</sup>, Patricia M. Spittal<sup>1</sup>

1. University of British Columbia, Vancouver, BC, 2. Splantsin te Secwepemc Nation, Enderby, BC

#### ► EPHP7.02

**HIV Point-of-Care Testing (HIV POCT): Mobilizing for Change at the National Level (E)**

**Jacqueline Gahagan**<sup>1</sup>, Brian Condran<sup>1</sup>, Mohammad Hajizadeh<sup>1</sup>, Jason Kielly<sup>2</sup>, Nikki Pai<sup>3</sup>, Debbie Kelly<sup>2</sup>, REACH 2.0

1. Dalhousie University, Halifax, NS, 2. Memorial University of Newfoundland, St. John's, NL, 3. McGill University, Montreal, QC

#### ► EPHP7.03

**The importance of collaborative knowledge sharing: Enhancing Canada's policy advice mechanisms on HIV and AIDS under an integrated approach to STBBIs (E)**

**Jacqueline Gahagan**<sup>1</sup>, Michelle George<sup>2</sup>, Rodney Rousseau<sup>3</sup>, Ken Monteith<sup>4</sup>, Ciro Panessa<sup>5</sup>, Albert McLeod<sup>6</sup>, Gerry Mugford<sup>7</sup>, Curtis Cooper<sup>8</sup>, Denise Lambert<sup>9</sup>

1. Dalhousie University, Halifax, NS, 2. Tsleil-Waututh Nation, BC, BC, 3. University of Toronto, Toronto, ON, 4. COCQ-SIDA, Montreal, QC, 5. Northern Health Authority, Terrace, BC, 6. Two-Spirited People of Manitoba, Inc., Winnipeg, MB, 7. Memorial University of Newfoundland, St. John's, NL, 8. Ottawa Hospital Research Institute, Ottawa, ON, 9. Kimamow Atoskanow Foundation, Oneway, AB

#### ► EPHP7.04

**A 4-Year Longitudinal Event-Level Analysis of HIV Risk and Substance Use Among HIV-Negative and HIV-Positive Gay, Bisexual and Other Men Who Have Sex with Men (MSM) (E)**

**Nathan J. Lachowsky**<sup>1, 2</sup>, Zishan Cui<sup>1</sup>, Paul Sereda<sup>1</sup>, Ashleigh Rich<sup>1</sup>, Jody Jollimore<sup>4</sup>, Terry Howard<sup>3</sup>, Jesse Brown<sup>5</sup>, Eric A. Roth<sup>6, 7</sup>, Robert S. Hogg<sup>8, 1</sup>, David M. Moore<sup>1, 2</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. University of British Columbia, Vancouver, BC, 3. Positive Living BC, Vancouver, BC, 4. Health Initiative for Men, Vancouver, BC, 5. YouthCO HIV & Hep C Society, Vancouver, BC, 6. University of Victoria, Victoria, BC, 7. Centre for Addictions Research BC, Victoria, BC, 8. Simon Fraser University, Burnaby, BC

▶ **EPHP7.05****Decreasing community viral load (VL) among HIV-positive men who have sex with men (MSM) in British Columbia (BC): 2003-2014 (E)**

**David M. Moore**<sup>1, 2, 3</sup>, Jason Wong<sup>2</sup>, Zishan Cui<sup>1</sup>, Susan Shurgold<sup>1</sup>, Guillaume Colley<sup>1</sup>, Mark Tyndall<sup>3, 2</sup>, Nate Lachowsky<sup>1</sup>, Evan Adams<sup>4</sup>, Robert Hogg<sup>5, 1</sup>, Trevor Corneil<sup>6</sup>, Reka Gustafson<sup>7</sup>, Dee Hoyano<sup>8</sup>, Michelle Murti<sup>9</sup>, Sandra Allison<sup>10</sup>, Julio Montaner<sup>1, 3</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. BC Centre for Disease Control, Vancouver, BC, 3. Faculty of Medicine, University of British Columbia, Vancouver, BC, 4. First Nations Health Authority, Vancouver, BC, 5. Simon Fraser University, Burnaby, BC, 6. Interior Health, Kelowna, BC, 7. Vancouver Coastal Health, Vancouver, BC, 8. Island Health, Victoria, BC, 9. Fraser Health Authority, Surrey, BC, 10. Northern Health Authority, Prince George, BC

▶ **EPHP7.06****Temporal trends in HAART optimism and risky sexual behaviour among HIV-positive and HIV-negative men who have sex with men (MSM) in Vancouver (E)**

**David M. Moore**<sup>1, 6</sup>, Zishan Cui<sup>1</sup>, Nate Lachowsky<sup>1, 6</sup>, Paul Sereda<sup>1</sup>, Ashleigh Rich<sup>1</sup>, Eric Roth<sup>2</sup>, Henry Fisher Raymond<sup>3</sup>, Julio Montaner<sup>1, 6</sup>, Jason Wong<sup>5, 6</sup>, David Hall<sup>4</sup>, Robert Hogg<sup>5, 1</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. University of Victoria, Victoria, BC, 3. San Francisco Department of Public Health, San Francisco, CA, USA, 4. Vancouver Coastal Health, Vancouver, BC, 5. BC Centre for Disease Control, Vancouver, BC, 6. Faculty of Medicine, University of British Columbia, Vancouver, BC, 7. Simon Fraser University, Burnaby, BC

▶ **EPHP7.07****HIV Risk and Prevention Uptake among a Community Sample of Young Gay and other Men Who Have Sex with Men (MSM) and Transgender Women Sex Workers in Thailand (E)**

**Peter A. Newman**<sup>1</sup>, Surachet Rongprakhon<sup>2</sup>, Suchon Tejjan<sup>1, 3</sup>, Latsamy Soundala<sup>3</sup>

1. University of Toronto, Toronto, ON, 2. Rajamangala University of Technology Phra Nakhon, Bangkok, Thailand, 3. VOICES-Thailand Foundation, Chiang Mai, Thailand

▶ **EPHP7.08****Sexual risk reduction strategies among gay, bisexual and other men who have sex with men in Toronto, Canada: A Latent Class Analysis (E)**

**Syed W. Noor**<sup>1</sup>, Barry D. Adam<sup>2</sup>, Todd A. Coleman<sup>1</sup>, David J. Brennan<sup>3</sup>, Sandra Gardner<sup>4</sup>, Trevor A. Hart<sup>1</sup>

1. Ryerson University, Toronto, ON, 2. University of Windsor, Windsor, ON, 3. University of Toronto, Toronto, ON, 4. Ontario HIV Treatment Network, Toronto, ON

▶ **EPHP7.09****Antiretroviral therapy based HIV prevention awareness, acceptability and use among transgender gay and queer men: Findings from interviews in Vancouver, BC (E)**

**Ashleigh Rich**<sup>1</sup>, Everett D. Blackwell<sup>2</sup>, Kai Scott<sup>2</sup>, Nathan J. Lachowsky<sup>1, 3</sup>, Caitlin Johnston<sup>4</sup>, David M. Moore<sup>1, 3</sup>, Robert S. Hogg<sup>1, 4</sup>, Eric A. Roth<sup>5, 6</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. Momentum Health Study team, Vancouver, BC, 3. University of British Columbia, Vancouver, BC, 4. Simon Fraser University, Burnaby, BC, 5. University of Victoria, Victoria, BC, 6. Centre for Addictions Research BC, Victoria, BC

▶ **EPHP7.11****Communicating with the community among poor literacy key populations (E)**

Balasubramanya K. Venkataramaiah<sup>1</sup>, **Srinath Maddur Mallikarjuna**<sup>2</sup>, Mohan H. Lakkappa<sup>2</sup>, Sandeep H. <sup>1</sup>, Ramachandra R. Kadambar<sup>1</sup>, Shajy Isac<sup>2</sup>

1. Karnataka Health Promotion Trust, Bangalore, KA, India, 2. Centre for Global Public Health, Winnipeg, MB

**HIV Program Science****La science dans l'élaboration des programmes sur le VIH**▶ **EPHP8.01****Barriers and facilitators of retention in HIV care in high-income settings: A systematic review (E)**

Jason Globerman<sup>1</sup>, David Gogolishvili<sup>1</sup>, **Sanjana Mitra**<sup>1</sup>, Laura Schoffel<sup>1</sup>, Danielle Giliauskas<sup>1</sup>, Beth Rachlis<sup>1</sup>, Sean B. Rourke<sup>1, 2, 3</sup>

1. The Ontario HIV Treatment Network, Toronto, ON, 2. St. Michael's Hospital, Toronto, ON, 3. University of Toronto, Toronto, ON

▶ **EPHP8.02****Heterogeneity in the emerging trends and patterns of HIV transmission among key populations in Pakistan: a mathematical modeling study of survey data (E)**

**Dessalegn Y. Melesse**<sup>1</sup>, Leigh Anne Shafer<sup>2</sup>, Baser K. Achakzai<sup>3</sup>, Sofia Furqan<sup>3</sup>, Tahira Reza<sup>3</sup>, Faran Emmanuel<sup>1</sup>, James F. Blanchard<sup>1</sup>

1. Centre for Global Public Health, University of Manitoba, Winnipeg, MB, 2. Department of Internal Medicine, University of Manitoba, Winnipeg, MB, 3. National AIDS Control Program, National Institute of Health, Islamabad, Pakistan



## Interdisciplinary Epidemiology (Biological, Behavioural and Social) or Biopsychosocial Research

### Épidémiologie interdisciplinaire (biologique, comportementale et sociale) ou recherche biopsychosociale

#### ► EPHP9.01

#### Association Between Food Insecurity and Low CD4 Count Among HIV Infected People: A Systematic Review and Meta-Analysis (E)

Wusiman Aibibula<sup>1</sup>, Joseph Cox<sup>2</sup>, Anne-Marie Hamelin<sup>1</sup>, Hiroshi Mamiya<sup>1</sup>, Marina B. Klein<sup>1</sup>, Paul Brassard<sup>1</sup>

1. McGill University, Montreal, QC, 2. Public Health Department, CIUSSS du Centre-Est-de-l'Île-de-Montréal, Montreal, QC

#### ► EPHP9.02

#### Association Between Food Insecurity and HIV Viral Suppression: A Systematic Review and Meta-Analysis (E)

Wusiman Aibibula<sup>1</sup>, Joseph Cox<sup>2</sup>, Anne-Marie Hamelin<sup>1</sup>, Taylor McLinden<sup>1</sup>, Marina B. Klein<sup>1</sup>, Paul Brassard<sup>1</sup>

1. McGill University, Montreal, QC, 2. Public Health Department, CIUSSS du Centre-Est-de-l'Île-de-Montréal, Montreal, QC

#### ► EPHP9.03

#### Injection drug use is associated with food insecurity in HIV-HCV co-infected individuals in Canada (CTN264) – a sub-study of the Canadian Co-infection Cohort (CCC) (E)

Taylor McLinden<sup>1</sup>, Joseph Cox<sup>1, 2, 3</sup>, Anne-Marie Hamelin<sup>1</sup>, Erica E. Moodie<sup>1</sup>, Gilles Paradis<sup>1</sup>, Curtis Cooper<sup>4</sup>, John Gill<sup>5</sup>, Aranka Anema<sup>6</sup>, Sean B. Rourke<sup>7</sup>, Leo Wong<sup>2</sup>, Marina B. Klein<sup>2</sup>

1. Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, 2. Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, 3. CIHR Canadian HIV Trials Network, Vancouver, BC, 4. Department of Medicine, University of Ottawa, Ottawa, ON, 5. Southern Alberta HIV Clinic, Calgary, AB, 6. Department of Pediatrics, Harvard Medical School, Boston, MA, USA, 7. Department of Psychiatry, University of Toronto, Toronto, ON

## Introducing New Data Sources: Cohort Studies, Administrative Databases, Surveys, etc.

### Introduction de nouvelles sources de données : études de cohortes, bases de données administratives, enquêtes, etc.

#### ► EPHP10.01

#### A mixed methods study to characterize the organizational attributes of HIV care settings in Canada (E)

Claire E. Kendall<sup>1, 2, 3</sup>, Lisa M. Boucher<sup>1</sup>, Lois Crowe<sup>1</sup>, Sarah Lane<sup>4</sup>, Sean B. Rourke<sup>5, 6, 7</sup>, Shabnam Asghari<sup>8</sup>, Chris Kaposy<sup>8</sup>,

Ron Rosenes<sup>9</sup>, Phil Lundrigan<sup>9</sup>, Christine Bibeau<sup>9</sup>, Marissa Becker<sup>10</sup>, Clare Liddy<sup>1, 2</sup>

1. Bruyere Research Institute, Ottawa, ON, 2. Department of Family Medicine, University of Ottawa, Ottawa, ON, 3. Institute for Clinical Evaluative Sciences, Toronto, ON, 4. School of Public Health, University of Alberta, Edmonton, AB, 5. Ontario HIV Treatment Network, Toronto, ON, 6. Centre for Research on Inner City Health, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, 7. Department of Psychiatry, University of Toronto, Toronto, ON, 8. Faculty of Medicine, Memorial University of Newfoundland, St. John's, NL, 9. Living with HIV Team Grant Community Scholar, Toronto, ON, 10. Department of Medicine, University of Manitoba, Winnipeg, MB

► **EPHP10.02**

**Women with HIV are less likely to receive age-appropriate breast cancer screening compared to HIV negative women: A population-based study in Ontario, Canada (E)**

Claire E. Kendall<sup>1, 2, 5</sup>, Sharon Walmsley<sup>3, 4</sup>, Nathaniel Jember<sup>5</sup>, Ann Burchell<sup>8, 9, 5</sup>, Mona Loutfy<sup>6</sup>, Douglas G. Manuel<sup>7, 5, 1</sup>, Janet Rabout<sup>13, 14</sup>, Ron Rosenes<sup>15</sup>, Clare Liddy<sup>1, 2</sup>, Sean B. Rourke<sup>10, 11, 12</sup>, Tony Antoniou<sup>8, 9, 5</sup>

1. Bruyere Research Institute, Ottawa, ON, 2. Department of Family Medicine, University of Ottawa, Ottawa, ON, 3. Division of Infectious Diseases, University Health Network, Toronto, ON, 4. Department of Medicine, University of Toronto, Toronto, ON, 5. Institute for Clinical Evaluative Sciences, Toronto, ON, 6. Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON, 7. Ottawa Hospital Research Institute, Ottawa, ON, 8. Department of Family and Community Medicine, St. Michael's Hospital and Centre for Research on Inner City Health, Li Ka Shing Knowledge Institute, Toronto, ON, 9. Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, 10. Ontario HIV Treatment Network, Toronto, ON, 11. Centre for Research on Inner City Health, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, 12. Department of Psychiatry, University of Toronto, Toronto, ON, 13. Toronto General Research Institute, University Health Network, Toronto, ON, 14. University of Toronto, Toronto, ON, 15. Living with HIV Team Grant Community Scholar, Toronto, ON

► **EPHP10.03**

**Cluster Analyses of Physician Visits and Pharmaceutical Dispensations of HIV Positive Individuals Prior to HIV Diagnosis (E)**

Souradet Y. Shaw<sup>1</sup>, Leigh McClarty<sup>1</sup>, Laurie Ireland<sup>2</sup>, Carla Ens<sup>3</sup>, Bo Yu<sup>3</sup>, James F. Blanchard<sup>1</sup>, Ken Kasper<sup>4</sup>, Yoav Keynan<sup>1, 4</sup>, Marissa L. Becker<sup>1, 4</sup>

1. University of Manitoba, Winnipeg, MB, 2. Nine Circles Community Centre, Winnipeg, MB, 3. Manitoba Health, Winnipeg, MB, 4. Manitoba HIV Program, Winnipeg, MB

## Methodological Advances in Epidemiology, Public Health and Mathematical Modelling

### Progrès méthodologiques en épidémiologie, santé publique et modélisation mathématique

#### ► EPHP11.01

##### Importance of Epidemiological Tipping Point Ratio for ART Programme Success (E)

**Simon de Montigny**<sup>1</sup>, Dobromir T. Dimitrov<sup>2</sup>, Benoît R. Mâsse<sup>1</sup>, Kate M. Mitchell<sup>3</sup>, Marie-Claude Boily<sup>3</sup>

1. CHU Sainte-Justine Research Center, Montreal, QC, 2. Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 3. Department of Infectious Disease Epidemiology, Imperial College, London, United Kingdom

#### ► EPHP11.02

##### Do Modelling Assumptions About HIV Disease Progression On and Post-treatment Affect Estimates of Treatment Impact? (E)

Kanes Sucharitakul, Marie-Claude Boily, **Kate M. Mitchell**  
Imperial College London, London, United Kingdom

#### ► EPHP11.03

##### HIV intervention impact predictions from deterministic and individuals based models (E)

Romain Silhol<sup>1</sup>, Marc Brisson<sup>2, 3</sup>, John Williams<sup>1</sup>, Nicolas Van de Velde<sup>1</sup>, Michel Alary<sup>3</sup>, Michael Pickles<sup>1</sup>, Dobromir Dimitrov<sup>4</sup>, Peter Vickerman<sup>5</sup>, Marie-Claude Boily<sup>1, 6</sup>, **Kate M. Mitchell**<sup>1</sup>

1. Imperial College, London, United Kingdom, 2. URESP, Québec, QC, 3. Centre de recherche, CHU de Québec, Québec, QC, 4. Vaccine and Infectious Disease and Public Health Sciences Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 5. School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom, 6. HPTN modelling Center, Imperial College, London, United Kingdom

## Social Determinants of HIV Prevention, Risk, Testing, and Care

### Déterminants sociaux de la prévention, du risque, du dépistage et des soins concernant le VIH

#### ► EPHP13.01

##### Voluntary HIV testing: Factors associated with repeated HIV testing among a sample of HIV-negative gay and bisexual men living in Toronto, Ontario (E)

Todd A. Coleman<sup>1</sup>, **Syed W. Noor**<sup>1</sup>, Trevor A. Hart<sup>1</sup>, Barry Adam<sup>2, 4</sup>, David J. Brennan<sup>3</sup>, Sandra Gardner<sup>4</sup>, Alyssa N. Kelly<sup>1</sup>  
1. Ryerson University, Toronto, ON, 2. University of Windsor, Windsor, ON, 3. University of Toronto, Toronto, ON, 4. Ontario HIV Treatment Network, Toronto, ON

▶ **EPHP13.02****Place Matters: Key Findings of a Scoping Review on HIV point-of-care testing (HIV POCT) in Non-urban Settings (E)**

Jacqueline Gahagan<sup>1</sup>, Alexa Minichiello<sup>2</sup>, Zack Marshall<sup>3</sup>, Michelle Swab<sup>3</sup>, Shabnam Asghari<sup>3</sup>, Michael Schwandt<sup>4</sup>

1. Dalhousie University, Halifax, NS, 2. REACH, Toronto, ON, 3. Memorial University of Newfoundland, St. John's, NL, 4. University of Saskatchewan, Saskatoon, SK

▶ **EPHP13.03****Social and Structural Factors Associated with Greater Time Above an HIV Viral Load of 1500 Copies/mL Plasma among Illicit Drug Users in a Canadian Setting (E)**

Mary Clare Kennedy<sup>2,3</sup>, Evan Wood<sup>1,2</sup>, Thomas Kerr<sup>1,2</sup>, Julio Montaner<sup>1,4</sup>, **M-J Milloy**<sup>1,2</sup>

1. Department of Medicine, University of British Columbia, Vancouver, BC, 2. Urban Health Research Initiative, BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 3. School of Population and Public Health, University of British Columbia, Vancouver, BC, 4. BC Centre for Excellence in HIV/AIDS, Vancouver, BC

▶ **EPHP13.04****Socio-economic, Clinical and Behavioural Factors Associated With Late Initiation of Antiretroviral Therapy in British Columbia (BC) (E)**

**Sarah Kesselring**<sup>1</sup>, Surita Parashar<sup>1,2</sup>, Zishan Cui<sup>1</sup>, David Moore<sup>1,3</sup>, Natalia Oliveira<sup>1</sup>, Charles Osborne<sup>1</sup>, Angela Kaida<sup>1,2</sup>, Janice Duddy<sup>4</sup>, Hasina Samji<sup>3,5</sup>, Rosalind Baltzer-Turje<sup>6</sup>, Denis Nash<sup>7</sup>, Robert Hogg<sup>1,2</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. Simon Fraser University, Burnaby, AB, 3. University of British Columbia, Vancouver, BC, 4. Pacific AIDS Network, Vancouver, BC, 5. BC Centre for Disease Control, Vancouver, BC, 6. Dr. Peter AIDS Foundation, Vancouver, BC, 7. City University of New York School of Public Health, New York, NY, USA

▶ **EPHP13.05****Rurality is associated with an increased likelihood of readmission to hospital within 30 days among individuals living with HIV (E)**

**Lauren J. MacKenzie**<sup>1,2,3</sup>, Denise Jaworsky<sup>4</sup>, Lianping Ti<sup>3,4</sup>, Hayden Kremer<sup>3</sup>, Shahab Jabbari<sup>3</sup>, Oghenowede Eyawo<sup>3,5</sup>, Conrado Franco-Villalobos<sup>3</sup>, Susan Shurgold<sup>3</sup>, Guillaume Colley<sup>3</sup>, Robert S. Hogg<sup>3,5</sup>, Julio S. Montaner<sup>3,4</sup>, Mark W. Hull<sup>3,4</sup>

1. CIHR Canadian HIV Trials Network, Vancouver, BC, 2. Clinician Investigator Program, University of Manitoba, Winnipeg, MB, 3. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 4. Department of Medicine, University of British Columbia, Vancouver, BC, 5. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC

▶ **EPHP13.06****Differences in Sexual Behaviour and Access to ART are Insufficient to Explain Racial Disparities in HIV Risk for Men Who Have Sex with Men (MSM) in Baltimore (E)****Kate M. Mitchell**<sup>1</sup>, Dobromir Dimitrov<sup>2</sup>, Marie-Claude Boily<sup>1</sup>

1. Imperial College London, London, United Kingdom, 2. Fred Hutchinson Cancer Research Center, Seattle, WA, USA

▶ **EPHP13.07****Social Determinants of Delaying Initiation of Antiretroviral Therapy Beyond One Year After HIV Diagnosis (E)****Charles Osborne**<sup>1</sup>, Sarah Kesselring<sup>1</sup>, Surita Parashar<sup>1, 2</sup>, Zishan Cui<sup>1</sup>, David Moore<sup>1, 3</sup>, Natalia Oliveira<sup>1</sup>, Angela Kaida<sup>1, 2</sup>, Janice Duddy<sup>4</sup>, Hasina Samji<sup>3, 5</sup>, Rosalind Baltzer-Turje<sup>6</sup>, Denis Nash<sup>7</sup>, Robert Hogg<sup>1, 2</sup>

1. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. Simon Fraser University, Burnaby, BC, 3. University of British Columbia, Vancouver, BC, 4. Pacific AIDS Network, Vancouver, BC, 5. BC Centre for Disease Control, Vancouver, BC, 6. Dr. Peter AIDS Foundation, Vancouver, BC, 7. City University of New York School of Public Health, New York, NY, USA

▶ **EPHP13.08****Point of Care Testing: Reaching Street Involved People in Ottawa and Winnipeg (E)****Susan Rogers Van Katwyk**, Ann Jolly

University of Ottawa, Ottawa, ON

**Social Epidemiology of HIV Infection (Structural, Social and Individual Determinants)****Épidémiologie sociale de l'infection au VIH (déterminants structurels, sociaux et individuels)**▶ **EPHP14.01****The Positive Plus One Project: A national mixed-methods study of risk management, health and wellbeing for people living with HIV and their HIV-negative partners (E)****Liviana Calzavara**<sup>1</sup>, Joshua Mendelsohn<sup>2</sup>, **Sandra L. Bullock**<sup>1</sup>, Dan Allman<sup>1</sup>, Jean-Guy Baril<sup>22</sup>, Bronwyn Barrett<sup>7</sup>, Laura Bisailon<sup>9</sup>, Adam Bourne<sup>10</sup>, Ann Burchell<sup>11</sup>, Ken Clement<sup>4</sup>, Brian Conway<sup>12</sup>, Amrita Daftary<sup>1</sup>, Laurie Edmiston<sup>14</sup>, Brenda Gladstone<sup>1</sup>, Liz Harrop-Archibald<sup>15</sup>, Terry Howard<sup>3</sup>, James Iveniuk<sup>1</sup>, Gary Lacasse<sup>8</sup>, Bertrand Lebouché<sup>16</sup>, Mona Loutfy<sup>5</sup>, Renée Masching<sup>4</sup>, Ryan Meili<sup>17</sup>, Ted Myers<sup>1</sup>, Jeff Potts<sup>8</sup>, Jean-Pierre Routy<sup>16</sup>, Shannon Ryan<sup>18</sup>, Stephen Sanche<sup>17</sup>, Stuart Skinner<sup>21, 17</sup>, Kris Stewart<sup>19</sup>, Marcie Summers<sup>7</sup>, Wangari Tharao<sup>20</sup>, Tamara Thompson<sup>13</sup>, Chris Tsoukas<sup>16</sup>, Jocelyn Watchorn<sup>6</sup>, Alexander Wong<sup>21, 17</sup>

1. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, 2. Pace University, New York, NY, USA, 3. Positive

Living BC, Vancouver, BC, 4. Canadian Aboriginal AIDS Network (CAAN), Dartmouth, NS, 5. Women's College Hospital, Toronto, ON, 6. AIDS Committee of Toronto, Toronto, ON, 7. Postive Women's Network, Vancouver, BC, 8. Canadian AIDS Society, Ottawa, ON, 9. University of Toronto, Scarborough, Toronto, ON, 10. London School of Hygiene and Tropical Medicine, London, United Kingdom, 11. St. Michael's Hospital, Toronto, ON, 12. Vancouver ID Research and Care Centre Society, Vancouver, BC, 13. University of Western Ontario, London, ON, 14. Canadian AIDS Treatment Information Exchange (CATIE), Toronto, ON, 15. AIDS Coalition of nova Scotia (ACNS), Halifax, NS, 16. McGill University, Montreal, QC, 17. University of Saskatchewan, Saskatoon, SK, 18. The Black Coalition for AIDS Prevention (Black CAP), Toronto, ON, 19. Positive Living Program, Saskatoon Health Region, Saskatoon, SK, 20. Women's Health in Women's Hands, Toronto, ON, 21. Regina Qu'Appelle Health Region, Regina, SK, 22. Clinique Médicale du Quartier Latin, Montreal, QC

► **EPHP14.02**

**An Event-Level Analysis of Condomless Anal Sex among Gay, Bisexual, and Other Men who have Sex with Men (GBM) with Online-met Partners (E)**

**Kiffer G. Card**<sup>1, 4</sup>, Nathan J. Lachowsky<sup>1, 2</sup>, Michelle Cui<sup>1</sup>, Susan Shurgold<sup>1</sup>, Ashleigh Rich<sup>1</sup>, Maya Gislason<sup>4</sup>, Eric Roth<sup>3</sup>, David Moore<sup>1, 2</sup>, Robert S. Hogg<sup>1, 4</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. University of British Columbia, Vancouver, BC, 3. University of Victoria, Victoria, BC, 4. Simon Fraser University, Burnaby, BC

► **EPHP14.03**

**Resilience in Aging: Shaping Resiliency through a Supportive Housing Intervention (E)**

**Alexandra B. Collins**<sup>1</sup>, Zishan Cui<sup>1</sup>, Natalia Oliveira<sup>1</sup>, Guillaume Colley<sup>1</sup>, Kim Stacey<sup>2</sup>, Robert S. Hogg<sup>1, 3</sup>, Surita Parashar<sup>1</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. McLaren Housing Society, Vancouver, BC, 3. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC

► **EPHP14.04**

**The Community Pop-Up Clinic As a Tool of Engagement for Vulnerable Populations with HIV and HCV Infection (E)**

**Syune Hakobyan**

Vancouver ID Research and Care Centre Society, Vancouver, BC

► **EPHP14.06**

**Sexual Event-Level Analysis of Age-Disparate Partners Among Gay, Bisexual and other men who have sex with men (GBM) in Vancouver (E)**

Kalysha Closson<sup>1, 2</sup>, Nathan J. Lachowsky<sup>1, 3</sup>, Zishan Cui<sup>1</sup>, Susan Shurgold<sup>1</sup>, Paul Sereda<sup>1</sup>, Ashleigh Rich<sup>1</sup>, David M. Moore<sup>1, 3</sup>, **Eric Roth**<sup>4</sup>, Robert Hogg<sup>1, 2</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. Simon Fraser University, Burnaby, BC, 3. Faculty of Medicine UBC, Vancouver, BC, 4. University of Victoria, Victoria, BC

▶ **EPHP14.07****The prevalence and correlates of incarceration experience among women living with HIV in Canada (E)**

**Sally (Yue) Lin**<sup>1, 2</sup>, Ruth Elwood Martin<sup>3</sup>, M-J Milloy<sup>1</sup>, Allison Carter<sup>1, 2</sup>, Sophie Patterson<sup>1, 2</sup>, Kath Webster<sup>2</sup>, Marisol Desbiens<sup>4</sup>, Danièle Dubuc<sup>5</sup>, Valerie Nicholson<sup>2</sup>, Neora Pick<sup>6</sup>, Terry Howard<sup>7</sup>, Lu Wang<sup>1</sup>, Shahab Jabbari<sup>1</sup>, Karène Proulx-Boucher<sup>5</sup>, Allison Carlson<sup>4</sup>, Robert S. Hogg<sup>1, 2</sup>, Alexandra de Pokomandy<sup>5</sup>, Mona Loutfy<sup>4</sup>, Angela Kaida<sup>2</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. Simon Fraser University, Burnaby, BC, 3. Collaborating Centre for Prison Health and Education, School of Population and Public Health, University of British Columbia, Vancouver, BC, 4. Women's College Research Institute, Toronto, ON, 5. McGill University Health Centre, Montreal, QC, 6. Oak Tree Clinic, Vancouver, BC, 7. Positive Living British Columbia, Vancouver, BC

▶ **EPHP14.08****Comparison of Antiretroviral Treatment Interruptions Between Urban and Rural Populations with HIV Infection in British Columbia (E)**

Geoffrey Shumilak<sup>1, 2</sup>, **Denise Jaworsky**<sup>1</sup>, Lauren J. MacKenzie<sup>3, 4, 5</sup>, William Chau<sup>5</sup>, Wendy Zhang<sup>5</sup>, Viviane D. Lima<sup>1, 5</sup>, Robert S. Hogg<sup>5, 6</sup>, Julio S. Montaner<sup>1, 5</sup>, Mark Hull<sup>1, 2, 5</sup>

1. Department of Medicine, University of British Columbia, Vancouver, BC, 2. Division of Infectious Diseases, University of British Columbia, Vancouver, BC, 3. CIHR Canadian HIV Trials Network, Vancouver, BC, 4. Clinician Investigator Program, University of Manitoba, Winnipeg, MB, 5. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 6. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC

**Epidemiology and Public Health Sciences  
Other****Épidémiologie et santé publique, Autre**▶ **EPHP15.01****Practice guidelines in peer health navigation for people living with HIV: Guideline development process (E)**

**Logan Broeckeaert**<sup>1</sup>, Laurel Challacombe<sup>1</sup>, Christine Johnston<sup>1</sup>, Erica Lee<sup>1</sup>, Jason Altenberg<sup>2</sup>, Glen Bradford<sup>3</sup>, Vijaya Chikermane<sup>4</sup>, Miranda Compton<sup>5</sup>, Clarence Frenchman<sup>6</sup>, Holly Gauvin<sup>7</sup>, Scott Harrison<sup>8</sup>, Shazia Islam<sup>4</sup>, Murray Jose-Boerbridge<sup>10</sup>, Marvelous Muchenje<sup>11</sup>, Susanne Nasewich<sup>12</sup>, Mary Petty<sup>8</sup>, Sudin Sherchan<sup>4</sup>, Carol Strike<sup>13</sup>

1. CATIE, Toronto, ON, 2. South Riverdale Community Health Centre, Toronto, ON, 3. Positive Living BC, Vancouver, BC, 4. Alliance for South Asian AIDS Prevention, Toronto, ON, 5. Vancouver Coastal Health, Vancouver, BC, 6. Health Canada, Saskatoon, SK, 7. Elevate NWO, Thunder Bay, ON, 8. Providence Health Care, Vancouver, BC, 9. ASK Wellness Centre, Kamloops, BC, 10. Toronto People With AIDS Foundation, Toronto, ON, 11. Women's Health in Women's

Hands, Toronto, ON, 12. Regina Qu'Appelle Health Region, Regina, SK, 13. University of Toronto, Toronto, ON

▶ **EPHP15.02**

**Mobilizing Information, Preventing Infection: A Journey of Collaborative Knowledge Translation to Promote Youth-Oriented HIV/HCV Prevention in Nova Scotia (E)**

**Brian R. Condran**<sup>1</sup>, Jacqueline Gahagan<sup>1</sup>, Anik Dubé<sup>2</sup>, Gregory Harris<sup>3</sup>, Lois Jackson<sup>1</sup>, Michael Liddell<sup>5</sup>, Jo-Ann MacDonald<sup>4</sup>

1. Dalhousie University, Halifax, NS, 2. Université de Moncton, Moncton, NB, 3. Memorial University of Newfoundland, St. John's, NL, 4. University of Prince Edward Island, Charlottetown, PE, 5. OYOR Advisory Committee, Halifax, NS

▶ **EPHP15.03**

**Responsive and integrated programming approaches for priority populations in hepatitis C (E)**

Suzanne L. Fish, **Melisa Dickie**, Tim Rogers, Laurel Challacombe, Logan Broecker, Laurie Edmiston  
CATIE, Toronto, ON

▶ **EPHP15.04**

**Correlates of Hepatitis C Infection among Street-Involved Youth in Kingston, Ontario (E)**

**Rianne A. Gushulak**<sup>1</sup>, Stevenson Fergus<sup>1</sup>, Ashley O'Brien<sup>2</sup>  
1. Queen's University, Kingston, ON, 2. Kingston Community Health Centres, Kingston, ON

▶ **EPHP15.05**

**CATIE Forum: Making it Work, From planning to practice (E)**

**Christine Johnston**, Michael Bailey, Laurel Challacombe, Melisa Dickie, Laurie Edmiston, Tim Rogers  
CATIE, Toronto, ON

▶ **EPHP15.06**

**Engaging Health Care Providers in Rural and Remote Settings through a Live Course on Community-Based and Culturally Relevant HIV Diagnosis and Treatment in BC and SK (E)**

Kevin Pendergraft<sup>1</sup>, **Denise Thomas**<sup>2</sup>, Susanne Nasewich<sup>3</sup>, Amanda Galambos<sup>4</sup>, Merle Nightingale<sup>5</sup>, Denise Stokich<sup>6</sup>, Lisa Lockie<sup>7</sup>, Julie Kille<sup>8, 9</sup>, Kristin Westland<sup>1</sup>, Aslam Anis<sup>1, 10</sup>, Mark Tyndall<sup>11</sup>, Mary Kestler<sup>12, 13</sup>, Alexandra King<sup>1, 14, 15</sup>, Renee Masching<sup>16</sup>

1. CIHR Canadian HIV Trials Network, Vancouver, BC, 2. Canadian Association of Hepatology Nurses, Vancouver, BC, 3. Regina Qu'Appelle Health Region, Regina, SK, 4. SK HIV Provincial Leadership Team, Regina, SK, 5. Prairie North Health Region, Meadow Lake, SK, 6. Royal University Hospital, Saskatoon, SK, 7. Saskatchewan Ministry of Health, Regina, SK, 8. Canadian Association of Nurses in HIV/AIDS Care, Vancouver, BC, 9. Providence Health Care, Vancouver, BC, 10. School of Population and Public Health, University of British Columbia, Vancouver, BC, 11. BC Centre for Disease Control, Vancouver, BC, 12. BC Women's Hospital and Health Centre, Vancouver, BC, 13. Division of Infectious Diseases,



UBC Department of Medicine, Vancouver, BC, 14. Simon Fraser University, Faculty of Health Sciences, Burnaby, BC, 15. University of British Columbia Hospital, Vancouver, BC, 16. Canadian Aboriginal AIDS Network, Dartmouth, NS

## Track D: Social Sciences

### Volet D : Sciences sociales

## Aboriginal Health

### Santé des Autochtones

#### ► SSP1.01

#### **Increasing HIV Testing on Reserve: The Village of Wellness Toolkit (E)**

Sarah Levine<sup>1</sup>, Elizabeth Holliday<sup>1</sup>, Pamela Wilson<sup>2</sup>, Coreen Paul<sup>3</sup>, Mara Andrews<sup>4</sup>, **Ellen Demlow**<sup>1</sup>

1. Vancouver Coastal Health, Vancouver, BC, 2. Tagila Consulting, Bella Bella, BC, 3. Musqueam Indian Band, Vancouver, BC, 4. Kahui Tautoko Consulting, Vancouver, BC

#### ► SSP1.02

#### **Engaging Community in Guiding Research Excellence National Aboriginal Research Advisory Committee (E)**

Sherri Pooyak<sup>2</sup>, Marni Amirault<sup>2</sup>, **Renee Masching**<sup>2</sup>, Charlotte Loppie<sup>1</sup>

1. University of Victoria, Victoria, BC, 2. Canadian Aboriginal AIDS Network, Dartmouth, NS

#### ► SSP1.03

#### **Inuit Community Readiness: Adapting the Community Readiness Model with Inuit Communities for HIV Prevention (E)**

Audrey A. Steenbeek<sup>1</sup>, Soha Kneen<sup>2</sup>, **Jenny R. Rand**<sup>1</sup>, Marni Amirault<sup>3</sup>, Janet Curran<sup>1</sup>, Sherry Kadlun<sup>4</sup>, Igah Sanguya<sup>5</sup>, Diane Angma<sup>6</sup>

1. Dalhousie University, Halifax, NS, 2. Pauktuutit Inuit Women of Canada, Ottawa, ON, 3. Canadian Aboriginal AIDS Network, Dartmouth, NS, 4. Government of Nunavut, Kugluktuk, NU, 5. Government of Nunavut, Clyde River, NU, 6. Government of Nunavut, Arviat, NU

#### ► SSP1.04

#### **Positive Aging: Indigenous peoples aging with HIV/AIDS (E)**

Chaneesa Ryan<sup>1</sup>, Randy Jackson<sup>1</sup>, **Renée Masching**<sup>2</sup>, Alexandra King<sup>3</sup>, Chelsea Gabel<sup>1</sup>

1. McMaster University, Hamilton, ON, 2. Canadian Aboriginal Aids Network, Halifax, NS, 3. The University of British Columbia, Vancouver, BC

### ▶ SSP1.05

#### **The Cedar Project: Culture and language support resilience among young Indigenous women involved in sex work in Vancouver and Prince George, BC (E)**

**Richa Sharma**<sup>1</sup>, David Zamar<sup>2</sup>, Margo E. Pearce<sup>2</sup>, Sherri D. Pooyak<sup>3</sup>, Wunuxtsin M. Christian<sup>4</sup>, Martin T. Schechter<sup>1</sup>, Patricia M. Spittal<sup>1</sup>, Cedar Project Partnership<sup>5, 6, 7</sup>

1. School of Population and Public Health, University of British Columbia, Vancouver, BC, 2. Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, 3. Canadian Aboriginal AIDS Network, Victoria, BC, 4. Splotsin te Secwepemc Nation, Enderby, BC, 5. Prince George Native Friendship Centre, Prince George, BC, 6. Carrier Sekani Family Services, Prince George, BC, 7. Positive Living North, Prince George, BC

## **Combining Prevention Strategies: Social Scientific Perspectives**

### **Combinaison des stratégies de prévention : perspectives des sciences sociales**

#### ▶ SSP2.01

#### **Latino MSM at risk for HIV/STI's on Online Apps, in Toronto, Canada: The Urgent Need for Online Outreach services, a PROGRAM SCIENCE approach (E)**

Gerardo Betancourt<sup>1, 2</sup>, **Celeste Bilbao-Joseph**<sup>3</sup>

1. Faculty of Soc. Work, U of T, Toronto, ON, 2. HIV Prevention Program/CSSP, Toronto, ON, 3. Centre for Spanish-Speaking Peoples, Toronto, ON

#### ▶ SSP2.02

#### **JD and the Sunshine Band: The Continuing Story of Recreation as HIV Prevention (E)**

Margaret Ormond<sup>2</sup>, Heather Krepski<sup>1, 2</sup>, Chelsea Jalloh<sup>1, 2</sup>,

**Javier Mignone**<sup>1, 2</sup>, J.D. Ormond<sup>2</sup>, Gilbert Spence<sup>2</sup>

1. University of Manitoba, Winnipeg, MB, 2. Sunshine House, Winnipeg, MB

#### ▶ SSP2.03

#### **Sexual Health Assessment (SHA) Training: Increasing Provider Capacity Around HIV/STBBI Testing and Incorporating Best Practices Into Routine Health Care (E)**

**Tina A. Sorensen**, Heather Day, Aleasha Hacault, Jodie Layne  
Nine Circles Community Health Centre, Winnipeg, MB

## Critical Approaches to Community-Based Research

### Approches critiques à la recherche communautaire

#### ▶ SSP3.01

#### **Advancing Scoping Study Methodology in the HIV Community: Perceptions on Methodological Steps and Ways to Enhance Scoping Studies in HIV Community-Based Research (E)**

Larry Baxter<sup>2</sup>, Kelly K. O'Brien<sup>1</sup>, Heather Colquhoun<sup>1</sup>, Danielle Levac<sup>3</sup>, Ayesha Nayar<sup>1</sup>

1. University of Toronto, Toronto, ON, 2. Community Member, Halifax, NS, 3. Northeastern University, Boston, MA, USA

#### ▶ SSP3.03

#### **HAND MAPPING (HaM) is a 'scaled down' Body Mapping (BM) Evaluation Qualitative Method: Understanding Gay Sexual Health Practices and HIV/STI's Life Trajectories (E)**

Gerardo Betancourt<sup>1, 2</sup>, Celeste Bilbao-Joseph<sup>3</sup>

1. Faculty of Soc. Work, U of T, Toronto, ON, 2. HIV Prevention Program/CSSP, Toronto, ON, 3. Centre for Spanish-Speaking Peoples, Toronto, ON

#### ▶ SSP3.04

#### **PrEP arandote (Getting Ready): Theoretical Approaches for the Future Use of New HIV Prevention Technologies, Access Issues among Spanish-Speaking MSM in Canada (E)**

Gerardo Betancourt<sup>1, 2</sup>, Celeste Bilbao-Joseph<sup>3</sup>

1. Faculty of Soc. Work, U of T, Toronto, ON, 2. HIV Prevention Program/CSSP, Toronto, ON, 3. Centre for Spanish-Speaking Peoples, Toronto, ON

#### ▶ SSP3.05

#### **Using community mapping in a participatory consultation about PHA needs from an ASO: the Peel Region HIV/AIDS Network experience (E)**

Francisco Ibanez-Carrasco<sup>1</sup>, Nishit Sha<sup>2</sup>, Muluba Habayama<sup>2</sup>, Steve Gould<sup>2</sup>, Neil Burchell<sup>2</sup>, Phillip Banks<sup>2</sup>

1. Ontario HIV Treatment Network, Toronto, ON, 2. Peel HIV/AIDS Network, Peel, ON

#### ▶ SSP3.06

#### **Developing evidence informed interventions to promote resilience amongst Asian MSMs across life challenges- the MSM Resilience Dialogues (E)**

Alan T. Li<sup>1, 5</sup>, Richard Utama<sup>2</sup>, Christian Hui<sup>2</sup>, Noulmook Sutdhibhasilp<sup>2</sup>, Maurice K. Poon<sup>3</sup>, Josephine P. Wong<sup>4</sup>

1. Regent Park Community Health Centre, Toronto, ON, 2. Asian Community AIDS Services, Toronto, ON, 3. York University, Toronto, ON, 4. Ryerson University, Toronto, ON, 5. Committee for Accessible AIDS Treatment, Toronto, ON

▶ **SSP3.08**

**The BC People Living with HIV Stigma Index Project: Planning Phase Evaluation (E)**

Jonathan Postnikoff<sup>1</sup>, Andrea Langois<sup>3</sup>, **Janice Duddy<sup>3</sup>**, Catherine Worthington<sup>2</sup>

1. Positive Living BC, Vancouver, BC, 2. University of Victoria, Victoria, BC, 3. Pacific AIDS Network, Vancouver, BC

**Critical Social Theory: Applications and Advancements in Understanding the HIV Epidemic**

**Théorie sociale : Applications et progrès dans la compréhension de l'épidémie de VIH**

▶ **SSP4.01**

**Health Care Access Among Older HIV-Positive LGBTQ Adults: Conceptualizing the Field for Empirical Inquiry (E)**

**Hannah Kia**

University of Toronto, Toronto, ON

▶ **SSP4.02**

**“Sexual Health Messaging Trajectories:” Turning HIV Risk on its Head (E)**

**Allison Odger<sup>1</sup>**, Susan Frohlick<sup>2</sup>

1. York University, Toronto, ON, 2. University of British Columbia, Okanagan Campus, Kelowna, BC

**Engaging (with) Communities in HIV Research**

**Participation des collectivités à la recherche sur le VIH**

▶ **SSP5.01**

**“In Real Life”: Social, Communal, and Attitudinal Covariates of Online Sex-Seeking (OSS) among Gay, Bisexual, and other Men who have sex with men (GBM) in Vancouver (E)**

**Kiffer G. Card<sup>1,2</sup>**, Nathan J. Lachowsky<sup>1,3</sup>, Michelle Cui<sup>1</sup>, Susan Shurgold<sup>1</sup>, Ashleigh Rich<sup>1</sup>, Maya Gislason<sup>2</sup>, David Moore<sup>1,3</sup>, Eric Roth<sup>4</sup>, Robert S. Hogg<sup>1,2</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. Simon Fraser University, Burnaby, BC, 3. University of British Columbia, Vancouver, BC, 4. University of Victoria, Victoria, BC

▶ **SSP5.02****Yes We Can! Ensuring Momentum, Motivation and Morale in a long term Community Based Research Project: The Canadian HIV Women's Sexual and Reproductive Health Survey (E)**

Tracey P. Conway<sup>1</sup>, **Jacqueline Gahagan**<sup>2</sup>, Daniele Dubuc<sup>3</sup>, Marisol Desbiens<sup>1</sup>, Kath Webster<sup>5</sup>, Nadia OBrien<sup>3, 4</sup>, Allison Carter<sup>5, 6</sup>, Sally Lin<sup>5, 6</sup>, Allison Carlson<sup>1</sup>, Wangari Tharao<sup>7</sup>, Saara Greene<sup>8</sup>, Shayna Buhler<sup>9</sup>, Angela Kaida<sup>5</sup>, Alexandra de Pokomandy<sup>3, 4</sup>, Mona Loutfy<sup>1</sup>, CHIWOS Research Team<sup>1</sup>

1. Women's College Research Institute, Toronto, ON, 2. Dalhousie University, Halifax, NS, 3. McGill University, Family Medicine, Montreal, QC, 4. McGill University Health Centre, Montreal, QC, 5. Simon Fraser University, Faculty of Health Sciences, Vancouver, AB, 6. British Columbia Center for Excellence in HIV/AIDS, Vancouver, BC, 7. Women's Health in Women's Hands, Toronto, ON, 8. McMaster University, Hamilton, ON, 9. Interagency Coalition on AIDS and Development, Toronto, ON

▶ **SSP5.03****HIV, Social Work, and Brain Health: A Mixed-methods Community-based Research Study (E)**

**Andrew D. Eaton**<sup>1, 2</sup>, Jocelyn Watchorn<sup>1</sup>, Shelley L. Craig<sup>2</sup>, John W. McCullagh<sup>1</sup>, Chantal Mukandoli<sup>1</sup>, Robert Wallace<sup>1</sup>, David McClure<sup>1</sup>

1. ACT - AIDS Committee of Toronto, Toronto, ON, 2. Factor-Inwentash Faculty of Social Work at the University of Toronto, Toronto, ON

▶ **SSP5.04****Peer Researcher Support Project: Developing Support Tools for People Living with HIV Working in HIV Research (E)**

**Terry Howard**

Director of Research, Positive Living BC, Vancouver, BC

▶ **SSP5.05****PRA-plus: Building a Mentorship Program for Peer Research Associates Working in HIV Research (E)**

**Terry Howard**<sup>1</sup>, Surita Parashar<sup>2</sup>

1. Director of Research, Positive Living BC, Vancouver, BC, 2. BC Centre for Excellence in HIV/AIDS, Vancouver, BC

▶ **SSP5.06****HEADS UP! Using a modified DEPICT model for participatory analysis in a qualitative study of neurocognitive difficulties among people living with HIV (E)**

**Francisco Ibáñez-Carrasco**<sup>1</sup>, **Alex R. Terpstra**<sup>1</sup>, Catherine Worthington<sup>2</sup>, Soo Chan Carusone<sup>3</sup>, Liz Creal<sup>3</sup>, MH<sup>1</sup>, Allan Rae<sup>1</sup>, Rosalind Baltzer-Turje<sup>4</sup>, Patrick McDougall<sup>4</sup>, Martin Payne<sup>4</sup>, Claudia Medina<sup>1</sup>, Aiko Yamamoto<sup>5</sup>, Sean B. Rourke<sup>1, 6</sup>, Kelly O'Brien<sup>6</sup>

1. Ontario HIV Treatment Network, Toronto, ON, 2. University of Victoria, Victoria, BC, 3. Casey House, Toronto, ON, 4. Dr. Peter Centre, Vancouver, BC, 5. Providence Health Care, Vancouver, BC, 6. University of Toronto, Toronto, ON

▶ **SSP5.07****HEADS UP! Results of a qualitative study of the lived experience of HIV-associated neurocognitive disorder (E)**

**Francisco Ibáñez-Carrasco**<sup>1</sup>, **Alex R. Terpstra**<sup>1</sup>, Kelly O'Brien<sup>2</sup>, Soo Chan Carusone<sup>3</sup>, Liz Creal<sup>3</sup>, MH<sup>1</sup>, Allan Rae<sup>1</sup>, Rosalind Baltzer-Turje<sup>4</sup>, Patrick McDougall<sup>4</sup>, Martin Payne<sup>4</sup>, Claudia Medina<sup>1</sup>, Aiko Yamamoto<sup>5</sup>, Sean B. Rourke<sup>1, 2</sup>, Catherine Worthington<sup>6</sup>

1. Ontario HIV Treatment Network, Toronto, ON, 2. University of Toronto, Toronto, ON, 3. Casey House, Toronto, ON, 4. Dr. Peter Centre, Vancouver, BC, 5. Providence Health Care, Vancouver, BC, 6. University of Victoria, Victoria, BC

▶ **SSP5.08****Developing and Evaluating a Patient Engagement Intervention in the I-Score Study: Involving HIV Patients in the Improvement of Treatment Adherence (E)**

David Lessard<sup>1, 2, 3</sup>, **Kim Engler**<sup>2, 3</sup>, Isabelle Toupin<sup>1, 2, 3</sup>, Bertrand Lebouché<sup>1, 2, 3</sup>

1. McGill University, Department of Family Medicine, Montreal, QC, 2. McGill University Health Centre, Research Institute, Montreal, QC, 3. McGill University Health Centre, Royal Victoria Hospital, Chronic Viral Illness Service, Montreal, QC

▶ **SSP5.09****Engaging heterosexual men with HIV in prioritizing key messages about their community for exchange with policy makers and knowledge users (E)**

**Ralf J. MacGrady**<sup>1</sup>, Anne-Marie Tynan<sup>2</sup>, Joseph N. Djiometio<sup>2</sup>, Nancy Kou<sup>2</sup>, Tony Antoniou<sup>2</sup>

1. St. Micheal's Hospital (Toronto), Ottawa, ON, 2. St. Michael's Hospital, Toronto, ON

▶ **SSP5.10****Documenting best practices for scaling-up community based research (E)**

**Katelyn G. Merritt**<sup>1</sup>, Patrick McDougall<sup>2</sup>, Surita Parashar<sup>1</sup>, Saranee Fernando<sup>1</sup>, Alexandra B. Collins<sup>1</sup>, Rosalind Baltzer Turje<sup>2</sup>, Robert Hogg<sup>1</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. Dr. Peter Centre, Vancouver, BC

▶ **SSP5.11****Anti-inflammatory Drugs to Prevent HIV-1 Infection: Role of Community Engagement (E)**

**Lucy W. Mwangi**<sup>1</sup>, Julie Lajoie<sup>1, 2</sup>, Maureen Akolo<sup>3</sup>, John Mungai<sup>3</sup>, Juliana Cheuiyot<sup>3</sup>, Makubo Kimani<sup>3</sup>, Julius Oyugi<sup>1, 2</sup>, Joshua Kimani<sup>1, 2, 3</sup>, Keith R. Fowke<sup>1, 2</sup>

1. University of Nairobi, Nairobi, Kenya, 2. University of Manitoba, Winnipeg, MB, 3. Kenyan AIDS Control Program, Nairobi, Kenya

▶ **SSP5.12****Taking Culture Seriously in Biomedical HIV Prevention Trials: Promoting Meaningful Community Engagement in HIV Research (E)**

**Peter A. Newman**, Clara Rubincam, Ashley Lacombe-Duncan  
University of Toronto, Toronto, ON

▶ **SSP5.13****Planning and Community Engagement for HIV Cure Research in Canada: A Collaborative Program Between National Research Teams and Key Populations (E)**

**Robert J. Reinhard**<sup>1</sup>, **Jason Brophy**<sup>2</sup>, Eric Cohen<sup>1, 5</sup>, Hugo Soudeyans<sup>3</sup>, Keith Fowke<sup>4</sup>

1. Institut de recherches cliniques de Montreal, Montreal, QC, 2. Children's Hospital of Eastern Ontario, Ottawa, ON, 3. CHU Sainte Justine, Montreal, QC, 4. University of Manitoba, Department of Medical Microbiology, Winnipeg, MB, 5. Universite de Montreal, Department of Microbiology, Infectiology and Immunology, Montreal, QC

▶ **SSP5.14****Engagement and endorsement by a leading community organization facilitates research participation among people living with HIV and those at-risk in Ontario (E)**

**Sean B. Rourke**<sup>1, 2, 3</sup>, **James Watson**<sup>1</sup>, Winston Husbands<sup>3, 4</sup>, Catherine Worthington<sup>5</sup>, Don Willison<sup>3</sup>, Lori Chambers<sup>6</sup>, Barry Adam<sup>1, 7</sup>, Qiyun Shi<sup>1</sup>, Jason Globberman<sup>1</sup>, Tsegaye Bekele<sup>1</sup>

1. The Ontario HIV Treatment Network, Toronto, ON, 2. St. Michael's Hospital, Toronto, ON, 3. University of Toronto, Toronto, ON, 4. AIDS Committee of Toronto, Toronto, ON, 5. University of Victoria, Victoria, BC, 6. McMaster University, Hamilton, ON, 7. University of Windsor, Windsor, ON

▶ **SSP5.15****More than one model?: Lessons learned from an evaluation comparing traditional and activity-based advisory board models for CBR (E)**

Sarah Switzer<sup>1</sup>, **Soo Chan Carusone**<sup>2, 3</sup>, Adrian Guta<sup>4, 5</sup>, Carol Strike<sup>6, 7</sup>

1. York University, Toronto, ON, 2. Casey House, Toronto, ON, 3. McMaster University, Department of Clinical Epidemiology and Biostatistics, Hamilton, ON, 4. Carleton University, Department of Health Sciences, Ottawa, ON, 5. University of Ottawa, Faculty of Health Sciences, Ottawa, ON, 6. Centre for Addiction and Mental Health, Toronto, ON, 7. University of Toronto, Dalla Lana School of Public Health, Toronto, ON

▶ **SSP5.16****Developing a psychoeducational support group for serodiscordant couples: A collaborative, participatory approach (E)**

Jocelyn Watchorn<sup>1</sup>, Jessica Cattaneo<sup>1</sup>, **Andrew Eaton**<sup>1</sup>, **Celeste Bilbao-Joseph**<sup>2</sup>, Scott Bowler<sup>3</sup>, Charlotte Chagoya<sup>3</sup>, Michael Hazelton<sup>4</sup>, James Myslik<sup>4</sup>, Andrew Ross<sup>5</sup>, Lori Chambers<sup>6</sup>, Dana Gore<sup>4</sup>

1. ACT, Toronto, ON, 2. Centre for Spanish-Speaking Peoples,

Toronto, ON, 3. Mt. Sinai Hospital, Toronto, ON, 4. Family Services Toronto, Toronto, ON, 5. Village Family Health Team, Toronto, ON, 6. McMaster University, Hamilton, ON

► **SSP5.17**

**“What’s Hot with Peer Researchers?” Results of the evaluation of an online talk show about HIV peer researchers as non-formal education (E)**

**James Watson**<sup>1</sup>, Francisco Ibanez-Carrasco<sup>2</sup>, Ryan Kerr<sup>1</sup>, Maria Hatzipantelis<sup>1</sup>

1. Ontario HIV Treatment Network (OHTN), Toronto, ON, 2. Ontario HIV Treatment Network, Toronto, ON

► **SSP5.18**

**Community-based research strategies for recruiting a diverse cohort of women living with HIV in Canada (E)**

Kath Webster<sup>2</sup>, Allison Carter<sup>1, 2</sup>, Marisol Desbiens<sup>3</sup>, Danièle Dubuc<sup>4</sup>, Valerie Nicholson<sup>2</sup>, Kerrigan Beaver<sup>3</sup>, Claudine Gasingirwa<sup>3</sup>, Brigitte Ménard<sup>4</sup>, **Sally Y. Lin**<sup>1, 2</sup>, Karène Proulx-Boucher<sup>4</sup>, Jamie Thomas-Pavanel<sup>3</sup>, Nadia O’Brien<sup>4, 5</sup>, Kayla Mitchell<sup>2</sup>, Shahab Jabbari<sup>1</sup>, Erin Ding<sup>1</sup>, Robert S. Hogg<sup>1, 2</sup>, Alexandra de Pokomandy<sup>4, 5</sup>, Mona Loutfy<sup>3</sup>, Angela Kaida<sup>2</sup>

1. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, 3. Women’s College Research Institute, Women’s College Hospital, Toronto, ON, 4. Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, 5. Department of Family Medicine, McGill University, Montreal, QC

► **SSP5.19**

**The Meaning of “Community” and “Peers” from the Perspective of Those Affected by HIV (E)**

**Catherine Worthington**<sup>1</sup>, Lori Chambers<sup>2</sup>, Winston Husbands<sup>3</sup>, James Watson<sup>4</sup>, Don Willison<sup>5</sup>, Barry Adam<sup>6</sup>, Jason Globerman<sup>4</sup>

1. University of Victoria, Victoria, BC, 2. McMaster University, Hamilton, ON, 3. AIDS Committee of Toronto, Toronto, ON, 4. The Ontario HIV Treatment Network, Toronto, ON, 5. University of Toronto, Toronto, ON, 6. University of Windsor, Windsor, ON

## Everyday Actualities of Living with HIV

### Vivre avec le VIH au quotidien

► **SSP6.01**

**Supporting PHA Employment Preparedness- Lessons learnt from Legacy Pilot Program (E)**

Ciro A. Bisignano<sup>1</sup>, Maureen Owino<sup>1</sup>, Rajesh Pisharody<sup>3</sup>, Anna Demetrakopoulos<sup>4</sup>, **Alan Li**<sup>1, 2</sup>

1. Committee for Accessible AIDS Treatment, Toronto, ON, 2. Regent Park Community Health Centre, Toronto, ON, 3. Toronto People with AIDS Foundation, Toronto, ON, 4. AIDS Bereavement and Resiliency Program of Ontario, Toronto, ON



▶ **SSP6.02****Evaluation of Web-based tailored interventions to support PLHIV in the adoption of health promoting behaviours: an online randomized controlled trial (CTN 288) (E)**

José Côté<sup>1,2</sup>, Sylvie Cossette<sup>2</sup>, Pilar Ramirez Garcia<sup>2</sup>, Alexandra De Pokomandy<sup>3</sup>, Catherine Worthington<sup>4</sup>, Marie-Pierre Gagnon<sup>5</sup>, **Patricia Auger**<sup>1</sup>, François Boudreau<sup>6</sup>, Joyal Miranda<sup>7</sup>, Yann-Gaël Guéhéneuc<sup>8</sup>, Cécile Tremblay<sup>1</sup>, Ken Monteith<sup>9</sup>, Laurie Edmiston<sup>10</sup>

1. Research Centre of the Centre Hospitalier de l'Université de Montréal, Montréal, QC, 2. Faculty of Nursing, Université de Montréal, Montreal, QC, 3. Faculty of Medicine, McGill University, Montreal, QC, 4. Faculty of Human and Social Development, University of Victoria, Victoria, BC, 5. Research Centre of the Centre Hospitalier Universitaire de Québec, Quebec, QC, 6. Faculty of Nursing, Université du Québec à Trois-Rivières, Trois-Rivières, QC, 7. Ryerson University, Toronto, ON, 8. Department of Computer Engineering, Polytechnique Montréal, Montreal, QC, 9. COCQ-SIDA, Montreal, QC, 10. CATIE, Toronto, ON

▶ **SSP6.03****Improving health and reducing comorbidity associated with HIV: a Web-based tailored intervention to help people living with HIV make healthy choices (E)**

Pilar Ramirez Garcia<sup>2</sup>, José Côté<sup>1,2</sup>, Sylvie Cossette<sup>2</sup>, Geneviève Rouleau<sup>1</sup>, **Patricia Auger**<sup>1</sup>, François Boudreau<sup>3</sup>

1. Research Centre of the Centre Hospitalier de l'Université de Montréal, Montreal, QC, 2. Faculty of Nursing, Université de Montréal, Montreal, QC, 3. Faculty of Nursing, Université du Québec à Trois-Rivières, Trois-Rivières, QC

▶ **SSP6.04****HIV Stigma and Suicide among Canadian Gay and Bisexual men living with HIV (E)**

**Olivier Ferlatte**<sup>1</sup>, Travis S. Hottes<sup>1,2</sup>, Rick Marchand<sup>1</sup>, John Oliffe<sup>3</sup>, Terry Trussler<sup>1</sup>

1. Community-Based Research Centre for Gay Men's Health, Vancouver, BC, 2. University of Toronto, Toronto, ON, 3. University of British Columbia, Vancouver, BC

▶ **SSP6.05****Life after HIV disclosure: Analyzing barriers to gender-based violence service provision for women who experience post-disclosure violence in South Africa (E)**

**Khadija Ga'al**

York University, Toronto, ON

▶ **SSP6.06****Rethinking the experience of side effects in the context of HIV treatment: A qualitative study (E)**

**Marilou Gagnon**, Dave Holmes

University of Ottawa, Ottawa, ON

▶ **SSP6.08****Ethical Challenges in Healthcare for People Living with HIV: Notes from Qualitative Field Research of HIV Healthcare in Manitoba and Newfoundland (E)**

Nicole R. Greenspan<sup>1</sup>, Zack Marshall<sup>1</sup>, Jill Allison<sup>1</sup>, Chris Kaposy<sup>1</sup>, **Shelley Marshall**<sup>2</sup>

1. Memorial University of Newfoundland, St John's, NL, 2. Winnipeg Regional Health Authority, Winnipeg, MB

▶ **SSP6.09****Characterizing the Disability Experience among Adults Living with HIV: A Structural Equation Model Using the HIV Disability Questionnaire (E)**

**Kelly K. O'Brien**<sup>1</sup>, Steve Hanna<sup>2</sup>, Patricia Solomon<sup>2</sup>, Catherine Worthington<sup>3</sup>, Francisco Ibáñez-Carrasco<sup>4</sup>, Jacqueline Gahagan<sup>5</sup>, Stephanie A. Nixon<sup>1</sup>, Larry Baxter<sup>6</sup>, Soo Chan Carusone<sup>7</sup>, Murray Jose-Boerbridge<sup>8</sup>, Rosalind Baltzer Turje<sup>9</sup>, Patrick McDougall<sup>9</sup>, Gregory Robinson<sup>10</sup>, Tammy Reimer<sup>11</sup>, Ayesha Nayar<sup>1</sup>, Steve Tattle<sup>12</sup>, Tammy Yates<sup>12</sup>

1. University of Toronto, Toronto, ON, 2. McMaster University, Hamilton, ON, 3. University of Victoria, Victoria, BC, 4. Ontario HIV Treatment Network, Toronto, ON, 5. Dalhousie University, Halifax, NS, 6. Community Member, Halifax, NS, 7. Casey House, Toronto, ON, 8. Toronto PWA Foundation, Toronto, ON, 9. Dr. Peter AIDS Foundation, Vancouver, BC, 10. Community Member, Toronto, ON, 11. Nine Circles Community Health Centre, Winnipeg, MB, 12. Canadian Working Group on HIV and Rehabilitation, Toronto, ON

▶ **SSP6.10****Room for improvement: Knowledge exchange needs of people living with HIV (E)**

Laurel A. Challacombe, David McLay, Debbie Koenig, **Tim Rogers**, Erica Lee, Sane Dube, Zak Knowles  
CATIE, Toronto, ON

▶ **SSP6.11****Perspectives of People Living with HIV: Activity and Participation Needs When Living at a Distance From Specialized Services (E)**

**Alexandria M. Simms**, Gayle J. Restall  
University of Manitoba, Winnipeg, MB

**Gay, Bisexual and other Homosexually Active Men****Guais, bisexuels et autres hommes homosexuels actifs**▶ **SSP7.01****The Sex, Me & HCV Project: Four Videos for GBMSM at Risk of HCV and HIV/HCV Co-infection, and Service Providers (E)**

**Glenn Betteridge**  
CTAC, Toronto, ON

▶ **SSP7.02****Supporting Family Physicians to Provide Safe and Appropriate Care for Men who have Sex with Men: A Structural HIV Intervention (E)**Elizabeth Holliday<sup>1</sup>, Kaitlin Pelletier<sup>2</sup>, Allison Macbeth<sup>2</sup>, **Ellen Demlow**<sup>1</sup>

1. Vancouver Coastal Health, Vancouver, BC, 2. UBC Continuing Professional Development, Vancouver, BC

▶ **SSP7.03****Is the Number of Sexual Partners Still Important for Gay and Bisexual Men's HIV Prevention Programs? (E)****Eric A. Roth**<sup>1</sup>, Ashleigh Rich<sup>2</sup>, Nathan Lachowsky<sup>2</sup>, Kiffer Card<sup>3</sup>, Michelle Cui<sup>2</sup>, Paul Sereda<sup>2</sup>, Robert Birch<sup>4</sup>, David Moore<sup>7</sup>, Robert S. Hogg<sup>6</sup>

1. Centre for Addictions Research of BC, Victoria, BC, 2. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 3. Simon Fraser University, Vancouver, BC, 4. University of Victoria, Victoria, BC, 5. University of British Columbia, Vancouver, BC, 6. Simon Fraser University, Vancouver, BC, 7. University of British Columbia, Vancouver, BC

**Intervention Based Research in the Social Sciences: Theories, Methodologies, and Outcomes****La recherche interventionniste  
Intervention en sciences sociales :  
Théories, méthodes et résultats**▶ **SSP8.01****Peer Consultation Debriefing schematic for Navigating Emotional Triggers (NET): model from the MSAFIRI Study and ABRPO's Turning to One Another project (E)**Soraya Blot<sup>1, 5</sup>, Anna Demetrakopoulos<sup>2</sup>, Gladys Kwaramba<sup>5</sup>, Valerie Pierre-Pierre<sup>1</sup>, Wangari Tharao<sup>3, 5</sup>, Amrita Daftary<sup>4, 5</sup>, **Yvette Perreault**<sup>2</sup>

1. African and Caribbean Council on HIV/AIDS in Ontario, Toronto, ON, 2. AIDS Bereavement and Resiliency Program of Ontario, Toronto, ON, 3. Women's Health in Women's Hands, Toronto, ON, 4. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, 5. the MSAFIRI team, Toronto, ON

▶ **SSP8.02****Exploring the role of meal provision in promoting health and wellbeing among structurally vulnerable people living with HIV who use drugs (E)**Sarane M. Fernando<sup>1</sup>, Ryan McNeil<sup>1</sup>, Kalysha Closson<sup>2</sup>, Surita Parashar<sup>1</sup>, Carol Strike<sup>3</sup>, Susan Kirkland<sup>4</sup>, **Patrick McDougall**<sup>5</sup>, Rosalind Baltzer Turje<sup>5</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. Simon Fraser University, Burnaby, BC, 3. University of Toronto, Toronto, ON, 4. Dalhousie University, Halifax, NS, 5. Dr. Peter AIDS Foundation, Vancouver, BC

▶ **SSP8.03****The Adaptability of ‘The HIV Positive Sero-Status Disclosure Intervention/Model for African Caribbean and Black (ACB) Women’ among other populations (E)**

**Sandra L. Godoy**<sup>1</sup>, Wangari Tharao<sup>1</sup>, Marvelous Muchenje<sup>1</sup>, Fanta Ongoiba<sup>2</sup>, Murray Jose<sup>3</sup>, Alessandro Bisignano<sup>4</sup>, Nicci Stein<sup>5</sup>, Shannon Ryan<sup>6</sup>, Valerie Pierre-Pierre<sup>7</sup>, Ruth Cameron<sup>9</sup>, Jocelyn Watchorn<sup>11</sup>, Glen Walker<sup>8</sup>, Tim McClelland<sup>10</sup>, Haoua Inoua<sup>12</sup>

1. Women’s Health in Women’s Hands (WHIWH) Community Health Centre, Toronto, ON, 2. Africans in Partnership Against AIDS (APAA), Toronto, ON, 3. Toronto People With AIDS Foundation (PWA), Toronto, ON, 4. Committee for Accessible AIDS Treatment (CAAT), Toronto, ON, 5. The Teresa Group, Toronto, ON, 6. Black Coalition for AIDS Prevention (Black-CAP), Toronto, ON, 7. African and Caribbean Council on HIV/AIDS in Ontario (ACCHO), Toronto, ON, 8. Positive Living Niagara (PLN), Niagara, ON, 9. AIDS Committee of Cambridge, Kitchener, Waterloo and Area (ACCKWA), Waterloo, ON, 10. The AIDS Network, Hamilton, Hamilton, ON, 11. The AIDS Committee of Toronto (ACT), Toronto, ON, 12. The AIDS Committee of Ottawa (ACO), Ottawa, ON

▶ **SSP8.04****The McLaren blueprint: Investigating the impact of supportive housing on the health and well being of people living with HIV in Vancouver, British Columbia (E)**

Surita Parashar<sup>1</sup>, **Alexandra B. Collins**<sup>1</sup>, Natalia Oliveira<sup>1</sup>, Zishan Cui<sup>1</sup>, Heidi Safford<sup>1,3</sup>, Otto von Bischoffshausen<sup>1,3</sup>, Kim Stacey<sup>3</sup>, Robert S. Hogg<sup>1,2</sup>

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, 2. Simon Fraser University, Burnaby, BC, 3. McLaren Housing Society of British Columbia, Vancouver, BC

▶ **SSP8.05****Developing a Trauma Intervention for Women Living with HIV – Team Building and Pilot Development (E)**

**Anne C. Wagner**, Catherine Rutto, Jenny Gomez  
Ryerson University, Toronto, ON

**Organizational Strategies in the Context of Policy and Funding Shifts****Stratégies organisationnelles dans le contexte des changements dans la politique et le financement**▶ **SSP9.01****An Evaluation of Peer Engagement within Fife House: Successes and Challenges of PHA Involvement as Volunteers (E)**

Amrita Ahluwalia<sup>1,2</sup>, **Andre L. Ceranto**<sup>1</sup>, Charles Shames<sup>1</sup>, Claude Boucher<sup>1</sup>

1. Fife House Foundation, Toronto, ON, 2. Ryerson University, Toronto, ON

**▶ SSP9.02****HIV and STBBI Testing: The Implications for Shifting and Socially Constructed Policy Environments (E)**

**Brian R. Condran**, Jacqueline Gahagan  
Dalhousie University, Halifax, NS

**▶ SSP9.03****Adapting to a Changing Landscape: Developing Living Positive Victoria's 2015-2017 Community Engagement Strategy (E)**

**Andrew D. Eaton**<sup>1, 2</sup>, Brent Allan<sup>2</sup>, Suzy Malhotra<sup>2</sup>  
1. Factor-Inwentash Faculty of Social Work at the University of Toronto, Toronto, ON, 2. Living Positive Victoria, Melbourne, VIC, Australia

**▶ SSP9.04****Plugging into the Circuit Board: a collaborative role for research and communications in circulating HIV-related knowledge among community-based constituents (E)**

**Christopher Thomas**, Winston Husbands  
AIDS Committee of Toronto, Toronto, ON

**Sex, Sexuality and Gender: Populations across Diverse Contexts and Axes of Inequity****Sexe, sexualité et genre : Populations dans les contextes et axes divers d'inégalité****▶ SSP10.01****Latino Trans Women Support/Psychoeducational Group (E)**

**Celeste Bilbao-Joseph**  
Center for the Spanish Speaking Peoples, Toronto, ON

**Social, Structural and Systemic Drivers of HIV****Moteurs sociaux, structurels et systémiques du VIH****▶ SSP11.01****PrEP Promise and Peril: The Regulatory Pathways to Equitable, Affordable and Timely Access in Canada (E)**

**Glenn Betteridge**  
CTAC, Toronto, ON

▶ **SSP11.02****Strategies Addressing Intimate Partners Violence (IPV) Among Women in sex work – Incremental Reporting of Intimate Partner Violence Interfaced with HIV Risk (E)**

Sunitha BJ<sup>1</sup>, **Srinath Maddur Mallikarjuna**<sup>2</sup>, Mohan H. Lakkappa<sup>2</sup>, Shajy Isac<sup>2</sup>

1. Karnataka Health Promotion Trust, Bangalore, KA, India, 2. Centre for Global Public Health, Winnipeg, MB

▶ **SSP11.03****Addressing HIV/STI vulnerability: Applying the minority stress model to understand safer sex practices among lesbian, bisexual, and queer women (E)**

Carmen H. Logie<sup>1</sup>, **Ashley Lacombe-Duncan**<sup>1</sup>, Rachel K. MacKenzie<sup>2</sup>, Tonia Poteat<sup>3</sup>

1. Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, ON, 2. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, 3. Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA

▶ **SSP11.04****Social Determinants of Health as drivers of the HIV epidemic: An ethnographic analysis of the HIV-related needs of African refugee women in Toronto (E)**

Joanita M. Nakamwa<sup>1</sup>, **Wesley Oakes**<sup>2</sup>

1. Peer Educator, Africans in Partnership Against AIDS, Toronto, ON, 2. York University, Prevention Coordinator, Africans in Partnership Against AIDS, Toronto, ON

▶ **SSP11.05****Hammer and Baton in synergy: Forging Strategic Partnerships to reduce violence and stigma against Female Sex workers (E)**

Balasubramanya K. Venkataramaiah<sup>1</sup>, **Srinath Maddur Mallikarjuna**<sup>2</sup>, Ashokanand H. S<sup>1</sup>, Ramachandra R. Kadambar<sup>1</sup>, Sandeep H. <sup>1</sup>, Shajy Isac<sup>2</sup>

1. Karnataka Health Promotion Trust, Bangalore, KA, India, 2. CGPH, Winnipeg, MB

**Substance Use, Transmission Networks and Local Contexts of HIV Risk****Toxicomanies, réseaux de transmission et contextes locaux du risque concernant le VIH**▶ **SSP12.01****“Maybe if I stop the drugs, then maybe they’d care?” – Hospital care experiences of people living with HIV who use substances (E)**

**Soo Chan Carusone**<sup>1, 2</sup>, Adrian Guta<sup>3</sup>, Darrell H. Tan<sup>4</sup>, Curtis Cooper<sup>5</sup>, Karen de Prinse<sup>1</sup>, Bill O’Leary<sup>1, 7</sup>, Grant Cobb<sup>6</sup>, Tony Antoniou<sup>4</sup>, Ross Upshur<sup>7</sup>, Carol Strike<sup>7</sup>

1. Case House, Toronto, ON, 2. McMaster University, Hamilton,

ON, 3. Carleton University, Ottawa, ON, 4. St. Michael's Hospital, Toronto, ON, 5. Ottawa Hospital Research Institute, Ottawa, ON, 6. AIDS Committee of Ottawa, Ottawa, ON, 7. University of Toronto, Toronto, ON

## The Health of African, Caribbean and Black Communities

### La santé des collectivités africaines, antillaises et noires

#### ► SSP13.01

**Exploring the influence of racial discrimination and HIV-related stigma on quality of life among African, Caribbean and Black women living with HIV in Ontario (E)**

**Carmen H. Logie**<sup>1</sup>, Wangari Tharao<sup>2</sup>, Mona R. Loutfy<sup>3</sup>

1. University of Toronto, Toronto, ON, 2. Women's Health in Women's Hands Community Health Centre, Toronto, ON, 3. Women's College Research Institute, Women's College Hospital, Toronto, ON

#### ► SSP13.02

**Co-morbidity burden in persons with HIV originally from Africa and the Caribbean: a population-based study (E)**

**Irene K. Masinde**<sup>1, 7</sup>, Nathaniel Jembere<sup>2</sup>, Valérie Pierre-Pierre<sup>3</sup>, Tola Mbulaheni<sup>3</sup>, Fanta Ongoiba<sup>4</sup>, Anna Laziri<sup>4</sup>, Marvelous Muchenje<sup>5</sup>, Henry Luyombya<sup>6</sup>, Wangari Tharao<sup>7</sup>, Mona Loutfy<sup>7</sup>, Claire Kendall<sup>8</sup>, Janet Raboud<sup>9</sup>, Sean Rourke<sup>10</sup>, Ann Burchell<sup>1</sup>, Ahmed Bayoumi<sup>1</sup>, Tony Antoniou<sup>1</sup>

1. St. Michael's Hospital, Toronto, ON, 2. Institute for Clinical Evaluative Sciences, Toronto, ON, 3. African and Caribbean Council on HIV/AIDS in Ontario, Toronto, ON, 4. Africans in Partnership Against AIDS, Toronto, ON, 5. Women's Health in Women's Hands, Toronto, ON, 6. AIDS Committee of Toronto, Toronto, ON, 7. Women's College Research Institute, Toronto, ON, 8. C.T. Lamont Primary Health Care Research Centre, Bruyère Research Institute, Ottawa, ON, 9. Toronto General Research Institute, Toronto, ON, 10. Ontario HIV Treatment Network, Toronto, ON, 11. WCRI, Toronto, ON

#### ► SSP13.03

**Health service use in persons with HIV originally from Africa and the Caribbean: a population-based study (E)**

**Irene K. Masinde**<sup>1</sup>, Nathaniel Jembere<sup>8</sup>, Valérie Pierre-Pierre<sup>2</sup>, Tola Mbulaheni<sup>2</sup>, Fanta Ongoiba<sup>3</sup>, Anna Laziri<sup>3</sup>, Marvelous Muchenje<sup>4</sup>, Henry Luyombya<sup>5</sup>, Wangari Tharao<sup>4</sup>, Mona Loutfy<sup>1</sup>, Ahmed Bayoumi<sup>9</sup>, Ann Burchell<sup>9</sup>, Claire Kendall<sup>6</sup>, Sean Rourke<sup>10</sup>, Janet Raboud<sup>7</sup>, Tony Antoniou<sup>9</sup>

1. WCRI, Toronto, ON, 2. African and Caribbean Council on HIV/AIDS in Ontario, Toronto, ON, 3. Africans in Partnership Against AIDS, Toronto, ON, 4. Women's Health in Women's Hands, Toronto, ON, 5. AIDS Committee of Toronto, Toronto, ON, 6. C.T. Lamont Primary Health Care Research Centre, Bruyère Research Institute, Ottawa, ON, 7. Toronto General Research Institute, Toronto, ON, 8. Institute for Clinical Evaluative Sciences, Toronto, ON, 9. St. Michael's Hospital, Toronto, ON,

10. Ontario HIV Treatment Network, Toronto, ON

▶ **SSP13.04**

**En Avant: Implementing an Impact-Focused HIV/AIDS Research Strategy for African, Caribbean and Black Communities in Ontario (E)**

Tola Mbulaheni<sup>1</sup>, Henry Luyombya<sup>2</sup>, Hugues Loemba<sup>3</sup>, **LaRon E. Nelson**<sup>4</sup>, Mbaka Wadham<sup>5</sup>, Rupert Kaul<sup>6</sup>, Shamara Baidooobonso<sup>7</sup>, Sonia Gaudry<sup>7</sup>, Valérie Pierre-Pierre<sup>1</sup>, Wangari Tharao<sup>8</sup>, Winston Husbands<sup>2</sup>

1. African and Caribbean Council on HIV/AIDS in Ontario, Toronto, ON, 2. AIDS Committee of Toronto, Toronto, ON, 3. University of Ottawa, Ottawa, ON, 4. University of Rochester, Rochester, NY, USA, 5. Regional HIV/AIDS Connection, London, ON, 6. University of Toronto, Toronto, ON, 7. Ontario HIV Treatment Network, Toronto, ON, 8. Women's Health in Women's Hands Community Health Centre, Toronto, ON

▶ **SSP13.05**

**"I have no small vision for this group": (non)Disclosure and Stigma in Positive African Women's Mobilizing in a Prairie Urban Centre (E)**

**Paula Migliardi**<sup>1,2</sup>, Simret Daniel<sup>1</sup>, Pumulo Roddy<sup>1</sup>, The Immigrant Women's Group<sup>1</sup>

1. Sexuality Education Resource Centre MB, Winnipeg, MB, 2. University of Manitoba, Winnipeg, MB

▶ **SSP13.06**

**Meaningfully Engaging Heterosexual Black Men in Responses to HIV in Ontario: Lessons from weSpeak a Critical Community-Based Research Program (E)**

Desmond Miller<sup>1</sup>, Winston Husbands<sup>5</sup>, Neema Jangu<sup>2</sup>, Solomon Lome<sup>3</sup>, Martin McIntosh<sup>4</sup>, **Josephine P. Wong**<sup>1</sup>

1. Ryerson University, Toronto, ON, 2. University of Windsor, Windsor, ON, 3. University of Ottawa, Ottawa, ON, 4. Western University, London, ON, 5. AIDS Committee of Toronto, Toronto, ON

▶ **SSP13.07**

**Knowledge Translation of HIV Research with Policy-Makers, Health Workers, and the Media in Sub-Saharan Africa: Successes and Lessons Learned (E)**

**Stephanie Nixon**<sup>1,2</sup>, Cathy Cameron<sup>2</sup>, Verusia Chetty<sup>3</sup>, Saul Cobbing<sup>3</sup>, Lynn Cockburn<sup>2</sup>, Margaret Mweshi<sup>4</sup>, Eliakim K. Moses<sup>5</sup>, Hellen Myezwa<sup>6</sup>, Esther M. Nkandu<sup>4</sup>, Sam Nyingcho<sup>2</sup>, Carilus Okidi<sup>7</sup>, Florence Omoroh<sup>5</sup>, Joanne Potterton<sup>6</sup>, Stephen Tattle<sup>8</sup>, Tammy Yates<sup>8</sup>

1. University of Toronto, Toronto, ON, 2. International Centre for Disability and Rehabilitation (ICDR), Toronto, ON, 3. University of KwaZulu-Natal, Durban, South Africa, 4. University of Zambia, Lusaka, Zambia, 5. Kenya Medical Training College, Homa Bay, Kenya, 6. University of the Witwatersrand, Johannesburg, South Africa, 7. Disability Service Program, Homa Bay, Kenya, 8. Canadian Working Group on HIV and Rehabilitation (CWGHR), Toronto, ON



## The Medico-Legal Borderland: Criminalization, Law, Policy and Resistance La frontière médico-légale Criminalisation, droit, politique et résistance

### ▶ SSP14.01

**Awareness of the Supreme Court ruling on HIV non-disclosure among people living with HIV who use illicit drugs in a Canadian setting (E)**

**Sophie E. Patterson**<sup>1, 2</sup>, Angela Kaida<sup>1</sup>, Sabina Dobrer<sup>2</sup>, Gina Ogilvie<sup>3</sup>, Robert Hogg<sup>1, 2</sup>, Thomas Kerr<sup>2, 4</sup>, Evan Wood<sup>2, 4</sup>, Julio Montaner<sup>2, 4</sup>, M-J Milloy<sup>2</sup>

1. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, 2. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, 3. British Columbia Women's Hospital and Healthcare Centre, Vancouver, BC, 4. Department of Medicine, University of British Columbia, Vancouver, BC

### ▶ SSP14.02

**Women and HIV: The realities of violence and criminalization (E)**

Melissa Medjuck, **Donna Tennant**, **Sangam G**, Erin Seatter  
Positive Women's Network, Vancouver, BC

## Social Sciences Other

### Sciences sociales, Autre

### ▶ SSP15.01

**Towards Greater and More Meaningful Involvement of PHAs: An Evaluation of the Impact of Peer Engagement Project (E)**

**Amrita Ahluwalia**<sup>1, 2</sup>, Andre Ceranto<sup>1</sup>, Charles Shames<sup>1</sup>, Claude Boucher<sup>1</sup>

1. Fife House Foundation, Toronto, ON, 2. Ryerson University, Toronto, ON

### ▶ SSP15.02

**When Less is More: The Pruning of Social Networks by HIV-Positive Older Adults (E)**

Charles A. Emlet<sup>1, 4</sup>, Lesley M. Harris<sup>2</sup>, **David J. Brennan**<sup>3</sup>, Charles Furlotte<sup>4</sup>, Christina M. Pierpaoli<sup>5</sup>

1. University of Washington Tacoma, Tacoma, WA, USA, 2. University of Louisville, Louisville, KY, USA, 3. University of Toronto, Toronto, ON, 4. McMaster University, Hamilton, ON, 5. University of Alabama, Tuscaloosa, AL, USA

### ▶ SSP15.03

**The Benefits of Summer Camp in Building Self-esteem and Resilience with HIV-affected Children and Youth (E)**

**Nicci Stein**<sup>1</sup>, Samara Carroll<sup>1</sup>, Jason Brophy<sup>2</sup>, Sarah Chown<sup>3</sup>

1. The Teresa Group, Toronto, ON, 2. Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, 3. YouthCo HIV and HepC Society, Vancouver, BC

**▶ SSP15.04****Supporting local community capacity building to serve newcomer PHAs across Ontario, lessons learnt from the provincial HIV and Immigration training program (E)**

Raj Jagwani<sup>1</sup>, Alan Li<sup>1, 2</sup>, Meagan Johnston<sup>3</sup>, Maureen Owino<sup>1</sup>  
1. Committee for Accessible AIDS Treatment, Toronto, ON, 2. Regent Park Community Health Centre, Toronto, ON, 3. HIV & AIDS Legal Clinic Ontario, Toronto, ON

**▶ SSP15.05****Evaluation of media coverage and publicity for “Je suis séropo,” a Quebec anti-stigmatization communications campaign (E)**

René Légaré  
COCQ-SIDA, Montréal, QC

**▶ SSP15.06****HIV Stigma and HIV Invisibility: Key barriers students' Readiness to Engage in HIV care and prevention education (E)**

Sandra W. Nansereko<sup>1</sup>, Quinton Kayiwa<sup>2</sup>, Patricia Nakayiwa<sup>3</sup>  
1. Makerere Institute of Social Development, Makerere, Kampala, Uganda, 2. National Youth Council, Kampala, Uganda, 3. Kasangati Youth HIV/AIDS Initiatives, Kampala, Uganda

**▶ SSP15.07****Case Study: CATIE's Hepatitis C Ethnocultural Education, Outreach, and Social Marketing Program (E)**

Hywel J. Tuscano, Fozia Tanveer, Mélisa Dickie, Logan Broekaert  
CATIE, Toronto, ON

# Author Index

## Index des auteurs

### A

Abdool Karim, Quarraisha . . . . .	130, 153
Abdool Karim, Salim . . . . .	130, 153
Abdulghani, Omer . . . . .	125
Abdulwahab, Kamal . . . . .	173
Abimiku, Alash'le . . . . .	118
Abou, Max . . . . .	127, 152, 156
Abrenica, Bernard . . . . .	149
Achakzai, Baser K. . . . .	190
Adam, Barry D. . . . .	126, 189, 193, 205, 206
Adams, Evan . . . . .	189
Adams, Kelsey L. . . . .	134
Aden, Muna . . . . .	123
Adjudani, Arash . . . . .	173
Adonsu-Hoyi, Yawa . . . . .	160
Adrienne, Meyers A. . . . .	145
Aguinaldo, Jeffrey . . . . .	139
Ahamad, Keith . . . . .	187
Ahluwalia, Amrita . . . . .	139, 210, 215
Ahmed, Rabia . . . . .	173, 176
Ahmed, Tareq . . . . .	185, 186
Aibibula, Wusiman . . . . .	191
Ajaykumar, Abhinav . . . . .	163, 169
Akagi, Linda A. . . . .	113
Akinwumi, Segun M. . . . .	134
Akolo, Maureen . . . . .	118, 127, 204
Al-Bayati, Karam . . . . .	152
Alam, Anadil . . . . .	130
Alam, Nazmul . . . . .	130
Alary, Michel . . . . .	193
Alavi, Maryam . . . . .	120
Albert, Danica . . . . .	146
Alimenti, Ariane . . . . .	113, 114, 136, 138, 172, 173
Allan, Brent . . . . .	211
Allison, Jill . . . . .	208
Allison, Sandra . . . . .	189
Allman, Dan . . . . .	195
Alonso, Maria . . . . .	112, 153
Alsahafi, Nirmin . . . . .	133, 156
Altenberg, Jason . . . . .	197
Alvarez, Maria . . . . .	120, 137
Ambagala, Aruna P. . . . .	152
Ameli, Masoud . . . . .	133
Amirault, Marni D. . . . .	117, 199
Anaquod, Jaqueline . . . . .	117
Ancuta, Petronela . . . . .	143, 145
Anderlini, Erin . . . . .	132
Anderson, Peter L. . . . .	176
Andreani, Guadalupe . . . . .	118
Andrews, Mara . . . . .	199
Anema, Aranka . . . . .	191
Angel, Jonathan B. . . . .	134, 158, 163

Angma, Diane . . . . .	199
Anipindi, Varun . . . . .	113, 149
Anis, Aslam . . . . .	198
Anmole, Gursev . . . . .	134, 157
Ansari, Aftab A. . . . .	130
Anstett, Kaitlin . . . . .	112, 154
Antoniou, Tony . . . . .	122, 167, 169, 171, 176 178, 192, 204, 212, 213
Antony, Joseph M. . . . .	152
Anzala, Omu . . . . .	143, 175
Ao, Zhujun . . . . .	153, 158, 156, 158
Apidi, Winnie A. . . . .	145, 147
Arbess, Gordon . . . . .	120
Archary, Derseree . . . . .	153
Archibald, Chris P. . . . .	129, 138, 137, 185
Ares, Linda . . . . .	159, 161
Argento, Elena . . . . .	140
Arias, Manuel . . . . .	120
Armour, Rosemary . . . . .	137
Arnold, Kelly B. . . . .	153
Arora, Nikita . . . . .	124
Arroyave, Luisa F. . . . .	168
Arshad, Omair . . . . .	142
Arthos, James. . . . .	130
Arts, Eric. . . . .	130, 148, 151, 152, 157, 158, 178
Asad, Sabah . . . . .	133
Asahchop, Eugene L. . . . .	134, 150, 157
Asghari, Shabnam . . . . .	191, 194
Ashkar, Ali A. . . . .	113, 149
Auger, Patricia . . . . .	129, 207
Avila, Santiago . . . . .	157
Ayalew, Yohannes . . . . .	125

**B**

Bacon, Jean . . . . .	122, 136
Bagaya, Bernard S. . . . .	151
Baidoobonso, Shamara . . . . .	214
Bailey, Kim . . . . .	184
Bailey, Michael . . . . .	198
Bailey, Robert . . . . .	121
Baker, Glen B. . . . .	150
Balgobin, Anisha. . . . .	130
Ball, Blake T. . . . .	112, 118, 143, 144, 145, 146 147, 148, 149, 153, 159, 161
Balogun, Kayode A. . . . .	112
Balshaw, Robert . . . . .	116
Baltzer Turje, Rosalind . . . . .	122, 187, 194, 195, 203, 204, 208, 209
Bangsberg, David R. . . . .	130, 162
Banko, Nicole S. . . . .	112
Banks, Phillip . . . . .	201
Baraki, Bemuluyigza . . . . .	147
Baril, Jean-Guy. . . . .	143, 160, 164, 186, 195
Barr, Stephen D. . . . .	119
Barreto, Daniella F. . . . .	124
Barrett, Bronwyn . . . . .	195
Barrios, Rolando. . . . .	113, 136, 138, 164, 168
Bauer, Greta R. . . . .	116
Baxter, Larry . . . . .	201, 208
Bayoumi, Ahmed M. . . . .	120, 169, 176, 178, 213
Beaver, Kerrigan. . . . .	123, 131, 132, 174, 206
Becker, Marissa . . . . .	128, 138, 146, 179, 180, 182, 191, 192
Becu, Annelies . . . . .	187

Bédard, Caroline . . . . .	121, 185
Beech, Leslie . . . . .	166
Beitari, Saina . . . . .	134
Bekele, Tsegaye M. . . . .	136, 205
Bekker, Linda-Gail . . . . .	182
Belanger, Maud . . . . .	146
Belle-Isle, Lynne . . . . .	140
Benko, Erika . . . . .	119, 146
Benoit, Anita . . . . .	123, 124, 131, 136, 174
Benoit, Cecilia . . . . .	140
Benz Tramer, Cara . . . . .	129
Berard, Alicia R. . . . .	156
Berger, Sara . . . . .	173
Bergeron, Michele . . . . .	159, 161
Bergin, Colm . . . . .	179
Bernard, Nicole . . . . .	143, 146
Bernier, Anne-Marie . . . . .	155
Betancourt, Gerardo . . . . .	200, 201
Betim, Andre L. . . . .	140, 175
Betteridge, Glenn . . . . .	208, 211
Bhatnagar, Sahir . . . . .	183
Bibeau, Christine . . . . .	138, 191
Bielawny, Tomasz M. . . . .	147, 153
Bigelow, Jenn . . . . .	131, 132
Bilbao-Joseph, Celeste . . . . .	200, 201, 205, 211
Biondi, Mia J. . . . .	143
Birch, Robert . . . . .	209
Bird-Naytowhow, Kelley . . . . .	128
Birse, Kenzie . . . . .	118, 127, 152, 153, 156
Bisailon, Laura . . . . .	125, 195
Bisignano, Alessandro . . . . .	125, 210
Bisignano, Ciro A. . . . .	206
Bitnun, Ari . . . . .	114, 136, 138, 166, 172, 174, 176
BJ, Sunitha . . . . .	212
Bjorkman, Pamela J. . . . .	155
Blackwell, Everett D. . . . .	190
Blanchard, James F. . . . .	147, 190, 192
Blot, Soraya . . . . .	115, 209
Boily-Larouche, Geneviève . . . . .	118, 127, 144, 145, 150, 151, 162
Boily, Marie-Claude . . . . .	182, 193, 195
Boissonnault, Michel . . . . .	115
Bond, Virginia A. . . . .	139
Bondy, Greg . . . . .	170
Bondy, Lise . . . . .	168
Borgia, Sergio . . . . .	121
Bosire, Rose . . . . .	118
Boucher, Claude . . . . .	210, 215
Boucher, Lisa M. . . . .	131, 132, 191
Boucher, Marc . . . . .	119
Boudreau, François . . . . .	207
Bourassa, Carrie A. . . . .	117
Bourbonnais, Anne . . . . .	162
Bourne, Adam . . . . .	195
Bower, Mark . . . . .	169
Bowes, Jennifer . . . . .	136
Bowler, Scott . . . . .	205
Boyd, Rob . . . . .	132
Bradford, Glen . . . . .	197
Brainard, Diana . . . . .	121, 165
Branch, Donald R. . . . .	119
Branton, William G. . . . .	134, 150, 157
Brassard, Nathalie . . . . .	133, 156

Brassard, Paul	191
Brassard, Pierre	146
Brennan, David J.	126, 140, 189, 193, 215
Brenner, Bluma G.	144, 154
Breton, Jessica	173
Brisebois, Josee	163
Brisson, Marc	193
Brockman, Mark A.	130, 134, 147, 155, 156, 157
Broeckeaert, Logan	197, 198, 216
Broliden, Kristina	118, 144, 145
Brooks, James	129, 147, 159, 161, 177
Brophy, Jason C.	114, 136, 138, 172, 176, 205, 215
Brouillette, Marie-Josée	135
Brown, Darren	169, 171
Brown, Jesse	185, 188
Brownlee, Patrick	117
Brownrigg, Bobbi	182, 184, 187
Bruce, Sharon G.	128
Brumme, Chanson J.	130
Brumme, Zabrina L.	130, 147, 148, 155, 157
Bruneau, Julie	146, 183
Brunet, Laurence	121
Brunetta, Jason	163, 166
Budd, Matthew	136
Buhler, Shayna	203
Bullock, Sandra L.	195
Burchell, Ann	115, 122, 123, 131, 136, 166, 169 171, 174, 176, 178, 192, 195, 213
Burchell, Neil	201
Burgener, Adam	118, 127, 152, 153, 156
Byakwaga, Helen	130

**C**

Cahill, Julia	162, 177
Calder-Kent, Barb	160
Callebaut, Christian	163
Calli, Kristina	136
Calzavara, Liviana	115, 195
Cameron, Cathy	139, 214
Cameron, Ruth	210
Campbell, Douglas	176
Canadian Observation Cohort (CANOC) Collaboration	165
Canadian Perinatal HIV/AIDS Surveillance Network	114
Canadian Public Health Labs	159
Cao, Huyen	177
Cao, Wei	186
Capina, Rupert	129, 137, 150, 159, 161
Carballo-Diéguez, Alex	127
Card, Kiffer G.	196, 202, 209
Carlson, Allison	114, 123, 124, 131, 174, 197, 203
Carlson, Jonathan	130, 149
Carnochan, Tara	132
Carrington, Mary N.	130
Carroll, Samara	215
Carter, Allison	114, 123, 124, 131, 174, 178, 197, 203, 206
Carvalho, Adriana	177
Cassidy, Sara M.	165
Castro, Diana M.	129
Caswell, Debbie	160
Cattaneo, Jessica	126, 205
Cavanagh, Alice	120
Cedar Project Partnership	117, 123, 128, 200

Ceranto, Andre L. . . . .	140, 210, 215
Cescon, Angela . . . . .	165
Chacko, Sara . . . . .	170
Chagoya, Charlotte . . . . .	205
Challacombe, Laurel A. . . . .	197, 198, 208
Chambers, Lori A. . . . .	126, 139, 205, 206
Chan Carusone, Soo . . . . .	203, 204, 205, 208, 212
Chan, Jacqueline K. . . . .	152
Chan, Shanna D. . . . .	182
Chan, Warren C. . . . .	143
Chan, Wing F. . . . .	150
Charest, Louise . . . . .	115, 127
Chase, Rob. . . . .	131, 132
Châtel, Liam . . . . .	156
Chau, William . . . . .	128, 136, 138, 197
Chavoshi, Negar . . . . .	188
Chegwidden, Will . . . . .	171
Chen, Kun. . . . .	143
Chen, Yufei . . . . .	151, 155
Cheng, Andrew . . . . .	163
Chernesky, Max . . . . .	120
Cheruiyot, Julianna . . . . .	118, 127, 144, 145, 150, 151, 162, 204
Chetty, Verusia . . . . .	214
Cheuk, Eve . . . . .	128, 138, 180
Cheung, Peter. . . . .	154, 155
Chew, Marianne . . . . .	113, 149
Chia, Jason. . . . .	164, 165, 170
Chikermane, Vijaya . . . . .	126, 197
CHIWOS Research Team . . . . .	114, 123, 203
Choi, Stephanie . . . . .	136
Cholette, Francois . . . . .	147, 150, 156, 159, 160, 161
Chomont, Nicolas . . . . .	156, 172
Chong, Patrick . . . . .	152
Chopra, Abha . . . . .	147
Chown, Sarah . . . . .	172, 215
Christian, Wayne M. . . . .	117, 123, 128, 188, 200
Chu, Tianxin . . . . .	138
Chun, Tae-Wook . . . . .	156
Ciaran, Aiken . . . . .	137
Cicala, Claudia . . . . .	130
CIHR Team on Cellular Aging and HIV Comorbidities in Women and Children (CARMA) . . . . .	136
Claffey, Austin . . . . .	169
Clarke, Amanda . . . . .	168
Clement, Ken . . . . .	195
Cleret-Buhot, Aurelie. . . . .	145
Closson, Kalysha . . . . .	185, 196, 209
Cobarrubias, Kyle . . . . .	130, 157
Cobb, Grant . . . . .	212
Cobbing, Saul . . . . .	214
Cockburn, Lynn. . . . .	214
Cohen, Eric. . . . .	205
Cohen, Jeffrey. . . . .	183
Colantonio, David . . . . .	176
Colby-Germinario, Susan . . . . .	154
Coleman, Macon D. . . . .	119
Coleman, Todd A. . . . .	189, 193
Colley, Guillame . . . . .	114, 124, 131, 135, 138 170, 174, 186, 189, 194, 196
Collins, Alexandra B. . . . .	136, 196, 204, 210
Collins, Evan. . . . .	136
Colquhoun, Heather . . . . .	201

Compton, Miranda	197
Condran, Brian R.	188, 198, 211
Conroy, Andrea L.	113
Consolacion, Theodora B.	187
Conway, Brian	163, 173, 183, 195
Conway, Tracey P.	131, 174, 203
Cook, Darrel	137
Coombs, Daniel	116
Cooper, Curtis L.	120, 121, 143, 165, 166, 167 171, 178, 183, 188, 191, 212
Corneil, Trevor	189
Corsi, Daniel J.	166
Cossette, Sylvie	207
Costiniuk, Cecilia	121, 160, 172
Cote, Helene C.	119, 136, 142, 163, 169
Côté, José	129, 162, 207
Côté, Pierre	164
Côté, Sandra C.	134, 158
Cotte, Laurent	168
Courter, Joel R.	133
Coutu, Mathieu	133, 155
Cox, Joseph	120, 172, 183, 191
Craig, Shelley L.	203
Cranston, Ross D.	127
Crawley, Angela M.	143
Creal, Liz	203, 204
Crowe, Lois	191
Csordas, Fatima C.	152
Cui, Michelle	196, 202, 209
Cui, Zishan	164, 185, 188, 189, 194, 195, 196, 210
Cule, Stephen	185
Cullen, Walter	187
Curran, Janet	199
Custodio, Joseph	177
Cutillas, Vincent	112
Czarnecki, Christopher K.	112, 147, 148, 153, 155

**D**

Da Fonseca, Sandrina	145
Daar, Eric	163
Daftary, Amrita	115, 195, 209
Daher, Aïcha	134
Daly, Caroline	179
Daly, Patty	138
Daniel, Simret	214
Daniuk, Christina	129, 137, 153, 159
Das, Moupali	163, 168, 177
Dau, Lauren	163
Davies, Christina	184
Davlut, Derek	152
Day, David M.	116
Day, Heather	200
Day, Irene	115
de Kiewit, Alexandra	124
De Leon, Maricar	156
de Montigny, Simon	127, 193
de Pokomandy, Alexandra	114, 123, 124, 131, 135 174, 178, 197, 203, 206, 207
de Prinse, Karen	212
Deering, Kathleen N.	124
Del Corpo, Olivier	134
Delcanto, Sugandhi	128



Delmas, Philippe . . . . .	129
Demetrakopoulos, Anna . . . . .	206, 209
Demlow, Sarah E. . . . .	138, 199, 209
Desbiens, Marisol . . . . .	114, 123, 124, 131, 139
. . . . .	174, 178, 197, 203, 206
Deshaies, Lucie . . . . .	183
Deshiere, Alexandre . . . . .	113, 149
Deyman, Megan . . . . .	132
Dhami, Parminder . . . . .	185
Di Gravio, Eric J. . . . .	119
Diallo, Tamsir O. . . . .	159, 161
Dickie, Melisa . . . . .	198, 216
Diener, Tania . . . . .	129
Dieumegard, Hinatea . . . . .	172
Dikeakos, Jimmy D. . . . .	157
Dil, Nyla . . . . .	145
Dimitrov, Dobromir . . . . .	127, 182, 193, 195
Ding, Erin . . . . .	114, 124, 131, 174, 197
Ding, Erin . . . . .	123, 131, 165, 178, 206
Ding, Shilei . . . . .	133, 156, 155
Djiometio, Joseph N. . . . .	171, 204
Dmytryshyn, Jennifer . . . . .	166
Dobrer, Sabina . . . . .	124, 179, 215
Doering, Kelsie . . . . .	162
Domselaar, Gary V. . . . .	172
Donelle, Lori . . . . .	181
Dong, Huiru . . . . .	122, 179, 186
Dong, Weiyan . . . . .	113
Donnell, Deborah . . . . .	182
Dore, Gregory . . . . .	120
Dorsey, Grant . . . . .	113
Doucette, Karen . . . . .	155
Douglas, Deborah A. . . . .	161
Doupe, Glen . . . . .	187
Doyle, Eileen . . . . .	177
Drolet, Martine . . . . .	183
Dubé, Anik . . . . .	198
Dube, Sane . . . . .	208
Dubuc, Daniele . . . . .	123, 124, 178, 197, 203, 206
Duddy, Janice . . . . .	194, 195, 202
Duff, Putu . . . . .	124
Dupuy, Franck . . . . .	146
Dwivedi, Girish . . . . .	170

## E

Eaton, Andrew D. . . . .	203, 205, 211
Edmiston, Laurie . . . . .	195, 198, 207
Egana, Mikel . . . . .	179
El Far, Mohamed . . . . .	143
Elkashab, Magdy . . . . .	121
Elwood Martin, Ruth . . . . .	197
Emlet, Charles A. . . . .	215
Emmanuel, Faran . . . . .	147, 190
End, Carla . . . . .	138, 192
Engler, Kim . . . . .	179, 204
ennabil, nourane . . . . .	135
Enns, Eric J. . . . .	150, 161, 177
Enyioma, Adaobi . . . . .	128
Erickson, Adam . . . . .	179
Estaquier, Jerome . . . . .	118
Etcheverry, Emily . . . . .	132
Eyawo, Oghenowede . . . . .	136, 137, 168, 170, 185, 186, 194

**F**

Falkenhagen, Alexander	133
Faller, Elliott M.	140, 170, 175
Falutz, Julian	168
Fantus, Sophia	140
Farah, Bashir	175
Farr Zuend, Christina	151
Fay, Shauna	180
Febo, Irma	127
Feld, Jordan	121, 143
Fellows, Lesley K.	135
Fergus, Stevenson	198
Ferlatte, Olivier	181, 207
Fernando, Saranee M.	187, 204, 209
Finzi, Andrés	133, 156, 155
Fischer, Benedikt	116
Fish, Suzanne L.	198
Fisher Raymond, Henry	189
Flesher, Devyn	132
Flowers, Paul	181
Flynn, John V.	131, 132
Foisy, Michelle M.	173, 176, 177
Fong, Ignatius	166
Forde, Cuisle	179
Fordyce, Marshall	163, 168
Fortier, Yasmina	118
Fowke, Keith R.	118, 127, 144, 145, 150 151, 154, 161, 162, 204, 205
Fowler, Shawn	126, 175
Franco-Villalobos, Conrado	168, 185, 186, 194
Fraser, Chris	183
Frenchman, Clarence	197
Friedman, Alon	180
Friesen, Karen	113, 172, 179
Fristensky, Brian	148
Frohlick, Sue E.	202
Fromentin, Rémi	156
Fudge, Neva	143
Fujiwara, Esther	134
Fung, Kenneth	125
Furlotte, Charles	215
Furqan, Sofia	190
Fusco, Robert	112

**G**

G, Sangam	215
Ga'al, Khadija A.	207
Gabel, Chelsea	199
Gadawski, Izabella	142, 169
Gagnon, Marie-Pierre	207
Gagnon, Marilou	207
Gahagan, Jacqueline	188, 194, 198, 203, 208, 211
Galambos, Amanda	198
Galanakis, Chrissi	115, 121, 127, 185
Galano, Eliana	129
Gali, Brent J.	170
Gallant, Joel	163
Gallant, Maureen	143
Gamble, Joel	113
Gamella, Juan F.	129
Ganase, Bruce F.	163
Gao, Yong	151, 178

Gardner, Sandra . . . . .	122, 126, 136, 189, 193
Garrett, Nigel . . . . .	130
Gasingirwa, Claudine . . . . .	206
Gatignol, Anne . . . . .	134
Gaudieri, Silvana . . . . .	147
Gaudry, Sonia . . . . .	214
Gauvin, Holly . . . . .	197
George, Michelle . . . . .	188
German, Polina . . . . .	165
Gervais, Laverne . . . . .	128
Gesink, Dionne . . . . .	117
Giannakis, Andreas . . . . .	135
Gibson, Richard M. . . . .	130
Giguere, Pierre . . . . .	177
Gilbert, Mark . . . . .	116, 136, 138, 167, 181, 187
Gilchrist, Jody . . . . .	120
Giliauskas, Danielle . . . . .	190
Gill, John . . . . .	121, 129, 134, 160, 183, 191
Gilley, Meghan . . . . .	173
Girard, Lauren M. . . . .	152
Gislason, Maya . . . . .	196, 202
Gladstone, Brenda . . . . .	195
Glazier, Richard . . . . .	122, 169
Globerman, Jason . . . . .	136, 190, 205, 206
Godbout, Caroline . . . . .	125
Godin, Gaston . . . . .	162
Godoy, Sandra L. . . . .	210
Gogolishvili, David . . . . .	190
Goktepe, Ozge . . . . .	113
Goldenberg, Shira M. . . . .	124
Golubkov, Olga . . . . .	154
Gomez, Jenny . . . . .	210
Gonzalez-Serna, Alejandro . . . . .	169
Gore, Dana . . . . .	205
Gormley, John . . . . .	179
Gosselin, Annie . . . . .	145
Gough, Kevin . . . . .	120, 166
Gould, Steve . . . . .	201
Goulet, Jean-Philippe . . . . .	145
Gounni, Abdelilah S. . . . .	145
Grace, Daniel . . . . .	116, 181
Grant, Chris . . . . .	153
Grant, Michael . . . . .	143
Grant, Robert M. . . . .	182
Gravel, Catherine . . . . .	119
Graydon, Colin G. . . . .	144
Grebely, Jason . . . . .	113
Greenbloom, Susan . . . . .	121
Greene, Saara . . . . .	117, 124, 132, 175, 203
Greenspan, Nicole R. . . . .	208
Grennan, Troy . . . . .	115, 120, 126, 166, 167, 175, 182, 184, 187
Grinspoon, Steven . . . . .	168
Gu, Jijin. . . . .	152, 155
Guéhéneuc, Yann-Gaël . . . . .	162, 207
Guiguere, Rebecca . . . . .	127
Guillemi, Silvia A. . . . .	113, 115, 135, 170, 179
Gupta, Shivani . . . . .	172
Gushulak, Rieanne A. . . . .	198
Gustafson, Reka . . . . .	138, 189
Guta, Adrian . . . . .	205, 212
Guthrie, Brandon . . . . .	118

**H**

Habayama, Muluba . . . . .	201
Hacault, Aleasha . . . . .	200
Haeryfar, Mansour . . . . .	157
Hagen, Briana . . . . .	129
Hahn, Beatrice H. . . . .	133
Haider, Shariq . . . . .	183
Haig, Thomas A. . . . .	124
Hajizadeh, Mohammad . . . . .	188
Hakobyan, Syune . . . . .	166, 173, 174, 179, 196
Hall, David . . . . .	185, 189
Hall, Elise . . . . .	177
Halverson, Jessica . . . . .	138
Hamel, Nicolas . . . . .	127
Hamelin, Anne-Marie . . . . .	191
Hamilton, Katie . . . . .	171
Han, Yingshan . . . . .	154
Hanass-Hancock, Jill . . . . .	139
Hanna, Steve . . . . .	208
Harding, Richard . . . . .	169
Harrigan, P. Richard . . . . .	113, 128, 129, 130, 163, 169, 176, 178
Harris, Angela . . . . .	144
Harris, Gregory . . . . .	198
Harris, Lesley M. . . . .	215
Harris, Marianne . . . . .	115, 135, 143, 163, 170
Harrison, Scott . . . . .	197
Harrop-Archibald, Liz . . . . .	195
Hart, Trevor A. . . . .	116, 126, 171, 175, 189, 193
Hassounah, Said . . . . .	152, 154
Hastings, Colin . . . . .	125
Hatala, Andrew R. . . . .	128
Hatzipantelis, Maria . . . . .	206
Havliir, Diane V. . . . .	113
Hawkes, Jennifer . . . . .	165
Hawkes, Michael . . . . .	113, 172
Hawkins, Camilla . . . . .	171
Hayashi, Kanna . . . . .	169
Hazelton, Michael . . . . .	205
Heath, John J. . . . .	143
Heath, Kate . . . . .	138
Henderson, David M. . . . .	167
Henderson, Earl W. . . . .	123, 128
Hennink, Maurice . . . . .	129
Henrick, Bethany M. . . . .	118
Hensley-McBain, Tiffany . . . . .	156
Herpai, Nicole . . . . .	138
Hill, Charles . . . . .	117
Hill, Janet E. . . . .	112
Hill, Jessica L. . . . .	152
Ho, Emmanuel . . . . .	151, 152, 155
Ho, John K. . . . .	147, 149, 159, 160
Hoffman Russell, Justen N. . . . .	152
Hogg, Robert S. . . . .	114, 123, 124, 128, 131, 136, 137, 148 164, 165, 168, 170, 174, 178, 179, 185 186, 187, 188, 189, 190, 194, 195, 196 197, 196, 197, 202, 204, 206, 209, 210, 215
Hogg, William . . . . .	122
Hollett, Natasha . . . . .	161, 162
Holliday, Elizabeth . . . . .	199, 209
Holmes, Dave . . . . .	207
Holtz, Timothy H. . . . .	182
Horacsek, Joshua . . . . .	148

Hornsberger, Alicia . . . . .	172, 184
Horsman, Greg . . . . .	129
Horwitz, Marc S. . . . .	151
Hot, Aurélie . . . . .	124
Hottes, Travis S. . . . .	167, 207
Houle, Steeve . . . . .	165
Houzeau, Marie . . . . .	124
Howard, Terry . . . . .	188, 195, 197, 203
Howe, Anita. . . . .	113
Hoyano, Dee . . . . .	189
Hsiung, Ging-Yuek R. . . . .	135, 170
Hu, Jia . . . . .	182
Huang, Jing . . . . .	153, 156
Huang, KC . . . . .	121
Hubaux, Jean-Pierre. . . . .	164
Huchet, Emmanuelle . . . . .	115, 121, 127, 185
Hughes, Christine A. . . . .	176
Hughes, James P. . . . .	182
Huhn, Gregory . . . . .	163
Hui, Christian . . . . .	125, 201
Huibner, Sanja . . . . .	119, 146
Hull, Mark . . . . .	115, 120, 128, 135, 136, 137, 163, 165, 166 167, 168, 170, 178, 182, 183, 185, 186, 194, 197
Hunt, Nina R. . . . .	119
Hunt, Peter W. . . . .	130
Hunter, Jon . . . . .	136
Husbands, Winston. . . . .	115, 125, 126, 138, 205, 206, 211, 214
Hyland, Robert . . . . .	121

## I

Ibanescu, Ilinca. . . . .	154
Ibanez-Carrasco, Francisco . . . . .	201, 203, 204, 206, 208
Illsley, Shohan. . . . .	128
Immigrant Women's Group, The . . . . .	214
Inoua, Haoua . . . . .	210
Ion, Allyson . . . . .	117, 132, 175
Ireland, Laurie F. . . . .	138, 180, 182, 192
Isac, Shajy . . . . .	190, 212
Islam, Nazrul. . . . .	181
Islam, Shazia . . . . .	126, 197
Iveniuk, James . . . . .	195
Izquierdo-Useros, Nuria . . . . .	133

## J

Jabbari, Shahab . . . . .	114, 115, 123, 124, 128, 131, 137 168, 170, 174, 178, 185, 194, 197, 206
Jackson, Lois . . . . .	198
Jackson, Randy . . . . .	117, 199
Jagwani, Raj . . . . .	216
Jalloh, Chelsea. . . . .	200
Jamie Thomas-Pavanel, Jamie. . . . .	206
Jang, Dan . . . . .	120
Jangu, Neema . . . . .	214
Janjua, Naveed. . . . .	120, 137, 181, 182
Jaoko, Walter . . . . .	175
Jaworsky, Denise . . . . .	128, 194, 197
Jayanna, Krishnamurthy. . . . .	161
Jembere, Nathaniel. . . . .	192, 213
Jenabian, Mohammad-Ali. . . . .	146, 160, 164
Jennex, James . . . . .	140
Ji, Hezhao. . . . .	150, 159, 161, 172, 177
Jiang, Depeng . . . . .	149

Jiang, Wei	178
Jimena Escamilla Gómez, Tania	157
Jin, Steven	134
John, Mina	147
Johnson, Aaron L.	157
Johnston, Caitlin	190
Johnston, Christine	197, 198
Johnston, Meagan	216
Jollimore, Jody	140, 185, 188
Jolly, Ann	195
Jones, Bradley R.	148
Jongbloed, Kate	117, 123, 128
Jorritsma, Jessica	147
Jose-Boerbridge, Murray	197, 208
Jose, Murray	210
Joseph, Michelle	162
Joshi, Sadhna	133
Joy, Jeffrey B.	113, 148
Juno, Jennifer A.	144, 154

**K**

Kabogo, Joseph	172
Kadambar, Ramachandra R.	190, 212
Kadivar, Kiana	147, 159, 160, 159, 160
Kadkhoda, Kamran	160
Kadlun, Sherry	199
Kaida, Angela	114, 123, 124, 131, 174, 178 179, 194, 195, 197, 203, 206, 215
Kain, Kevin C.	113
Kakkar, Fatima	114, 119, 136, 138, 172, 173, 176
Kamya, Moses	113
Kandel, Gabor	119
Kangabe, Rose	139
Kaposy, Chris	191, 208
Karam, Jessica	177
Karatzios, Chris	114
Karniychuk, Uladzimir	113, 149
Kashem, Mohammad A.	148
Kasper, Ken	138, 146, 163, 168, 179, 182, 192
Kaufmann, Daniel E.	133, 156
Kaul, Rupert	115, 119, 138, 146, 166, 214
Kaushic, Charu	113, 144, 149
KAVI	175
Kawuma, Annet	162
Kayiwa, Quinton	216
Kazemi, Mina	123
Keen, Soha	199
Kelly, Alyssa N.	193
Kelly, Cathy	170
Kelly, Deborah V.	188
Kendall, Claire E.	122, 131, 132, 136, 138 169, 176, 180, 192, 191, 213
Kennedy, Mary Clare	194
Kennedy, V Logan	123, 124, 174, 175
Kerba, Jean P.	127
Kerr, Ryan	206
Kerr, Thomas	122, 186, 194, 215
Kesselring, Sarah	185, 194, 195
Kestler, Mary	113, 123, 131, 172, 174, 178, 184, 198
Keynan, Yoav	138, 146, 158, 168, 179, 180, 182, 192
Khan, Muhammad N.	173
Khan, Sarah	166, 174

Khan, Sarwat T.	143
Kia, Hossein	202
Kiani, Ghazal	164
Kiarie, James	118
Kiazyk, Sandra	143
Kielly, Jason	188
Kille, Julie	198
Kim, Brian H.	166
Kim, Connie J.	119, 146
Kim, Jisung	143
Kim, John	147, 159, 160, 159, 160
Kimani, Joshua	118, 127, 144, 145, 146, 147 148, 149, 150, 151, 162, 204
Kimani, Makobu	127, 145, 150, 151, 204
King, Alexandra	198, 199
Kinloch, Natalie N.	130
Kirchhoff, Frank	155
Kirkby, Don R.	113
Kirkland, Susan	209
Klakowicz, Piotr	167
Klaponski, Natasha	150
Klatt, Nichole R.	156
Klein, Katja	148, 157
Klein, Marina B.	120, 121, 122, 135, 165 167, 172, 178, 183, 191
Kleinstein, Sarah	165
Klimas, Jan	187
Knowles, Zak	208
Knox, David C.	176
Kobinger, Gary	112, 153, 155
Koenig, Debbie	208
Kohio, Hinnisan P.	119
Konrad, Stephanie	184
Kou, Nancy	204
Kovacs, Colin	119, 146
Kowatsch, Monika M.	144, 150, 151
Kowdley, K	165
Kozlowski, Hannah N.	119
Krajden, Mel	120, 137, 181, 184, 187
Krell, Shannon	172
Kremer, Hayden	194
Krepski, Heather	200
Kronfli, Nadine	123, 131, 174
Krusi, Andrea	140
Krust, Bernard	118
Kuang, Tallie	134
Kuo, Margot E.	120, 137, 181
Kurdyak, Paul	176
Kushwaha, Sameer	138
Kwag, Michael	116
Kwaramba, Gladys	209
Kwo, Paul	165
Kyeyune, Fred	130

## L

La, David	148, 149, 150, 160
Lacap, Philip	112, 146, 148, 153
Lacasse, Gary	195
Lachowsky, Nathan J.	115, 140, 148, 165, 181, 185 188, 189, 190, 196, 202, 209
Lacombe-Duncan, Ashley	123, 205, 212
Laforge, Mireille	118

Lajoie, Julie . . . . .	118, 127, 144, 145, 150, 151, 162, 204
Lakkappa, Mohan H.. . . . .	190, 212
Lalonde, Christine . . . . .	131, 132
Lam, Albert . . . . .	143
Lamarre, Valerie . . . . .	114, 119, 173
Lambert, Denise . . . . .	188
Land, Allison . . . . .	157
Landry, Gabrielle . . . . .	127
Landy, Rachel . . . . .	116
Lane, Sarah . . . . .	191
Langlois, Andrea . . . . .	132
Langlois, Marc-André . . . . .	158
Langois, Andrea . . . . .	202
Lapointe, Normand . . . . .	114, 119, 138, 173
Lapple, Alicia . . . . .	184
Laroche, Daniel Jonathan . . . . .	127
Larose-Hebert, Katharine . . . . .	131, 132
Larsson, John . . . . .	175
Lau, Cindy . . . . .	169, 176
Lau, Elaine . . . . .	176
Lau, Vickie . . . . .	166
Lauffenberger, Douglas A. . . . .	153
Lauscher, Darren . . . . .	132
Lavigne, Carole . . . . .	156
Lavoie, Stephanie . . . . .	121, 127, 159, 160, 159, 160, 185
Lawless, James . . . . .	126
Layne, Jodie . . . . .	200
Laziri, Anna . . . . .	213
Le Champion, Armelle . . . . .	119
Leary, Shay . . . . .	147
Leask, Kerry . . . . .	130
Leblanc, Mariama . . . . .	139
LeBlanc, Roger . . . . .	160, 164, 172, 186
Lebouché, Bertrand . . . . .	135, 146, 160, 164 172, 179, 186, 195, 204
Lee Kwok Choong, Christopher . . . . .	187
Lee, Emma R. . . . .	150, 159, 160, 161, 208
Lee, Erica . . . . .	197
Lee, Guinevere Q. . . . .	130
Lee, Mona . . . . .	132
Lee, Terry . . . . .	114, 138, 143
Légaré, René . . . . .	216
Legault, Mario . . . . .	186
Leng, Jing . . . . .	154
Lennox, Lynda . . . . .	135, 172
Leonard, Lynne E. . . . .	115
Leontyev, Danila . . . . .	119
Lepik, Katherine J. . . . .	113, 168
Leslie, Alia . . . . .	165
Lessard, David . . . . .	179, 204
Lester, Richard . . . . .	113
Levac, Danielle . . . . .	201
Levett, Paul . . . . .	129, 160
Levine, Sarah J. . . . .	199
Lewis, George K. . . . .	156
Lewis, Johanna . . . . .	175
Lewis, M.E. S. . . . .	136
Li, Alan T. . . . .	125, 175, 201, 206, 216
Li, Hongzhao . . . . .	153, 155
Li, Lin . . . . .	153
Li, Qiong . . . . .	185
Li, Yuejin . . . . .	151, 178



Liang, Binhua . . . . .	148, 149, 150, 172, 177
Liang, Jiaming . . . . .	144, 154
Liang, Richard H. . . . .	113
Liao, Lingjie . . . . .	178
Liddell, Michael . . . . .	198
Liddy, Clare . . . . .	138, 180, 192, 191
Liebenberg, Lenine J. . . . .	153
Light, Lucia . . . . .	122
Lim, Elgin . . . . .	116
Lima, Viviane D. . . . .	113, 128, 136, 164, 168, 170, 197
Lin, Sally (Yue) . . . . .	114, 124, 179, 197, 203, 206
Lindsay, Joanne . . . . .	139
Ling, Sean H. . . . .	135, 170
Lipski, Kara . . . . .	150, 151
Liu, Juan . . . . .	115, 166
Liu, Lewis R. . . . .	148, 153
Lockie, Llsa . . . . .	198
Loemba, Hugues . . . . .	214
Logie, Carmen H. . . . .	117, 123, 124, 174, 212, 213
Lome, Solomon . . . . .	214
Longpre, Daniele . . . . .	115, 121, 127, 185
Lopez, Paul . . . . .	153, 157
Lopez, Rene . . . . .	125
Loppie, Charlotte . . . . .	117, 199
Lorgeoux, Rene-Pierre . . . . .	177
Loughrain, Kirsti . . . . .	171
Loutfy, Mona . . . . .	114, 115, 120, 123, 124, 131, 165 166, 167, 169, 174, 175, 176, 178 192, 195, 197, 203, 206, 213
Loy, Aisling . . . . .	179
Lu, Jeffrey . . . . .	112
Luetkemeyer, Anne . . . . .	165
Lundrigan, Phil . . . . .	191
Luo, Ma . . . . .	112, 146, 147, 148, 149, 150, 153, 155
Luyombya, Henry . . . . .	125, 213, 214
Ly, Valentina . . . . .	150
Lys, Candice . . . . .	117

## M

Ma, Grace . . . . .	177
Ma, Huiting . . . . .	170
Maan, Evelyn J. . . . .	113, 136, 184
MacArthur, Ian . . . . .	149
MacAuley, Maggie . . . . .	181
Macbeth, Allison . . . . .	209
MacDonald, Jo-Ann . . . . .	198
Macdonald, Kelly S. . . . .	152, 161, 175
MacDonald, Lauren . . . . .	138
MacGillivray, Jay . . . . .	124
MacGrady, Ralf J. . . . .	204
Machado, Daisy M. . . . .	129
Machouf, Nimã . . . . .	115, 121, 127, 165, 167, 178, 185
Machuki, Zipporah . . . . .	143
Mack, Mandy . . . . .	123
MacKenzie, Lauren J. . . . .	128, 194, 197
MacKenzie, Rachel K. . . . .	212
MacNeill, Nancy . . . . .	117
Macphail, Gisela . . . . .	183
MacPherson, Paul . . . . .	140, 170, 175
Maddur, Srinath . . . . .	190, 212
Mah, Allison D. . . . .	184
Maina, Ayub K. . . . .	145

Maitland, Dale . . . . .	125
Mak, Donna . . . . .	184
Makaroff, Sylvia . . . . .	167
Malhotra, Suzy . . . . .	211
Mallal, Simon . . . . .	147
Malloch, Laurie . . . . .	159, 160
Mamik, Manmeet K. . . . .	157
Mamiya, Hiroshi . . . . .	191
Mamputu, Jean-Claude . . . . .	168
Mann, Jamie F. . . . .	152, 157
Mann, Janessa . . . . .	129
Mannheimer, Sharon . . . . .	182
Manning, Elizabeth . . . . .	125
Mansoor, Leila E. . . . .	153
Manuel, Douglas G. . . . .	122, 192
Marchand, Rick . . . . .	207
Markle, Tristan . . . . .	134, 156, 157
Marotta, Paul . . . . .	121
Marsh, Angie K. . . . .	152
Marshall, Shelley . . . . .	184, 208
Marshall, Zack . . . . .	131, 132, 194, 208
Marsolais, Christian . . . . .	168
Martel-Laferriere, Valerie . . . . .	120, 121
Martin, Alana . . . . .	131, 132
Martin, Jeff N. . . . .	130
Martin, Susan . . . . .	181
Martinez-Picado, Javier . . . . .	133
Masching, Renee . . . . .	117, 195, 198, 199
Masinde, Irene K. . . . .	213
Mâsse, Benoît R. . . . .	127, 193
Masson, Lindi . . . . .	153
Mathias, Anita . . . . .	167, 177
Maunder, Robert . . . . .	136
Maxwell, John . . . . .	126, 175
Mayer, Kenneth H. . . . .	127
Mayo, Nancy E. . . . .	135
Mazulli, Tony . . . . .	113, 149
Mbulaheni, Tola . . . . .	115, 125, 213, 214
McCallister, Scott . . . . .	163
McCarthy, Stephen D. . . . .	119
McClarty, Leigh M. . . . .	138, 180, 192
McClemon, Tim. . . . .	210
McClure, David . . . . .	203
McConnell, Meghan . . . . .	174
McCorrister, Stuart . . . . .	118, 152, 156
McCoubrey, Hillary . . . . .	147
McCullagh, John W. . . . .	203
McDaid, Lisa . . . . .	181
McDermott, Adam . . . . .	179
McDonald, Chloe R. . . . .	113
McDonnell, Esther . . . . .	171
McDougall, Patrick . . . . .	187, 203, 204, 208, 209
McGee, Frank . . . . .	122, 136
McGovern, Mark . . . . .	183
McGovern, Rachel A. . . . .	113
McGowan, Ian . . . . .	127
McGrail, Kimberlyn . . . . .	170
McGuinty, Michaeline . . . . .	166
McIntosh, Martin . . . . .	214
McKenzie, Brienne A. . . . .	157
McKinnon, Lyle R. . . . .	130, 149, 153
McLaren, Paul J. . . . .	133, 148, 161, 164

McLay, David	208
McLeod, Albert	188
McLinden, Taylor	191
McNally, John	167
McNeil, Ryan	187, 209
McQueen, Melanie	162
Mead, Annabel	187
Medina, Claudia	203, 204
Medjuck, Melissa	215
Meeme, Cisily K.	145
Meguro, Kotoo	184
Mehraj, Vikram	146, 160, 164, 186
Mei, Chong	137
Meili, Ryan	128, 184, 195
Melesse, Dessalegn Y.	190
Melillo, Bruno N.	133
Ménard, Brigitte	206
Mendelsohn, Joshua	195
Menon, Anitha	139
Mensah, Maria N.	124
Merke Epp, Tanya	161
Merritt, Katelyn G.	187, 204
Mesa, Christine	143, 145
Mesplède, Thibault R.	112, 144, 152, 154
Meyers, Adrienne F.	159, 161
Michelow, Warren	116
Migliardi, Paula	214
Mignone, Javier	161, 200
Miller, Desmond	214
Milloy, M-J.	122, 178, 179, 186, 187, 194, 197, 215
Min, Jeong Eun.	122
Ming, Kevin	143
Mingjin, Yan	163
Minichiello, Alexa	194
Miranda, Joyal	207
Mirau, Dean	182, 187
Mishra, Sharmistha	120
Mistafa, Brynn	160
Mitchell, Kate M.	182, 193, 195
Mitchell, Kayla	206
Mitra, Sanjana	190
Mogalian, Erik	167
Mohammadi, Hakimeh	112
Moll, Sandra	180
Money, Deborah	113, 114, 138, 163, 184
Montaner, Julio	113, 115, 122, 128, 135, 136, 138 137, 148, 164, 163, 165, 166, 168, 170 178, 179, 185, 186, 189, 194, 197, 215
Monteiro, Patricia	145
Monteith, Ken	124, 188, 207
Montessori, Val	166
Montgomery, Carolyn	167
Moodie, Erica	183, 191
Moore, David M.	114, 115, 148, 170, 182, 185, 187 188, 189, 190, 194, 195, 196, 202, 209
Morshed, Mubnii	167
Mortazavi, Shervin	135, 170
Moses, Erin	214
Moses, Stephen	161
Moukambi, Felicien	118
Muchenje, Marvelous	197, 210, 213
Mueller, Kristen	113, 149

Mugford, Gerry . . . . .	188
Mugenyi, Peter . . . . .	130
Muhammad, Morshed . . . . .	184
Mukandoli, Chantal . . . . .	203
Mulcahy, Fiona . . . . .	179
Mungai, John . . . . .	118, 127, 204
Muñoz-Fernández, Maria Angeles . . . . .	169
Murooka, Thomas . . . . .	149, 157
Murphy, Daniel . . . . .	115
Murphy, Kellie . . . . .	176
Murphy, Pauline . . . . .	168
Murray, Melanie C. . . . .	113, 172, 184
Murti, Michelle . . . . .	187, 189
Mussavi Rizi, Seyed Ali . . . . .	137
Muzoora, Conrad . . . . .	130
Mwamba, Chanda . . . . .	139
Mwangi, Lucy W. . . . .	118, 127, 144, 204
Mweshi, Margaret . . . . .	214
Mwimanzi, Philip . . . . .	134
Myers, Ted . . . . .	126, 195
Myezwa, Hellen . . . . .	214
Mykhalovskiy, Eric . . . . .	125
Myslik, James . . . . .	205

## N

Nabulime, Eva . . . . .	130
Naccarato, Mark . . . . .	177
Naggie, Susanna . . . . .	165
Nahar, Quamrun . . . . .	130
Naik, Sarjita . . . . .	165, 167
Nakamwa, Joanita M. . . . .	212
Nakayiwa, Patricia . . . . .	216
Nankya, Immaculate . . . . .	130, 148, 158
Nansereko, Sandra W. . . . .	216
Nasewich, Susanne . . . . .	129, 197, 198
Nash, Denis . . . . .	194, 195
Natha, Macky . . . . .	165, 167
Nathoo, Afshan . . . . .	138
Nava, Maribel S. . . . .	157
Nawaz, Fatima . . . . .	130
Nayar, Ayesha . . . . .	201, 208
Ndashimye, Emmanuel . . . . .	130
Nebroski, Michelle . . . . .	148
Nelson, LaRon E. . . . .	115, 138, 214
Nelson, Mark . . . . .	169
Newman, Peter A. . . . .	189, 205
Ng, Dione . . . . .	159, 160
Ngo, Hugh . . . . .	167
Nguyen, Philip V. . . . .	113, 149
Nicholson, Valerie . . . . .	123, 131, 132, 174, 197, 206
Nickel, Gabrielle . . . . .	130, 148
Nicoletti, Pauline . . . . .	119
Nightingale, Merle . . . . .	198
Nixon, Stephanie . . . . .	139, 208, 214
Njoki, Jane . . . . .	150, 151
Nkandu, Esther M. . . . .	214
Nomellini, John F. . . . .	151
Noor, Syed W. . . . .	116, 126, 189, 193
Nosyk, Bohdan . . . . .	178
Notifiable Disease Surveillance and Population Health Branch Teams . . . . .	129
Nowicki, Deborah . . . . .	184

Nutter, Alison . . . . .	173
Nygaard, Vicki . . . . .	132
Nyingcho, Sam . . . . .	214
Nykoluk, Mikaela . . . . .	112, 150, 153
Nyman, Sheila . . . . .	117

## O

O'Brien, Ashley . . . . .	198
O'Brien, Kelly K. . . . .	, 180, 201, 203, 204, 208
O'Brien, Nadia . . . . .	124, 131, 174, 206
O'Byrne, Patrick . . . . .	140, 175
O'Campo, Pat . . . . .	124
O'Cleirigh, Conall . . . . .	136
O'Leary, Bill . . . . .	212
O'Neill, Tyler J. . . . .	171
Oakes, Wesley . . . . .	125, 212
OBrien, Nadia . . . . .	203
ODEa, Siobhan . . . . .	179
Odger, Allison R. . . . .	202
Ogilvie, Gina . . . . .	115, 116, 123, 167, 182, 184, 215
Ogunnaike-Cooke, Susanna . . . . .	129, 138, 137, 185
Okidi, Carilus . . . . .	214
Oliffe, John . . . . .	207
Oliveira, Maureen . . . . .	152, 154
Oliveira, Natalia . . . . .	187, 194, 195, 196, 210
Olson, Lanna . . . . .	173
Omange, Robert W. . . . .	145, 148, 153
Omollo, Kenneth . . . . .	, 144, 145, 150, 151
Omoroh, Florence . . . . .	214
Ongoiba, Fanta . . . . .	125, 210, 213
Ontario HIV Treatment Network Cohort Study . . . . .	122
Ormond, J.D. . . . .	200
Ormond, Margaret . . . . .	200
Orysiuk, Dallas . . . . .	147
Osborne, Charles . . . . .	132, 185, 194, 195
Osinusi, Anu . . . . .	167
Osman, Nathan . . . . .	154
Ostrowski, Mario . . . . .	119, 143, 175, 177
Otis, Joanne . . . . .	, 162
Otterstatter, Michael . . . . .	182
Owino, Maureen . . . . .	206, 216
Oyugi, Julius . . . . .	, 118, 127, 143, 144, 145, 150, 151, 161, 204

## P

Pagliuzza, Amélie . . . . .	172
Pai, Nikki . . . . .	188
Pakzad, Zahra . . . . .	173, 184
Palmer, Kenneth E. . . . .	152
Panessa, Ciro . . . . .	188
Pang, Phillip . . . . .	177
Pankrac, Joshua . . . . .	157
Pantopoulos, Kostas . . . . .	122
Paparisto, Ermela . . . . .	119
Papp, Eszter . . . . .	112, 113
Paradis, Gilles . . . . .	191
Paramel Jayaprakash, Teenus . . . . .	112
Parashar, Surita . . . . .	122, 164, 187, 194, 195
. . . . .	196, 203, 204, 209, 210
Park, Jongwoo . . . . .	133
Passmore, Jo-Ann S. . . . .	153
Paterson, Ryan F. . . . .	168
Patrick, David . . . . .	116

Patterson, Aileen . . . . .	150, 159, 177
Patterson, Mo H. . . . .	112
Patterson, Sophie E. . . . .	123, 164, 165, 179, 197, 215
Patterson, Thomas . . . . .	185
Paul, Coreen . . . . .	199
Pauls, Greta . . . . .	167
Pauly, Bernadette . . . . .	140
Payne, Martin . . . . .	203, 204
Payne, Michael . . . . .	128
Pazgier, Marzena . . . . .	155
Pearce, Margo E. . . . .	117, 123, 128, 200
Pearl, Tamara . . . . .	128
Pelletier, Kaitlin . . . . .	209
Pendergraft, Kevin R. . . . .	198
Perciani, Catia T. . . . .	175
Perreault, Yvette . . . . .	209
Persad, Yasmeen . . . . .	123
Peterson, Jen . . . . .	128
Petty, Mary . . . . .	197
Pexos, Costas . . . . .	135, 172
Pham, Hanh T. . . . .	154
Pick, Neora . . . . .	113, 114, 131, 172, 174, 179, 183, 184, 197
Pickles, Michael . . . . .	193
Picotte, Heather J. . . . .	132
Pierpaoli, Christina M. . . . .	215
Pierre-Pierre, Valerie. . . . .	125, 138, 209, 210, 213, 214
Pilon, Richard . . . . .	152
Pineau, Dave . . . . .	131, 132
Pinto, Jorge . . . . .	112
Pisharody, Rajesh . . . . .	139, 206
Planas, Delphine Y. . . . .	145
Plante, Iradele R. . . . .	181
Plesniarski, Andrew M. . . . .	145
Plews, Margot . . . . .	159, 161
Plourde, Pierre J. . . . .	184
Plummer, Andrew . . . . .	163
Plummer, Francis A. . . . .	112, 145, 146, 147, 148 149, 150, 153, 155
Poitras, Margaret . . . . .	117
Poliquin, Marc . . . . .	121, 185
Ponte, Rosalie. . . . .	146, 160, 164, 186
Poon, Art F. . . . .	113, 148
Poon, Maurice K. . . . .	201
Pooyak, Sherri . . . . .	132, 199, 200
Positive Brain Health Now investigators . . . . .	135
Post, Frank . . . . .	168
Postnikoff, Jonathan . . . . .	202
Poteat, Tonia . . . . .	212
Potterton, Joanne . . . . .	214
Potts, Jeff . . . . .	195
Power, Christopher B. . . . .	134, 150, 157
Powis, Jeff. . . . .	183
Prentice, Tracey M. . . . .	117
Prévost, Jérémie . . . . .	155
Proctor, Elizabeth . . . . .	153
Proulx-Boucher, Karène . . . . .	114, 123, 124, 197, 206
Proulx-Boucher, Karène . . . . .	131, 174
Pyne, Diane . . . . .	173

## Q

Qian, Feng . . . . .	178
Qiu, Annie . . . . .	113, 163
Quinones-Mateu, Miguel . . . . .	130

**R**

Rabazanahary, Henintsoa	118
Raboud, Janet	126, 165, 167, 169, 171 175, 176, 178, 192, 213
Rachlis, Anita	122, 171, 183
Rachlis, Beth	122, 136, 190
Racine, Gina	118
Rae, Allan	203, 204
Rahimi, Asa	157
Rahman, Syeda	159
Raisaro, Jean-Louis	164
Rajikan, Roslee	187
Ramdahin, Sue	145
Ramirez Garcia, Pilar	162, 207
Ramji, Alnoor	121
Ran, Xiaozhuo	158
Rand, Jenny R.	199
Ranganath, Nischal	134, 158
Rank, Claudia	129, 137
Rauw, Gail	150
Raycraft, Tyler	173
Raymond Marchand, Laurence	119
REACH 2.0	188
Read, Stanley	133, 166, 172, 174, 176
Rebbapragada, Anu	143, 166
Reed, Julie	129
Reimer, Joss N.	184
Reimer, Tammy	128, 180, 208
Reinhard, Robert J.	205
Rekart, Michael	116
Remis, Robert	166
Renaud, Christian	114, 173
Renner, Tyler M.	158
Reschny, Jamie A.	132, 140
Restall, Gayle	128, 132, 180, 208
Reyes-Teran, Gustavo	157
Reza, Tahira	190
Rhee, Martin	163
Rich, Ashleigh	148, 185, 188, 189, 190, 196, 202, 209
Rich, Rosemary	171
Richard, Jonathan	133, 156
Richert, Quinlan D.	146
Richmond, Meika	153
Rickey, Daniel W.	151
Riddell, Jennifer	184
Rieb, Launette	187
Robbins, Marjorie	113, 154, 155
Robinson, Gregory	208
Robinson, Linda J.	162, 177
Robitaille, Lynda	118
Robson, Gail	166
Roddy, Pumulo	132, 214
Rodrigues, Vasco	118
Roesslein, Kay	139
Roger, Kerstin	132
Rogers Van Katwyk, Susan	195
Rogers, Tim	198, 208
Rohl, Maria	144
Rohringer, Taryn J.	119
Rojas, Carlos	129, 161
Rollet-Kurhajec, Kathleen C.	121
Romas, Laura	118, 127, 156
Ronald, Allan	161

Rooke, Eddie	128
Rose, Tiffany	131, 132
Rosenes, Ron	192, 191
Rosenthal, Kenneth L.	118
Ross, Andrew	205
Ross, Craig	184
Rossi, Carmine	120, 167
Roth, Eric A.	148, 178, 185, 188, 189, 190, 196, 202, 209
Rothenberg, Richard	116
Rouleau, Danielle	183
Rouleau, Geneviève	162, 207
Roungprakhon, Surachet	189
Rourke, Sean B.	122, 136, 169, 171, 176, 178 190, 191, 192, 203, 204, 205, 213
Rousseau, Rodney	119, 146, 188
Routy, Jean-Pierre	143, 144, 145, 146 160, 164, 172, 186, 195
Ruane, Peter	163
Rubincam, Clara	205
Rueda, Sergio O.	136, 171
Rueda, Zulma	146, 168
Rutto, Catherine	210
Ryan, Chaneesa R.	199
Ryan, Shannon	115, 125, 195, 210

**S**

S, Ashokanand H.	212
Sa, Ting	138
Saberi, Sara	163
Sadr, Aida	167
Sahajpal, Rahul	176
Sajwani, Karim	167
Sakac, Darinka	119
Salata, Robert	130
Sales, Ramon J.	149
Salit, Irving	120
Salters, Kate	114
Samji, Hasina	120, 165, 167, 181, 182, 184, 194, 195
Sampathkumar, Raghavan	149
Samson, Lindy	114, 136, 138, 172, 176
Sanche, Stephen	178, 195
Sandeep H.	190, 212
Sanders, Chris	125
Sandhu, Jat	138
Sandstrom, Paul	112, 129, 137, 147, 150, 152 153, 155, 156, 159, 161, 177
Sandstrom, Teslin S.	134, 158
Sanford, Heidi	210
Sanguya, Igah	199
Sattha, Beheroze	142
Sauter, Daniel	155
Sauve, Laura J.	114, 138, 172, 173
Scarborough, Robert J.	134
Schanzer, Dena	138
Scharf, Louise	155
Schechter, Martin T.	117, 123, 128, 188, 200
Scheim, Ayden I.	116
Schellenberg, John J.	112
Schnubb, Alexandre	126
Schoffel, Laura	190
Schroeder, Lukas T.	146
Schultz-Darken, Nancy	153



Schwandt, Michael	128, 194
Scott-Herridge, Joel	149
Scott, Kai	190
Scott, Susan	135
Seatter, Erin	215
Sebastiani, Giada	122, 135, 172
Sereda, Paul	114, 124, 185, 188, 189, 196, 209
Serghides, Lena	112, 113, 114
Serlin, Yonatan	180
Seto, Winnie	176
Sha, Nishit	201
Shadabi, Elnaz	112, 149
Shafer, Leigh Anne	190
Shafiei Sabet, Maryam	187
Shafraan, Stephen	121, 155, 167
Shahabi, Kamnoosh	119, 146
Shahid, Anika	154, 155
Shamess, Charles	210, 215
Shannon, Kate	124, 140
Shao, Yiming	178
Sharma, Malika	143
Sharma, Richa	200
Sharma, Shawn	173
Shattock, Robin J.	157
Shaw, George M.	133
Shaw, Souradet Y.	138, 179, 184, 192
Shea, Patrick	165
Shen, Gong	167
Sherchan, Sudin	126, 197
Sherpa, Chhiring D.	126
Shi, Qiyun	205
Short, W	168
Shoveller, Jeannie	136
Shu, Xin	119
Shumilak, Geoffrey	128, 197
Shurgold, Susan	148, 189, 194, 196, 202
Sidhu, Manraj	154, 155
Silhol, Romain	193
Silvestre, Ricardo	118
Simms, Alexandria M.	208
Simwaba, Phillimon	139
Singer, Joel	138
Singh, Ameeta	120, 173
Singh, Jastaranpreet	133
Singhroy, Diane N.	154
Sinyinza, Robert	139
Siou, Kaitlin	114
Sivro, Aida	130
Siwale, Margaret	139
Skinner, Stuart	195
Small, William	187
Smieja, Marek	120, 174
Smit, John	151
Smith, Amos B. III	133
Smith, Danielle M.	185, 186
Smith, Graham	166
Smitten, Jennifer	172
Sodroski, Joseph	133
Soje, Patrick	125
Solomon, Patricia	139, 180, 208
Songok, Elijah	172
Soor, Jaspreet	126

Sorensen, Tina A. . . . .	200
Soudeyns, Hugo . . . . .	119, 172, 205
Soul, Geoff . . . . .	153
Souleymanov, Rusty . . . . .	140
Soundala, Latsamy . . . . .	189
Soundaramourty, Calayselvy . . . . .	118
Spence, Gilbert . . . . .	200
Spira, Bonnie . . . . .	154
Spittal, Patricia M. . . . .	117, 123, 128, 188, 200
St. Jean, Jessica . . . . .	124
Stacey, Kim . . . . .	196, 210
Stalker, Andrew T. . . . .	144, 151, 154
Stamm, Luisa . . . . .	165, 167
Stanley, Daina . . . . .	175
Stanley, Takara . . . . .	168
Stark, Wendy . . . . .	187
Steenbeek, Audrey A. . . . .	199
Stein, Nicci . . . . .	210, 215
Steinberg, Malcolm . . . . .	116
Steingart, Chris . . . . .	183
Stephen, Sandy . . . . .	184
Stephenson, Kristine . . . . .	185
Stevens, Elizabeth . . . . .	171
Stewart, Kris . . . . .	183, 195
Stokich, Denise . . . . .	198
Strike, Carol . . . . .	197, 205, 209, 212
Stürzel, Christina . . . . .	155
Su, Ruey-Chyi . . . . .	144, 145, 147, 149, 153
Subramanian, Yazhini . . . . .	173
Sucharitakul, Kanen . . . . .	193
Sulkowski, Mark . . . . .	165
Sullivan, Theres . . . . .	128, 132
Summers, Marcie . . . . .	195
Surette, Mike . . . . .	144
Sutdhibhasilp, Noulmook . . . . .	201
Sutherland, Jessica E. . . . .	116
Svarovskaia, Evguenia . . . . .	121
Swab, Michelle . . . . .	194
Swain, Mark . . . . .	121
Switzer, Sarah . . . . .	205
Syed, Abdullah . . . . .	143
Sylvain, H�el�ene . . . . .	129
Szabo, Jason . . . . .	135

## T

Tai, Vera . . . . .	113
Taljaard, Monica . . . . .	122
Tam, Edward . . . . .	121
Tan, Darrell H. . . . .	120, 126, 166, 175, 176, 212
Tan, Xiaoli . . . . .	156
Tang, David . . . . .	112, 153, 155
Tang, Vera . . . . .	158
Tanner, Zachary P. . . . .	165
Tanveer, Fozia . . . . .	216
Tarasuk, Jill . . . . .	185
Tatari, Nazanin . . . . .	145
Tattle, Stephen . . . . .	139, 208, 214
Taylor, Chrissy . . . . .	124, 140
Taylor, Darlene . . . . .	116
Taylor, Matthew . . . . .	140
Taylor, Tracy . . . . .	129, 137, 150, 159, 161, 177
Telenti, Amalio . . . . .	133, 164

Tennant, Donna	215
Tepjan, Suchon	189
Terpstra, Alex	203, 204
Thabane, Lehana	174
Tharao, Wangari	115, 123, 124, 131, 138, 174 195, 203, 209, 210, 213, 214
Thi Pham, Hanh	154
Thomas, Christopher	211
Thomas, Denise	198
Thomas, Réjean	115, 121, 127, 160, 164, 183, 185, 186
Thompson, Laura	147
Thompson, Tamara	195
Thumath, M.	184
Ti, Lianping	122, 137, 164, 194
Tian, Meijuan	151, 178
Tinmouth, Jill	120, 166, 171
Toews, Julia	146
Tom, Sean K.	119
Tomas, Kristina	138
Tossonian, Harout	163
Toupin, Isabelle	204
Toy, Junine	113, 166
Trahan, Marie-Julie	173
Trajtman, Adriana	146, 158
Traore, Yannick L.	151, 155
Travers, Robb	116
Tremblay-McLean, Alexandra	146
Tremblay, Cécile	143, 160, 162, 164, 186, 207
Tremblay, Michel J.	113, 149
Trepanier, Janie	183
Trottier, Benoit	115, 121, 127, 143, 160, 163, 164, 185
Trussler, Terry	207
Tseng, Alice	168, 177
Tsoukas, Chris	165, 167, 178, 195
Tu, David	167
Tuff, Jeffrey F.	112, 150, 153
Tuscano, Hywel J.	216
Tyler, Shaun	150
Tynan, Anne-Marie	171, 204
Tyndall, Mark	120, 121, 131, 132, 137 167, 181, 182, 184, 189, 198

## U

Ulloa, Ana	113
Underhill, Angela A.	175
Upshur, Ross	212
Utama, Richard	125, 201

## V

Vachon, Marie-Louise	121
Vafadary, Sahand	173, 174, 179
Vahedi, Fatemah	113, 149
Vajravelu, Saipriya	180
Valela, Nicholas	140, 175
Van de Velde, Nicolas	193
Van Domselaar, Gary	177
van Gaalen, Sarah M.	168
Van Nynatten, Logan R.	157
Vanderkloot, Mark	129, 137
Vaneechoutte, Mario	112
Vaporojan, Lilia	179
Vaudry, Wendy	138

Veazey, Ronald . . . . .	157
Vega, Jose . . . . .	151
Veillette, Maxime . . . . .	133, 155
Venkataramaiah, Balasubramanya K. . . . .	190, 212
Venner, Colin M. . . . .	130, 158
Venus, Kevin . . . . .	166
Vezina, Sylvie . . . . .	115, 121, 127, 185
Vickerman, Peter . . . . .	193
Vijayanathan, Haran . . . . .	126
von Bischoffshausen, Otto . . . . .	210
Vuille-Lessard, Elise . . . . .	135

## W

Wachihi, Charles . . . . .	147, 148
Wadham, Mbaka . . . . .	214
Wagner, Anne C. . . . .	210
Wagner, John . . . . .	122
Wai, Alan . . . . .	177
Wainberg, Mark . . . . .	112, 144, 152, 154
Walker, Bruce . . . . .	156
Walker, Glen . . . . .	210
Wallace, Robert . . . . .	203
Walmsley, Sharon . . . . .	121, 168, 178, 183, 192
Wang, Yimeng . . . . .	158
Wares, Melissa . . . . .	152
Waruk, Jillian L. . . . .	143
Watchorn, Jocelyn . . . . .	195, 203, 205, 210
Waters, Shannon . . . . .	188
Watson, Birgit . . . . .	163
Watson, James . . . . .	205, 206
Webster, Duncan . . . . .	183
Webster, Kath . . . . .	114, 123, 124, 131, 174, 178, 197, 203, 206
Wedgwood, O M. . . . .	168
Werker, Denise . . . . .	129
Werner, Lise . . . . .	153
Wessels, Jocelyn M. . . . .	113, 144, 149
Westland, Kristin . . . . .	198
Westmacott, Garrett . . . . .	118, 127, 152, 153, 156
Whitney, James . . . . .	112, 153
Wiebe, Tania . . . . .	180
Wilkin, Timothy . . . . .	163
Willems, Bernard . . . . .	121
Willer, David O. . . . .	152
Williams, John . . . . .	193
Willison, Don . . . . .	205, 206
Wilson, Pamela . . . . .	199
Wilton, James . . . . .	126, 175, 181
Withana Gamage, Niradha . . . . .	112
Wong, Alexander . . . . .	129, 178, 183, 195
Wong, DAvid K. . . . .	168
Wong, Gary . . . . .	155
Wong, Jason . . . . .	115, 137, 167, 181, 182, 184, 185, 187, 189
Wong, Josephine P. . . . .	125, 201, 214
Wong, Leo . . . . .	191
Wong, Nicholas . . . . .	121
Wong, Raymond W. . . . .	119
Wood, Carrie-Ann . . . . .	171
Wood, Evan . . . . .	122, 186, 187, 194, 215
Woods, Conan K. . . . .	113
Woods, Dan . . . . .	173
Woods, Matthew W. . . . .	119
Woods, Ryan . . . . .	120, 137

Worthington, Catherine . . . . .	, 117, 132, 187, 202, 203 204, 205, 206, 207, 208
Wylie, John . . . . .	161
<b>X</b>	
Xia, Fan . . . . .	182
<b>Y</b>	
Yamamoto, Aiko . . . . .	135, 170, 203, 204
Yan, Ping . . . . .	138
Yang, Qiuying . . . . .	138
Yang, Sidi o. . . . .	151, 155
Yang, Xuefen . . . . .	156, 159
Yao, Xiaojian . . . . .	118, 153, 158, 156, 158, 185
Yates, Tammy C. . . . .	, 139, 208, 214
Yeo, Jason . . . . .	187
Yeung, Bianca. . . . .	186
Yip, Benita . . . . .	113, 138, 164, 166
Yoshida, Eric. . . . .	121
Young, Ingrid. . . . .	181
Younger, Jaime . . . . .	122, 178
Yu, Amanda . . . . .	120, 137, 181
Yu, Bo . . . . .	192
Yuan, Xin-Yong . . . . .	155
Yudin, Mark H. . . . .	174, 175, 176
Yuen, Angela. . . . .	150
Yun, Chohee. . . . .	121
<b>Z</b>	
Zack, Julia . . . . .	177
Zahid, Butt . . . . .	181
Zamar, David . . . . .	200
Zhang, Fan . . . . .	138
Zhang, Jonathan Y. . . . .	119
Zhang, Nanhua. . . . .	138
Zhang, Wendy W. . . . .	113, 115, 128, 135, 136 137, 154, 155, 166, 170, 197
Zhang, Xu . . . . .	158
Zhang, Yuwei . . . . .	145
Zhao, Chongbo. . . . .	153
Zhu, Chuanwu . . . . .	178
Zhu, Rong. . . . .	156
Zhu, Yu . . . . .	157
Zoccole, Art . . . . .	123, 139
Zoubchenok, Daria . . . . .	133
Zubi, Hadaf. . . . .	181
Zúñiga-Pflücker, Juan C. . . . .	133

## Notes

A series of horizontal dotted lines for taking notes.

## MONTRÉAL



© Tourisme Montréal, Stéphan Poulin

APRIL 6-9 / DU 6 À 9 AVRIL

The 26<sup>th</sup> Annual Canadian Conference on HIV/AIDS Research will take place in Montréal, Quebec from April 6-9, 2017. Our 2017 Conference will celebrate 26 years of Canadian leadership in HIV research with a world-class roster of special guest speakers.

Make sure to arrive early and stay on afterwards as Montréal has something for everyone. Whether you have a passion for gourmet food, exciting nightlife, or one of kind cultural festivals, you will feel at home in Montréal. There is no wonder Montréal has a reputation as one of the liveliest cities in North America.

From the cobblestone streets and historic architecture in Old Montréal, to the sleek office towers in downtown and panoramic views from Mont Royal, Montréal really stands out. This modern metropolis has grown from a tiny village into a destination that shines on the international stage.

Join us in April 2017 for a few exciting days of learning, networking and exploring. We look forward to seeing you in Montréal in 2017!

Le 26<sup>e</sup> Congrès annuel canadien de recherche sur le VIH/sida aura lieu à Montréal du 6 au 9 avril 2017. Le Congrès 2017 soulignera 26 années de leadership canadien en recherche sur le VIH, avec une brochette de calibre mondial de conférenciers spéciaux.

Assurez-vous d'arriver tôt et de prolonger un peu votre séjour, car Montréal a quelque chose à offrir à tous et à chacun. Que vous ayez une passion pour les mets raffinés, la vie nocturne palpitante ou des festivals culturels à nuls autres pareils, vous vous sentirez chez vous à Montréal. Rien d'étonnant que Montréal ait la réputation d'être l'une des villes les plus vivantes de l'Amérique du Nord.

Des rues en pavés aux chefs d'œuvre architecturaux historiques du Vieux-Montréal en passant par les gracieuses tours à bureaux du centre ville et aux panoramas offerts du haut du Mont Royal, Montréal se distingue à tout point de vue. De minuscule petit village, Montréal est devenue une métropole moderne, la destination qui se distingue sur la scène internationale.

Soyez des nôtres en avril 2017 pour y passer quelques jours exaltants d'apprentissage, de réseautage et d'exploration. Nous aurons grand plaisir à vous accueillir à Montréal en 2017!




Sébastien Roy



© Tourisme Montréal



## DOWNTOWN MAP / PLAN DU CENTRE-VILLE



**RBC Convention Centre Winnipeg** – 375 York Avenue

**Delta Winnipeg** – 350 St. Mary Avenue


**Canadian Museum For Human Rights** – 85 Israel Asper Way




# Venue Plan / Plan de lieu

## North Building, RBC Convention Centre Édifice Nord, Centre des congrès RBC

### GROUND FLOOR REZ-DE-CHAUSSÉE



### SECOND FLOOR DEUXIÈME ÉTAGE



### LEGEND / LÉGENDE

- Plenary, Special Sessions and Symposia / Séances plénières, séances spéciales et colloques : **1, 2 & 11, 12, 13**
- Concurrent Oral Abstract Sessions / Séances simultanées de présentation des abrégés :
- Basic Sciences / Sciences fondamentales : **4**
- Clinical Sciences / Sciences cliniques : **7-8**
- Epidemiology and Public Health Sciences / Épidémiologie et sciences de la santé publique : **3**
- Social Sciences / Sciences sociales : **9-10**
- Exhibit and Poster Hall / Salle des exposants et de présentation des affiches : **2FGH**
- Positive Lounge / Salon des personnes séropositives : **VIP Salon**
- Speaker Ready Room / Salle de préparation des conférenciers : **17**

# Program at a Glance / Aperçu du programme

## Wednesday, May 11 Mercredi 11 mai

**07:30 – 17:00** Charleswood A, Second Floor, Delta Winnipeg  
Ancillary Event / Événement connexe  
**Canadian HIV/AIDS Pharmacists Network Annual General Meeting**  
Assemblée générale annuelle (AGA) de l'Association canadienne des pharmaciens en VIH/SIDA

## Thursday, May 12 / Jeudi 12 mai

**07:45 – 16:00** Delta A, Second Floor, Delta Winnipeg  
Workshop / Atelier  
**CAHR New HIV Researcher Workshop**  
Atelier destiné aux nouveaux chercheurs dans le domaine du VIH

**08:00 – 16:00** Meeting Room 3, Ground Level, North Bldg.  
Ancillary Event / Événement connexe  
**CHVI ACO Annual Meeting – HIV Vaccine Research and Development in Canada: How Vaccines Fit within the Prevention Landscape**  
Assemblée annuelle du BCA de l'ICVV – La recherche-développement de vaccins contre le VIH au Canada : la place des vaccins dans le paysage de la prévention

**08:30 – 12:00** Kildonan Room, Second Floor, Delta Winnipeg  
Ancillary Event / Événement connexe  
**Mobilizing Across Canada to Build Effective Responses to HIV in African, Caribbean and Black Communities**  
Mobilisation pancanadienne pour élaborer une réponse efficace contre le VIH dans les collectivités africaines, caraïbéennes et noires

**08:30 – 16:00** Delta B, Second Floor, Delta Winnipeg  
Ancillary Event / Événement connexe  
**3<sup>rd</sup> International Forum on HIV and Rehabilitation Research – HIV and Aging**  
3<sup>e</sup> Forum international de la recherche sur le VIH et la réinsertion sociale – Le VIH et le vieillissement

**08:30 – 16:00** Meeting Room 9-10, Ground Level, North Bldg.  
Ancillary Event / Événement connexe  
**Engage Team Meeting 2016**  
Réunion 2016 de l'équipe d'Engage

**10:00 – 16:00** Sunshine House, 646 Logan Avenue, Winnipeg  
Ancillary Event / Événement connexe  
**PrEP in the Context of Sex Work: Possibilities and Limitations**  
La PrEP dans le contexte du travail du sexe : Possibilités et limites

**12:00 – 16:00** Charleswood A, Second Floor, Delta Winnipeg  
Ancillary Event / Événement connexe  
**CIHR Implementation Science Component 1 Grantees Workshop**  
Atelier des candidats retenus de la composante 1 – Science de la mise en oeuvre des IRSC

**13:00 – 16:00** Delta C, Second Floor, Delta Winnipeg  
Ancillary Event / Événement connexe  
**Transforming Canada's Approach to Drugs: A National Conversation**  
Transformer l'approche du Canada aux médicaments : dialogue national

**14:00 – 16:00** Kildonan Room, Second Floor, Delta Winnipeg  
**CATIE-CAHR Learning Institute**  
Institut d'apprentissage CATIE-ACRV

**16:15 – 17:15** Meeting Rooms 1-2 & 11-13, Ground Level, North Bldg.  
Symposium / Colloque  
**Canadian Guidelines on HIV PrEP and nPEP**  
Lignes directrices canadiennes sur la PrEP et la PPE dans le contexte du VIH

**17:30 – 19:00** Meeting Rooms 1-2 & 11-13, Ground Level, North Bldg.  
Plenary / Séance plénière  
**Conference Opening and Mark A. Wainberg Lecture / Ouverture du congrès et conférence Mark Wainberg**  
**HIV Prevention: Local to Global and Back to the Future**  
Prévention du VIH : Du local au mondial et retour vers le futur

**19:00 – 20:00** Rooms 2FGH, Second Floor, North Bldg.  
Social Event / Événement social  
**Opening Reception**  
Réception d'accueil du congrès

## Friday, May 13 / Vendredi 13 mai

**07:45 – 09:00** Meeting Rooms 1-2 & 11-13, Ground Level, North Bldg.  
Symposium / Colloque  
**Vaccine Research Plenary – HIV Vaccines: Maintaining the Momentum**  
Plénière sur la recherche vaccinale – Vaccins anti VIH : Maintenir l'élan

**09:00 – 09:45** Meeting Rooms 1-2 & 11-13, Ground Level, North Bldg.  
**Clinical Sciences Plenary / Séance plénière sur les sciences cliniques**  
**PrEP at Age 5: Growing up Fast**  
La PrEP à cinq ans : Croissance rapide!

**09:45 – 10:30** Meeting Rooms 1-2 & 11-13, Ground Level, North Bldg.  
Social Sciences Plenary / Séance plénière sur les sciences sociales  
**Evidentiary Sovereignty across Three Continents: Critical Ethnographies of Community-based HIV Research**  
La souveraineté de la preuve entre trois continents : Ethnographies critiques de la recherche communautaire sur le VIH

**10:30 – 11:00** Rooms 2FGH, Second Floor, North Bldg.  
**Exhibit and Poster Viewing – Refreshment Break / Exposition et présentation d'affiches – Pause-rafraîchissements**

**11:00 – 12:30** Session descriptions begin on page 112 / Les descriptions des séances commencent à la page 112  
Concurrent Oral Abstract Sessions  
Séances simultanées de présentation orale des abrégés

**12:30 – 14:00** Meeting Rooms 1-2 & 11-13, Ground Level, North Bldg.  
Lunch Special Session  
Déjeuner-colloque  
**Living Longer and Living Well with HIV: Reaching New Heights in Healthy Aging**  
Vivre plus longtemps et vivre bien avec le VIH : de nouveaux sommets pour vieillir en santé

**14:00 – 15:00** Rooms 2FGH, Second Floor, North Bldg.  
**Exhibit and Poster Viewing – Refreshment Break with Poster Authors Present**  
Exposition et présentation d'affiches – Pause-rafraîchissements en présence des auteurs

**15:00 – 17:00** Session descriptions begin on page 118 / Les descriptions des séances commencent à la page 118  
Concurrent Oral Abstract Sessions  
Séances simultanées de présentation orale des abrégés

**17:00 – 18:30** Meeting Rooms 1-2 & 11-13, Ground Level, North Bldg.  
Symposium / Colloque  
**Measuring the National HIV Cascade & the UNAIDS 90-90-90 Targets**  
Mesure de la cascade nationale du traitement du VIH et les cibles 90-90-90 de l'ONUSIDA

**18:30 – 20:15** Meeting Room 7-8, Ground Level, North Bldg.  
**CATIE-CAHR Learning Institute**  
Institut d'apprentissage CATIE-ACRV

**18:30 – 20:00** Meeting Room 3, Ground Level, North Bldg.  
Meeting / Assemblée  
**CAHR Annual General Meeting and Reception**  
Assemblée générale annuelle de l'ACRV et réception

## Saturday, May 14 / Samedi 14 mai

**07:15 – 08:50** Meeting Rooms 1-2 & 11-13, Ground Level, North Bldg.  
Symposium / Colloque  
**CIHR Canadian HIV Trials Network Postdoctoral Fellows Breakfast Symposium**  
Petit-déjeuner colloque des boursiers postdoctoraux du Réseau canadien pour les essais VIH des IRSC

**07:30 – 8:45** Charleswood A, Second Floor, Delta Winnipeg  
Ancillary Event / Événement connexe  
**Manitoba HIV Collective Impact Research, Evaluation & Action Network – Networking Breakfast**  
Réseau de recherche, d'évaluation et d'action du Manitoba sur les répercussions collectives du VIH – petit-déjeuner de réseautage

**09:00 – 09:45** Meeting Rooms 1-2 & 11-13, Ground Level, North Bldg.  
Basic Sciences Plenary / Séance plénière sur les sciences fondamentales  
**Can Inflammation in Chronic HIV Infection Be Reversed?**  
Peut-on inverser l'inflammation dans l'infection chronique au VIH?

**09:45 – 10:30** Meeting Rooms 1-2 & 11-13, Ground Level, North Bldg.  
Epidemiology and Public Health Sciences Plenary / Séance plénière sur les Épidémiologie et sciences de la santé publique  
**Community Mobilization and Structural Interventions in HIV Prevention Programs**  
Mobilisation de la collectivité et interventions structurelles dans les programmes de prévention du VIH

**10:30 – 11:00** Rooms 2FGH, Second Floor, North Bldg.  
**Exhibit and Poster Viewing – Refreshment Break / Exposition et présentation d'affiches – Pause-rafraîchissements**

**11:00 – 12:30** Session descriptions begin on page 126 / Les descriptions des séances commencent à la page 126  
Concurrent Multi-disciplinary Oral Abstract Session / Séances simultanées de présentation orale des abrégés (multidisciplinaire)

**12:30 – 14:00** Meeting Rooms 1-2 & 11-13, Ground Level, North Bldg.  
Lunch Symposium / Déjeuner-colloque  
**The ART of Managing HIV/HCV Co-infection in the Era of New DAAs**  
L'ART de gérer les co-infections VIH/VHC l'époque des nouveaux antiviraux directs

**14:00 – 15:00** Rooms 2FGH, Second Floor, North Bldg.  
**Exhibit and Poster Viewing – Refreshment Break with Poster Authors Present**  
Exposition et présentation d'affiches – Pause-rafraîchissements en présence des auteurs

**15:00 – 17:00** Session descriptions begin on page 133 / Les descriptions des séances commencent à la page 133  
Concurrent Oral Abstract Sessions  
Séances simultanées de présentation orale des abrégés

**17:00 – 18:30** Meeting Room 4, Ground Level, North Bldg.  
Concurrent Special Session / Séance spéciale simultanée  
**HIV Prevention and Engagement in Care for Indigenous Peoples**  
Prévention du VIH et engagement de soins pour les peuples autochtones

**17:00 – 18:30** Meeting Rooms 1-2 & 11-13, Ground Level, North Bldg.  
Concurrent Special Session / Séance spéciale simultanée

**Immune Activation and HIV Target Cells: What do we know, what are the next big questions, and can we intervene?**  
L'activation immunitaire et les cellules cibles du VIH : État du savoir actuel, les grandes questions qui se posent et... pouvons-nous intervenir?

**18:30 – 20:15** Meeting Room 7-8, Ground Level, North Bldg.  
**CATIE-CAHR Learning Institute**  
Institut d'apprentissage CATIE-ACRV

**19:00 – 01:00** Canadian Museum for Human Rights  
Social Event / Événement social  
**Gala Party / Soirée de gala**

## Sunday, May 15 / Dimanche 15 mai

**09:45 – 11:15** Meeting Rooms 1-2 & 11-13, Ground Level, North Bldg.  
Special Session / Séance spéciale  
**The Future of Manitoba's Global Impact in HIV Research**  
L'avenir du poids mondial du Manitoba dans la recherche sur le VIH

**11:30 – 12:00** Meeting Rooms 1-2 & 11-13, Ground Level, North Bldg.  
Plenary / Séance plénière  
**Learning at the Front Lines: Community Rapporteur Session – CATIE-CAHR Learning Institute Participants**  
Séance des rapporteurs communautaires – Participants à l'Institut d'apprentissage CATIE-ACRV

**12:00 – 12:30** Meeting Rooms 1-2 & 11-13, Ground Level, North Bldg.  
Plenary / Séance plénière  
**Awards and Closing Remarks**  
Remise des prix et mot de la fin

## Monday, May 16 / Lundi 16 mai

**09:00 – 17:00** Delta Winnipeg  
Ancillary Event / Événement connexe  
**Canadian AIDS Society – Forum, Members' Caucus and Annual Meeting**  
Société canadienne du sida – Forum, caucus des membres et assemblée annuelle

### Registration / Inscription

South East Concourse, Ground Floor, North Building, RBC Convention Centre

Thursday, May 12 / Jeudi 12 mai	08:30 – 19:00
Friday, May 13 / Vendredi 13 mai	07:00 – 17:00
Saturday, May 14 / Samedi 14 mai	08:30 – 17:00
Sunday, May 15 / Dimanche 15 mai	08:30 – 12:30

### Speaker Ready Room / Salle de préparation des conférenciers

Meeting Room 17, Ground Floor, North Building, RBC Convention Centre

Thursday, May 12 / Jeudi 12 mai	13:00 – 17:00
Friday, May 13 / Vendredi 13 mai	07:30 – 15:30
Saturday, May 14 / Samedi 14 mai	07:30 – 15:30

### Positive Lounge / Salon des personnes séropositives

VIP Salon, Ground Floor, North Building, RBC Convention Centre

Thursday, May 12 / Jeudi 12 mai	14:00 – 20:00
Friday, May 13 / Vendredi 13 mai	07:30 – 18:00
Saturday, May 14 / Samedi 14 mai	07:30 – 18:00
Sunday, May 15 / Dimanche 15 mai	08:30 – 12:00

### Exhibition / Exposition

2FGH – Second Floor, North Building, RBC Convention Centre

Thursday, May 12 / Jeudi 12 mai	19:00 – 20:00
Friday, May 13 / Vendredi 13 mai	08:30 – 15:30
Saturday, May 14 / Samedi 14 mai	08:30 – 15:30

### Concurrent Oral Abstract Sessions

Séances simultanées de présentation orale des abrégés

**Track A: Basic Sciences / Volet A : Sciences fondamentales**  
Meeting Room 4, Ground Level, North Building

**Track B: Clinical Sciences / Volet B : Sciences cliniques**  
Meeting Room 7-8, Ground Level, North Building

**Track C: Epidemiology and Public Health Sciences**  
Volet C: Sciences épidémiologie et santé publique  
Meeting Room 3, Ground Level, North Building

**Track D: Social Sciences / Volet D : Sciences sociales**  
Meeting Room 9-10, Ground Level, North Building

All sessions take place at the RBC Convention Centre, unless otherwise specified.  
Sauf avis contraire, toutes les séances ont lieu à Palais des congrès du RBC.